treatment;samples;sample_type;contact_country;age_diag;age_metas;sex;loc_melan;os_event;os_days;stage;response;study;cell_type;deconv_value;loc_melan2;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872328;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,006576794;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872329;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,009365538;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872330;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,008912954;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872331;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,008877898;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872332;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,095010049;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872333;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,021193715;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872334;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872335;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,012509083;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872336;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,008111616;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872337;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,007384534;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872338;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,255822549;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872339;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,007671889;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872340;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,062735961;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872341;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,011248899;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872342;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,030933017;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872343;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,016748481;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872344;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,021399462;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872345;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,008485718;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872346;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,017541827;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872347;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,005740846;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872348;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,013855974;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872349;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,008661311;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872350;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,006888685;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872351;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,005026949;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872352;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,018762731;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872353;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,015596568;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872354;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,015522997;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872355;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,011260072;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872356;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,020009993;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872357;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872358;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,236939312;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872359;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,014076245;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872360;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,004941412;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872361;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,010498662;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872362;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,014051935;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872363;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,013373759;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872364;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,033224618;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872365;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,107604644;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872366;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,011112341;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872367;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,003661192;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872368;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,012402104;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872369;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,00398035;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872370;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,014042416;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872371;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,03091415;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872372;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,003648276;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872373;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,017550915;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872374;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872375;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,007510514;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872376;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872377;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,033509527;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872378;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,012354709;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872379;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,003787954;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872380;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,012363152;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872381;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,007873393;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872382;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;B.cells;0,010112197;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872383;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;B.cells;0,015888512;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872384;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;B.cells;0,008481127;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872385;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;B.cells;0,010095779;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872386;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;B.cells;0,023964824;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872387;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;B.cells;5,54E-04;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872388;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;B.cells;0,011073468;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872389;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;B.cells;0,008946305;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872390;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;B.cells;0,011659946;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872391;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;B.cells;0,01146094;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872392;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;B.cells;0,008607317;NA;
Standard (dacarbazine monotherapy; DTIC);GSM550966;Metastatic;Sweden;60;62;Male;Trunk;1;373;IV;NA;GSE22155_GPL6102;B.cells;0,75232376;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550967;Metastatic;Sweden;54;59;Female;Lower extremity;1;181;IV;NA;GSE22155_GPL6102;B.cells;0,068669388;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550968;Metastatic;Sweden;40;53;Male;Head;1;436;IV;NA;GSE22155_GPL6102;B.cells;0,110862925;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550969;Metastatic;Sweden;54;61;Female;Lower extremity;1;82;IV;NA;GSE22155_GPL6102;B.cells;0,018979352;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550970;Metastatic;Sweden;45;47;Male;Lower extremity;1;646;IV;NA;GSE22155_GPL6102;B.cells;0,023665963;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550971;Metastatic;Sweden;68;68;Male;No primary detected;1;114;IV;NA;GSE22155_GPL6102;B.cells;0,068006127;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550972;Metastatic;Sweden;36;38;Male;Upper extremity, acral;1;322;IV;NA;GSE22155_GPL6102;B.cells;0,017748042;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550973;Metastatic;Sweden;63;65;Female;Trunk;1;46;IV;NA;GSE22155_GPL6102;B.cells;0,057125512;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550974;Metastatic;Sweden;51;51;Male;No primary detected;0;3509;IV;NA;GSE22155_GPL6102;B.cells;0,043265064;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550975;Metastatic;Sweden;79;86;Male;Head;1;65;IV;NA;GSE22155_GPL6102;B.cells;0,06094689;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550976;Metastatic;Sweden;50;51;Male;Trunk;1;14;IV;NA;GSE22155_GPL6102;B.cells;0,058338392;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550977;Metastatic;Sweden;58;59;Female;Upper extremity;1;27;IV;NA;GSE22155_GPL6102;B.cells;0,032494009;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550978;Metastatic;Sweden;36;36;Male;No primary detected;-;-;III;NA;GSE22155_GPL6102;B.cells;0,032357881;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550979;Metastatic;Sweden;60;66;Female;Upper extremity;1;45;IV;NA;GSE22155_GPL6102;B.cells;0,027246839;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550980;Metastatic;Sweden;53;53;Female;No primary detected;1;10;IV;NA;GSE22155_GPL6102;B.cells;0,01901003;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550981;Metastatic;Sweden;27;32;Female;Trunk;0;2711;IV;NA;GSE22155_GPL6102;B.cells;0,045973092;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550982;Metastatic;Sweden;49;51;Male;Lower extremity;1;32;IV;NA;GSE22155_GPL6102;B.cells;0,0365242;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550983;Metastatic;Sweden;62;63;Male;No primary detected;1;55;IV;NA;GSE22155_GPL6102;B.cells;0,030350887;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550984;Metastatic;Sweden;50;71;Male;Upper extremity;1;91;IV;NA;GSE22155_GPL6102;B.cells;0,001254417;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550985;Metastatic;Sweden;49;63;Female;Trunk;1;804;IV;NA;GSE22155_GPL6102;B.cells;0,016352628;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550986;Metastatic;Sweden;55;61;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;B.cells;0,041301758;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550987;Metastatic;Sweden;55;80;Male;Trunk;1;25;IV;NA;GSE22155_GPL6102;B.cells;0,006072905;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550988;Metastatic;Sweden;78;78;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;B.cells;0,074282215;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550989;Metastatic;Sweden;56;57;Male;No primary detected;1;50;IV;NA;GSE22155_GPL6102;B.cells;0,021704112;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550990;Metastatic;Sweden;74;76;Female;Head;1;156;IV;NA;GSE22155_GPL6102;B.cells;0,03505617;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550991;Metastatic;Sweden;53;70;Male;Trunk;1;219;IV;NA;GSE22155_GPL6102;B.cells;0,020160288;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550992;Metastatic;Sweden;36;49;Male;Trunk;1;266;IV;NA;GSE22155_GPL6102;B.cells;0,139006252;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550993;Metastatic;Sweden;33;33;Male;No primary detected;1;1075;IV;NA;GSE22155_GPL6102;B.cells;0,142151406;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550994;Metastatic;Sweden;67;67;Female;No primary detected;1;201;IV;NA;GSE22155_GPL6102;B.cells;0,042378502;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550995;Metastatic;Sweden;72;74;Male;Trunk;1;247;IV;NA;GSE22155_GPL6102;B.cells;0,037550661;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550996;Metastatic;Sweden;27;31;Female;Trunk;1;414;IV;NA;GSE22155_GPL6102;B.cells;0,045455959;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550997;Metastatic;Sweden;32;43;Female;No primary detected;1;108;IV;NA;GSE22155_GPL6102;B.cells;0,085228978;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550998;Metastatic;Sweden;59;61;Female;Trunk;-;-;III;NA;GSE22155_GPL6102;B.cells;0,21300919;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550999;Metastatic;Sweden;61;61;Male;No primary detected;1;281;IV;NA;GSE22155_GPL6102;B.cells;0,097322299;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551000;Metastatic;Sweden;73;73;Male;Head and eye;1;221;IV;NA;GSE22155_GPL6102;B.cells;0,076010045;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551001;Metastatic;Sweden;54;55;Male;Trunk;1;102;IV;NA;GSE22155_GPL6102;B.cells;0,019969088;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551002;Metastatic;Sweden;68;68;Female;No primary detected;1;301;IV;NA;GSE22155_GPL6102;B.cells;0,059275471;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551003;Metastatic;Sweden;62;68;Female;Trunk;1;64;IV;NA;GSE22155_GPL6102;B.cells;0,044600126;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551004;Metastatic;Sweden;35;36;Female;No primary detected;1;375;IV;NA;GSE22155_GPL6102;B.cells;0,029320332;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551005;Metastatic;Sweden;76;79;Female;Trunk;1;218;IV;NA;GSE22155_GPL6102;B.cells;0,031923729;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551006;Metastatic;Sweden;66;68;Male;Head;1;1478;IV;NA;GSE22155_GPL6102;B.cells;0,031398405;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551007;Metastatic;Sweden;46;52;Female;Trunk;1;13;IV;NA;GSE22155_GPL6102;B.cells;0,014442454;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551008;Metastatic;Sweden;65;67;Male;Trunk;1;254;IV;NA;GSE22155_GPL6102;B.cells;0,088536778;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551009;Metastatic;Sweden;70;70;Female;Upper extremity;1;16;IV;NA;GSE22155_GPL6102;B.cells;0,059679048;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551010;Metastatic;Sweden;68;72;Male;Trunk;1;430;IV;NA;GSE22155_GPL6102;B.cells;0,037863336;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551011;Metastatic;Sweden;82;84;Male;Trunk;1;63;IV;NA;GSE22155_GPL6102;B.cells;0,109865362;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551012;Metastatic;Sweden;35;68;Male;Upper extremity;0;1198;IV;NA;GSE22155_GPL6102;B.cells;0,04137155;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551013;Metastatic;Sweden;31;38;Male;Trunk;-;-;III;NA;GSE22155_GPL6102;B.cells;0,63680112;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551014;Metastatic;Sweden;79;79;Female;Trunk;0;927;IV;NA;GSE22155_GPL6102;B.cells;0,084939456;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551015;Metastatic;Sweden;77;82;Female;Upper extremity;1;325;IV;NA;GSE22155_GPL6102;B.cells;0,047627565;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551016;Metastatic;Sweden;72;76;Male;Lower extremity;1;44;IV;NA;GSE22155_GPL6102;B.cells;0,037415162;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551017;Metastatic;Sweden;75;75;Female;Lower extremity;0;895;IV;NA;GSE22155_GPL6102;B.cells;0,094279228;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551018;Metastatic;Sweden;58;61;Male;Trunk;0;836;IV;NA;GSE22155_GPL6102;B.cells;0,168949399;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551019;Metastatic;Sweden;71;74;Female;Lower extremity, acral;0;786;IV;NA;GSE22155_GPL6102;B.cells;0,030734504;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551020;Metastatic;Sweden;65;76;Male;Trunk;1;244;IV;NA;GSE22155_GPL6102;B.cells;0,039436666;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551021;Metastatic;Sweden;25;25;Female;Lower extremity;1;78;IV;NA;GSE22155_GPL6102;B.cells;0,075965141;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551022;Metastatic;Sweden;50;75;Male;Trunk;1;29;IV;NA;GSE22155_GPL6102;B.cells;0,044279412;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551023;Metastatic;Sweden;75;76;Male;Acral;1;44;IV;NA;GSE22155_GPL6947;B.cells;0,033247076;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551024;Metastatic;Sweden;63;64;Female;Genital;1;747;IV;NA;GSE22155_GPL6947;B.cells;0,05181542;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551025;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;B.cells;0,039723272;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551026;Metastatic;Sweden;68;68;Female;GI tractus;1;367;IV;NA;GSE22155_GPL6947;B.cells;0,047679352;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551027;Metastatic;Sweden;58;60;Male;Eye;1;7;IV;NA;GSE22155_GPL6947;B.cells;0,04608559;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551028;Metastatic;Sweden;49;63;Male;Trunk;1;309;IV;NA;GSE22155_GPL6947;B.cells;0,177719051;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551029;Metastatic;Sweden;56;55;Female;Trunk;1;32;IV;NA;GSE22155_GPL6947;B.cells;0,065602286;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551030;Metastatic;Sweden;74;74;Male;Trunk;1;79;IV;NA;GSE22155_GPL6947;B.cells;0,044526261;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551031;Metastatic;Sweden;41;42;Female;Eye;1;349;IV;NA;GSE22155_GPL6947;B.cells;0,031401456;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551032;Metastatic;Sweden;49;51;Female;Mucosa, head;1;13;IV;NA;GSE22155_GPL6947;B.cells;0,035315565;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551033;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;B.cells;0,042619403;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551034;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;B.cells;0,044674326;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551035;Metastatic;Sweden;56;56;Male;GI tractus;1;37;IV;NA;GSE22155_GPL6947;B.cells;0,052977608;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551036;Metastatic;Sweden;45;74;Male;No primary;1;183;IV;NA;GSE22155_GPL6947;B.cells;0,042460457;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551037;Metastatic;Sweden;72;75;Female;Head;1;39;IV;NA;GSE22155_GPL6947;B.cells;0,085384609;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551038;Metastatic;Sweden;61;68;Female;Eye;1;513;IV;NA;GSE22155_GPL6947;B.cells;0,07619938;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551039;Metastatic;Sweden;66;68;Male;Trunk;1;584;IV;NA;GSE22155_GPL6947;B.cells;0,055678902;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551040;Metastatic;Sweden;42;44;Male;Head;1;1148;IV;NA;GSE22155_GPL6947;B.cells;0,066829316;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551041;Metastatic;Sweden;54;56;Female;Trunk;1;153;IV;NA;GSE22155_GPL6947;B.cells;0,054314416;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551042;Metastatic;Sweden;48;50;Male;Trunk;1;141;IV;NA;GSE22155_GPL6947;B.cells;0,035878653;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551043;Metastatic;Sweden;58;67;Female;Acral;1;334;IV;NA;GSE22155_GPL6947;B.cells;0,03508025;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551044;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;B.cells;0,038989595;Metastasis
untreated;GSM1220412;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;B.cells;0,087241909;Metastasis;
dabrafenib;GSM1220413;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,034754511;cutaneous or subcutaneous;
untreated;GSM1220414;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,052031481;cutaneous or subcutaneous;
dabrafenib;GSM1220415;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,032107255;cutaneous or subcutaneous;
untreated;GSM1220416;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,076065977;cutaneous or subcutaneous;
dabrafenib;GSM1220417;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,029499181;cutaneous or subcutaneous;
dabrafenib;GSM1220418;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,045624198;cutaneous or subcutaneous;
untreated;GSM1220419;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;B.cells;0,015947903;Metastasis;
dabrafenib;GSM1220420;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;B.cells;0,040245811;Metastasis;
untreated;GSM1220421;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,060467749;cutaneous or subcutaneous;
dabrafenib;GSM1220422;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,0619076;cutaneous or subcutaneous;
dabrafenib;GSM1220423;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,04553608;cutaneous or subcutaneous;
untreated;GSM1220424;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,050616376;cutaneous or subcutaneous;
untreated;GSM1220425;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,04564125;cutaneous or subcutaneous;
dabrafenib;GSM1220426;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;B.cells;0,081630981;Metastasis;
untreated;GSM1220427;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,017315685;cutaneous or subcutaneous;
untreated;GSM1220428;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,021327211;cutaneous or subcutaneous;
dabrafenib;GSM1220429;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,024370495;cutaneous or subcutaneous;
dabrafenib;GSM1220430;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,054618949;cutaneous or subcutaneous;
untreated;GSM1220431;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,045161588;cutaneous or subcutaneous;
dabrafenib;GSM1220432;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,025010866;cutaneous or subcutaneous;
untreated;GSM1220433;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,040609007;cutaneous or subcutaneous;
untreated;GSM1220434;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,03656408;cutaneous or subcutaneous;
dabrafenib;GSM1220435;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,033561079;cutaneous or subcutaneous;
dabrafenib;GSM1220436;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,022272948;cutaneous or subcutaneous;
dabrafenib;GSM1220437;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,014500372;cutaneous or subcutaneous;
untreated;GSM1220438;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;B.cells;0,007350587;Metastasis;
untreated;GSM1220439;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;B.cells;0,011308061;Metastasis;
dabrafenib;GSM1220440;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,026669907;cutaneous or subcutaneous;
dabrafenib;GSM1220441;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;B.cells;0,018263613;Metastasis;
dabrafenib;GSM1220442;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,027521623;cutaneous or subcutaneous;
dabrafenib;GSM1220443;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;B.cells;0,01708595;Metastasis;
untreated;GSM1220444;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;B.cells;0,046552353;Metastasis;
dabrafenib;GSM1220445;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,060283867;cutaneous or subcutaneous;
untreated;GSM1220446;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,040815943;cutaneous or subcutaneous;
untreated;GSM1220447;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,036564134;cutaneous or subcutaneous;
dabrafenib;GSM1220448;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,046520297;cutaneous or subcutaneous;
untreated;GSM1220449;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;B.cells;0,014212973;Metastasis;
dabrafenib;GSM1220450;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,031883989;cutaneous or subcutaneous;
untreated;GSM1220451;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;B.cells;0,029476189;Metastasis;
dabrafenib;GSM1220452;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;B.cells;0,042701094;Metastasis;
untreated;GSM1220453;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,05973408;cutaneous or subcutaneous;
untreated;GSM1220454;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,065060732;cutaneous or subcutaneous;
dabrafenib;GSM1220455;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;B.cells;0,035602516;Metastasis;
dabrafenib;GSM1220456;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,016462435;cutaneous or subcutaneous;
untreated;GSM1220457;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,024943718;cutaneous or subcutaneous;
dabrafenib;GSM1220458;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;B.cells;0,030219512;Metastasis;
untreated;GSM1220459;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,033877277;cutaneous or subcutaneous;
vemurafenib;GSM1220460;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,018852917;cutaneous or subcutaneous;
untreated;GSM1220461;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,026471291;cutaneous or subcutaneous;
untreated;GSM1220462;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,025240032;cutaneous or subcutaneous;
vemurafenib;GSM1220463;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,032386993;cutaneous or subcutaneous;
untreated;GSM1220464;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;B.cells;0,026478365;Metastasis;
vemurafenib;GSM1220465;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,033834318;cutaneous or subcutaneous;
untreated;GSM1220466;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,047347865;cutaneous or subcutaneous;
vemurafenib;GSM1220467;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,051267347;cutaneous or subcutaneous;
vemurafenib;GSM1220468;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,059591627;cutaneous or subcutaneous;
vemurafenib;GSM1220469;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,025710905;cutaneous or subcutaneous;
vemurafenib;GSM1220470;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,02385355;cutaneous or subcutaneous;
untreated;GSM1220471;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;B.cells;0,023438814;cutaneous or subcutaneous;
vemurafenib;GSM1220472;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;B.cells;0,066248103;Metastasis;
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;B.cells;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;B.cells;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;B.cells;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;B.cells;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;B.cells;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;B.cells;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;B.cells;0;Metastasis
untreated;GSM1315904;Primary Tumor;Australia;19;22;Female;NA;0;4342,8;Stage II;not sustained response;GSE54467;B.cells;0,071370712;NA;
untreated;GSM1315905;Primary Tumor;Australia;53;56;Male;NA;1;1418,4;Stage II;NA;GSE54467;B.cells;0,067507787;NA;
untreated;GSM1315906;Primary Tumor;Australia;52;53;Female;NA;1;698,4;Stage II;NA;GSE54467;B.cells;0,046085493;NA;
untreated;GSM1315907;Primary Tumor;Australia;51;52;Male;NA;0;3330,6;Stage I;not sustained response;GSE54467;B.cells;0,108301101;NA;
untreated;GSM1315908;Primary Tumor;Australia;47;51;Male;NA;1;4283,4;Stage II;NA;GSE54467;B.cells;0,06655793;NA;
untreated;GSM1315909;Primary Tumor;Australia;61;64;Male;NA;1;1540,5;Stage I;NA;GSE54467;B.cells;0,053109735;NA;
untreated;GSM1315910;Primary Tumor;Australia;46;52;Female;NA;0;6957,3;Stage I;not sustained response;GSE54467;B.cells;0,069377974;NA;
untreated;GSM1315911;Primary Tumor;Australia;61;75;Male;NA;1;5484,9;Stage I;NA;GSE54467;B.cells;0,045742414;NA;
untreated;GSM1315912;Primary Tumor;Australia;84;87;Female;NA;1;1491,3;Stage I;NA;GSE54467;B.cells;0,081169974;NA;
untreated;GSM1315913;Primary Tumor;Australia;44;44;Female;NA;0;3899,7;Stage III;not sustained response;GSE54467;B.cells;0,146054914;NA;
untreated;GSM1315914;Primary Tumor;Australia;64;72;Male;NA;1;3322,8;Stage I;NA;GSE54467;B.cells;0,067228895;NA;
untreated;GSM1315915;Primary Tumor;Australia;31;31;Male;NA;0;3034,8;Stage III;not sustained response;GSE54467;B.cells;0,096081731;NA;
untreated;GSM1315916;Primary Tumor;Australia;63;65;Male;NA;1;654,9;Stage II;NA;GSE54467;B.cells;0,075782769;NA;
untreated;GSM1315917;Primary Tumor;Australia;58;59;Male;NA;1;1098,6;Stage III;NA;GSE54467;B.cells;0,056490974;NA;
untreated;GSM1315918;Primary Tumor;Australia;56;67;Male;NA;0;6538,2;Stage Unknown;not sustained response;GSE54467;B.cells;0,24680053;NA;
untreated;GSM1315919;Primary Tumor;Australia;48;57;Female;NA;1;3603,9;Stage II;NA;GSE54467;B.cells;0,074794708;NA;
untreated;GSM1315920;Primary Tumor;Australia;69;70;Male;NA;1;261,3;Stage III;NA;GSE54467;B.cells;0,06299705;NA;
untreated;GSM1315921;Primary Tumor;Australia;76;77;Male;NA;1;593,7;Stage II;NA;GSE54467;B.cells;0,131242453;NA;
untreated;GSM1315922;Primary Tumor;Australia;54;55;Female;NA;1;592,8;Stage III;NA;GSE54467;B.cells;0,15111813;NA;
untreated;GSM1315923;Primary Tumor;Australia;82;85;Male;NA;1;2242,8;Stage II;responder;GSE54467;B.cells;0,042225199;NA;
untreated;GSM1315924;Primary Tumor;Australia;79;80;Male;NA;0;2393,7;Stage I;not sustained response;GSE54467;B.cells;0,059018862;NA;
untreated;GSM1315925;Primary Tumor;Australia;50;54;Male;NA;0;2986,5;Stage II;not sustained response;GSE54467;B.cells;0,133468844;NA;
untreated;GSM1315926;Primary Tumor;Australia;57;57;Female;NA;0;305,7;Stage III;non-responder;GSE54467;B.cells;0,068767274;NA;
untreated;GSM1315927;Primary Tumor;Australia;32;45;Male;NA;0;7826,4;Stage I;not sustained response;GSE54467;B.cells;0,088685981;NA;
untreated;GSM1315928;Primary Tumor;Australia;77;78;Female;NA;1;589,8;Stage III;NA;GSE54467;B.cells;0,064503815;NA;
untreated;GSM1315929;Primary Tumor;Australia;56;56;Male;NA;1;588,9;Stage III;NA;GSE54467;B.cells;0,074244224;NA;
untreated;GSM1315930;Primary Tumor;Australia;39;40;Female;NA;1;644,1;Stage II;NA;GSE54467;B.cells;0,133566596;NA;
untreated;GSM1315931;Primary Tumor;Australia;84;87;Female;NA;1;3090;Stage II;NA;GSE54467;B.cells;0,170657705;NA;
untreated;GSM1315932;Primary Tumor;Australia;57;60;Female;NA;1;1734,9;Stage II;NA;GSE54467;B.cells;0,059304611;NA;
untreated;GSM1315933;Primary Tumor;Australia;23;28;Male;NA;1;3096;Stage I;NA;GSE54467;B.cells;0,172241658;NA;
untreated;GSM1315934;Primary Tumor;Australia;63;66;Male;NA;1;3007,2;Stage I;NA;GSE54467;B.cells;0,102011734;NA;
untreated;GSM1315935;Primary Tumor;Australia;53;54;Male;NA;1;723,9;Stage II;NA;GSE54467;B.cells;0,064497071;NA;
untreated;GSM1315936;Primary Tumor;Australia;72;72;Male;NA;0;3205,5;Stage II;not sustained response;GSE54467;B.cells;0,061065732;NA;
untreated;GSM1315937;Primary Tumor;Australia;60;67;Male;NA;1;3228,3;Stage I;NA;GSE54467;B.cells;0,065230477;NA;
untreated;GSM1315938;Primary Tumor;Australia;67;69;Male;NA;1;864,9;Stage II;NA;GSE54467;B.cells;0,16710042;NA;
untreated;GSM1315939;Primary Tumor;Australia;61;61;Male;NA;1;325,5;Stage III;NA;GSE54467;B.cells;0,071573787;NA;
untreated;GSM1315940;Primary Tumor;Australia;35;54;Male;NA;0;8526,6;Stage II;not sustained response;GSE54467;B.cells;0,201701059;NA;
untreated;GSM1315941;Primary Tumor;Australia;60;63;Male;NA;1;2886,9;Stage II;responder;GSE54467;B.cells;0,192234159;NA;
untreated;GSM1315942;Primary Tumor;Australia;30;30;Male;NA;0;2114,7;Stage III;not sustained response;GSE54467;B.cells;0,056436848;NA;
untreated;GSM1315943;Primary Tumor;Australia;66;67;Male;NA;1;508,8;Stage II;NA;GSE54467;B.cells;0,388704393;NA;
untreated;GSM1315944;Primary Tumor;Australia;50;54;Female;NA;1;2062,5;Stage II;NA;GSE54467;B.cells;0,208495107;NA;
untreated;GSM1315945;Primary Tumor;Australia;28;30;Male;NA;1;3093,9;Stage II;NA;GSE54467;B.cells;0,086094525;NA;
untreated;GSM1315946;Primary Tumor;Australia;58;60;Male;NA;1;1426,2;Stage I;NA;GSE54467;B.cells;0,103392867;NA;
untreated;GSM1315947;Primary Tumor;Australia;66;69;Female;NA;1;1518,9;Stage III;NA;GSE54467;B.cells;0,102464757;NA;
untreated;GSM1315948;Primary Tumor;Australia;49;57;Female;NA;0;6582,6;Stage I;not sustained response;GSE54467;B.cells;0,103052436;NA;
untreated;GSM1315949;Primary Tumor;Australia;69;69;Male;NA;1;446,7;Stage III;NA;GSE54467;B.cells;0,331186771;NA;
untreated;GSM1315950;Primary Tumor;Australia;55;56;Male;NA;0;3286,5;Stage III;not sustained response;GSE54467;B.cells;0,048404932;NA;
untreated;GSM1315951;Primary Tumor;Australia;52;58;Male;NA;1;3098,1;Stage I;NA;GSE54467;B.cells;0,051897272;NA;
untreated;GSM1315952;Primary Tumor;Australia;61;74;Female;NA;1;4687,8;Stage I;NA;GSE54467;B.cells;0,04876076;NA;
untreated;GSM1315953;Primary Tumor;Australia;74;75;Male;NA;1;1845,3;Stage I;responder;GSE54467;B.cells;0,120455799;NA;
untreated;GSM1315954;Primary Tumor;Australia;40;40;Male;NA;0;2916,6;Stage III;not sustained response;GSE54467;B.cells;0,055903309;NA;
untreated;GSM1315955;Primary Tumor;Australia;36;44;Male;NA;0;6242,4;Stage II;non-responder;GSE54467;B.cells;0,108919605;NA;
untreated;GSM1315956;Primary Tumor;Australia;70;73;Female;NA;0;3861,3;Stage II;not sustained response;GSE54467;B.cells;0,176294058;NA;
untreated;GSM1315957;Primary Tumor;Australia;67;67;Male;NA;0;1219,2;Stage III;not sustained response;GSE54467;B.cells;0,256378907;NA;
untreated;GSM1315958;Primary Tumor;Australia;53;66;Male;NA;1;5252,1;Stage I;NA;GSE54467;B.cells;0,085668995;NA;
untreated;GSM1315959;Primary Tumor;Australia;64;64;Female;NA;0;3633,6;Stage III;not sustained response;GSE54467;B.cells;0,157871034;NA;
untreated;GSM1315960;Primary Tumor;Australia;59;61;Male;NA;0;5126,7;Stage I;not sustained response;GSE54467;B.cells;0,170381827;NA;
untreated;GSM1315961;Primary Tumor;Australia;78;88;Male;NA;1;6904,2;Stage I;NA;GSE54467;B.cells;0,130249476;NA;
untreated;GSM1315962;Primary Tumor;Australia;62;64;Male;NA;0;3878,1;Stage I;not sustained response;GSE54467;B.cells;0,103882872;NA;
untreated;GSM1315963;Primary Tumor;Australia;30;63;Male;NA;1;12093,9;Stage I;NA;GSE54467;B.cells;0,129395481;NA;
untreated;GSM1315964;Primary Tumor;Australia;40;46;Female;NA;1;2208,3;Stage III;NA;GSE54467;B.cells;0,059602745;NA;
untreated;GSM1315965;Primary Tumor;Australia;58;63;Female;NA;1;3665,1;Stage II;NA;GSE54467;B.cells;0,182075909;NA;
untreated;GSM1315966;Primary Tumor;Australia;39;40;Female;NA;0;3431,4;Stage I;not sustained response;GSE54467;B.cells;0,114760232;NA;
untreated;GSM1315967;Primary Tumor;Australia;49;50;Male;NA;1;650,1;Stage I;NA;GSE54467;B.cells;0,046076631;NA;
untreated;GSM1315968;Primary Tumor;Australia;50;51;Male;NA;0;4334,7;Stage II;not sustained response;GSE54467;B.cells;0,197270055;NA;
untreated;GSM1315969;Primary Tumor;Australia;24;24;Male;NA;0;1256,4;Stage III;not sustained response;GSE54467;B.cells;0,0819414;NA;
untreated;GSM1315970;Primary Tumor;Australia;70;73;Female;NA;0;2782,5;Stage II;not sustained response;GSE54467;B.cells;0,066924447;NA;
untreated;GSM1315971;Primary Tumor;Australia;83;86;Male;NA;1;1875;Stage II;responder;GSE54467;B.cells;0,525599138;NA;
untreated;GSM1315972;Primary Tumor;Australia;68;75;Female;NA;0;6019,5;Stage I;not sustained response;GSE54467;B.cells;0,123655318;NA;
untreated;GSM1315973;Primary Tumor;Australia;47;47;Male;NA;0;1506;Stage III;not sustained response;GSE54467;B.cells;0,076325915;NA;
untreated;GSM1315974;Primary Tumor;Australia;48;48;Female;NA;0;2405,7;Stage I;not sustained response;GSE54467;B.cells;0,065338507;NA;
untreated;GSM1315975;Primary Tumor;Australia;52;53;Male;NA;1;582;Stage III;NA;GSE54467;B.cells;0,057997176;NA;
untreated;GSM1315976;Primary Tumor;Australia;60;67;Female;NA;0;5314,2;Stage I;non-responder;GSE54467;B.cells;0,070710079;NA;
untreated;GSM1315977;Primary Tumor;Australia;45;50;Female;NA;1;3722,4;Stage II;NA;GSE54467;B.cells;0,0993832;NA;
untreated;GSM1315978;Primary Tumor;Australia;68;73;Female;NA;1;3316,8;Stage I;NA;GSE54467;B.cells;0,098332858;NA;
untreated;GSM1315979;Primary Tumor;Australia;78;80;Male;NA;0;1305,9;Stage I;NA;GSE54467;B.cells;0,051755494;NA;
untreated;GSM1315980;Primary Tumor;Australia;56;56;Female;NA;1;708,3;Stage II;NA;GSE54467;B.cells;0,038160437;NA;
untreated;GSM1315981;Primary Tumor;Australia;74;74;Female;NA;1;121,2;Stage II;NA;GSE54467;B.cells;0,062047047;NA;
untreated;GSM1315982;Primary Tumor;Australia;66;75;Male;NA;1;3691,8;Stage I;NA;GSE54467;B.cells;0,077374184;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872328;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,013042648;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872329;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872330;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872331;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872332;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,023051942;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872333;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,034594835;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872334;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,042228705;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872335;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,008716048;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872336;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,067036817;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872337;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,018662904;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872338;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,010382411;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872339;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,031882653;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872340;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;1,99E-04;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872341;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,004263284;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872342;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,022327625;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872343;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,028478729;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872344;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,012010355;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872345;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,014854177;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872346;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,003421568;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872347;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,05563262;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872348;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,024203251;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872349;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,03175965;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872350;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,032346622;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872351;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,005413887;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872352;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,037730916;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872353;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,048784082;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872354;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,025795739;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872355;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,013208015;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872356;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,032981679;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872357;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,016280744;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872358;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,027221409;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872359;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,029474227;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872360;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;6,58E-04;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872361;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872362;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,003824655;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872363;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,013602908;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872364;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,188402504;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872365;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,019000832;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872366;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,056226759;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872367;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,006740497;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872368;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,015152022;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872369;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872370;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,045251375;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872371;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872372;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,00885783;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872373;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,024226587;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872374;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,034956543;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872375;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,01753921;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872376;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,012063374;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872377;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,017978165;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872378;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,002681425;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872379;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872380;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,008679205;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872381;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872382;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M1;0,019478987;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872383;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M1;0,009071343;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872384;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M1;0,043828242;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872385;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M1;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872386;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M1;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872387;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M1;0,020658077;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872388;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M1;0,006703052;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872389;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M1;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872390;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M1;0,004928423;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872391;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M1;0,038246958;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872392;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M1;0,019951679;NA;
Standard (dacarbazine monotherapy; DTIC);GSM550966;Metastatic;Sweden;60;62;Male;Trunk;1;373;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,021278217;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550967;Metastatic;Sweden;54;59;Female;Lower extremity;1;181;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,005072787;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550968;Metastatic;Sweden;40;53;Male;Head;1;436;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,023503692;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550969;Metastatic;Sweden;54;61;Female;Lower extremity;1;82;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,012156963;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550970;Metastatic;Sweden;45;47;Male;Lower extremity;1;646;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,013462317;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550971;Metastatic;Sweden;68;68;Male;No primary detected;1;114;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,012716235;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550972;Metastatic;Sweden;36;38;Male;Upper extremity, acral;1;322;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,002711225;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550973;Metastatic;Sweden;63;65;Female;Trunk;1;46;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,025202429;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550974;Metastatic;Sweden;51;51;Male;No primary detected;0;3509;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,006110189;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550975;Metastatic;Sweden;79;86;Male;Head;1;65;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,032704275;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550976;Metastatic;Sweden;50;51;Male;Trunk;1;14;IV;NA;GSE22155_GPL6102;Macrophages.M1;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550977;Metastatic;Sweden;58;59;Female;Upper extremity;1;27;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,013713886;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550978;Metastatic;Sweden;36;36;Male;No primary detected;-;-;III;NA;GSE22155_GPL6102;Macrophages.M1;0,008491627;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550979;Metastatic;Sweden;60;66;Female;Upper extremity;1;45;IV;NA;GSE22155_GPL6102;Macrophages.M1;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550980;Metastatic;Sweden;53;53;Female;No primary detected;1;10;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,160613184;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550981;Metastatic;Sweden;27;32;Female;Trunk;0;2711;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,014959451;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550982;Metastatic;Sweden;49;51;Male;Lower extremity;1;32;IV;NA;GSE22155_GPL6102;Macrophages.M1;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550983;Metastatic;Sweden;62;63;Male;No primary detected;1;55;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,027206472;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550984;Metastatic;Sweden;50;71;Male;Upper extremity;1;91;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,012592804;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550985;Metastatic;Sweden;49;63;Female;Trunk;1;804;IV;NA;GSE22155_GPL6102;Macrophages.M1;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550986;Metastatic;Sweden;55;61;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,016785126;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550987;Metastatic;Sweden;55;80;Male;Trunk;1;25;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,048534471;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550988;Metastatic;Sweden;78;78;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,018984563;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550989;Metastatic;Sweden;56;57;Male;No primary detected;1;50;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,007226396;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550990;Metastatic;Sweden;74;76;Female;Head;1;156;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,034419857;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550991;Metastatic;Sweden;53;70;Male;Trunk;1;219;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,028802802;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550992;Metastatic;Sweden;36;49;Male;Trunk;1;266;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,0175331;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550993;Metastatic;Sweden;33;33;Male;No primary detected;1;1075;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,052990899;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550994;Metastatic;Sweden;67;67;Female;No primary detected;1;201;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,020438903;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550995;Metastatic;Sweden;72;74;Male;Trunk;1;247;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,01725379;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550996;Metastatic;Sweden;27;31;Female;Trunk;1;414;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,027025816;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550997;Metastatic;Sweden;32;43;Female;No primary detected;1;108;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,046622448;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550998;Metastatic;Sweden;59;61;Female;Trunk;-;-;III;NA;GSE22155_GPL6102;Macrophages.M1;0,042342739;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550999;Metastatic;Sweden;61;61;Male;No primary detected;1;281;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,003710309;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551000;Metastatic;Sweden;73;73;Male;Head and eye;1;221;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,031048916;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551001;Metastatic;Sweden;54;55;Male;Trunk;1;102;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,016638084;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551002;Metastatic;Sweden;68;68;Female;No primary detected;1;301;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,039364354;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551003;Metastatic;Sweden;62;68;Female;Trunk;1;64;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,018907132;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551004;Metastatic;Sweden;35;36;Female;No primary detected;1;375;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,038157126;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551005;Metastatic;Sweden;76;79;Female;Trunk;1;218;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,015875298;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551006;Metastatic;Sweden;66;68;Male;Head;1;1478;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,028538757;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551007;Metastatic;Sweden;46;52;Female;Trunk;1;13;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,028419689;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551008;Metastatic;Sweden;65;67;Male;Trunk;1;254;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,004647876;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551009;Metastatic;Sweden;70;70;Female;Upper extremity;1;16;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,004556648;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551010;Metastatic;Sweden;68;72;Male;Trunk;1;430;IV;NA;GSE22155_GPL6102;Macrophages.M1;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551011;Metastatic;Sweden;82;84;Male;Trunk;1;63;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,03755358;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551012;Metastatic;Sweden;35;68;Male;Upper extremity;0;1198;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,018233527;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551013;Metastatic;Sweden;31;38;Male;Trunk;-;-;III;NA;GSE22155_GPL6102;Macrophages.M1;0,036352235;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551014;Metastatic;Sweden;79;79;Female;Trunk;0;927;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,06435649;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551015;Metastatic;Sweden;77;82;Female;Upper extremity;1;325;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,014891921;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551016;Metastatic;Sweden;72;76;Male;Lower extremity;1;44;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,002322905;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551017;Metastatic;Sweden;75;75;Female;Lower extremity;0;895;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,042264811;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551018;Metastatic;Sweden;58;61;Male;Trunk;0;836;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,015991144;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551019;Metastatic;Sweden;71;74;Female;Lower extremity, acral;0;786;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,022310374;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551020;Metastatic;Sweden;65;76;Male;Trunk;1;244;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,008148185;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551021;Metastatic;Sweden;25;25;Female;Lower extremity;1;78;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,019935427;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551022;Metastatic;Sweden;50;75;Male;Trunk;1;29;IV;NA;GSE22155_GPL6102;Macrophages.M1;0,015585815;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551023;Metastatic;Sweden;75;76;Male;Acral;1;44;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,02835533;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551024;Metastatic;Sweden;63;64;Female;Genital;1;747;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,008096829;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551025;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,022364216;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551026;Metastatic;Sweden;68;68;Female;GI tractus;1;367;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,010495679;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551027;Metastatic;Sweden;58;60;Male;Eye;1;7;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,019040525;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551028;Metastatic;Sweden;49;63;Male;Trunk;1;309;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,037261152;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551029;Metastatic;Sweden;56;55;Female;Trunk;1;32;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,012884301;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551030;Metastatic;Sweden;74;74;Male;Trunk;1;79;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,01588109;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551031;Metastatic;Sweden;41;42;Female;Eye;1;349;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,025255862;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551032;Metastatic;Sweden;49;51;Female;Mucosa, head;1;13;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,021514673;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551033;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,007641317;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551034;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,007468366;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551035;Metastatic;Sweden;56;56;Male;GI tractus;1;37;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,021870623;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551036;Metastatic;Sweden;45;74;Male;No primary;1;183;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,01982818;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551037;Metastatic;Sweden;72;75;Female;Head;1;39;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,010588322;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551038;Metastatic;Sweden;61;68;Female;Eye;1;513;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,016640744;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551039;Metastatic;Sweden;66;68;Male;Trunk;1;584;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,012617826;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551040;Metastatic;Sweden;42;44;Male;Head;1;1148;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,029424533;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551041;Metastatic;Sweden;54;56;Female;Trunk;1;153;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,016541003;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551042;Metastatic;Sweden;48;50;Male;Trunk;1;141;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,028088581;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551043;Metastatic;Sweden;58;67;Female;Acral;1;334;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,025470784;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551044;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;Macrophages.M1;0,02496662;Metastasis
untreated;GSM1220412;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,015430388;Metastasis;
dabrafenib;GSM1220413;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,005883892;cutaneous or subcutaneous;
untreated;GSM1220414;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;7,44E-04;cutaneous or subcutaneous;
dabrafenib;GSM1220415;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,008849871;cutaneous or subcutaneous;
untreated;GSM1220416;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
dabrafenib;GSM1220417;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
dabrafenib;GSM1220418;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,005865449;cutaneous or subcutaneous;
untreated;GSM1220419;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;Metastasis;
dabrafenib;GSM1220420;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,002908115;Metastasis;
untreated;GSM1220421;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,003240466;cutaneous or subcutaneous;
dabrafenib;GSM1220422;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,016003476;cutaneous or subcutaneous;
dabrafenib;GSM1220423;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;2,52E-04;cutaneous or subcutaneous;
untreated;GSM1220424;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,028304163;cutaneous or subcutaneous;
untreated;GSM1220425;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,032988076;cutaneous or subcutaneous;
dabrafenib;GSM1220426;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,016690933;Metastasis;
untreated;GSM1220427;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,026422254;cutaneous or subcutaneous;
untreated;GSM1220428;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,002581299;cutaneous or subcutaneous;
dabrafenib;GSM1220429;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
dabrafenib;GSM1220430;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
untreated;GSM1220431;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,018247983;cutaneous or subcutaneous;
dabrafenib;GSM1220432;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,018179482;cutaneous or subcutaneous;
untreated;GSM1220433;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,004964219;cutaneous or subcutaneous;
untreated;GSM1220434;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,005830714;cutaneous or subcutaneous;
dabrafenib;GSM1220435;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
dabrafenib;GSM1220436;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
dabrafenib;GSM1220437;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
untreated;GSM1220438;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;Metastasis;
untreated;GSM1220439;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,001265087;Metastasis;
dabrafenib;GSM1220440;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
dabrafenib;GSM1220441;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;Metastasis;
dabrafenib;GSM1220442;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
dabrafenib;GSM1220443;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;Metastasis;
untreated;GSM1220444;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,003171412;Metastasis;
dabrafenib;GSM1220445;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,002929075;cutaneous or subcutaneous;
untreated;GSM1220446;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
untreated;GSM1220447;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
dabrafenib;GSM1220448;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
untreated;GSM1220449;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,005692759;Metastasis;
dabrafenib;GSM1220450;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,015427409;cutaneous or subcutaneous;
untreated;GSM1220451;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,012013677;Metastasis;
dabrafenib;GSM1220452;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,017785512;Metastasis;
untreated;GSM1220453;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,003776759;cutaneous or subcutaneous;
untreated;GSM1220454;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,002667167;cutaneous or subcutaneous;
dabrafenib;GSM1220455;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,009108396;Metastasis;
dabrafenib;GSM1220456;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,006255036;cutaneous or subcutaneous;
untreated;GSM1220457;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;1,08E-04;cutaneous or subcutaneous;
dabrafenib;GSM1220458;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,002154591;Metastasis;
untreated;GSM1220459;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,006394517;cutaneous or subcutaneous;
vemurafenib;GSM1220460;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
untreated;GSM1220461;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;5,12E-04;cutaneous or subcutaneous;
untreated;GSM1220462;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
vemurafenib;GSM1220463;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
untreated;GSM1220464;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;Metastasis;
vemurafenib;GSM1220465;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,019199366;cutaneous or subcutaneous;
untreated;GSM1220466;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
vemurafenib;GSM1220467;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,010390909;cutaneous or subcutaneous;
vemurafenib;GSM1220468;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,006942272;cutaneous or subcutaneous;
vemurafenib;GSM1220469;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,009772901;cutaneous or subcutaneous;
vemurafenib;GSM1220470;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,065605931;cutaneous or subcutaneous;
untreated;GSM1220471;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M1;0;cutaneous or subcutaneous;
vemurafenib;GSM1220472;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;Macrophages.M1;0,00826449;Metastasis;
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;Macrophages.M1;0,051489137;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;Macrophages.M1;0,051489137;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,057650066;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,057650066;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,040484702;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,040484702;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;Macrophages.M1;0,050921752;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;Macrophages.M1;0,050921752;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,034380696;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,034380696;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,073040075;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,073040075;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;Macrophages.M1;0,038509732;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;Macrophages.M1;0,038509732;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;Macrophages.M1;0,025775501;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;Macrophages.M1;0,025775501;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;Macrophages.M1;0,19944512;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;Macrophages.M1;0,19944512;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,035557577;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,035557577;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,118871124;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,118871124;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;Macrophages.M1;0,078995576;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;Macrophages.M1;0,078995576;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;Macrophages.M1;0,047475025;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;Macrophages.M1;0,047475025;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;Macrophages.M1;0,063660654;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;Macrophages.M1;0,063660654;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,078786772;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,078786772;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;Macrophages.M1;0,093002355;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;Macrophages.M1;0,093002355;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,03090307;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,03090307;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;Macrophages.M1;0,041592585;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;Macrophages.M1;0,041592585;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,061739337;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,061739337;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;Macrophages.M1;0,046414416;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;Macrophages.M1;0,046414416;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;Macrophages.M1;0,053327802;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;Macrophages.M1;0,053327802;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Macrophages.M1;0,063775344;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Macrophages.M1;0,063775344;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;Macrophages.M1;0,196820456;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;Macrophages.M1;0,196820456;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,051363187;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,051363187;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;Macrophages.M1;0,10159047;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;Macrophages.M1;0,10159047;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,097373348;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,097373348;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,050184805;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,050184805;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,050208037;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,050208037;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;Macrophages.M1;0,028911563;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;Macrophages.M1;0,028911563;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,058331727;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,058331727;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,040122544;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,040122544;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;Macrophages.M1;0,036430486;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;Macrophages.M1;0,036430486;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,014818681;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,014818681;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;Macrophages.M1;0,047007082;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;Macrophages.M1;0,047007082;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,058087502;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,058087502;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,109353207;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,109353207;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;Macrophages.M1;0,02770913;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;Macrophages.M1;0,02770913;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;Macrophages.M1;0,05296765;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;Macrophages.M1;0,05296765;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,065696173;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,065696173;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;Macrophages.M1;0,011705381;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;Macrophages.M1;0,011705381;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;Macrophages.M1;0,112184149;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;Macrophages.M1;0,112184149;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;Macrophages.M1;0,165910221;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;Macrophages.M1;0,165910221;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,03633628;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,03633628;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,031496389;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,031496389;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,039106817;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,039106817;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;Macrophages.M1;0,07028445;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;Macrophages.M1;0,07028445;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,075412149;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,075412149;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;Macrophages.M1;0,045982172;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;Macrophages.M1;0,045982172;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;Macrophages.M1;0,050148704;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;Macrophages.M1;0,050148704;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;Macrophages.M1;0,048449016;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;Macrophages.M1;0,048449016;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;Macrophages.M1;0,039168905;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;Macrophages.M1;0,039168905;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,036755094;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,036755094;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,030642749;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,030642749;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,049918296;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,049918296;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,090912556;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,090912556;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,052674115;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,052674115;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,240978409;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,240978409;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,025494326;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,025494326;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,025909556;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,025909556;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;Macrophages.M1;0,043347983;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;Macrophages.M1;0,043347983;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,043518822;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,043518822;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,033655154;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,033655154;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,090232964;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,090232964;NA
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;Macrophages.M1;0,046642324;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;Macrophages.M1;0,046642324;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,060415619;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,060415619;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,038867465;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,038867465;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;Macrophages.M1;0,084736619;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;Macrophages.M1;0,084736619;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,047664217;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,047664217;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,046002852;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,046002852;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;Macrophages.M1;0,039846466;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;Macrophages.M1;0,039846466;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;Macrophages.M1;0,037904746;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;Macrophages.M1;0,037904746;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,131795159;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,131795159;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,036428382;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,036428382;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,071092495;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,071092495;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,009187705;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,009187705;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,097024021;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,097024021;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,093117972;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,093117972;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,052895232;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,052895232;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,034414507;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,034414507;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,051585407;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,051585407;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,082803787;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,082803787;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;Macrophages.M1;0,506045778;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;Macrophages.M1;0,506045778;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;Macrophages.M1;0,055174447;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;Macrophages.M1;0,055174447;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,100384474;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,100384474;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,089123677;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,089123677;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;Macrophages.M1;0,050396957;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;Macrophages.M1;0,050396957;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;Macrophages.M1;0,158041391;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;Macrophages.M1;0,158041391;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;Macrophages.M1;0,069733286;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;Macrophages.M1;0,069733286;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;Macrophages.M1;0,044636981;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;Macrophages.M1;0,044636981;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,03928578;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,03928578;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,071210474;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,071210474;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;Macrophages.M1;0,060833474;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;Macrophages.M1;0,060833474;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,02728654;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,02728654;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;Macrophages.M1;0,123035926;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;Macrophages.M1;0,123035926;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,057949215;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,057949215;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,082555571;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,082555571;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;Macrophages.M1;0,074025501;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;Macrophages.M1;0,074025501;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;Macrophages.M1;0,058321143;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;Macrophages.M1;0,058321143;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;Macrophages.M1;0,056012851;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;Macrophages.M1;0,056012851;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;Macrophages.M1;0,037722127;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;Macrophages.M1;0,037722127;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,107271828;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,107271828;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,066172195;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,066172195;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;Macrophages.M1;0,040715997;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;Macrophages.M1;0,040715997;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;Macrophages.M1;0,064143529;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;Macrophages.M1;0,064143529;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,095278935;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,095278935;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;Macrophages.M1;0,048431525;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;Macrophages.M1;0,048431525;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;Macrophages.M1;0,043856944;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;Macrophages.M1;0,043856944;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,056021771;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,056021771;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;Macrophages.M1;0,178344795;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;Macrophages.M1;0,178344795;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;Macrophages.M1;0,09794464;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;Macrophages.M1;0,09794464;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;Macrophages.M1;0,029473322;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;Macrophages.M1;0,029473322;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;Macrophages.M1;0,042982095;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;Macrophages.M1;0,042982095;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,057162284;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,057162284;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;Macrophages.M1;0,064363636;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;Macrophages.M1;0,064363636;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;Macrophages.M1;0,068303261;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;Macrophages.M1;0,068303261;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,022692209;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,022692209;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;Macrophages.M1;0,081856513;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;Macrophages.M1;0,081856513;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;Macrophages.M1;0,057103932;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;Macrophages.M1;0,057103932;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Macrophages.M1;0,02915027;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Macrophages.M1;0,02915027;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;Macrophages.M1;0,096551712;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;Macrophages.M1;0,096551712;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,036622719;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,036622719;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,012251616;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,012251616;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;Macrophages.M1;0,022281361;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;Macrophages.M1;0,022281361;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,137350296;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,137350296;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;Macrophages.M1;0,06661619;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;Macrophages.M1;0,06661619;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,071657709;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,071657709;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;Macrophages.M1;0,048863175;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;Macrophages.M1;0,048863175;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;Macrophages.M1;0,071186909;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;Macrophages.M1;0,071186909;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,019386447;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,019386447;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;Macrophages.M1;0,855784596;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;Macrophages.M1;0,855784596;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;Macrophages.M1;0,062508025;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;Macrophages.M1;0,062508025;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,036847936;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,036847936;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,049130607;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,049130607;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;Macrophages.M1;0,326002536;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;Macrophages.M1;0,326002536;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,048634094;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,048634094;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;Macrophages.M1;0,042463043;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;Macrophages.M1;0,042463043;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,096131399;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,096131399;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;Macrophages.M1;0,057339548;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;Macrophages.M1;0,057339548;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,087559054;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,087559054;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,054027296;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,054027296;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,096109385;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,096109385;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,052661654;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,052661654;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,051793407;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,051793407;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,032562272;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,032562272;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;Macrophages.M1;0,051506517;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;Macrophages.M1;0,051506517;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;Macrophages.M1;0,079640842;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;Macrophages.M1;0,079640842;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,057990037;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,057990037;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,043870365;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,043870365;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;Macrophages.M1;0,042547672;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;Macrophages.M1;0,042547672;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,03799207;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,03799207;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;Macrophages.M1;0,452265446;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;Macrophages.M1;0,452265446;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,126787928;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,126787928;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,050734074;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,050734074;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,057879902;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,057879902;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;Macrophages.M1;0,054201931;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;Macrophages.M1;0,054201931;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,063785712;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,063785712;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,040387835;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,040387835;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,073903131;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,073903131;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;Macrophages.M1;0,017997327;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;Macrophages.M1;0,017997327;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;Macrophages.M1;0,039237693;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;Macrophages.M1;0,039237693;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;Macrophages.M1;0,040187125;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;Macrophages.M1;0,040187125;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;Macrophages.M1;0,034422994;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;Macrophages.M1;0,034422994;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,032756872;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,032756872;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,107902238;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,107902238;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,092818458;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,092818458;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,067974063;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,067974063;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,047313119;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,047313119;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,04901452;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,04901452;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,030330015;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,030330015;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;Macrophages.M1;0,208255253;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;Macrophages.M1;0,208255253;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,100522215;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,100522215;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,04271659;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,04271659;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;Macrophages.M1;0,055947178;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;Macrophages.M1;0,055947178;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,058706306;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,058706306;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;Macrophages.M1;0,065613188;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;Macrophages.M1;0,065613188;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,02363976;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,02363976;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;Macrophages.M1;0,076458125;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;Macrophages.M1;0,076458125;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,100050848;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,100050848;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;Macrophages.M1;0,217123659;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;Macrophages.M1;0,217123659;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;Macrophages.M1;0,057620354;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;Macrophages.M1;0,057620354;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,028519809;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,028519809;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,050002196;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,050002196;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;Macrophages.M1;0,127122057;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;Macrophages.M1;0,127122057;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,058128306;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,058128306;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;Macrophages.M1;0,152407862;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;Macrophages.M1;0,152407862;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;Macrophages.M1;0,070841833;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;Macrophages.M1;0,070841833;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;Macrophages.M1;0,034706521;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;Macrophages.M1;0,034706521;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,044142538;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,044142538;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,032873722;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,032873722;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;Macrophages.M1;0,042497538;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;Macrophages.M1;0,042497538;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;Macrophages.M1;0,085274309;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;Macrophages.M1;0,085274309;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;Macrophages.M1;0,043801447;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;Macrophages.M1;0,043801447;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;Macrophages.M1;0,072988782;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;Macrophages.M1;0,072988782;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,035929438;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,035929438;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,027657113;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,027657113;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;Macrophages.M1;0,047611374;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;Macrophages.M1;0,047611374;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,033432307;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,033432307;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;Macrophages.M1;0,168787689;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;Macrophages.M1;0,168787689;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;Macrophages.M1;0,043632429;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;Macrophages.M1;0,043632429;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;Macrophages.M1;0,075459738;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;Macrophages.M1;0,075459738;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;Macrophages.M1;0,044112681;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;Macrophages.M1;0,044112681;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;Macrophages.M1;0,03475333;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;Macrophages.M1;0,03475333;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,028986217;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,028986217;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;Macrophages.M1;0,064232442;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;Macrophages.M1;0,064232442;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;Macrophages.M1;0,046470431;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;Macrophages.M1;0,046470431;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,063454288;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,063454288;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,122551518;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,122551518;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;Macrophages.M1;0,091274125;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;Macrophages.M1;0,091274125;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,112680982;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,112680982;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,100449684;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,100449684;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,065441975;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,065441975;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;Macrophages.M1;0,072038452;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;Macrophages.M1;0,072038452;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;Macrophages.M1;0,085573238;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;Macrophages.M1;0,085573238;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,021874628;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,021874628;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;Macrophages.M1;0,055601853;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;Macrophages.M1;0,055601853;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,042203784;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,042203784;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,055203961;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,055203961;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,029928117;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,029928117;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,055885517;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,055885517;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;Macrophages.M1;0,093528448;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;Macrophages.M1;0,093528448;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,052547471;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,052547471;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,07469162;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,07469162;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,055674515;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,055674515;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,068672225;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,068672225;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;Macrophages.M1;0,044733803;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;Macrophages.M1;0,044733803;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;Macrophages.M1;0,042584405;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;Macrophages.M1;0,042584405;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,04943864;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,04943864;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;Macrophages.M1;0,055000323;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;Macrophages.M1;0,055000323;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,022475229;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,022475229;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,027123879;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,027123879;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,057869024;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,057869024;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;Macrophages.M1;0,062437623;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;Macrophages.M1;0,062437623;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,043366368;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,043366368;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,045972403;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,045972403;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,051547972;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,051547972;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;Macrophages.M1;0,08852219;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;Macrophages.M1;0,08852219;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;Macrophages.M1;0,039852611;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;Macrophages.M1;0,039852611;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,108026295;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,108026295;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,026877239;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,026877239;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;Macrophages.M1;0,042347606;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;Macrophages.M1;0,042347606;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Macrophages.M1;0,045041995;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Macrophages.M1;0,045041995;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;Macrophages.M1;0,0862149;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;Macrophages.M1;0,0862149;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,035451844;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,035451844;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;Macrophages.M1;0,056403175;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;Macrophages.M1;0,056403175;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,062691748;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,062691748;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;Macrophages.M1;0,079094757;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;Macrophages.M1;0,079094757;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;Macrophages.M1;0,129695628;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;Macrophages.M1;0,129695628;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;Macrophages.M1;0,096308557;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;Macrophages.M1;0,096308557;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,028980346;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,028980346;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,030070764;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,030070764;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,074984999;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,074984999;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,097036457;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,097036457;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;Macrophages.M1;0,041214178;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;Macrophages.M1;0,041214178;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;Macrophages.M1;0,051348722;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;Macrophages.M1;0,051348722;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;Macrophages.M1;0,034587766;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;Macrophages.M1;0,034587766;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,039256165;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,039256165;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,045391194;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,045391194;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;Macrophages.M1;0,076162131;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;Macrophages.M1;0,076162131;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;Macrophages.M1;0,090466489;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;Macrophages.M1;0,090466489;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;Macrophages.M1;0,077870457;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;Macrophages.M1;0,077870457;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,038435149;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,038435149;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;Macrophages.M1;0,028317664;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;Macrophages.M1;0,028317664;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;Macrophages.M1;0,074665671;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;Macrophages.M1;0,074665671;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,202543074;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,202543074;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;Macrophages.M1;0,22506285;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;Macrophages.M1;0,22506285;NA
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;Macrophages.M1;0,038870839;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;Macrophages.M1;0,038870839;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;Macrophages.M1;0,070653309;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;Macrophages.M1;0,070653309;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;Macrophages.M1;0,108944684;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;Macrophages.M1;0,108944684;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;Macrophages.M1;0,070015898;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;Macrophages.M1;0,070015898;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;Macrophages.M1;0,027313012;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;Macrophages.M1;0,027313012;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;Macrophages.M1;0,066981502;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;Macrophages.M1;0,066981502;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,065199966;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,065199966;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;Macrophages.M1;0,027489698;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;Macrophages.M1;0,027489698;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,0472211;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,0472211;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,044630135;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,044630135;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;Macrophages.M1;0,082766068;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;Macrophages.M1;0,082766068;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;Macrophages.M1;0,079314647;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;Macrophages.M1;0,079314647;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;Macrophages.M1;0,096390082;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;Macrophages.M1;0,096390082;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,033161771;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,033161771;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;Macrophages.M1;0,059223251;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;Macrophages.M1;0,059223251;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,048134267;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,048134267;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;Macrophages.M1;0,057351545;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;Macrophages.M1;0,057351545;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;Macrophages.M1;0,055586316;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;Macrophages.M1;0,055586316;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,106243822;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,106243822;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,030281951;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,030281951;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,104092438;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,104092438;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;Macrophages.M1;0,054576883;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;Macrophages.M1;0,054576883;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,026457264;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,026457264;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;Macrophages.M1;0,038890602;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;Macrophages.M1;0,038890602;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;Macrophages.M1;0,052290691;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;Macrophages.M1;0,052290691;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;Macrophages.M1;0,032596601;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;Macrophages.M1;0,032596601;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;Macrophages.M1;0,025657271;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;Macrophages.M1;0,025657271;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;Macrophages.M1;0,03994828;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;Macrophages.M1;0,03994828;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;Macrophages.M1;0,099524857;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;Macrophages.M1;0,099524857;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;Macrophages.M1;0,098029858;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;Macrophages.M1;0,098029858;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;Macrophages.M1;0,132455714;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;Macrophages.M1;0,132455714;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,078279697;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,078279697;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;Macrophages.M1;0,059548399;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;Macrophages.M1;0,059548399;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Macrophages.M1;0,028323005;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Macrophages.M1;0,028323005;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;Macrophages.M1;0,022439802;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;Macrophages.M1;0,022439802;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;Macrophages.M1;0,044185277;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;Macrophages.M1;0,044185277;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,044646009;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,044646009;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,19177839;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,19177839;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,04691227;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,04691227;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,046392914;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,046392914;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,017904594;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,017904594;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;1;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;1;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,024217042;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,024217042;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,140185189;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,140185189;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,078284753;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,078284753;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;Macrophages.M1;0,044981151;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;Macrophages.M1;0,044981151;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,047957041;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,047957041;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,019158224;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,019158224;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,039235664;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,039235664;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;Macrophages.M1;0,060247648;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;Macrophages.M1;0,060247648;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,038201669;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,038201669;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;Macrophages.M1;0,036520934;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;Macrophages.M1;0,036520934;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;Macrophages.M1;0,023973793;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;Macrophages.M1;0,023973793;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;Macrophages.M1;0,057011224;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;Macrophages.M1;0,057011224;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,023213498;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,023213498;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;Macrophages.M1;0,195640491;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;Macrophages.M1;0,195640491;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,052788106;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,052788106;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,054653643;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,054653643;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,03679837;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,03679837;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,022401259;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,022401259;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;Macrophages.M1;0,032345388;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;Macrophages.M1;0,032345388;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,055583344;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,055583344;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,052111999;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,052111999;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,08279891;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,08279891;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,0626931;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,0626931;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;Macrophages.M1;0,046487749;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;Macrophages.M1;0,046487749;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,070612257;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,070612257;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,044102406;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,044102406;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,062541459;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,062541459;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;Macrophages.M1;0,031425587;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;Macrophages.M1;0,031425587;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,041687928;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,041687928;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,020692844;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,020692844;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,051841998;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,051841998;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,058821789;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,058821789;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;Macrophages.M1;0,081238894;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;Macrophages.M1;0,081238894;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;Macrophages.M1;0,057008963;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;Macrophages.M1;0,057008963;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,094320893;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,094320893;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;Macrophages.M1;0,047149293;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;Macrophages.M1;0,047149293;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,044617733;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,044617733;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,053642186;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,053642186;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,038651568;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,038651568;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,078844924;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,078844924;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,03552004;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,03552004;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,062677682;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,062677682;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,063225544;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,063225544;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;Macrophages.M1;0,050146659;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;Macrophages.M1;0,050146659;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,066747883;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,066747883;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,095859058;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,095859058;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,198200742;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,198200742;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,096005432;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,096005432;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;Macrophages.M1;0,054159131;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;Macrophages.M1;0,054159131;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,063178461;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,063178461;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,054210525;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,054210525;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;Macrophages.M1;0,029463799;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;Macrophages.M1;0,029463799;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,096266882;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,096266882;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;Macrophages.M1;0,096512503;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;Macrophages.M1;0,096512503;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,095934069;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,095934069;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,023649073;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,023649073;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,048950225;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,048950225;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,060203076;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,060203076;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;Macrophages.M1;0,040009218;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;Macrophages.M1;0,040009218;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,088738793;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,088738793;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,037520389;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,037520389;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;Macrophages.M1;0,087916648;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;Macrophages.M1;0,087916648;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,095142516;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,095142516;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;Macrophages.M1;0,046489805;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;Macrophages.M1;0,046489805;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;Macrophages.M1;0,031852383;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;Macrophages.M1;0,031852383;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;Macrophages.M1;0,06730117;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;Macrophages.M1;0,06730117;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,14877132;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,14877132;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,022680743;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,022680743;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,082620682;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,082620682;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;Macrophages.M1;0,048586223;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;Macrophages.M1;0,048586223;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;Macrophages.M1;0,01604389;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;Macrophages.M1;0,01604389;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,080553497;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,080553497;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;Macrophages.M1;0,039527119;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;Macrophages.M1;0,039527119;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;Macrophages.M1;0,042645731;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;Macrophages.M1;0,042645731;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,035562851;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,035562851;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,021646141;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,021646141;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,273195813;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,273195813;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,06201539;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,06201539;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;Macrophages.M1;0,067132096;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;Macrophages.M1;0,067132096;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,032323687;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,032323687;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;Macrophages.M1;0,045604863;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;Macrophages.M1;0,045604863;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,05461099;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,05461099;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;Macrophages.M1;0,093299253;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;Macrophages.M1;0,093299253;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,136189677;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M1;0,136189677;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;Macrophages.M1;0,030388877;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;Macrophages.M1;0,030388877;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;Macrophages.M1;0,051531193;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;Macrophages.M1;0,051531193;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,023426581;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,023426581;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;Macrophages.M1;0,089622079;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;Macrophages.M1;0,089622079;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,033297221;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,033297221;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,111293571;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,111293571;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;Macrophages.M1;0,054748345;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;Macrophages.M1;0,054748345;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;Macrophages.M1;0,59385574;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;Macrophages.M1;0,59385574;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;Macrophages.M1;0,143010562;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;Macrophages.M1;0,143010562;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,036394968;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,036394968;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;Macrophages.M1;0,053365822;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;Macrophages.M1;0,053365822;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,105374873;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,105374873;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;Macrophages.M1;0,029073664;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;Macrophages.M1;0,029073664;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,039218922;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,039218922;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;Macrophages.M1;0,029425176;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;Macrophages.M1;0,029425176;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,107307173;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,107307173;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;Macrophages.M1;0,045849809;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;Macrophages.M1;0,045849809;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,070521543;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,070521543;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;Macrophages.M1;0,037696202;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;Macrophages.M1;0,037696202;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;Macrophages.M1;0,055187298;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;Macrophages.M1;0,055187298;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,049528553;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,049528553;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,207303262;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,207303262;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;Macrophages.M1;0,086962516;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;Macrophages.M1;0,086962516;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;Macrophages.M1;0,089694674;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;Macrophages.M1;0,089694674;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,018558643;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,018558643;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;Macrophages.M1;0,064846212;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;Macrophages.M1;0,064846212;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;Macrophages.M1;0,018022402;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;Macrophages.M1;0,018022402;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,006806531;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,006806531;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;Macrophages.M1;0,013594424;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;Macrophages.M1;0,013594424;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;Macrophages.M1;0,135131359;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;Macrophages.M1;0,135131359;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;Macrophages.M1;0,055132202;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;Macrophages.M1;0,055132202;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,060759714;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,060759714;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,073645986;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,073645986;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;Macrophages.M1;0,052396364;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;Macrophages.M1;0,052396364;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;Macrophages.M1;0,042773798;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;Macrophages.M1;0,042773798;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,04707943;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,04707943;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,117188333;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,117188333;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,094496888;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,094496888;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;Macrophages.M1;0,057167445;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;Macrophages.M1;0,057167445;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;Macrophages.M1;0,053719377;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;Macrophages.M1;0,053719377;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,064285205;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,064285205;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,028424445;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,028424445;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,079099957;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Macrophages.M1;0,079099957;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,123532518;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,123532518;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,069857746;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,069857746;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,059813575;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,059813575;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,042722354;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,042722354;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;Macrophages.M1;0,105781175;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;Macrophages.M1;0,105781175;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;Macrophages.M1;0,050588922;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;Macrophages.M1;0,050588922;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;Macrophages.M1;0,062855489;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;Macrophages.M1;0,062855489;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,056934861;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,056934861;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;Macrophages.M1;0,062006949;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;Macrophages.M1;0,062006949;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;Macrophages.M1;0,01813368;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;Macrophages.M1;0,01813368;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,030244022;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,030244022;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,043481729;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,043481729;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;Macrophages.M1;0,087333336;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;Macrophages.M1;0,087333336;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,030935606;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,030935606;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;Macrophages.M1;0,017040718;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;Macrophages.M1;0,017040718;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;Macrophages.M1;0,037810225;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;Macrophages.M1;0,037810225;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;Macrophages.M1;0,040038848;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;Macrophages.M1;0,040038848;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,040739167;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,040739167;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,04149618;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,04149618;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;Macrophages.M1;0,101897103;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;Macrophages.M1;0,101897103;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,010271816;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,010271816;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,02953207;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,02953207;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,228928051;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M1;0,228928051;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;Macrophages.M1;0,081530191;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;Macrophages.M1;0,081530191;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,037201115;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,037201115;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;Macrophages.M1;0,189914823;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;Macrophages.M1;0,189914823;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;Macrophages.M1;0,102264592;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;Macrophages.M1;0,102264592;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,108670478;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M1;0,108670478;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;Macrophages.M1;0,049213213;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;Macrophages.M1;0,049213213;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;Macrophages.M1;0,028516685;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;Macrophages.M1;0,028516685;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,118443811;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,118443811;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;Macrophages.M1;0,042647828;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;Macrophages.M1;0,042647828;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,04950549;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,04950549;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,080191948;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M1;0,080191948;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;Macrophages.M1;0,034876542;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;Macrophages.M1;0,034876542;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,103332973;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M1;0,103332973;Metastasis
untreated;GSM1315904;Primary Tumor;Australia;19;22;Female;NA;0;4342,8;Stage II;not sustained response;GSE54467;Macrophages.M1;0,029540978;NA;
untreated;GSM1315905;Primary Tumor;Australia;53;56;Male;NA;1;1418,4;Stage II;NA;GSE54467;Macrophages.M1;0,002280241;NA;
untreated;GSM1315906;Primary Tumor;Australia;52;53;Female;NA;1;698,4;Stage II;NA;GSE54467;Macrophages.M1;0,003736917;NA;
untreated;GSM1315907;Primary Tumor;Australia;51;52;Male;NA;0;3330,6;Stage I;not sustained response;GSE54467;Macrophages.M1;0,042393917;NA;
untreated;GSM1315908;Primary Tumor;Australia;47;51;Male;NA;1;4283,4;Stage II;NA;GSE54467;Macrophages.M1;0,006183979;NA;
untreated;GSM1315909;Primary Tumor;Australia;61;64;Male;NA;1;1540,5;Stage I;NA;GSE54467;Macrophages.M1;0,005684206;NA;
untreated;GSM1315910;Primary Tumor;Australia;46;52;Female;NA;0;6957,3;Stage I;not sustained response;GSE54467;Macrophages.M1;0,021222923;NA;
untreated;GSM1315911;Primary Tumor;Australia;61;75;Male;NA;1;5484,9;Stage I;NA;GSE54467;Macrophages.M1;0,00702099;NA;
untreated;GSM1315912;Primary Tumor;Australia;84;87;Female;NA;1;1491,3;Stage I;NA;GSE54467;Macrophages.M1;0,004078693;NA;
untreated;GSM1315913;Primary Tumor;Australia;44;44;Female;NA;0;3899,7;Stage III;not sustained response;GSE54467;Macrophages.M1;0,022355124;NA;
untreated;GSM1315914;Primary Tumor;Australia;64;72;Male;NA;1;3322,8;Stage I;NA;GSE54467;Macrophages.M1;0,005344305;NA;
untreated;GSM1315915;Primary Tumor;Australia;31;31;Male;NA;0;3034,8;Stage III;not sustained response;GSE54467;Macrophages.M1;0,020830571;NA;
untreated;GSM1315916;Primary Tumor;Australia;63;65;Male;NA;1;654,9;Stage II;NA;GSE54467;Macrophages.M1;0,019251741;NA;
untreated;GSM1315917;Primary Tumor;Australia;58;59;Male;NA;1;1098,6;Stage III;NA;GSE54467;Macrophages.M1;0,003338109;NA;
untreated;GSM1315918;Primary Tumor;Australia;56;67;Male;NA;0;6538,2;Stage Unknown;not sustained response;GSE54467;Macrophages.M1;0,008685381;NA;
untreated;GSM1315919;Primary Tumor;Australia;48;57;Female;NA;1;3603,9;Stage II;NA;GSE54467;Macrophages.M1;0,013688704;NA;
untreated;GSM1315920;Primary Tumor;Australia;69;70;Male;NA;1;261,3;Stage III;NA;GSE54467;Macrophages.M1;0,002703173;NA;
untreated;GSM1315921;Primary Tumor;Australia;76;77;Male;NA;1;593,7;Stage II;NA;GSE54467;Macrophages.M1;0,025437148;NA;
untreated;GSM1315922;Primary Tumor;Australia;54;55;Female;NA;1;592,8;Stage III;NA;GSE54467;Macrophages.M1;0,02138984;NA;
untreated;GSM1315923;Primary Tumor;Australia;82;85;Male;NA;1;2242,8;Stage II;responder;GSE54467;Macrophages.M1;0,04039997;NA;
untreated;GSM1315924;Primary Tumor;Australia;79;80;Male;NA;0;2393,7;Stage I;not sustained response;GSE54467;Macrophages.M1;0,047010128;NA;
untreated;GSM1315925;Primary Tumor;Australia;50;54;Male;NA;0;2986,5;Stage II;not sustained response;GSE54467;Macrophages.M1;0,020606252;NA;
untreated;GSM1315926;Primary Tumor;Australia;57;57;Female;NA;0;305,7;Stage III;non-responder;GSE54467;Macrophages.M1;0,004560811;NA;
untreated;GSM1315927;Primary Tumor;Australia;32;45;Male;NA;0;7826,4;Stage I;not sustained response;GSE54467;Macrophages.M1;0,011460355;NA;
untreated;GSM1315928;Primary Tumor;Australia;77;78;Female;NA;1;589,8;Stage III;NA;GSE54467;Macrophages.M1;0,003218205;NA;
untreated;GSM1315929;Primary Tumor;Australia;56;56;Male;NA;1;588,9;Stage III;NA;GSE54467;Macrophages.M1;0,016124379;NA;
untreated;GSM1315930;Primary Tumor;Australia;39;40;Female;NA;1;644,1;Stage II;NA;GSE54467;Macrophages.M1;0,033033913;NA;
untreated;GSM1315931;Primary Tumor;Australia;84;87;Female;NA;1;3090;Stage II;NA;GSE54467;Macrophages.M1;0,028225876;NA;
untreated;GSM1315932;Primary Tumor;Australia;57;60;Female;NA;1;1734,9;Stage II;NA;GSE54467;Macrophages.M1;0;NA;
untreated;GSM1315933;Primary Tumor;Australia;23;28;Male;NA;1;3096;Stage I;NA;GSE54467;Macrophages.M1;0,019726138;NA;
untreated;GSM1315934;Primary Tumor;Australia;63;66;Male;NA;1;3007,2;Stage I;NA;GSE54467;Macrophages.M1;0;NA;
untreated;GSM1315935;Primary Tumor;Australia;53;54;Male;NA;1;723,9;Stage II;NA;GSE54467;Macrophages.M1;0,003967117;NA;
untreated;GSM1315936;Primary Tumor;Australia;72;72;Male;NA;0;3205,5;Stage II;not sustained response;GSE54467;Macrophages.M1;0,008936132;NA;
untreated;GSM1315937;Primary Tumor;Australia;60;67;Male;NA;1;3228,3;Stage I;NA;GSE54467;Macrophages.M1;0,002507802;NA;
untreated;GSM1315938;Primary Tumor;Australia;67;69;Male;NA;1;864,9;Stage II;NA;GSE54467;Macrophages.M1;0;NA;
untreated;GSM1315939;Primary Tumor;Australia;61;61;Male;NA;1;325,5;Stage III;NA;GSE54467;Macrophages.M1;0,021263968;NA;
untreated;GSM1315940;Primary Tumor;Australia;35;54;Male;NA;0;8526,6;Stage II;not sustained response;GSE54467;Macrophages.M1;0,026021182;NA;
untreated;GSM1315941;Primary Tumor;Australia;60;63;Male;NA;1;2886,9;Stage II;responder;GSE54467;Macrophages.M1;0,011581895;NA;
untreated;GSM1315942;Primary Tumor;Australia;30;30;Male;NA;0;2114,7;Stage III;not sustained response;GSE54467;Macrophages.M1;0,026652909;NA;
untreated;GSM1315943;Primary Tumor;Australia;66;67;Male;NA;1;508,8;Stage II;NA;GSE54467;Macrophages.M1;0,010282615;NA;
untreated;GSM1315944;Primary Tumor;Australia;50;54;Female;NA;1;2062,5;Stage II;NA;GSE54467;Macrophages.M1;0,02383388;NA;
untreated;GSM1315945;Primary Tumor;Australia;28;30;Male;NA;1;3093,9;Stage II;NA;GSE54467;Macrophages.M1;0,018137715;NA;
untreated;GSM1315946;Primary Tumor;Australia;58;60;Male;NA;1;1426,2;Stage I;NA;GSE54467;Macrophages.M1;0,007553257;NA;
untreated;GSM1315947;Primary Tumor;Australia;66;69;Female;NA;1;1518,9;Stage III;NA;GSE54467;Macrophages.M1;0,012361903;NA;
untreated;GSM1315948;Primary Tumor;Australia;49;57;Female;NA;0;6582,6;Stage I;not sustained response;GSE54467;Macrophages.M1;0,003896414;NA;
untreated;GSM1315949;Primary Tumor;Australia;69;69;Male;NA;1;446,7;Stage III;NA;GSE54467;Macrophages.M1;0,030862657;NA;
untreated;GSM1315950;Primary Tumor;Australia;55;56;Male;NA;0;3286,5;Stage III;not sustained response;GSE54467;Macrophages.M1;0,021624754;NA;
untreated;GSM1315951;Primary Tumor;Australia;52;58;Male;NA;1;3098,1;Stage I;NA;GSE54467;Macrophages.M1;0,002575321;NA;
untreated;GSM1315952;Primary Tumor;Australia;61;74;Female;NA;1;4687,8;Stage I;NA;GSE54467;Macrophages.M1;0,017107285;NA;
untreated;GSM1315953;Primary Tumor;Australia;74;75;Male;NA;1;1845,3;Stage I;responder;GSE54467;Macrophages.M1;0,076653047;NA;
untreated;GSM1315954;Primary Tumor;Australia;40;40;Male;NA;0;2916,6;Stage III;not sustained response;GSE54467;Macrophages.M1;0,014063301;NA;
untreated;GSM1315955;Primary Tumor;Australia;36;44;Male;NA;0;6242,4;Stage II;non-responder;GSE54467;Macrophages.M1;0,028138193;NA;
untreated;GSM1315956;Primary Tumor;Australia;70;73;Female;NA;0;3861,3;Stage II;not sustained response;GSE54467;Macrophages.M1;0,076164925;NA;
untreated;GSM1315957;Primary Tumor;Australia;67;67;Male;NA;0;1219,2;Stage III;not sustained response;GSE54467;Macrophages.M1;0,006926239;NA;
untreated;GSM1315958;Primary Tumor;Australia;53;66;Male;NA;1;5252,1;Stage I;NA;GSE54467;Macrophages.M1;0,026149323;NA;
untreated;GSM1315959;Primary Tumor;Australia;64;64;Female;NA;0;3633,6;Stage III;not sustained response;GSE54467;Macrophages.M1;0,004087942;NA;
untreated;GSM1315960;Primary Tumor;Australia;59;61;Male;NA;0;5126,7;Stage I;not sustained response;GSE54467;Macrophages.M1;0,082577376;NA;
untreated;GSM1315961;Primary Tumor;Australia;78;88;Male;NA;1;6904,2;Stage I;NA;GSE54467;Macrophages.M1;0,023763429;NA;
untreated;GSM1315962;Primary Tumor;Australia;62;64;Male;NA;0;3878,1;Stage I;not sustained response;GSE54467;Macrophages.M1;0,082072881;NA;
untreated;GSM1315963;Primary Tumor;Australia;30;63;Male;NA;1;12093,9;Stage I;NA;GSE54467;Macrophages.M1;0,007098498;NA;
untreated;GSM1315964;Primary Tumor;Australia;40;46;Female;NA;1;2208,3;Stage III;NA;GSE54467;Macrophages.M1;0,017963358;NA;
untreated;GSM1315965;Primary Tumor;Australia;58;63;Female;NA;1;3665,1;Stage II;NA;GSE54467;Macrophages.M1;0,004664143;NA;
untreated;GSM1315966;Primary Tumor;Australia;39;40;Female;NA;0;3431,4;Stage I;not sustained response;GSE54467;Macrophages.M1;0,021504429;NA;
untreated;GSM1315967;Primary Tumor;Australia;49;50;Male;NA;1;650,1;Stage I;NA;GSE54467;Macrophages.M1;0,020430464;NA;
untreated;GSM1315968;Primary Tumor;Australia;50;51;Male;NA;0;4334,7;Stage II;not sustained response;GSE54467;Macrophages.M1;0,019314271;NA;
untreated;GSM1315969;Primary Tumor;Australia;24;24;Male;NA;0;1256,4;Stage III;not sustained response;GSE54467;Macrophages.M1;0,011912202;NA;
untreated;GSM1315970;Primary Tumor;Australia;70;73;Female;NA;0;2782,5;Stage II;not sustained response;GSE54467;Macrophages.M1;0;NA;
untreated;GSM1315971;Primary Tumor;Australia;83;86;Male;NA;1;1875;Stage II;responder;GSE54467;Macrophages.M1;0,015037934;NA;
untreated;GSM1315972;Primary Tumor;Australia;68;75;Female;NA;0;6019,5;Stage I;not sustained response;GSE54467;Macrophages.M1;0,029865022;NA;
untreated;GSM1315973;Primary Tumor;Australia;47;47;Male;NA;0;1506;Stage III;not sustained response;GSE54467;Macrophages.M1;0,021836364;NA;
untreated;GSM1315974;Primary Tumor;Australia;48;48;Female;NA;0;2405,7;Stage I;not sustained response;GSE54467;Macrophages.M1;0,023861362;NA;
untreated;GSM1315975;Primary Tumor;Australia;52;53;Male;NA;1;582;Stage III;NA;GSE54467;Macrophages.M1;6,34E-04;NA;
untreated;GSM1315976;Primary Tumor;Australia;60;67;Female;NA;0;5314,2;Stage I;non-responder;GSE54467;Macrophages.M1;0,072950492;NA;
untreated;GSM1315977;Primary Tumor;Australia;45;50;Female;NA;1;3722,4;Stage II;NA;GSE54467;Macrophages.M1;0,005912845;NA;
untreated;GSM1315978;Primary Tumor;Australia;68;73;Female;NA;1;3316,8;Stage I;NA;GSE54467;Macrophages.M1;0,00782288;NA;
untreated;GSM1315979;Primary Tumor;Australia;78;80;Male;NA;0;1305,9;Stage I;NA;GSE54467;Macrophages.M1;0,001423618;NA;
untreated;GSM1315980;Primary Tumor;Australia;56;56;Female;NA;1;708,3;Stage II;NA;GSE54467;Macrophages.M1;0,001030238;NA;
untreated;GSM1315981;Primary Tumor;Australia;74;74;Female;NA;1;121,2;Stage II;NA;GSE54467;Macrophages.M1;0,009216735;NA;
untreated;GSM1315982;Primary Tumor;Australia;66;75;Male;NA;1;3691,8;Stage I;NA;GSE54467;Macrophages.M1;0,035124459;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872328;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872329;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,011225226;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872330;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,033787063;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872331;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,029835672;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872332;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,047448236;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872333;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,079134592;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872334;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,036575608;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872335;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,026436357;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872336;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,045395563;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872337;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,052389388;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872338;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,066739928;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872339;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,064190812;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872340;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,010584404;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872341;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,048048127;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872342;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,123518998;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872343;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,039928159;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872344;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,050923561;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872345;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872346;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,030007525;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872347;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,07603712;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872348;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,021419741;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872349;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,014422202;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872350;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,030418794;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872351;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,007108668;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872352;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,041386601;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872353;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,079144099;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872354;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,031922118;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872355;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,00888134;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872356;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,030890611;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872357;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,020204538;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872358;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,058883236;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872359;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,032667869;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872360;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,002979418;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872361;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872362;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872363;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,039636449;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872364;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,059042026;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872365;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,052788809;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872366;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,06047731;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872367;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,002553956;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872368;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872369;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872370;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,025668275;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872371;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,00153148;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872372;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,012995578;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872373;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,008093222;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872374;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,048657864;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872375;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,034622304;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872376;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,027555827;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872377;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,117876779;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872378;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,077221242;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872379;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872380;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872381;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872382;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Macrophages.M2;0,002815467;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872383;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Macrophages.M2;0,004449788;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872384;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M2;0,022144022;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872385;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M2;0,002978265;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872386;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M2;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872387;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M2;0,010638761;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872388;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M2;0,00309909;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872389;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M2;0,005434999;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872390;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M2;0,036869448;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872391;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M2;0,110200795;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872392;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Macrophages.M2;0,011619911;NA;
Standard (dacarbazine monotherapy; DTIC);GSM550966;Metastatic;Sweden;60;62;Male;Trunk;1;373;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,037198275;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550967;Metastatic;Sweden;54;59;Female;Lower extremity;1;181;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,023619189;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550968;Metastatic;Sweden;40;53;Male;Head;1;436;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,135237222;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550969;Metastatic;Sweden;54;61;Female;Lower extremity;1;82;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,045576609;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550970;Metastatic;Sweden;45;47;Male;Lower extremity;1;646;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,06912907;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550971;Metastatic;Sweden;68;68;Male;No primary detected;1;114;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,021274723;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550972;Metastatic;Sweden;36;38;Male;Upper extremity, acral;1;322;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,05447926;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550973;Metastatic;Sweden;63;65;Female;Trunk;1;46;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,105276418;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550974;Metastatic;Sweden;51;51;Male;No primary detected;0;3509;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,126438694;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550975;Metastatic;Sweden;79;86;Male;Head;1;65;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,056082148;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550976;Metastatic;Sweden;50;51;Male;Trunk;1;14;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,002785308;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550977;Metastatic;Sweden;58;59;Female;Upper extremity;1;27;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,016737016;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550978;Metastatic;Sweden;36;36;Male;No primary detected;-;-;III;NA;GSE22155_GPL6102;Macrophages.M2;0,015285474;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550979;Metastatic;Sweden;60;66;Female;Upper extremity;1;45;IV;NA;GSE22155_GPL6102;Macrophages.M2;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550980;Metastatic;Sweden;53;53;Female;No primary detected;1;10;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,038491473;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550981;Metastatic;Sweden;27;32;Female;Trunk;0;2711;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,014506446;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550982;Metastatic;Sweden;49;51;Male;Lower extremity;1;32;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,18102878;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550983;Metastatic;Sweden;62;63;Male;No primary detected;1;55;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,060966963;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550984;Metastatic;Sweden;50;71;Male;Upper extremity;1;91;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,043139188;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550985;Metastatic;Sweden;49;63;Female;Trunk;1;804;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,012702497;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550986;Metastatic;Sweden;55;61;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,025474076;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550987;Metastatic;Sweden;55;80;Male;Trunk;1;25;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,068617247;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550988;Metastatic;Sweden;78;78;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,041195122;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550989;Metastatic;Sweden;56;57;Male;No primary detected;1;50;IV;NA;GSE22155_GPL6102;Macrophages.M2;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550990;Metastatic;Sweden;74;76;Female;Head;1;156;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,119251071;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550991;Metastatic;Sweden;53;70;Male;Trunk;1;219;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,006367238;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550992;Metastatic;Sweden;36;49;Male;Trunk;1;266;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,032135063;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550993;Metastatic;Sweden;33;33;Male;No primary detected;1;1075;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,081033317;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550994;Metastatic;Sweden;67;67;Female;No primary detected;1;201;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,017827057;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550995;Metastatic;Sweden;72;74;Male;Trunk;1;247;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,071737726;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550996;Metastatic;Sweden;27;31;Female;Trunk;1;414;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,022414867;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550997;Metastatic;Sweden;32;43;Female;No primary detected;1;108;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,097443199;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550998;Metastatic;Sweden;59;61;Female;Trunk;-;-;III;NA;GSE22155_GPL6102;Macrophages.M2;0,042614782;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550999;Metastatic;Sweden;61;61;Male;No primary detected;1;281;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,008708353;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551000;Metastatic;Sweden;73;73;Male;Head and eye;1;221;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,025600309;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551001;Metastatic;Sweden;54;55;Male;Trunk;1;102;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,047612;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551002;Metastatic;Sweden;68;68;Female;No primary detected;1;301;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,008052607;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551003;Metastatic;Sweden;62;68;Female;Trunk;1;64;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,020697879;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551004;Metastatic;Sweden;35;36;Female;No primary detected;1;375;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,022021961;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551005;Metastatic;Sweden;76;79;Female;Trunk;1;218;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,078711679;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551006;Metastatic;Sweden;66;68;Male;Head;1;1478;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,013799526;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551007;Metastatic;Sweden;46;52;Female;Trunk;1;13;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,00981303;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551008;Metastatic;Sweden;65;67;Male;Trunk;1;254;IV;NA;GSE22155_GPL6102;Macrophages.M2;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551009;Metastatic;Sweden;70;70;Female;Upper extremity;1;16;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,031270476;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551010;Metastatic;Sweden;68;72;Male;Trunk;1;430;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,087535773;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551011;Metastatic;Sweden;82;84;Male;Trunk;1;63;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,111832672;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551012;Metastatic;Sweden;35;68;Male;Upper extremity;0;1198;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,053264423;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551013;Metastatic;Sweden;31;38;Male;Trunk;-;-;III;NA;GSE22155_GPL6102;Macrophages.M2;0,017932054;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551014;Metastatic;Sweden;79;79;Female;Trunk;0;927;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,075847413;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551015;Metastatic;Sweden;77;82;Female;Upper extremity;1;325;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,012784809;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551016;Metastatic;Sweden;72;76;Male;Lower extremity;1;44;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,008646427;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551017;Metastatic;Sweden;75;75;Female;Lower extremity;0;895;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,035894044;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551018;Metastatic;Sweden;58;61;Male;Trunk;0;836;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,04114933;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551019;Metastatic;Sweden;71;74;Female;Lower extremity, acral;0;786;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,039143873;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551020;Metastatic;Sweden;65;76;Male;Trunk;1;244;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,026776274;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551021;Metastatic;Sweden;25;25;Female;Lower extremity;1;78;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,026926017;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551022;Metastatic;Sweden;50;75;Male;Trunk;1;29;IV;NA;GSE22155_GPL6102;Macrophages.M2;0,015528393;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551023;Metastatic;Sweden;75;76;Male;Acral;1;44;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,04062556;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551024;Metastatic;Sweden;63;64;Female;Genital;1;747;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,026267846;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551025;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,042470342;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551026;Metastatic;Sweden;68;68;Female;GI tractus;1;367;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,025327611;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551027;Metastatic;Sweden;58;60;Male;Eye;1;7;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,042268309;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551028;Metastatic;Sweden;49;63;Male;Trunk;1;309;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,026666604;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551029;Metastatic;Sweden;56;55;Female;Trunk;1;32;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,020687425;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551030;Metastatic;Sweden;74;74;Male;Trunk;1;79;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,060116361;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551031;Metastatic;Sweden;41;42;Female;Eye;1;349;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,048669193;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551032;Metastatic;Sweden;49;51;Female;Mucosa, head;1;13;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,043386496;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551033;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,022820745;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551034;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,021353601;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551035;Metastatic;Sweden;56;56;Male;GI tractus;1;37;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,043094095;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551036;Metastatic;Sweden;45;74;Male;No primary;1;183;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,035164336;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551037;Metastatic;Sweden;72;75;Female;Head;1;39;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,02715383;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551038;Metastatic;Sweden;61;68;Female;Eye;1;513;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,052741208;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551039;Metastatic;Sweden;66;68;Male;Trunk;1;584;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,027448308;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551040;Metastatic;Sweden;42;44;Male;Head;1;1148;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,060303618;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551041;Metastatic;Sweden;54;56;Female;Trunk;1;153;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,032631188;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551042;Metastatic;Sweden;48;50;Male;Trunk;1;141;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,058102178;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551043;Metastatic;Sweden;58;67;Female;Acral;1;334;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,049201195;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551044;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;Macrophages.M2;0,041845069;Metastasis
untreated;GSM1220412;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,015220341;Metastasis;
dabrafenib;GSM1220413;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0;cutaneous or subcutaneous;
untreated;GSM1220414;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,039934399;cutaneous or subcutaneous;
dabrafenib;GSM1220415;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,042326881;cutaneous or subcutaneous;
untreated;GSM1220416;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0;cutaneous or subcutaneous;
dabrafenib;GSM1220417;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,005026023;cutaneous or subcutaneous;
dabrafenib;GSM1220418;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,024994188;cutaneous or subcutaneous;
untreated;GSM1220419;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,010698287;Metastasis;
dabrafenib;GSM1220420;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,010632134;Metastasis;
untreated;GSM1220421;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,007272887;cutaneous or subcutaneous;
dabrafenib;GSM1220422;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,044881616;cutaneous or subcutaneous;
dabrafenib;GSM1220423;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,016275143;cutaneous or subcutaneous;
untreated;GSM1220424;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,048566595;cutaneous or subcutaneous;
untreated;GSM1220425;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,039895716;cutaneous or subcutaneous;
dabrafenib;GSM1220426;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,024950507;Metastasis;
untreated;GSM1220427;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,041445136;cutaneous or subcutaneous;
untreated;GSM1220428;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,050921113;cutaneous or subcutaneous;
dabrafenib;GSM1220429;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,055557371;cutaneous or subcutaneous;
dabrafenib;GSM1220430;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,017053216;cutaneous or subcutaneous;
untreated;GSM1220431;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,055306733;cutaneous or subcutaneous;
dabrafenib;GSM1220432;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,056798891;cutaneous or subcutaneous;
untreated;GSM1220433;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,027843864;cutaneous or subcutaneous;
untreated;GSM1220434;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,032648625;cutaneous or subcutaneous;
dabrafenib;GSM1220435;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,065331109;cutaneous or subcutaneous;
dabrafenib;GSM1220436;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,046075224;cutaneous or subcutaneous;
dabrafenib;GSM1220437;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,016372719;cutaneous or subcutaneous;
untreated;GSM1220438;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,0063491;Metastasis;
untreated;GSM1220439;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,005620934;Metastasis;
dabrafenib;GSM1220440;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,025265701;cutaneous or subcutaneous;
dabrafenib;GSM1220441;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Macrophages.M2;0;Metastasis;
dabrafenib;GSM1220442;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,028743652;cutaneous or subcutaneous;
dabrafenib;GSM1220443;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,004099798;Metastasis;
untreated;GSM1220444;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,016919588;Metastasis;
dabrafenib;GSM1220445;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,017401577;cutaneous or subcutaneous;
untreated;GSM1220446;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,005333474;cutaneous or subcutaneous;
untreated;GSM1220447;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,007991435;cutaneous or subcutaneous;
dabrafenib;GSM1220448;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,019631063;cutaneous or subcutaneous;
untreated;GSM1220449;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,0154386;Metastasis;
dabrafenib;GSM1220450;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,029956226;cutaneous or subcutaneous;
untreated;GSM1220451;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,014001521;Metastasis;
dabrafenib;GSM1220452;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,032391657;Metastasis;
untreated;GSM1220453;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,032428433;cutaneous or subcutaneous;
untreated;GSM1220454;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,038227065;cutaneous or subcutaneous;
dabrafenib;GSM1220455;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,015357273;Metastasis;
dabrafenib;GSM1220456;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,017328023;cutaneous or subcutaneous;
untreated;GSM1220457;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,001087552;cutaneous or subcutaneous;
dabrafenib;GSM1220458;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,013317865;Metastasis;
untreated;GSM1220459;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,036260141;cutaneous or subcutaneous;
vemurafenib;GSM1220460;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,038916368;cutaneous or subcutaneous;
untreated;GSM1220461;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,00669637;cutaneous or subcutaneous;
untreated;GSM1220462;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,006997126;cutaneous or subcutaneous;
vemurafenib;GSM1220463;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0;cutaneous or subcutaneous;
untreated;GSM1220464;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,012764171;Metastasis;
vemurafenib;GSM1220465;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,068268559;cutaneous or subcutaneous;
untreated;GSM1220466;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,001067619;cutaneous or subcutaneous;
vemurafenib;GSM1220467;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,01190408;cutaneous or subcutaneous;
vemurafenib;GSM1220468;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,010505377;cutaneous or subcutaneous;
vemurafenib;GSM1220469;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,024641704;cutaneous or subcutaneous;
vemurafenib;GSM1220470;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0;cutaneous or subcutaneous;
untreated;GSM1220471;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,021845751;cutaneous or subcutaneous;
vemurafenib;GSM1220472;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;Macrophages.M2;0,020712088;Metastasis;
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;Macrophages.M2;0,011886702;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;Macrophages.M2;0,011886702;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,013309005;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,013309005;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,009346236;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,009346236;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;Macrophages.M2;0,011755717;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;Macrophages.M2;0,011755717;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,007937074;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,007937074;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,016861919;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,016861919;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;Macrophages.M2;0,008890297;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;Macrophages.M2;0,008890297;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;Macrophages.M2;0,005950492;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;Macrophages.M2;0,005950492;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;Macrophages.M2;0,046043592;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;Macrophages.M2;0,046043592;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,008208767;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,008208767;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,027442404;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,027442404;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;Macrophages.M2;0,018236797;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;Macrophages.M2;0,018236797;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;Macrophages.M2;0,010960011;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;Macrophages.M2;0,010960011;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;Macrophages.M2;0,014696601;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;Macrophages.M2;0,014696601;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,018188592;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,018188592;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;Macrophages.M2;0,02147038;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;Macrophages.M2;0,02147038;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,007134235;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,007134235;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;Macrophages.M2;0,009602;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;Macrophages.M2;0,009602;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,014253048;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,014253048;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;Macrophages.M2;0,01071516;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;Macrophages.M2;0,01071516;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;Macrophages.M2;0,012311174;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;Macrophages.M2;0,012311174;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Macrophages.M2;0,014723077;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Macrophages.M2;0,014723077;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;Macrophages.M2;0,045437666;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;Macrophages.M2;0,045437666;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,011857626;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,011857626;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;Macrophages.M2;0,023453019;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;Macrophages.M2;0,023453019;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,02247946;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,02247946;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,011585586;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,011585586;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,01159095;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,01159095;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;Macrophages.M2;0,006674479;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;Macrophages.M2;0,006674479;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,013466372;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,013466372;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,009262628;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,009262628;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;Macrophages.M2;0,008410285;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;Macrophages.M2;0,008410285;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,003421018;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,003421018;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;Macrophages.M2;0,010851982;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;Macrophages.M2;0,010851982;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,013409991;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,013409991;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,025245112;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,025245112;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;Macrophages.M2;0,006396887;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;Macrophages.M2;0,006396887;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;Macrophages.M2;0,01222803;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;Macrophages.M2;0,01222803;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,015166517;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,015166517;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;Macrophages.M2;0,002702286;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;Macrophages.M2;0,002702286;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;Macrophages.M2;0,025898659;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;Macrophages.M2;0,025898659;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;Macrophages.M2;0,038301776;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;Macrophages.M2;0,038301776;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,008388537;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,008388537;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,007271208;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,007271208;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,009028139;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,009028139;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;Macrophages.M2;0,016225759;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;Macrophages.M2;0,016225759;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,017409532;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,017409532;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;Macrophages.M2;0,010615373;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;Macrophages.M2;0,010615373;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;Macrophages.M2;0,011577252;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;Macrophages.M2;0,011577252;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;Macrophages.M2;0,011184865;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;Macrophages.M2;0,011184865;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;Macrophages.M2;0,009042473;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;Macrophages.M2;0,009042473;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,008485224;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,008485224;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,007074138;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,007074138;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,011524061;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,011524061;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,020987932;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,020987932;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,012160264;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,012160264;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,055631902;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,055631902;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,005885581;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,005885581;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,00598144;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,00598144;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;Macrophages.M2;0,010007248;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;Macrophages.M2;0,010007248;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,010046688;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,010046688;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,007769577;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,007769577;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,020831043;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,020831043;NA
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;Macrophages.M2;0,010767775;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;Macrophages.M2;0,010767775;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,013947456;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,013947456;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,008972883;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,008972883;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;Macrophages.M2;0,019562164;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;Macrophages.M2;0,019562164;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,011003687;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,011003687;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,010620147;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,010620147;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;Macrophages.M2;0,009198894;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;Macrophages.M2;0,009198894;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;Macrophages.M2;0,008750631;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;Macrophages.M2;0,008750631;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,030426026;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,030426026;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,0084098;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,0084098;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,016412303;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,016412303;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,002121059;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,002121059;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,022398815;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,022398815;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,021497071;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,021497071;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,012211311;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,012211311;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,00794488;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,00794488;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,011908927;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,011908927;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,019115954;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,019115954;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;Macrophages.M2;0,116824947;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;Macrophages.M2;0,116824947;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;Macrophages.M2;0,012737487;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;Macrophages.M2;0,012737487;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,023174604;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,023174604;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,020574954;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,020574954;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;Macrophages.M2;0,011634563;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;Macrophages.M2;0,011634563;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;Macrophages.M2;0,036485191;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;Macrophages.M2;0,036485191;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;Macrophages.M2;0,016098518;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;Macrophages.M2;0,016098518;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;Macrophages.M2;0,010304824;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;Macrophages.M2;0,010304824;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,009069454;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,009069454;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,01643954;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,01643954;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;Macrophages.M2;0,014043922;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;Macrophages.M2;0,014043922;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,006299328;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,006299328;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;Macrophages.M2;0,028403883;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;Macrophages.M2;0,028403883;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,013378066;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,013378066;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,019058651;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,019058651;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;Macrophages.M2;0,017089413;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;Macrophages.M2;0,017089413;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;Macrophages.M2;0,013463929;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;Macrophages.M2;0,013463929;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;Macrophages.M2;0,01293104;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;Macrophages.M2;0,01293104;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;Macrophages.M2;0,008708472;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;Macrophages.M2;0,008708472;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,024764608;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,024764608;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,015276411;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,015276411;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;Macrophages.M2;0,009399632;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;Macrophages.M2;0,009399632;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;Macrophages.M2;0,014808076;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;Macrophages.M2;0,014808076;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,021995948;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,021995948;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;Macrophages.M2;0,011180827;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;Macrophages.M2;0,011180827;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;Macrophages.M2;0,010124746;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;Macrophages.M2;0,010124746;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,012933099;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,012933099;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;Macrophages.M2;0,041172404;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;Macrophages.M2;0,041172404;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;Macrophages.M2;0,022611348;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;Macrophages.M2;0,022611348;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;Macrophages.M2;0,006804165;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;Macrophages.M2;0,006804165;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;Macrophages.M2;0,00992278;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;Macrophages.M2;0,00992278;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,013196396;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,013196396;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;Macrophages.M2;0,014858889;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;Macrophages.M2;0,014858889;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;Macrophages.M2;0,015768385;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;Macrophages.M2;0,015768385;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,005238688;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,005238688;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;Macrophages.M2;0,018897268;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;Macrophages.M2;0,018897268;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;Macrophages.M2;0,013182925;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;Macrophages.M2;0,013182925;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Macrophages.M2;0,006729586;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Macrophages.M2;0,006729586;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;Macrophages.M2;0,022289779;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;Macrophages.M2;0,022289779;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,008454664;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,008454664;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,002828389;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,002828389;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;Macrophages.M2;0,00514384;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;Macrophages.M2;0,00514384;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,031708477;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,031708477;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;Macrophages.M2;0,015378911;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;Macrophages.M2;0,015378911;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,016542788;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,016542788;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;Macrophages.M2;0,011280477;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;Macrophages.M2;0,011280477;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;Macrophages.M2;0,0164341;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;Macrophages.M2;0,0164341;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,004475525;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,004475525;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;Macrophages.M2;0,144215404;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;Macrophages.M2;0,144215404;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;Macrophages.M2;0,014430506;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;Macrophages.M2;0,014430506;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,008506657;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,008506657;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,011342216;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,011342216;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;Macrophages.M2;0,075260441;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;Macrophages.M2;0,075260441;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,011227592;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,011227592;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;Macrophages.M2;0,009802952;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;Macrophages.M2;0,009802952;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,022192746;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,022192746;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;Macrophages.M2;0,013237319;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;Macrophages.M2;0,013237319;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,020213747;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,020213747;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,012472658;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,012472658;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,022187664;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,022187664;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,012157388;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,012157388;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,011956946;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,011956946;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,007517276;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,007517276;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;Macrophages.M2;0,011890715;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;Macrophages.M2;0,011890715;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;Macrophages.M2;0,018385761;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;Macrophages.M2;0,018385761;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,01338749;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,01338749;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,010127845;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,010127845;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;Macrophages.M2;0,00982249;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;Macrophages.M2;0,00982249;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,00877079;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,00877079;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;Macrophages.M2;0,104409301;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;Macrophages.M2;0,104409301;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,029270065;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,029270065;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,01171239;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,01171239;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,013362065;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,013362065;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;Macrophages.M2;0,012512974;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;Macrophages.M2;0,012512974;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,014725471;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,014725471;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,009323873;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,009323873;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,017061162;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,017061162;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;Macrophages.M2;0,004154835;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;Macrophages.M2;0,004154835;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;Macrophages.M2;0,009058353;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;Macrophages.M2;0,009058353;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;Macrophages.M2;0,009277538;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;Macrophages.M2;0,009277538;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;Macrophages.M2;0,007946839;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;Macrophages.M2;0,007946839;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,007562201;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,007562201;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,024910144;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,024910144;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,021427925;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,021427925;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,015692387;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,015692387;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,010922633;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,010922633;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,011315416;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,011315416;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,00700194;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,00700194;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;Macrophages.M2;0,048077486;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;Macrophages.M2;0,048077486;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,023206403;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,023206403;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,009861486;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,009861486;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;Macrophages.M2;0,012915879;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;Macrophages.M2;0,012915879;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,013552847;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,013552847;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;Macrophages.M2;0,015147359;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;Macrophages.M2;0,015147359;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,005457438;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,005457438;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;Macrophages.M2;0,017651004;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;Macrophages.M2;0,017651004;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,023097584;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,023097584;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;Macrophages.M2;0,050124832;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;Macrophages.M2;0,050124832;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;Macrophages.M2;0,013302146;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;Macrophages.M2;0,013302146;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,006584039;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,006584039;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,01154343;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,01154343;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;Macrophages.M2;0,029347201;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;Macrophages.M2;0,029347201;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,013419411;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,013419411;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;Macrophages.M2;0,035184643;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;Macrophages.M2;0,035184643;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;Macrophages.M2;0,016354436;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;Macrophages.M2;0,016354436;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;Macrophages.M2;0,008012294;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;Macrophages.M2;0,008012294;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,010190678;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,010190678;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,007589177;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,007589177;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;Macrophages.M2;0,009810916;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;Macrophages.M2;0,009810916;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;Macrophages.M2;0,019686295;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;Macrophages.M2;0,019686295;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;Macrophages.M2;0,010111934;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;Macrophages.M2;0,010111934;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;Macrophages.M2;0,016850077;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;Macrophages.M2;0,016850077;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,008294615;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,008294615;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,006384878;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,006384878;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;Macrophages.M2;0,010991488;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;Macrophages.M2;0,010991488;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,007718131;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,007718131;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;Macrophages.M2;0,038966064;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;Macrophages.M2;0,038966064;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;Macrophages.M2;0,010072915;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;Macrophages.M2;0,010072915;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;Macrophages.M2;0,017420518;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;Macrophages.M2;0,017420518;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;Macrophages.M2;0,010183785;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;Macrophages.M2;0,010183785;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;Macrophages.M2;0,0080231;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;Macrophages.M2;0,0080231;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,006691713;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,006691713;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;Macrophages.M2;0,014828602;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;Macrophages.M2;0,014828602;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;Macrophages.M2;0,010728092;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;Macrophages.M2;0,010728092;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,014648959;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,014648959;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,028292054;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,028292054;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;Macrophages.M2;0,021071403;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;Macrophages.M2;0,021071403;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,026013357;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,026013357;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,023189659;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,023189659;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,015107833;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,015107833;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;Macrophages.M2;0,016630685;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;Macrophages.M2;0,016630685;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;Macrophages.M2;0,019755306;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;Macrophages.M2;0,019755306;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,005049943;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,005049943;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;Macrophages.M2;0,012836158;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;Macrophages.M2;0,012836158;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,0097431;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,0097431;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,012744301;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,012744301;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,006909159;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,006909159;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,012901644;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,012901644;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;Macrophages.M2;0,021591833;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;Macrophages.M2;0,021591833;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,012131028;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,012131028;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,017243192;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,017243192;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,012852932;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,012852932;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,015853564;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,015853564;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;Macrophages.M2;0,010327176;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;Macrophages.M2;0,010327176;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;Macrophages.M2;0,00983097;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;Macrophages.M2;0,00983097;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,011413328;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,011413328;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;Macrophages.M2;0,012697289;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;Macrophages.M2;0,012697289;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,005188597;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,005188597;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,006261777;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,006261777;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,013359553;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,013359553;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;Macrophages.M2;0,014414253;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;Macrophages.M2;0,014414253;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,010011493;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,010011493;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,010613118;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,010613118;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,011900285;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,011900285;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;Macrophages.M2;0,020436096;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;Macrophages.M2;0,020436096;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;Macrophages.M2;0,009200312;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;Macrophages.M2;0,009200312;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,024938783;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,024938783;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,006204838;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,006204838;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;Macrophages.M2;0,009776303;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;Macrophages.M2;0,009776303;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Macrophages.M2;0,010398325;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Macrophages.M2;0,010398325;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;Macrophages.M2;0,019903438;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;Macrophages.M2;0,019903438;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,008184358;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,008184358;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;Macrophages.M2;0,01302115;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;Macrophages.M2;0,01302115;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,01447292;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,01447292;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;Macrophages.M2;0,018259693;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;Macrophages.M2;0,018259693;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;Macrophages.M2;0,029941332;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;Macrophages.M2;0,029941332;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;Macrophages.M2;0,022233644;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;Macrophages.M2;0,022233644;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,006690358;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,006690358;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,00694209;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,00694209;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,017310921;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,017310921;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,022401686;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,022401686;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;Macrophages.M2;0,009514641;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;Macrophages.M2;0,009514641;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;Macrophages.M2;0,011854286;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;Macrophages.M2;0,011854286;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;Macrophages.M2;0,007984878;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;Macrophages.M2;0,007984878;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,009062618;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,009062618;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,010478941;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,010478941;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;Macrophages.M2;0,017582672;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;Macrophages.M2;0,017582672;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;Macrophages.M2;0,020884954;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;Macrophages.M2;0,020884954;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;Macrophages.M2;0,017977053;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;Macrophages.M2;0,017977053;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,008873079;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,008873079;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;Macrophages.M2;0,006537372;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;Macrophages.M2;0,006537372;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;Macrophages.M2;0,017237201;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;Macrophages.M2;0,017237201;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,046758781;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,046758781;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;Macrophages.M2;0,051957661;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;Macrophages.M2;0,051957661;NA
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;Macrophages.M2;0,008973662;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;Macrophages.M2;0,008973662;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;Macrophages.M2;0,016310914;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;Macrophages.M2;0,016310914;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;Macrophages.M2;0,025150801;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;Macrophages.M2;0,025150801;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;Macrophages.M2;0,016163762;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;Macrophages.M2;0,016163762;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;Macrophages.M2;0,00630544;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;Macrophages.M2;0,00630544;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;Macrophages.M2;0,015463246;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;Macrophages.M2;0,015463246;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,015051963;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,015051963;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;Macrophages.M2;0,006346229;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;Macrophages.M2;0,006346229;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,01090139;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,01090139;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,010303244;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,010303244;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;Macrophages.M2;0,019107246;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;Macrophages.M2;0,019107246;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;Macrophages.M2;0,018310456;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;Macrophages.M2;0,018310456;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;Macrophages.M2;0,022252465;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;Macrophages.M2;0,022252465;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,007655675;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,007655675;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;Macrophages.M2;0,013672188;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;Macrophages.M2;0,013672188;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,011112202;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,011112202;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;Macrophages.M2;0,013240089;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;Macrophages.M2;0,013240089;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;Macrophages.M2;0,012832571;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;Macrophages.M2;0,012832571;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,024527284;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,024527284;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,006990844;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,006990844;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,024030619;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,024030619;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;Macrophages.M2;0,012599535;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;Macrophages.M2;0,012599535;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,006107883;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,006107883;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;Macrophages.M2;0,008978224;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;Macrophages.M2;0,008978224;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;Macrophages.M2;0,012071748;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;Macrophages.M2;0,012071748;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;Macrophages.M2;0,007525201;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;Macrophages.M2;0,007525201;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;Macrophages.M2;0,005923198;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;Macrophages.M2;0,005923198;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;Macrophages.M2;0,009222398;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;Macrophages.M2;0,009222398;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;Macrophages.M2;0,022976154;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;Macrophages.M2;0,022976154;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;Macrophages.M2;0,022631021;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;Macrophages.M2;0,022631021;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;Macrophages.M2;0,030578521;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;Macrophages.M2;0,030578521;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,01807153;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,01807153;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;Macrophages.M2;0,013747251;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;Macrophages.M2;0,013747251;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Macrophages.M2;0,006538605;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Macrophages.M2;0,006538605;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;Macrophages.M2;0,005180418;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;Macrophages.M2;0,005180418;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;Macrophages.M2;0,010200545;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;Macrophages.M2;0,010200545;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,010306909;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,010306909;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,044273663;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,044273663;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,010830094;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,010830094;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,010710196;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,010710196;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,004133427;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,004133427;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,005590709;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,005590709;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,032362936;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,032362936;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,018072697;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,018072697;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;Macrophages.M2;0,010384279;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;Macrophages.M2;0,010384279;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,011071288;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,011071288;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,004422838;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,004422838;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,009057885;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,009057885;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;Macrophages.M2;0,013908679;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;Macrophages.M2;0,013908679;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,008819178;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,008819178;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;Macrophages.M2;0,008431166;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;Macrophages.M2;0,008431166;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;Macrophages.M2;0,005534553;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;Macrophages.M2;0,005534553;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;Macrophages.M2;0,013161523;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;Macrophages.M2;0,013161523;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,005359032;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,005359032;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;Macrophages.M2;0,045165261;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;Macrophages.M2;0,045165261;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,01218658;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,01218658;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,012617255;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,012617255;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,008495215;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,008495215;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,00517152;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,00517152;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;Macrophages.M2;0,007467206;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;Macrophages.M2;0,007467206;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,012831884;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,012831884;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,012030495;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,012030495;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,019114828;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,019114828;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,014473232;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,014473232;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;Macrophages.M2;0,01073209;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;Macrophages.M2;0,01073209;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,016301437;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,016301437;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,010181413;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,010181413;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,014438224;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,014438224;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;Macrophages.M2;0,007254862;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;Macrophages.M2;0,007254862;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,009624011;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,009624011;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,004777118;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,004777118;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,011968163;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,011968163;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,013579507;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,013579507;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;Macrophages.M2;0,018754686;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;Macrophages.M2;0,018754686;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;Macrophages.M2;0,013161001;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;Macrophages.M2;0,013161001;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,021774775;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,021774775;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;Macrophages.M2;0,010884813;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;Macrophages.M2;0,010884813;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,010300381;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,010300381;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,012383752;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,012383752;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,008923041;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,008923041;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,018202017;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,018202017;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,008200101;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,008200101;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,014469673;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,014469673;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,014596151;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,014596151;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;Macrophages.M2;0,01157678;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;Macrophages.M2;0,01157678;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,015409313;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,015409313;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,022129874;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,022129874;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,045756316;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,045756316;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,022163665;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,022163665;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;Macrophages.M2;0,012503093;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;Macrophages.M2;0,012503093;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,014585282;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,014585282;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,012514958;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,012514958;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;Macrophages.M2;0,006801967;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;Macrophages.M2;0,006801967;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,022224023;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,022224023;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;Macrophages.M2;0,022280727;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;Macrophages.M2;0,022280727;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,022147191;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,022147191;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,005459588;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,005459588;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,011300573;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,011300573;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,013898389;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,013898389;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;Macrophages.M2;0,009236466;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;Macrophages.M2;0,009236466;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,0204861;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,0204861;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,008661899;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,008661899;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;Macrophages.M2;0,020296301;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;Macrophages.M2;0,020296301;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,021964454;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,021964454;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;Macrophages.M2;0,010732564;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;Macrophages.M2;0,010732564;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;Macrophages.M2;0,007353392;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;Macrophages.M2;0,007353392;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;Macrophages.M2;0,015537044;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;Macrophages.M2;0,015537044;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,034345117;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,034345117;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,005236041;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,005236041;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,019073683;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,019073683;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;Macrophages.M2;0,01121654;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;Macrophages.M2;0,01121654;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;Macrophages.M2;0,003703868;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;Macrophages.M2;0,003703868;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,018596456;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,018596456;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;Macrophages.M2;0,00912517;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;Macrophages.M2;0,00912517;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;Macrophages.M2;0,009845127;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;Macrophages.M2;0,009845127;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,008209985;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,008209985;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,004997194;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,004997194;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,063069561;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,063069561;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,014316777;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,014316777;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;Macrophages.M2;0,015498012;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;Macrophages.M2;0,015498012;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,007462197;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,007462197;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;Macrophages.M2;0,010528268;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;Macrophages.M2;0,010528268;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,012607409;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,012607409;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;Macrophages.M2;0,021538921;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;Macrophages.M2;0,021538921;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,031440538;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Macrophages.M2;0,031440538;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;Macrophages.M2;0,007015529;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;Macrophages.M2;0,007015529;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;Macrophages.M2;0,011896411;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;Macrophages.M2;0,011896411;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,005408224;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,005408224;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;Macrophages.M2;0,020690014;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;Macrophages.M2;0,020690014;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,007686945;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,007686945;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,025693062;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,025693062;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;Macrophages.M2;0,012639118;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;Macrophages.M2;0,012639118;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;Macrophages.M2;0,137096617;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;Macrophages.M2;0,137096617;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;Macrophages.M2;0,033015197;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;Macrophages.M2;0,033015197;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,008402086;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,008402086;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;Macrophages.M2;0,012319951;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;Macrophages.M2;0,012319951;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,02432668;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,02432668;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;Macrophages.M2;0,006711901;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;Macrophages.M2;0,006711901;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,00905402;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,00905402;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;Macrophages.M2;0,006793051;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;Macrophages.M2;0,006793051;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,024772768;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,024772768;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;Macrophages.M2;0,010584816;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;Macrophages.M2;0,010584816;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,016280494;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,016280494;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;Macrophages.M2;0,008702487;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;Macrophages.M2;0,008702487;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;Macrophages.M2;0,012740454;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;Macrophages.M2;0,012740454;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,011434085;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,011434085;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,04785771;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,04785771;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;Macrophages.M2;0,020076032;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;Macrophages.M2;0,020076032;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;Macrophages.M2;0,020706774;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;Macrophages.M2;0,020706774;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,00428442;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,00428442;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;Macrophages.M2;0,014970296;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;Macrophages.M2;0,014970296;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;Macrophages.M2;0,004160624;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;Macrophages.M2;0,004160624;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,001571345;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,001571345;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;Macrophages.M2;0,003138388;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;Macrophages.M2;0,003138388;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;Macrophages.M2;0,031196216;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;Macrophages.M2;0,031196216;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;Macrophages.M2;0,012727735;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;Macrophages.M2;0,012727735;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,014026893;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,014026893;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,017001798;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,017001798;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;Macrophages.M2;0,012096144;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;Macrophages.M2;0,012096144;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;Macrophages.M2;0,009874693;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;Macrophages.M2;0,009874693;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,010868684;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,010868684;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,027053917;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,027053917;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,021815405;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,021815405;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;Macrophages.M2;0,013197588;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;Macrophages.M2;0,013197588;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;Macrophages.M2;0,012401572;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;Macrophages.M2;0,012401572;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,014840783;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,014840783;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,006562023;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,006562023;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,018260894;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Macrophages.M2;0,018260894;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,028518526;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,028518526;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,016127251;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,016127251;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,013808469;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,013808469;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,009862817;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,009862817;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;Macrophages.M2;0,024420478;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;Macrophages.M2;0,024420478;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;Macrophages.M2;0,01167888;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;Macrophages.M2;0,01167888;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;Macrophages.M2;0,014510721;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;Macrophages.M2;0,014510721;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,013143894;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,013143894;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;Macrophages.M2;0,014314828;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;Macrophages.M2;0,014314828;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;Macrophages.M2;0,004186313;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;Macrophages.M2;0,004186313;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,006982088;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,006982088;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,010038125;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,010038125;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;Macrophages.M2;0,020161639;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;Macrophages.M2;0,020161639;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,007141746;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,007141746;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;Macrophages.M2;0,003933994;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;Macrophages.M2;0,003933994;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;Macrophages.M2;0,00872881;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;Macrophages.M2;0,00872881;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;Macrophages.M2;0,009243306;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;Macrophages.M2;0,009243306;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,009404981;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,009404981;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,009579744;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,009579744;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;Macrophages.M2;0,023523807;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;Macrophages.M2;0,023523807;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,002371336;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,002371336;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,006817728;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,006817728;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,052849976;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Macrophages.M2;0,052849976;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;Macrophages.M2;0,018821934;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;Macrophages.M2;0,018821934;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,008588192;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,008588192;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;Macrophages.M2;0,043843442;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;Macrophages.M2;0,043843442;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;Macrophages.M2;0,023608645;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;Macrophages.M2;0,023608645;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,025087499;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Macrophages.M2;0,025087499;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;Macrophages.M2;0,011361286;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;Macrophages.M2;0,011361286;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;Macrophages.M2;0,006583318;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;Macrophages.M2;0,006583318;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,027343755;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,027343755;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;Macrophages.M2;0,009845611;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;Macrophages.M2;0,009845611;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,011428761;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,011428761;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,018512989;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Macrophages.M2;0,018512989;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;Macrophages.M2;0,008051544;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;Macrophages.M2;0,008051544;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,02385529;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Macrophages.M2;0,02385529;Metastasis
untreated;GSM1315904;Primary Tumor;Australia;19;22;Female;NA;0;4342,8;Stage II;not sustained response;GSE54467;Macrophages.M2;0,037785454;NA;
untreated;GSM1315905;Primary Tumor;Australia;53;56;Male;NA;1;1418,4;Stage II;NA;GSE54467;Macrophages.M2;0,020473216;NA;
untreated;GSM1315906;Primary Tumor;Australia;52;53;Female;NA;1;698,4;Stage II;NA;GSE54467;Macrophages.M2;0,024133557;NA;
untreated;GSM1315907;Primary Tumor;Australia;51;52;Male;NA;0;3330,6;Stage I;not sustained response;GSE54467;Macrophages.M2;0,036942498;NA;
untreated;GSM1315908;Primary Tumor;Australia;47;51;Male;NA;1;4283,4;Stage II;NA;GSE54467;Macrophages.M2;0,03336854;NA;
untreated;GSM1315909;Primary Tumor;Australia;61;64;Male;NA;1;1540,5;Stage I;NA;GSE54467;Macrophages.M2;0,025011898;NA;
untreated;GSM1315910;Primary Tumor;Australia;46;52;Female;NA;0;6957,3;Stage I;not sustained response;GSE54467;Macrophages.M2;0,039614849;NA;
untreated;GSM1315911;Primary Tumor;Australia;61;75;Male;NA;1;5484,9;Stage I;NA;GSE54467;Macrophages.M2;0,023283985;NA;
untreated;GSM1315912;Primary Tumor;Australia;84;87;Female;NA;1;1491,3;Stage I;NA;GSE54467;Macrophages.M2;0,032191404;NA;
untreated;GSM1315913;Primary Tumor;Australia;44;44;Female;NA;0;3899,7;Stage III;not sustained response;GSE54467;Macrophages.M2;0,020973429;NA;
untreated;GSM1315914;Primary Tumor;Australia;64;72;Male;NA;1;3322,8;Stage I;NA;GSE54467;Macrophages.M2;0,024421211;NA;
untreated;GSM1315915;Primary Tumor;Australia;31;31;Male;NA;0;3034,8;Stage III;not sustained response;GSE54467;Macrophages.M2;0,082855374;NA;
untreated;GSM1315916;Primary Tumor;Australia;63;65;Male;NA;1;654,9;Stage II;NA;GSE54467;Macrophages.M2;0,027008901;NA;
untreated;GSM1315917;Primary Tumor;Australia;58;59;Male;NA;1;1098,6;Stage III;NA;GSE54467;Macrophages.M2;0,034208086;NA;
untreated;GSM1315918;Primary Tumor;Australia;56;67;Male;NA;0;6538,2;Stage Unknown;not sustained response;GSE54467;Macrophages.M2;0,028254564;NA;
untreated;GSM1315919;Primary Tumor;Australia;48;57;Female;NA;1;3603,9;Stage II;NA;GSE54467;Macrophages.M2;0,042052702;NA;
untreated;GSM1315920;Primary Tumor;Australia;69;70;Male;NA;1;261,3;Stage III;NA;GSE54467;Macrophages.M2;0,020984003;NA;
untreated;GSM1315921;Primary Tumor;Australia;76;77;Male;NA;1;593,7;Stage II;NA;GSE54467;Macrophages.M2;0,037622786;NA;
untreated;GSM1315922;Primary Tumor;Australia;54;55;Female;NA;1;592,8;Stage III;NA;GSE54467;Macrophages.M2;0,062549304;NA;
untreated;GSM1315923;Primary Tumor;Australia;82;85;Male;NA;1;2242,8;Stage II;responder;GSE54467;Macrophages.M2;0,019623297;NA;
untreated;GSM1315924;Primary Tumor;Australia;79;80;Male;NA;0;2393,7;Stage I;not sustained response;GSE54467;Macrophages.M2;0,045538902;NA;
untreated;GSM1315925;Primary Tumor;Australia;50;54;Male;NA;0;2986,5;Stage II;not sustained response;GSE54467;Macrophages.M2;0,045078234;NA;
untreated;GSM1315926;Primary Tumor;Australia;57;57;Female;NA;0;305,7;Stage III;non-responder;GSE54467;Macrophages.M2;0,03218893;NA;
untreated;GSM1315927;Primary Tumor;Australia;32;45;Male;NA;0;7826,4;Stage I;not sustained response;GSE54467;Macrophages.M2;0,031386;NA;
untreated;GSM1315928;Primary Tumor;Australia;77;78;Female;NA;1;589,8;Stage III;NA;GSE54467;Macrophages.M2;0,023919242;NA;
untreated;GSM1315929;Primary Tumor;Australia;56;56;Male;NA;1;588,9;Stage III;NA;GSE54467;Macrophages.M2;0,040820454;NA;
untreated;GSM1315930;Primary Tumor;Australia;39;40;Female;NA;1;644,1;Stage II;NA;GSE54467;Macrophages.M2;0,071912431;NA;
untreated;GSM1315931;Primary Tumor;Australia;84;87;Female;NA;1;3090;Stage II;NA;GSE54467;Macrophages.M2;0,009132911;NA;
untreated;GSM1315932;Primary Tumor;Australia;57;60;Female;NA;1;1734,9;Stage II;NA;GSE54467;Macrophages.M2;0,029902742;NA;
untreated;GSM1315933;Primary Tumor;Australia;23;28;Male;NA;1;3096;Stage I;NA;GSE54467;Macrophages.M2;0,040683194;NA;
untreated;GSM1315934;Primary Tumor;Australia;63;66;Male;NA;1;3007,2;Stage I;NA;GSE54467;Macrophages.M2;0,021398889;NA;
untreated;GSM1315935;Primary Tumor;Australia;53;54;Male;NA;1;723,9;Stage II;NA;GSE54467;Macrophages.M2;0,030325969;NA;
untreated;GSM1315936;Primary Tumor;Australia;72;72;Male;NA;0;3205,5;Stage II;not sustained response;GSE54467;Macrophages.M2;0,025869684;NA;
untreated;GSM1315937;Primary Tumor;Australia;60;67;Male;NA;1;3228,3;Stage I;NA;GSE54467;Macrophages.M2;0,025793814;NA;
untreated;GSM1315938;Primary Tumor;Australia;67;69;Male;NA;1;864,9;Stage II;NA;GSE54467;Macrophages.M2;0,032885562;NA;
untreated;GSM1315939;Primary Tumor;Australia;61;61;Male;NA;1;325,5;Stage III;NA;GSE54467;Macrophages.M2;0,029908378;NA;
untreated;GSM1315940;Primary Tumor;Australia;35;54;Male;NA;0;8526,6;Stage II;not sustained response;GSE54467;Macrophages.M2;0,043975028;NA;
untreated;GSM1315941;Primary Tumor;Australia;60;63;Male;NA;1;2886,9;Stage II;responder;GSE54467;Macrophages.M2;0,02283291;NA;
untreated;GSM1315942;Primary Tumor;Australia;30;30;Male;NA;0;2114,7;Stage III;not sustained response;GSE54467;Macrophages.M2;0,060729346;NA;
untreated;GSM1315943;Primary Tumor;Australia;66;67;Male;NA;1;508,8;Stage II;NA;GSE54467;Macrophages.M2;0,035579448;NA;
untreated;GSM1315944;Primary Tumor;Australia;50;54;Female;NA;1;2062,5;Stage II;NA;GSE54467;Macrophages.M2;0,05305777;NA;
untreated;GSM1315945;Primary Tumor;Australia;28;30;Male;NA;1;3093,9;Stage II;NA;GSE54467;Macrophages.M2;0,026509275;NA;
untreated;GSM1315946;Primary Tumor;Australia;58;60;Male;NA;1;1426,2;Stage I;NA;GSE54467;Macrophages.M2;0,034170906;NA;
untreated;GSM1315947;Primary Tumor;Australia;66;69;Female;NA;1;1518,9;Stage III;NA;GSE54467;Macrophages.M2;0,01499206;NA;
untreated;GSM1315948;Primary Tumor;Australia;49;57;Female;NA;0;6582,6;Stage I;not sustained response;GSE54467;Macrophages.M2;0,016517465;NA;
untreated;GSM1315949;Primary Tumor;Australia;69;69;Male;NA;1;446,7;Stage III;NA;GSE54467;Macrophages.M2;0,052083358;NA;
untreated;GSM1315950;Primary Tumor;Australia;55;56;Male;NA;0;3286,5;Stage III;not sustained response;GSE54467;Macrophages.M2;0,087873273;NA;
untreated;GSM1315951;Primary Tumor;Australia;52;58;Male;NA;1;3098,1;Stage I;NA;GSE54467;Macrophages.M2;0,020556095;NA;
untreated;GSM1315952;Primary Tumor;Australia;61;74;Female;NA;1;4687,8;Stage I;NA;GSE54467;Macrophages.M2;0,017020419;NA;
untreated;GSM1315953;Primary Tumor;Australia;74;75;Male;NA;1;1845,3;Stage I;responder;GSE54467;Macrophages.M2;0,034988204;NA;
untreated;GSM1315954;Primary Tumor;Australia;40;40;Male;NA;0;2916,6;Stage III;not sustained response;GSE54467;Macrophages.M2;0,035194232;NA;
untreated;GSM1315955;Primary Tumor;Australia;36;44;Male;NA;0;6242,4;Stage II;non-responder;GSE54467;Macrophages.M2;0,025208399;NA;
untreated;GSM1315956;Primary Tumor;Australia;70;73;Female;NA;0;3861,3;Stage II;not sustained response;GSE54467;Macrophages.M2;0,030600391;NA;
untreated;GSM1315957;Primary Tumor;Australia;67;67;Male;NA;0;1219,2;Stage III;not sustained response;GSE54467;Macrophages.M2;0,030520161;NA;
untreated;GSM1315958;Primary Tumor;Australia;53;66;Male;NA;1;5252,1;Stage I;NA;GSE54467;Macrophages.M2;0,030661494;NA;
untreated;GSM1315959;Primary Tumor;Australia;64;64;Female;NA;0;3633,6;Stage III;not sustained response;GSE54467;Macrophages.M2;0,038593614;NA;
untreated;GSM1315960;Primary Tumor;Australia;59;61;Male;NA;0;5126,7;Stage I;not sustained response;GSE54467;Macrophages.M2;0,045876843;NA;
untreated;GSM1315961;Primary Tumor;Australia;78;88;Male;NA;1;6904,2;Stage I;NA;GSE54467;Macrophages.M2;0,042226777;NA;
untreated;GSM1315962;Primary Tumor;Australia;62;64;Male;NA;0;3878,1;Stage I;not sustained response;GSE54467;Macrophages.M2;0,079221239;NA;
untreated;GSM1315963;Primary Tumor;Australia;30;63;Male;NA;1;12093,9;Stage I;NA;GSE54467;Macrophages.M2;0,018390494;NA;
untreated;GSM1315964;Primary Tumor;Australia;40;46;Female;NA;1;2208,3;Stage III;NA;GSE54467;Macrophages.M2;0,03720731;NA;
untreated;GSM1315965;Primary Tumor;Australia;58;63;Female;NA;1;3665,1;Stage II;NA;GSE54467;Macrophages.M2;0,034071894;NA;
untreated;GSM1315966;Primary Tumor;Australia;39;40;Female;NA;0;3431,4;Stage I;not sustained response;GSE54467;Macrophages.M2;0,035851142;NA;
untreated;GSM1315967;Primary Tumor;Australia;49;50;Male;NA;1;650,1;Stage I;NA;GSE54467;Macrophages.M2;0,022766388;NA;
untreated;GSM1315968;Primary Tumor;Australia;50;51;Male;NA;0;4334,7;Stage II;not sustained response;GSE54467;Macrophages.M2;0,02714741;NA;
untreated;GSM1315969;Primary Tumor;Australia;24;24;Male;NA;0;1256,4;Stage III;not sustained response;GSE54467;Macrophages.M2;0,028912252;NA;
untreated;GSM1315970;Primary Tumor;Australia;70;73;Female;NA;0;2782,5;Stage II;not sustained response;GSE54467;Macrophages.M2;0,028379891;NA;
untreated;GSM1315971;Primary Tumor;Australia;83;86;Male;NA;1;1875;Stage II;responder;GSE54467;Macrophages.M2;0,015627857;NA;
untreated;GSM1315972;Primary Tumor;Australia;68;75;Female;NA;0;6019,5;Stage I;not sustained response;GSE54467;Macrophages.M2;0,041171035;NA;
untreated;GSM1315973;Primary Tumor;Australia;47;47;Male;NA;0;1506;Stage III;not sustained response;GSE54467;Macrophages.M2;0,027451683;NA;
untreated;GSM1315974;Primary Tumor;Australia;48;48;Female;NA;0;2405,7;Stage I;not sustained response;GSE54467;Macrophages.M2;0,027381462;NA;
untreated;GSM1315975;Primary Tumor;Australia;52;53;Male;NA;1;582;Stage III;NA;GSE54467;Macrophages.M2;0,036219072;NA;
untreated;GSM1315976;Primary Tumor;Australia;60;67;Female;NA;0;5314,2;Stage I;non-responder;GSE54467;Macrophages.M2;0,012692174;NA;
untreated;GSM1315977;Primary Tumor;Australia;45;50;Female;NA;1;3722,4;Stage II;NA;GSE54467;Macrophages.M2;0,041581817;NA;
untreated;GSM1315978;Primary Tumor;Australia;68;73;Female;NA;1;3316,8;Stage I;NA;GSE54467;Macrophages.M2;0,035317416;NA;
untreated;GSM1315979;Primary Tumor;Australia;78;80;Male;NA;0;1305,9;Stage I;NA;GSE54467;Macrophages.M2;0,03604726;NA;
untreated;GSM1315980;Primary Tumor;Australia;56;56;Female;NA;1;708,3;Stage II;NA;GSE54467;Macrophages.M2;0,034157592;NA;
untreated;GSM1315981;Primary Tumor;Australia;74;74;Female;NA;1;121,2;Stage II;NA;GSE54467;Macrophages.M2;0,028056161;NA;
untreated;GSM1315982;Primary Tumor;Australia;66;75;Male;NA;1;3691,8;Stage I;NA;GSE54467;Macrophages.M2;0,047876823;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872328;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,096168649;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872329;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,104985212;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872330;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,08969266;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872331;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,055287908;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872332;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,130634161;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872333;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,048991721;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872334;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,0502192;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872335;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,047848242;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872336;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,020211244;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872337;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,029454299;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872338;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,032336952;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872339;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,032987643;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872340;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,024497748;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872341;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,046556603;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872342;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,063018789;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872343;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,014316168;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872344;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,034152669;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872345;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,043371109;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872346;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,074431103;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872347;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,030132307;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872348;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,030062193;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872349;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,071052019;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872350;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,060146073;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872351;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,014023351;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872352;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,011077831;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872353;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,025005641;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872354;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,028379596;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872355;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872356;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,019366639;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872357;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,05528894;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872358;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,003683376;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872359;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,072310957;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872360;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,073323243;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872361;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,035263998;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872362;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,052886211;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872363;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,003525177;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872364;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872365;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,01566429;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872366;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,010087675;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872367;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,003379034;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872368;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,099976682;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872369;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,073741702;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872370;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,007882915;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872371;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,08190638;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872372;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,007529032;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872373;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,027666616;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872374;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,050860417;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872375;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,051144269;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872376;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,067196572;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872377;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,091557344;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872378;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,127410222;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872379;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,111485189;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872380;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,074124044;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872381;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,074588734;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872382;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Monocytes;0,056414913;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872383;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Monocytes;0,039734682;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872384;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Monocytes;0,016621912;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872385;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Monocytes;0,043271685;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872386;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Monocytes;0,04360024;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872387;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Monocytes;0,030520672;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872388;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Monocytes;0,045379534;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872389;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Monocytes;0,027073792;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872390;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Monocytes;0,069892908;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872391;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Monocytes;0,028471874;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872392;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Monocytes;0,069663382;NA;
Standard (dacarbazine monotherapy; DTIC);GSM550966;Metastatic;Sweden;60;62;Male;Trunk;1;373;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550967;Metastatic;Sweden;54;59;Female;Lower extremity;1;181;IV;NA;GSE22155_GPL6102;Monocytes;0,04934554;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550968;Metastatic;Sweden;40;53;Male;Head;1;436;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550969;Metastatic;Sweden;54;61;Female;Lower extremity;1;82;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550970;Metastatic;Sweden;45;47;Male;Lower extremity;1;646;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550971;Metastatic;Sweden;68;68;Male;No primary detected;1;114;IV;NA;GSE22155_GPL6102;Monocytes;0,01240516;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550972;Metastatic;Sweden;36;38;Male;Upper extremity, acral;1;322;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550973;Metastatic;Sweden;63;65;Female;Trunk;1;46;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550974;Metastatic;Sweden;51;51;Male;No primary detected;0;3509;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550975;Metastatic;Sweden;79;86;Male;Head;1;65;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550976;Metastatic;Sweden;50;51;Male;Trunk;1;14;IV;NA;GSE22155_GPL6102;Monocytes;0,100009112;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550977;Metastatic;Sweden;58;59;Female;Upper extremity;1;27;IV;NA;GSE22155_GPL6102;Monocytes;0,007240626;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550978;Metastatic;Sweden;36;36;Male;No primary detected;-;-;III;NA;GSE22155_GPL6102;Monocytes;0,056855662;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550979;Metastatic;Sweden;60;66;Female;Upper extremity;1;45;IV;NA;GSE22155_GPL6102;Monocytes;0,119160927;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550980;Metastatic;Sweden;53;53;Female;No primary detected;1;10;IV;NA;GSE22155_GPL6102;Monocytes;0,153385324;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550981;Metastatic;Sweden;27;32;Female;Trunk;0;2711;IV;NA;GSE22155_GPL6102;Monocytes;0,120150204;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550982;Metastatic;Sweden;49;51;Male;Lower extremity;1;32;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550983;Metastatic;Sweden;62;63;Male;No primary detected;1;55;IV;NA;GSE22155_GPL6102;Monocytes;0,044375414;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550984;Metastatic;Sweden;50;71;Male;Upper extremity;1;91;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550985;Metastatic;Sweden;49;63;Female;Trunk;1;804;IV;NA;GSE22155_GPL6102;Monocytes;0,074152661;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550986;Metastatic;Sweden;55;61;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;Monocytes;0,001934619;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550987;Metastatic;Sweden;55;80;Male;Trunk;1;25;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550988;Metastatic;Sweden;78;78;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;Monocytes;9,24E-04;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550989;Metastatic;Sweden;56;57;Male;No primary detected;1;50;IV;NA;GSE22155_GPL6102;Monocytes;0,105823595;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550990;Metastatic;Sweden;74;76;Female;Head;1;156;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550991;Metastatic;Sweden;53;70;Male;Trunk;1;219;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550992;Metastatic;Sweden;36;49;Male;Trunk;1;266;IV;NA;GSE22155_GPL6102;Monocytes;0,046192253;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550993;Metastatic;Sweden;33;33;Male;No primary detected;1;1075;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550994;Metastatic;Sweden;67;67;Female;No primary detected;1;201;IV;NA;GSE22155_GPL6102;Monocytes;0,066870076;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550995;Metastatic;Sweden;72;74;Male;Trunk;1;247;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550996;Metastatic;Sweden;27;31;Female;Trunk;1;414;IV;NA;GSE22155_GPL6102;Monocytes;0,044770493;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550997;Metastatic;Sweden;32;43;Female;No primary detected;1;108;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550998;Metastatic;Sweden;59;61;Female;Trunk;-;-;III;NA;GSE22155_GPL6102;Monocytes;0,039836345;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550999;Metastatic;Sweden;61;61;Male;No primary detected;1;281;IV;NA;GSE22155_GPL6102;Monocytes;0,035382435;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551000;Metastatic;Sweden;73;73;Male;Head and eye;1;221;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551001;Metastatic;Sweden;54;55;Male;Trunk;1;102;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551002;Metastatic;Sweden;68;68;Female;No primary detected;1;301;IV;NA;GSE22155_GPL6102;Monocytes;0,034178674;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551003;Metastatic;Sweden;62;68;Female;Trunk;1;64;IV;NA;GSE22155_GPL6102;Monocytes;0,018141897;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551004;Metastatic;Sweden;35;36;Female;No primary detected;1;375;IV;NA;GSE22155_GPL6102;Monocytes;0,074535651;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551005;Metastatic;Sweden;76;79;Female;Trunk;1;218;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551006;Metastatic;Sweden;66;68;Male;Head;1;1478;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551007;Metastatic;Sweden;46;52;Female;Trunk;1;13;IV;NA;GSE22155_GPL6102;Monocytes;0,005906581;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551008;Metastatic;Sweden;65;67;Male;Trunk;1;254;IV;NA;GSE22155_GPL6102;Monocytes;0,070451616;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551009;Metastatic;Sweden;70;70;Female;Upper extremity;1;16;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551010;Metastatic;Sweden;68;72;Male;Trunk;1;430;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551011;Metastatic;Sweden;82;84;Male;Trunk;1;63;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551012;Metastatic;Sweden;35;68;Male;Upper extremity;0;1198;IV;NA;GSE22155_GPL6102;Monocytes;0,010364332;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551013;Metastatic;Sweden;31;38;Male;Trunk;-;-;III;NA;GSE22155_GPL6102;Monocytes;0,031412308;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551014;Metastatic;Sweden;79;79;Female;Trunk;0;927;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551015;Metastatic;Sweden;77;82;Female;Upper extremity;1;325;IV;NA;GSE22155_GPL6102;Monocytes;0,052308572;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551016;Metastatic;Sweden;72;76;Male;Lower extremity;1;44;IV;NA;GSE22155_GPL6102;Monocytes;0,09186509;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551017;Metastatic;Sweden;75;75;Female;Lower extremity;0;895;IV;NA;GSE22155_GPL6102;Monocytes;0,013274843;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551018;Metastatic;Sweden;58;61;Male;Trunk;0;836;IV;NA;GSE22155_GPL6102;Monocytes;0,085034543;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551019;Metastatic;Sweden;71;74;Female;Lower extremity, acral;0;786;IV;NA;GSE22155_GPL6102;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551020;Metastatic;Sweden;65;76;Male;Trunk;1;244;IV;NA;GSE22155_GPL6102;Monocytes;0,020519189;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551021;Metastatic;Sweden;25;25;Female;Lower extremity;1;78;IV;NA;GSE22155_GPL6102;Monocytes;0,02631554;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551022;Metastatic;Sweden;50;75;Male;Trunk;1;29;IV;NA;GSE22155_GPL6102;Monocytes;0,23683217;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551023;Metastatic;Sweden;75;76;Male;Acral;1;44;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551024;Metastatic;Sweden;63;64;Female;Genital;1;747;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551025;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551026;Metastatic;Sweden;68;68;Female;GI tractus;1;367;IV;NA;GSE22155_GPL6947;Monocytes;0,017958616;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551027;Metastatic;Sweden;58;60;Male;Eye;1;7;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551028;Metastatic;Sweden;49;63;Male;Trunk;1;309;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551029;Metastatic;Sweden;56;55;Female;Trunk;1;32;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551030;Metastatic;Sweden;74;74;Male;Trunk;1;79;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551031;Metastatic;Sweden;41;42;Female;Eye;1;349;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551032;Metastatic;Sweden;49;51;Female;Mucosa, head;1;13;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551033;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;Monocytes;0,034528587;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551034;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;Monocytes;0,041895165;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551035;Metastatic;Sweden;56;56;Male;GI tractus;1;37;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551036;Metastatic;Sweden;45;74;Male;No primary;1;183;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551037;Metastatic;Sweden;72;75;Female;Head;1;39;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551038;Metastatic;Sweden;61;68;Female;Eye;1;513;IV;NA;GSE22155_GPL6947;Monocytes;0,016274015;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551039;Metastatic;Sweden;66;68;Male;Trunk;1;584;IV;NA;GSE22155_GPL6947;Monocytes;0,014314082;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551040;Metastatic;Sweden;42;44;Male;Head;1;1148;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551041;Metastatic;Sweden;54;56;Female;Trunk;1;153;IV;NA;GSE22155_GPL6947;Monocytes;0,010863433;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551042;Metastatic;Sweden;48;50;Male;Trunk;1;141;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551043;Metastatic;Sweden;58;67;Female;Acral;1;334;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551044;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;Monocytes;0;Metastasis
untreated;GSM1220412;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Monocytes;0,024396118;Metastasis;
dabrafenib;GSM1220413;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,036725229;cutaneous or subcutaneous;
untreated;GSM1220414;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0;cutaneous or subcutaneous;
dabrafenib;GSM1220415;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,028877095;cutaneous or subcutaneous;
untreated;GSM1220416;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0;cutaneous or subcutaneous;
dabrafenib;GSM1220417;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,005174945;cutaneous or subcutaneous;
dabrafenib;GSM1220418;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,02265979;cutaneous or subcutaneous;
untreated;GSM1220419;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Monocytes;0,057551003;Metastasis;
dabrafenib;GSM1220420;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;Monocytes;0,09811667;Metastasis;
untreated;GSM1220421;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0;cutaneous or subcutaneous;
dabrafenib;GSM1220422;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,012715688;cutaneous or subcutaneous;
dabrafenib;GSM1220423;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,004606321;cutaneous or subcutaneous;
untreated;GSM1220424;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,051269316;cutaneous or subcutaneous;
untreated;GSM1220425;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,053767568;cutaneous or subcutaneous;
dabrafenib;GSM1220426;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Monocytes;0,064647212;Metastasis;
untreated;GSM1220427;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,044404759;cutaneous or subcutaneous;
untreated;GSM1220428;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,024394541;cutaneous or subcutaneous;
dabrafenib;GSM1220429;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,082181437;cutaneous or subcutaneous;
dabrafenib;GSM1220430;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,046221096;cutaneous or subcutaneous;
untreated;GSM1220431;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,042160353;cutaneous or subcutaneous;
dabrafenib;GSM1220432;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,022697736;cutaneous or subcutaneous;
untreated;GSM1220433;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,069935825;cutaneous or subcutaneous;
untreated;GSM1220434;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,063561254;cutaneous or subcutaneous;
dabrafenib;GSM1220435;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,066897157;cutaneous or subcutaneous;
dabrafenib;GSM1220436;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0;cutaneous or subcutaneous;
dabrafenib;GSM1220437;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0;cutaneous or subcutaneous;
untreated;GSM1220438;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Monocytes;0;Metastasis;
untreated;GSM1220439;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Monocytes;0;Metastasis;
dabrafenib;GSM1220440;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0;cutaneous or subcutaneous;
dabrafenib;GSM1220441;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Monocytes;0,039127881;Metastasis;
dabrafenib;GSM1220442;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0;cutaneous or subcutaneous;
dabrafenib;GSM1220443;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Monocytes;0,014120946;Metastasis;
untreated;GSM1220444;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Monocytes;6,84E-04;Metastasis;
dabrafenib;GSM1220445;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,030446949;cutaneous or subcutaneous;
untreated;GSM1220446;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,110329201;cutaneous or subcutaneous;
untreated;GSM1220447;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,099291242;cutaneous or subcutaneous;
dabrafenib;GSM1220448;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,043472344;cutaneous or subcutaneous;
untreated;GSM1220449;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Monocytes;0;Metastasis;
dabrafenib;GSM1220450;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,031986761;cutaneous or subcutaneous;
untreated;GSM1220451;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Monocytes;0,076732724;Metastasis;
dabrafenib;GSM1220452;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;Monocytes;0,035130621;Metastasis;
untreated;GSM1220453;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,026688985;cutaneous or subcutaneous;
untreated;GSM1220454;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,035455521;cutaneous or subcutaneous;
dabrafenib;GSM1220455;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;Monocytes;0,00634861;Metastasis;
dabrafenib;GSM1220456;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,021819059;cutaneous or subcutaneous;
untreated;GSM1220457;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,04023511;cutaneous or subcutaneous;
dabrafenib;GSM1220458;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Monocytes;0,007019406;Metastasis;
untreated;GSM1220459;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,080564091;cutaneous or subcutaneous;
vemurafenib;GSM1220460;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,034877488;cutaneous or subcutaneous;
untreated;GSM1220461;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,034534159;cutaneous or subcutaneous;
untreated;GSM1220462;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,03198972;cutaneous or subcutaneous;
vemurafenib;GSM1220463;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,03951396;cutaneous or subcutaneous;
untreated;GSM1220464;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Monocytes;0,017959809;Metastasis;
vemurafenib;GSM1220465;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,073981156;cutaneous or subcutaneous;
untreated;GSM1220466;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,013623541;cutaneous or subcutaneous;
vemurafenib;GSM1220467;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,050169044;cutaneous or subcutaneous;
vemurafenib;GSM1220468;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,023124569;cutaneous or subcutaneous;
vemurafenib;GSM1220469;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,048993391;cutaneous or subcutaneous;
vemurafenib;GSM1220470;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,018663169;cutaneous or subcutaneous;
untreated;GSM1220471;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Monocytes;0,033523274;cutaneous or subcutaneous;
vemurafenib;GSM1220472;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;Monocytes;0,013120634;Metastasis;
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;Monocytes;0,001390007;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;Monocytes;0,001390007;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001556328;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001556328;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,00109293;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,00109293;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;Monocytes;0,00137469;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;Monocytes;0,00137469;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;9,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;9,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001971799;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001971799;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;Monocytes;0,001039613;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;Monocytes;0,001039613;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;Monocytes;6,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;Monocytes;6,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;Monocytes;0,005384245;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;Monocytes;0,005384245;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;9,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;9,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,003209059;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,003209059;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;Monocytes;0,002132574;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;Monocytes;0,002132574;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;Monocytes;0,001281642;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;Monocytes;0,001281642;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;Monocytes;0,001718591;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;Monocytes;0,001718591;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,002126937;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,002126937;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;Monocytes;0,002510703;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;Monocytes;0,002510703;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;8,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;8,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;Monocytes;0,001122838;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;Monocytes;0,001122838;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001666723;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001666723;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;Monocytes;0,001253009;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;Monocytes;0,001253009;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;Monocytes;0,001439644;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;Monocytes;0,001439644;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Monocytes;0,001721687;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Monocytes;0,001721687;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;Monocytes;0,005313389;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;Monocytes;0,005313389;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;0,001386607;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;0,001386607;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;Monocytes;0,002742549;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;Monocytes;0,002742549;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002628703;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002628703;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;0,001354795;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;0,001354795;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Monocytes;0,001355422;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Monocytes;0,001355422;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;Monocytes;7,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;Monocytes;7,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,00157473;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,00157473;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001083153;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001083153;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;Monocytes;9,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;Monocytes;9,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;4,00E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;4,00E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;Monocytes;0,001269009;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;Monocytes;0,001269009;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001568137;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001568137;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,002952112;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,002952112;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;Monocytes;7,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;Monocytes;7,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;Monocytes;0,001429921;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;Monocytes;0,001429921;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001773542;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001773542;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;Monocytes;3,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;Monocytes;3,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;Monocytes;0,003028537;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;Monocytes;0,003028537;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;Monocytes;0,004478933;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;Monocytes;0,004478933;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;9,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;9,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;Monocytes;8,50E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;Monocytes;8,50E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,001055732;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,001055732;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;Monocytes;0,001897408;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;Monocytes;0,001897408;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,002035836;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,002035836;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;Monocytes;0,00124134;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;Monocytes;0,00124134;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;Monocytes;0,001353821;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;Monocytes;0,001353821;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;Monocytes;0,001307936;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;Monocytes;0,001307936;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;Monocytes;0,001057409;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;Monocytes;0,001057409;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;9,92E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;9,92E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;8,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;8,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,0013476;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,0013476;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002454286;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002454286;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001421997;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001421997;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Monocytes;0,006505482;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Monocytes;0,006505482;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;6,88E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;6,88E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;6,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;6,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;Monocytes;0,001170227;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;Monocytes;0,001170227;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Monocytes;0,001174839;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Monocytes;0,001174839;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;9,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;9,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;Monocytes;0,00243594;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;Monocytes;0,00243594;NA
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;Monocytes;0,001259162;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;Monocytes;0,001259162;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001630987;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001630987;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001049271;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001049271;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;Monocytes;0,00228756;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;Monocytes;0,00228756;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001286749;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001286749;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001241899;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001241899;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;Monocytes;0,0010757;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;Monocytes;0,0010757;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;Monocytes;0,001023281;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;Monocytes;0,001023281;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;Monocytes;0,003557958;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;Monocytes;0,003557958;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;9,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;9,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Monocytes;0,001919222;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Monocytes;0,001919222;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;2,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;2,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002619272;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002619272;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,002513824;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,002513824;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001427966;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001427966;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;9,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;9,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001392606;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001392606;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002235381;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002235381;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;Monocytes;0,013661274;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;Monocytes;0,013661274;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;Monocytes;0,001489496;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;Monocytes;0,001489496;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Monocytes;0,002709991;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Monocytes;0,002709991;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002405994;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002405994;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;Monocytes;0,001360522;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;Monocytes;0,001360522;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;Monocytes;0,004266505;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;Monocytes;0,004266505;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;Monocytes;0,001882528;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;Monocytes;0,001882528;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;Monocytes;0,001205025;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;Monocytes;0,001205025;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001060564;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001060564;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001922407;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001922407;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;Monocytes;0,001642268;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;Monocytes;0,001642268;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;7,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;7,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;Monocytes;0,003321493;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;Monocytes;0,003321493;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;0,001564404;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;0,001564404;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Monocytes;0,00222868;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Monocytes;0,00222868;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;Monocytes;0,001998401;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;Monocytes;0,001998401;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;Monocytes;0,001574445;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;Monocytes;0,001574445;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;Monocytes;0,00151213;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;Monocytes;0,00151213;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;Monocytes;0,001018351;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;Monocytes;0,001018351;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Monocytes;0,002895923;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Monocytes;0,002895923;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;Monocytes;0,001786393;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;Monocytes;0,001786393;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;Monocytes;0,001099174;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;Monocytes;0,001099174;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;Monocytes;0,001731627;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;Monocytes;0,001731627;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002572162;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002572162;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;Monocytes;0,001307463;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;Monocytes;0,001307463;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;Monocytes;0,001183967;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;Monocytes;0,001183967;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;Monocytes;0,001512371;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;Monocytes;0,001512371;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;Monocytes;0,004814618;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;Monocytes;0,004814618;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;Monocytes;0,002644125;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;Monocytes;0,002644125;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;Monocytes;7,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;Monocytes;7,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;Monocytes;0,00116035;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;Monocytes;0,00116035;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,00154316;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,00154316;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;Monocytes;0,001737569;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;Monocytes;0,001737569;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;Monocytes;0,001843923;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;Monocytes;0,001843923;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;6,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;6,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;Monocytes;0,002209808;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;Monocytes;0,002209808;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;Monocytes;0,001541585;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;Monocytes;0,001541585;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Monocytes;7,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Monocytes;7,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;Monocytes;0,002606522;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;Monocytes;0,002606522;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Monocytes;9,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Monocytes;9,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;3,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;3,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;Monocytes;6,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;Monocytes;6,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,003707925;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,003707925;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;Monocytes;0,001798379;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;Monocytes;0,001798379;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,00193448;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,00193448;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;Monocytes;0,001319116;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;Monocytes;0,001319116;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;Monocytes;0,00192177;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;Monocytes;0,00192177;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;5,23E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;5,23E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;Monocytes;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;Monocytes;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;Monocytes;0,001687474;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;Monocytes;0,001687474;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Monocytes;9,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Monocytes;9,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;0,001326336;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;0,001326336;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;Monocytes;0,008800804;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;Monocytes;0,008800804;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,001312932;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,001312932;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;Monocytes;0,001146337;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;Monocytes;0,001146337;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,002595175;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,002595175;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;Monocytes;0,001547945;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;Monocytes;0,001547945;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Monocytes;0,002363755;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Monocytes;0,002363755;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001458527;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001458527;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,002594581;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,002594581;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,00142166;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,00142166;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001398221;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001398221;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;8,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;8,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;Monocytes;0,001390476;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;Monocytes;0,001390476;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;Monocytes;0,002149994;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;Monocytes;0,002149994;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001565506;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001565506;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;0,00118433;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;0,00118433;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;Monocytes;0,001148622;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;Monocytes;0,001148622;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001025639;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001025639;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;Monocytes;0,012209413;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;Monocytes;0,012209413;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,003422782;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,003422782;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001369623;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001369623;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001562533;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001562533;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;Monocytes;0,001463242;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;Monocytes;0,001463242;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001721967;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001721967;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001090315;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001090315;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001995098;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001995098;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;Monocytes;4,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;Monocytes;4,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;Monocytes;0,001059266;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;Monocytes;0,001059266;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;Monocytes;0,001084897;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;Monocytes;0,001084897;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;Monocytes;9,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;Monocytes;9,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Monocytes;8,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Monocytes;8,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002912942;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002912942;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,002505738;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,002505738;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;Monocytes;0,001835036;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;Monocytes;0,001835036;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;Monocytes;0,001277271;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;Monocytes;0,001277271;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Monocytes;0,001323202;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Monocytes;0,001323202;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;8,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;8,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;Monocytes;0,005622084;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;Monocytes;0,005622084;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,00271371;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,00271371;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001153182;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001153182;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;Monocytes;0,001510357;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;Monocytes;0,001510357;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001584843;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001584843;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;Monocytes;0,001771302;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;Monocytes;0,001771302;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Monocytes;6,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Monocytes;6,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;Monocytes;0,002064073;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;Monocytes;0,002064073;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,002700985;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,002700985;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;Monocytes;0,005861497;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;Monocytes;0,005861497;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;Monocytes;0,001555526;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;Monocytes;0,001555526;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;7,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;7,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001349865;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001349865;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;Monocytes;0,003431802;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;Monocytes;0,003431802;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Monocytes;0,001569239;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Monocytes;0,001569239;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;Monocytes;0,004114421;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;Monocytes;0,004114421;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;Monocytes;0,001912455;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;Monocytes;0,001912455;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;Monocytes;9,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;Monocytes;9,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001191677;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001191677;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Monocytes;8,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Monocytes;8,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;Monocytes;0,001147269;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;Monocytes;0,001147269;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;Monocytes;0,002302076;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;Monocytes;0,002302076;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;Monocytes;0,001182469;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;Monocytes;0,001182469;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;Monocytes;0,001970414;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;Monocytes;0,001970414;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Monocytes;9,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Monocytes;9,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;7,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;7,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;Monocytes;0,001285322;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;Monocytes;0,001285322;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Monocytes;9,03E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Monocytes;9,03E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;Monocytes;0,004556613;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;Monocytes;0,004556613;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;Monocytes;0,001177906;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;Monocytes;0,001177906;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;Monocytes;0,00203712;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;Monocytes;0,00203712;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;Monocytes;0,001190871;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;Monocytes;0,001190871;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;Monocytes;9,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;Monocytes;9,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;7,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;7,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;Monocytes;0,001734027;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;Monocytes;0,001734027;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;Monocytes;0,001254521;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;Monocytes;0,001254521;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,00171302;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,00171302;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;Monocytes;0,003308416;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;Monocytes;0,003308416;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;Monocytes;0,002464047;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;Monocytes;0,002464047;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,003041949;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,003041949;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002711752;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002711752;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001766679;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001766679;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;Monocytes;0,001944759;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;Monocytes;0,001944759;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;Monocytes;0,002310146;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;Monocytes;0,002310146;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;5,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;5,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;Monocytes;0,001501034;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;Monocytes;0,001501034;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Monocytes;0,001139339;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Monocytes;0,001139339;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;0,001490293;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;0,001490293;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;8,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;8,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;0,001508692;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;0,001508692;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;Monocytes;0,002524905;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;Monocytes;0,002524905;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001418578;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001418578;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,002016384;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,002016384;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001502996;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001502996;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001853884;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001853884;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;Monocytes;0,001207639;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;Monocytes;0,001207639;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;Monocytes;0,001149614;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;Monocytes;0,001149614;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001334652;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001334652;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;Monocytes;0,001484795;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;Monocytes;0,001484795;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;6,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;6,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;7,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;7,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001562239;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001562239;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;Monocytes;0,001685574;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;Monocytes;0,001685574;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001170724;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001170724;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001241077;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001241077;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;Monocytes;0,001391595;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;Monocytes;0,001391595;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;Monocytes;0,002389756;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;Monocytes;0,002389756;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;Monocytes;0,001075866;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;Monocytes;0,001075866;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002916291;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002916291;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;7,26E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;7,26E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;Monocytes;0,001143221;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;Monocytes;0,001143221;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Monocytes;0,001215959;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Monocytes;0,001215959;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;Monocytes;0,002327468;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;Monocytes;0,002327468;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Monocytes;9,57E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Monocytes;9,57E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;Monocytes;0,001522667;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;Monocytes;0,001522667;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001692434;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001692434;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;Monocytes;0,002135252;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;Monocytes;0,002135252;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;Monocytes;0,003501279;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;Monocytes;0,003501279;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;Monocytes;0,002599958;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;Monocytes;0,002599958;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;7,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;7,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;8,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;8,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Monocytes;0,002024304;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Monocytes;0,002024304;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,002619608;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,002619608;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;Monocytes;0,001112623;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;Monocytes;0,001112623;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;Monocytes;0,001386216;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;Monocytes;0,001386216;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;Monocytes;9,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;Monocytes;9,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001059764;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001059764;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001225386;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001225386;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;Monocytes;0,002056082;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;Monocytes;0,002056082;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;Monocytes;0,002442244;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;Monocytes;0,002442244;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;Monocytes;0,0021022;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;Monocytes;0,0021022;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;0,0010376;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;0,0010376;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;Monocytes;7,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;Monocytes;7,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;Monocytes;0,002015684;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;Monocytes;0,002015684;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,005467877;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,005467877;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;Monocytes;0,006075824;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;Monocytes;0,006075824;NA
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;Monocytes;0,001049362;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;Monocytes;0,001049362;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;Monocytes;0,001907365;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;Monocytes;0,001907365;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;Monocytes;0,002941084;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;Monocytes;0,002941084;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;Monocytes;0,001890158;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;Monocytes;0,001890158;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;Monocytes;7,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;Monocytes;7,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;Monocytes;0,001808241;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;Monocytes;0,001808241;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001760146;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001760146;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;Monocytes;7,42E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;Monocytes;7,42E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001274787;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001274787;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001204841;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001204841;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;Monocytes;0,002234363;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;Monocytes;0,002234363;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;Monocytes;0,002141188;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;Monocytes;0,002141188;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;Monocytes;0,002602158;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;Monocytes;0,002602158;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;8,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;8,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;Monocytes;0,001598798;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;Monocytes;0,001598798;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001299439;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001299439;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;Monocytes;0,001548269;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;Monocytes;0,001548269;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;Monocytes;0,001500615;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;Monocytes;0,001500615;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;Monocytes;0,002868171;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;Monocytes;0,002868171;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;8,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;8,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Monocytes;0,002810092;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Monocytes;0,002810092;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;Monocytes;0,001473364;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;Monocytes;0,001473364;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Monocytes;7,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Monocytes;7,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;Monocytes;0,001049895;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;Monocytes;0,001049895;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;Monocytes;0,001411646;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;Monocytes;0,001411646;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;Monocytes;8,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;Monocytes;8,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;Monocytes;6,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;Monocytes;6,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;Monocytes;0,001078449;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;Monocytes;0,001078449;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;Monocytes;0,002686785;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;Monocytes;0,002686785;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;Monocytes;0,002646426;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;Monocytes;0,002646426;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;Monocytes;0,003575791;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;Monocytes;0,003575791;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;0,002113248;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;0,002113248;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;Monocytes;0,001607576;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;Monocytes;0,001607576;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Monocytes;7,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Monocytes;7,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;Monocytes;6,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;Monocytes;6,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;Monocytes;0,001192831;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;Monocytes;0,001192831;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Monocytes;0,001205269;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Monocytes;0,001205269;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Monocytes;0,005177273;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Monocytes;0,005177273;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001266449;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001266449;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;Monocytes;0,001252429;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;Monocytes;0,001252429;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;4,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;4,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;6,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;6,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,003784456;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,003784456;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002113385;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002113385;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;Monocytes;0,001214317;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;Monocytes;0,001214317;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001294654;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001294654;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Monocytes;5,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Monocytes;5,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001059211;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001059211;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;Monocytes;0,001626453;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;Monocytes;0,001626453;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Monocytes;0,001031297;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Monocytes;0,001031297;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;Monocytes;9,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;Monocytes;9,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;Monocytes;6,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;Monocytes;6,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;Monocytes;0,001539082;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;Monocytes;0,001539082;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;6,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;6,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;Monocytes;0,005281535;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;Monocytes;0,005281535;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001425074;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001425074;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001475436;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,001475436;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;Monocytes;9,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;Monocytes;9,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;6,05E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;6,05E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;Monocytes;8,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;Monocytes;8,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001500535;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001500535;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001406822;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001406822;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002235249;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002235249;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001692471;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001692471;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;Monocytes;0,001254989;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;Monocytes;0,001254989;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001906257;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001906257;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;Monocytes;0,001190594;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;Monocytes;0,001190594;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001688377;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001688377;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;Monocytes;8,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;Monocytes;8,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001125412;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001125412;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;5,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;5,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001399533;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001399533;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,00158796;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,00158796;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;Monocytes;0,002193135;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;Monocytes;0,002193135;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;Monocytes;0,001539021;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;Monocytes;0,001539021;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,002546298;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,002546298;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;Monocytes;0,001272848;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;Monocytes;0,001272848;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001204506;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001204506;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001448131;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001448131;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001043442;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001043442;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Monocytes;0,002128507;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Monocytes;0,002128507;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;9,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;9,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001692054;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001692054;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001706844;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001706844;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;Monocytes;0,001353765;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;Monocytes;0,001353765;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;0,001801934;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;0,001801934;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002587823;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002587823;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;0,005350651;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;0,005350651;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Monocytes;0,002591774;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Monocytes;0,002591774;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;Monocytes;0,001462087;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;Monocytes;0,001462087;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;0,001705573;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;0,001705573;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Monocytes;0,001463474;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Monocytes;0,001463474;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;Monocytes;7,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;Monocytes;7,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,002598832;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Monocytes;0,002598832;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;Monocytes;0,002605463;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;Monocytes;0,002605463;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002589848;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002589848;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;6,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;6,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001321466;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001321466;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,00162525;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,00162525;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;Monocytes;0,001080094;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;Monocytes;0,001080094;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;0,002395603;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;0,002395603;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001012905;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001012905;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;Monocytes;0,002373409;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;Monocytes;0,002373409;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002568479;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002568479;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;Monocytes;0,001255044;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;Monocytes;0,001255044;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;Monocytes;8,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;Monocytes;8,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;Monocytes;0,001816871;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;Monocytes;0,001816871;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;0,004016249;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;0,004016249;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;6,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;6,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;Monocytes;0,002230438;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;Monocytes;0,002230438;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;Monocytes;0,00131164;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;Monocytes;0,00131164;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;Monocytes;4,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;Monocytes;4,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002174632;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002174632;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;Monocytes;0,001067079;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;Monocytes;0,001067079;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;Monocytes;0,001151269;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;Monocytes;0,001151269;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Monocytes;9,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Monocytes;9,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;Monocytes;5,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;Monocytes;5,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,007375227;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,007375227;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;0,001674175;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;0,001674175;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;Monocytes;0,001812306;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;Monocytes;0,001812306;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;8,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;8,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;Monocytes;0,001231154;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;Monocytes;0,001231154;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001474285;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001474285;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;Monocytes;0,002518718;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;Monocytes;0,002518718;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Monocytes;0,003676593;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Monocytes;0,003676593;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;Monocytes;8,20E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;Monocytes;8,20E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;Monocytes;0,001391142;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;Monocytes;0,001391142;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;6,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;6,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;Monocytes;0,002419449;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;Monocytes;0,002419449;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;8,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;8,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,003004495;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,003004495;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;Monocytes;0,001477993;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;Monocytes;0,001477993;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;Monocytes;0,016031802;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;Monocytes;0,016031802;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;Monocytes;0,003860731;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;Monocytes;0,003860731;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;9,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;9,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;Monocytes;0,00144067;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;Monocytes;0,00144067;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002844713;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,002844713;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;Monocytes;7,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;Monocytes;7,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001058759;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001058759;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;Monocytes;7,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;Monocytes;7,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002896877;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002896877;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;Monocytes;0,001237767;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;Monocytes;0,001237767;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001903808;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001903808;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;Monocytes;0,001017651;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;Monocytes;0,001017651;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;Monocytes;0,001489843;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;Monocytes;0,001489843;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;0,001337079;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Monocytes;0,001337079;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;0,005596384;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;0,005596384;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;Monocytes;0,002347651;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;Monocytes;0,002347651;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;Monocytes;0,002421408;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;Monocytes;0,002421408;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;5,01E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;5,01E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;Monocytes;0,001750596;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;Monocytes;0,001750596;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;Monocytes;4,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;Monocytes;4,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;1,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;1,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;Monocytes;3,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;Monocytes;3,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;Monocytes;0,003648023;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;Monocytes;0,003648023;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;Monocytes;0,001488356;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;Monocytes;0,001488356;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001640277;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001640277;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001988156;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001988156;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;Monocytes;0,001414499;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;Monocytes;0,001414499;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;Monocytes;0,001154727;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;Monocytes;0,001154727;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001270962;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001270962;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,00316363;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,00316363;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Monocytes;0,002551049;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Monocytes;0,002551049;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;Monocytes;0,001543299;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;Monocytes;0,001543299;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;Monocytes;0,001450215;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;Monocytes;0,001450215;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001735451;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Monocytes;0,001735451;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;7,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;7,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Monocytes;0,002135392;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Monocytes;0,002135392;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,003334899;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,003334899;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001885888;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,001885888;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Monocytes;0,001614735;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Monocytes;0,001614735;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001153338;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,001153338;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;Monocytes;0,002855681;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;Monocytes;0,002855681;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;Monocytes;0,001365705;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;Monocytes;0,001365705;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;Monocytes;0,001696854;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;Monocytes;0,001696854;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,00153702;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,00153702;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;Monocytes;0,001673947;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;Monocytes;0,001673947;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;Monocytes;4,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;Monocytes;4,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;8,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;8,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,001173838;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Monocytes;0,001173838;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;Monocytes;0,002357661;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;Monocytes;0,002357661;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;8,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;8,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;Monocytes;4,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;Monocytes;4,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;Monocytes;0,001020729;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;Monocytes;0,001020729;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;Monocytes;0,001080894;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;Monocytes;0,001080894;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Monocytes;0,0010998;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Monocytes;0,0010998;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;Monocytes;0,001120236;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;Monocytes;0,001120236;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;Monocytes;0,002750827;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;Monocytes;0,002750827;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;2,77E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;2,77E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;7,97E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Monocytes;7,97E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;0,00618017;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Monocytes;0,00618017;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;Monocytes;0,002200999;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;Monocytes;0,002200999;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001004286;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001004286;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;Monocytes;0,005126964;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;Monocytes;0,005126964;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;Monocytes;0,002760747;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;Monocytes;0,002760747;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,002933681;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Monocytes;0,002933681;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;Monocytes;0,001328566;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;Monocytes;0,001328566;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;Monocytes;7,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;Monocytes;7,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,003197524;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,003197524;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;Monocytes;0,001151326;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;Monocytes;0,001151326;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001336456;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,001336456;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002164872;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Monocytes;0,002164872;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;Monocytes;9,42E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;Monocytes;9,42E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,00278959;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Monocytes;0,00278959;Metastasis
untreated;GSM1315904;Primary Tumor;Australia;19;22;Female;NA;0;4342,8;Stage II;not sustained response;GSE54467;Monocytes;0,009140893;NA;
untreated;GSM1315905;Primary Tumor;Australia;53;56;Male;NA;1;1418,4;Stage II;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315906;Primary Tumor;Australia;52;53;Female;NA;1;698,4;Stage II;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315907;Primary Tumor;Australia;51;52;Male;NA;0;3330,6;Stage I;not sustained response;GSE54467;Monocytes;0,004897682;NA;
untreated;GSM1315908;Primary Tumor;Australia;47;51;Male;NA;1;4283,4;Stage II;NA;GSE54467;Monocytes;0,008784912;NA;
untreated;GSM1315909;Primary Tumor;Australia;61;64;Male;NA;1;1540,5;Stage I;NA;GSE54467;Monocytes;0,033548005;NA;
untreated;GSM1315910;Primary Tumor;Australia;46;52;Female;NA;0;6957,3;Stage I;not sustained response;GSE54467;Monocytes;0,020785266;NA;
untreated;GSM1315911;Primary Tumor;Australia;61;75;Male;NA;1;5484,9;Stage I;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315912;Primary Tumor;Australia;84;87;Female;NA;1;1491,3;Stage I;NA;GSE54467;Monocytes;0,007804099;NA;
untreated;GSM1315913;Primary Tumor;Australia;44;44;Female;NA;0;3899,7;Stage III;not sustained response;GSE54467;Monocytes;0,00628991;NA;
untreated;GSM1315914;Primary Tumor;Australia;64;72;Male;NA;1;3322,8;Stage I;NA;GSE54467;Monocytes;0,004602623;NA;
untreated;GSM1315915;Primary Tumor;Australia;31;31;Male;NA;0;3034,8;Stage III;not sustained response;GSE54467;Monocytes;0,012268171;NA;
untreated;GSM1315916;Primary Tumor;Australia;63;65;Male;NA;1;654,9;Stage II;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315917;Primary Tumor;Australia;58;59;Male;NA;1;1098,6;Stage III;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315918;Primary Tumor;Australia;56;67;Male;NA;0;6538,2;Stage Unknown;not sustained response;GSE54467;Monocytes;0;NA;
untreated;GSM1315919;Primary Tumor;Australia;48;57;Female;NA;1;3603,9;Stage II;NA;GSE54467;Monocytes;0,014421921;NA;
untreated;GSM1315920;Primary Tumor;Australia;69;70;Male;NA;1;261,3;Stage III;NA;GSE54467;Monocytes;0,066400447;NA;
untreated;GSM1315921;Primary Tumor;Australia;76;77;Male;NA;1;593,7;Stage II;NA;GSE54467;Monocytes;3,51E-04;NA;
untreated;GSM1315922;Primary Tumor;Australia;54;55;Female;NA;1;592,8;Stage III;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315923;Primary Tumor;Australia;82;85;Male;NA;1;2242,8;Stage II;responder;GSE54467;Monocytes;0;NA;
untreated;GSM1315924;Primary Tumor;Australia;79;80;Male;NA;0;2393,7;Stage I;not sustained response;GSE54467;Monocytes;0;NA;
untreated;GSM1315925;Primary Tumor;Australia;50;54;Male;NA;0;2986,5;Stage II;not sustained response;GSE54467;Monocytes;0,026158458;NA;
untreated;GSM1315926;Primary Tumor;Australia;57;57;Female;NA;0;305,7;Stage III;non-responder;GSE54467;Monocytes;0;NA;
untreated;GSM1315927;Primary Tumor;Australia;32;45;Male;NA;0;7826,4;Stage I;not sustained response;GSE54467;Monocytes;0;NA;
untreated;GSM1315928;Primary Tumor;Australia;77;78;Female;NA;1;589,8;Stage III;NA;GSE54467;Monocytes;0,020521004;NA;
untreated;GSM1315929;Primary Tumor;Australia;56;56;Male;NA;1;588,9;Stage III;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315930;Primary Tumor;Australia;39;40;Female;NA;1;644,1;Stage II;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315931;Primary Tumor;Australia;84;87;Female;NA;1;3090;Stage II;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315932;Primary Tumor;Australia;57;60;Female;NA;1;1734,9;Stage II;NA;GSE54467;Monocytes;0,027174848;NA;
untreated;GSM1315933;Primary Tumor;Australia;23;28;Male;NA;1;3096;Stage I;NA;GSE54467;Monocytes;0,013464719;NA;
untreated;GSM1315934;Primary Tumor;Australia;63;66;Male;NA;1;3007,2;Stage I;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315935;Primary Tumor;Australia;53;54;Male;NA;1;723,9;Stage II;NA;GSE54467;Monocytes;0,033538278;NA;
untreated;GSM1315936;Primary Tumor;Australia;72;72;Male;NA;0;3205,5;Stage II;not sustained response;GSE54467;Monocytes;0,019802794;NA;
untreated;GSM1315937;Primary Tumor;Australia;60;67;Male;NA;1;3228,3;Stage I;NA;GSE54467;Monocytes;0,036870301;NA;
untreated;GSM1315938;Primary Tumor;Australia;67;69;Male;NA;1;864,9;Stage II;NA;GSE54467;Monocytes;0,024361519;NA;
untreated;GSM1315939;Primary Tumor;Australia;61;61;Male;NA;1;325,5;Stage III;NA;GSE54467;Monocytes;5,26E-04;NA;
untreated;GSM1315940;Primary Tumor;Australia;35;54;Male;NA;0;8526,6;Stage II;not sustained response;GSE54467;Monocytes;0;NA;
untreated;GSM1315941;Primary Tumor;Australia;60;63;Male;NA;1;2886,9;Stage II;responder;GSE54467;Monocytes;0;NA;
untreated;GSM1315942;Primary Tumor;Australia;30;30;Male;NA;0;2114,7;Stage III;not sustained response;GSE54467;Monocytes;0,011840218;NA;
untreated;GSM1315943;Primary Tumor;Australia;66;67;Male;NA;1;508,8;Stage II;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315944;Primary Tumor;Australia;50;54;Female;NA;1;2062,5;Stage II;NA;GSE54467;Monocytes;0,032421681;NA;
untreated;GSM1315945;Primary Tumor;Australia;28;30;Male;NA;1;3093,9;Stage II;NA;GSE54467;Monocytes;0,017046911;NA;
untreated;GSM1315946;Primary Tumor;Australia;58;60;Male;NA;1;1426,2;Stage I;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315947;Primary Tumor;Australia;66;69;Female;NA;1;1518,9;Stage III;NA;GSE54467;Monocytes;0,005891524;NA;
untreated;GSM1315948;Primary Tumor;Australia;49;57;Female;NA;0;6582,6;Stage I;not sustained response;GSE54467;Monocytes;0;NA;
untreated;GSM1315949;Primary Tumor;Australia;69;69;Male;NA;1;446,7;Stage III;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315950;Primary Tumor;Australia;55;56;Male;NA;0;3286,5;Stage III;not sustained response;GSE54467;Monocytes;0;NA;
untreated;GSM1315951;Primary Tumor;Australia;52;58;Male;NA;1;3098,1;Stage I;NA;GSE54467;Monocytes;0,019469307;NA;
untreated;GSM1315952;Primary Tumor;Australia;61;74;Female;NA;1;4687,8;Stage I;NA;GSE54467;Monocytes;0,017745236;NA;
untreated;GSM1315953;Primary Tumor;Australia;74;75;Male;NA;1;1845,3;Stage I;responder;GSE54467;Monocytes;0;NA;
untreated;GSM1315954;Primary Tumor;Australia;40;40;Male;NA;0;2916,6;Stage III;not sustained response;GSE54467;Monocytes;0,012001175;NA;
untreated;GSM1315955;Primary Tumor;Australia;36;44;Male;NA;0;6242,4;Stage II;non-responder;GSE54467;Monocytes;0,01481411;NA;
untreated;GSM1315956;Primary Tumor;Australia;70;73;Female;NA;0;3861,3;Stage II;not sustained response;GSE54467;Monocytes;0;NA;
untreated;GSM1315957;Primary Tumor;Australia;67;67;Male;NA;0;1219,2;Stage III;not sustained response;GSE54467;Monocytes;0;NA;
untreated;GSM1315958;Primary Tumor;Australia;53;66;Male;NA;1;5252,1;Stage I;NA;GSE54467;Monocytes;0,051997298;NA;
untreated;GSM1315959;Primary Tumor;Australia;64;64;Female;NA;0;3633,6;Stage III;not sustained response;GSE54467;Monocytes;0,021014864;NA;
untreated;GSM1315960;Primary Tumor;Australia;59;61;Male;NA;0;5126,7;Stage I;not sustained response;GSE54467;Monocytes;0;NA;
untreated;GSM1315961;Primary Tumor;Australia;78;88;Male;NA;1;6904,2;Stage I;NA;GSE54467;Monocytes;0,021746064;NA;
untreated;GSM1315962;Primary Tumor;Australia;62;64;Male;NA;0;3878,1;Stage I;not sustained response;GSE54467;Monocytes;0;NA;
untreated;GSM1315963;Primary Tumor;Australia;30;63;Male;NA;1;12093,9;Stage I;NA;GSE54467;Monocytes;0,027069078;NA;
untreated;GSM1315964;Primary Tumor;Australia;40;46;Female;NA;1;2208,3;Stage III;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315965;Primary Tumor;Australia;58;63;Female;NA;1;3665,1;Stage II;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315966;Primary Tumor;Australia;39;40;Female;NA;0;3431,4;Stage I;not sustained response;GSE54467;Monocytes;8,80E-04;NA;
untreated;GSM1315967;Primary Tumor;Australia;49;50;Male;NA;1;650,1;Stage I;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315968;Primary Tumor;Australia;50;51;Male;NA;0;4334,7;Stage II;not sustained response;GSE54467;Monocytes;0;NA;
untreated;GSM1315969;Primary Tumor;Australia;24;24;Male;NA;0;1256,4;Stage III;not sustained response;GSE54467;Monocytes;0;NA;
untreated;GSM1315970;Primary Tumor;Australia;70;73;Female;NA;0;2782,5;Stage II;not sustained response;GSE54467;Monocytes;0;NA;
untreated;GSM1315971;Primary Tumor;Australia;83;86;Male;NA;1;1875;Stage II;responder;GSE54467;Monocytes;0;NA;
untreated;GSM1315972;Primary Tumor;Australia;68;75;Female;NA;0;6019,5;Stage I;not sustained response;GSE54467;Monocytes;0;NA;
untreated;GSM1315973;Primary Tumor;Australia;47;47;Male;NA;0;1506;Stage III;not sustained response;GSE54467;Monocytes;0,004746847;NA;
untreated;GSM1315974;Primary Tumor;Australia;48;48;Female;NA;0;2405,7;Stage I;not sustained response;GSE54467;Monocytes;0,004351942;NA;
untreated;GSM1315975;Primary Tumor;Australia;52;53;Male;NA;1;582;Stage III;NA;GSE54467;Monocytes;0,011009885;NA;
untreated;GSM1315976;Primary Tumor;Australia;60;67;Female;NA;0;5314,2;Stage I;non-responder;GSE54467;Monocytes;0;NA;
untreated;GSM1315977;Primary Tumor;Australia;45;50;Female;NA;1;3722,4;Stage II;NA;GSE54467;Monocytes;0,023004001;NA;
untreated;GSM1315978;Primary Tumor;Australia;68;73;Female;NA;1;3316,8;Stage I;NA;GSE54467;Monocytes;0,002364928;NA;
untreated;GSM1315979;Primary Tumor;Australia;78;80;Male;NA;0;1305,9;Stage I;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315980;Primary Tumor;Australia;56;56;Female;NA;1;708,3;Stage II;NA;GSE54467;Monocytes;0,009777748;NA;
untreated;GSM1315981;Primary Tumor;Australia;74;74;Female;NA;1;121,2;Stage II;NA;GSE54467;Monocytes;0;NA;
untreated;GSM1315982;Primary Tumor;Australia;66;75;Male;NA;1;3691,8;Stage I;NA;GSE54467;Monocytes;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872328;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872329;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872330;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872331;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872332;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872333;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0,006243347;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872334;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872335;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872336;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0,031336694;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872337;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872338;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872339;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0,008968357;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872340;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872341;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872342;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872343;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0,033809076;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872344;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0,00810812;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872345;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872346;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872347;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872348;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872349;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872350;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872351;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0,094720478;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872352;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0,020250277;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872353;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0,013666432;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872354;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0,029848883;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872355;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0,124313502;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872356;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0,012930983;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872357;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872358;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872359;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872360;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872361;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872362;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0,028017313;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872363;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0,073164774;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872364;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872365;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0,028113285;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872366;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872367;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0,112508936;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872368;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872369;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0,045569247;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872370;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0,011928043;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872371;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872372;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0,095462775;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872373;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0,012535992;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872374;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872375;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872376;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872377;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872378;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872379;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872380;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872381;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0,052207701;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872382;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872383;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872384;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Neutrophils;0,004358835;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872385;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Neutrophils;0,004706375;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872386;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872387;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Neutrophils;0,032015832;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872388;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872389;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Neutrophils;0,03043125;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872390;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Neutrophils;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872391;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Neutrophils;0,002611011;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872392;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Neutrophils;0;NA;
Standard (dacarbazine monotherapy; DTIC);GSM550966;Metastatic;Sweden;60;62;Male;Trunk;1;373;IV;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550967;Metastatic;Sweden;54;59;Female;Lower extremity;1;181;IV;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550968;Metastatic;Sweden;40;53;Male;Head;1;436;IV;NA;GSE22155_GPL6102;Neutrophils;0,030011394;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550969;Metastatic;Sweden;54;61;Female;Lower extremity;1;82;IV;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550970;Metastatic;Sweden;45;47;Male;Lower extremity;1;646;IV;NA;GSE22155_GPL6102;Neutrophils;0,06331185;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550971;Metastatic;Sweden;68;68;Male;No primary detected;1;114;IV;NA;GSE22155_GPL6102;Neutrophils;0,024319401;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550972;Metastatic;Sweden;36;38;Male;Upper extremity, acral;1;322;IV;NA;GSE22155_GPL6102;Neutrophils;0,13694476;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550973;Metastatic;Sweden;63;65;Female;Trunk;1;46;IV;NA;GSE22155_GPL6102;Neutrophils;0,055127407;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550974;Metastatic;Sweden;51;51;Male;No primary detected;0;3509;IV;NA;GSE22155_GPL6102;Neutrophils;0,026534413;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550975;Metastatic;Sweden;79;86;Male;Head;1;65;IV;NA;GSE22155_GPL6102;Neutrophils;0,039974841;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550976;Metastatic;Sweden;50;51;Male;Trunk;1;14;IV;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550977;Metastatic;Sweden;58;59;Female;Upper extremity;1;27;IV;NA;GSE22155_GPL6102;Neutrophils;0,054569374;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550978;Metastatic;Sweden;36;36;Male;No primary detected;-;-;III;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550979;Metastatic;Sweden;60;66;Female;Upper extremity;1;45;IV;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550980;Metastatic;Sweden;53;53;Female;No primary detected;1;10;IV;NA;GSE22155_GPL6102;Neutrophils;0,290156667;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550981;Metastatic;Sweden;27;32;Female;Trunk;0;2711;IV;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550982;Metastatic;Sweden;49;51;Male;Lower extremity;1;32;IV;NA;GSE22155_GPL6102;Neutrophils;0,142701681;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550983;Metastatic;Sweden;62;63;Male;No primary detected;1;55;IV;NA;GSE22155_GPL6102;Neutrophils;0,112850515;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550984;Metastatic;Sweden;50;71;Male;Upper extremity;1;91;IV;NA;GSE22155_GPL6102;Neutrophils;0,001092694;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550985;Metastatic;Sweden;49;63;Female;Trunk;1;804;IV;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550986;Metastatic;Sweden;55;61;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;Neutrophils;0,059102407;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550987;Metastatic;Sweden;55;80;Male;Trunk;1;25;IV;NA;GSE22155_GPL6102;Neutrophils;0,059333316;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550988;Metastatic;Sweden;78;78;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;Neutrophils;0,050509406;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550989;Metastatic;Sweden;56;57;Male;No primary detected;1;50;IV;NA;GSE22155_GPL6102;Neutrophils;0,044974463;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550990;Metastatic;Sweden;74;76;Female;Head;1;156;IV;NA;GSE22155_GPL6102;Neutrophils;0,038404863;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550991;Metastatic;Sweden;53;70;Male;Trunk;1;219;IV;NA;GSE22155_GPL6102;Neutrophils;0,229305659;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550992;Metastatic;Sweden;36;49;Male;Trunk;1;266;IV;NA;GSE22155_GPL6102;Neutrophils;0,005100541;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550993;Metastatic;Sweden;33;33;Male;No primary detected;1;1075;IV;NA;GSE22155_GPL6102;Neutrophils;0,04223309;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550994;Metastatic;Sweden;67;67;Female;No primary detected;1;201;IV;NA;GSE22155_GPL6102;Neutrophils;0,013616745;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550995;Metastatic;Sweden;72;74;Male;Trunk;1;247;IV;NA;GSE22155_GPL6102;Neutrophils;0,031045295;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550996;Metastatic;Sweden;27;31;Female;Trunk;1;414;IV;NA;GSE22155_GPL6102;Neutrophils;0,01780912;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550997;Metastatic;Sweden;32;43;Female;No primary detected;1;108;IV;NA;GSE22155_GPL6102;Neutrophils;0,062575309;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550998;Metastatic;Sweden;59;61;Female;Trunk;-;-;III;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550999;Metastatic;Sweden;61;61;Male;No primary detected;1;281;IV;NA;GSE22155_GPL6102;Neutrophils;0,005527873;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551000;Metastatic;Sweden;73;73;Male;Head and eye;1;221;IV;NA;GSE22155_GPL6102;Neutrophils;0,111845053;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551001;Metastatic;Sweden;54;55;Male;Trunk;1;102;IV;NA;GSE22155_GPL6102;Neutrophils;0,058859741;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551002;Metastatic;Sweden;68;68;Female;No primary detected;1;301;IV;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551003;Metastatic;Sweden;62;68;Female;Trunk;1;64;IV;NA;GSE22155_GPL6102;Neutrophils;0,03279765;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551004;Metastatic;Sweden;35;36;Female;No primary detected;1;375;IV;NA;GSE22155_GPL6102;Neutrophils;0,02070827;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551005;Metastatic;Sweden;76;79;Female;Trunk;1;218;IV;NA;GSE22155_GPL6102;Neutrophils;0,02578966;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551006;Metastatic;Sweden;66;68;Male;Head;1;1478;IV;NA;GSE22155_GPL6102;Neutrophils;0,097669879;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551007;Metastatic;Sweden;46;52;Female;Trunk;1;13;IV;NA;GSE22155_GPL6102;Neutrophils;0,055034935;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551008;Metastatic;Sweden;65;67;Male;Trunk;1;254;IV;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551009;Metastatic;Sweden;70;70;Female;Upper extremity;1;16;IV;NA;GSE22155_GPL6102;Neutrophils;0,044649583;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551010;Metastatic;Sweden;68;72;Male;Trunk;1;430;IV;NA;GSE22155_GPL6102;Neutrophils;0,140809851;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551011;Metastatic;Sweden;82;84;Male;Trunk;1;63;IV;NA;GSE22155_GPL6102;Neutrophils;0,077200128;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551012;Metastatic;Sweden;35;68;Male;Upper extremity;0;1198;IV;NA;GSE22155_GPL6102;Neutrophils;0,00356405;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551013;Metastatic;Sweden;31;38;Male;Trunk;-;-;III;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551014;Metastatic;Sweden;79;79;Female;Trunk;0;927;IV;NA;GSE22155_GPL6102;Neutrophils;0,082500784;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551015;Metastatic;Sweden;77;82;Female;Upper extremity;1;325;IV;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551016;Metastatic;Sweden;72;76;Male;Lower extremity;1;44;IV;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551017;Metastatic;Sweden;75;75;Female;Lower extremity;0;895;IV;NA;GSE22155_GPL6102;Neutrophils;0,080605041;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551018;Metastatic;Sweden;58;61;Male;Trunk;0;836;IV;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551019;Metastatic;Sweden;71;74;Female;Lower extremity, acral;0;786;IV;NA;GSE22155_GPL6102;Neutrophils;0,063116009;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551020;Metastatic;Sweden;65;76;Male;Trunk;1;244;IV;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551021;Metastatic;Sweden;25;25;Female;Lower extremity;1;78;IV;NA;GSE22155_GPL6102;Neutrophils;0,053608218;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551022;Metastatic;Sweden;50;75;Male;Trunk;1;29;IV;NA;GSE22155_GPL6102;Neutrophils;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551023;Metastatic;Sweden;75;76;Male;Acral;1;44;IV;NA;GSE22155_GPL6947;Neutrophils;0,137466305;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551024;Metastatic;Sweden;63;64;Female;Genital;1;747;IV;NA;GSE22155_GPL6947;Neutrophils;0,076362037;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551025;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;Neutrophils;0,115799013;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551026;Metastatic;Sweden;68;68;Female;GI tractus;1;367;IV;NA;GSE22155_GPL6947;Neutrophils;0,061116365;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551027;Metastatic;Sweden;58;60;Male;Eye;1;7;IV;NA;GSE22155_GPL6947;Neutrophils;0,075777764;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551028;Metastatic;Sweden;49;63;Male;Trunk;1;309;IV;NA;GSE22155_GPL6947;Neutrophils;0,067647702;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551029;Metastatic;Sweden;56;55;Female;Trunk;1;32;IV;NA;GSE22155_GPL6947;Neutrophils;0,113031521;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551030;Metastatic;Sweden;74;74;Male;Trunk;1;79;IV;NA;GSE22155_GPL6947;Neutrophils;0,10434446;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551031;Metastatic;Sweden;41;42;Female;Eye;1;349;IV;NA;GSE22155_GPL6947;Neutrophils;0,147840321;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551032;Metastatic;Sweden;49;51;Female;Mucosa, head;1;13;IV;NA;GSE22155_GPL6947;Neutrophils;0,10482045;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551033;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;Neutrophils;0,074830549;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551034;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;Neutrophils;0,069568426;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551035;Metastatic;Sweden;56;56;Male;GI tractus;1;37;IV;NA;GSE22155_GPL6947;Neutrophils;0,089199357;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551036;Metastatic;Sweden;45;74;Male;No primary;1;183;IV;NA;GSE22155_GPL6947;Neutrophils;0,09031733;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551037;Metastatic;Sweden;72;75;Female;Head;1;39;IV;NA;GSE22155_GPL6947;Neutrophils;0,09051443;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551038;Metastatic;Sweden;61;68;Female;Eye;1;513;IV;NA;GSE22155_GPL6947;Neutrophils;0,075117231;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551039;Metastatic;Sweden;66;68;Male;Trunk;1;584;IV;NA;GSE22155_GPL6947;Neutrophils;0,070340932;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551040;Metastatic;Sweden;42;44;Male;Head;1;1148;IV;NA;GSE22155_GPL6947;Neutrophils;0,073210836;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551041;Metastatic;Sweden;54;56;Female;Trunk;1;153;IV;NA;GSE22155_GPL6947;Neutrophils;0,090346237;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551042;Metastatic;Sweden;48;50;Male;Trunk;1;141;IV;NA;GSE22155_GPL6947;Neutrophils;0,185870945;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551043;Metastatic;Sweden;58;67;Female;Acral;1;334;IV;NA;GSE22155_GPL6947;Neutrophils;0,111842388;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551044;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;Neutrophils;0,106145162;Metastasis
untreated;GSM1220412;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Neutrophils;0;Metastasis;
dabrafenib;GSM1220413;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0;cutaneous or subcutaneous;
untreated;GSM1220414;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,093599979;cutaneous or subcutaneous;
dabrafenib;GSM1220415;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,042133908;cutaneous or subcutaneous;
untreated;GSM1220416;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,010291338;cutaneous or subcutaneous;
dabrafenib;GSM1220417;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,00725213;cutaneous or subcutaneous;
dabrafenib;GSM1220418;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,025867867;cutaneous or subcutaneous;
untreated;GSM1220419;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Neutrophils;0;Metastasis;
dabrafenib;GSM1220420;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;Neutrophils;0;Metastasis;
untreated;GSM1220421;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,059124551;cutaneous or subcutaneous;
dabrafenib;GSM1220422;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,01420476;cutaneous or subcutaneous;
dabrafenib;GSM1220423;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,01407435;cutaneous or subcutaneous;
untreated;GSM1220424;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,026811258;cutaneous or subcutaneous;
untreated;GSM1220425;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,02056874;cutaneous or subcutaneous;
dabrafenib;GSM1220426;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Neutrophils;0,054359911;Metastasis;
untreated;GSM1220427;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,030998906;cutaneous or subcutaneous;
untreated;GSM1220428;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,013199841;cutaneous or subcutaneous;
dabrafenib;GSM1220429;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0;cutaneous or subcutaneous;
dabrafenib;GSM1220430;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0;cutaneous or subcutaneous;
untreated;GSM1220431;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,02038906;cutaneous or subcutaneous;
dabrafenib;GSM1220432;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,025297879;cutaneous or subcutaneous;
untreated;GSM1220433;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,038478594;cutaneous or subcutaneous;
untreated;GSM1220434;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,032489658;cutaneous or subcutaneous;
dabrafenib;GSM1220435;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0;cutaneous or subcutaneous;
dabrafenib;GSM1220436;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,099912395;cutaneous or subcutaneous;
dabrafenib;GSM1220437;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,053306284;cutaneous or subcutaneous;
untreated;GSM1220438;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Neutrophils;0;Metastasis;
untreated;GSM1220439;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Neutrophils;0;Metastasis;
dabrafenib;GSM1220440;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0;cutaneous or subcutaneous;
dabrafenib;GSM1220441;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Neutrophils;0;Metastasis;
dabrafenib;GSM1220442;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0;cutaneous or subcutaneous;
dabrafenib;GSM1220443;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Neutrophils;0;Metastasis;
untreated;GSM1220444;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Neutrophils;0,063185325;Metastasis;
dabrafenib;GSM1220445;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,022975919;cutaneous or subcutaneous;
untreated;GSM1220446;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0;cutaneous or subcutaneous;
untreated;GSM1220447;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0;cutaneous or subcutaneous;
dabrafenib;GSM1220448;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0;cutaneous or subcutaneous;
untreated;GSM1220449;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Neutrophils;0,031595677;Metastasis;
dabrafenib;GSM1220450;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,035874639;cutaneous or subcutaneous;
untreated;GSM1220451;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Neutrophils;0,009202665;Metastasis;
dabrafenib;GSM1220452;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;Neutrophils;0,004425549;Metastasis;
untreated;GSM1220453;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,043724997;cutaneous or subcutaneous;
untreated;GSM1220454;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,04121186;cutaneous or subcutaneous;
dabrafenib;GSM1220455;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;Neutrophils;0,017691962;Metastasis;
dabrafenib;GSM1220456;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,046168187;cutaneous or subcutaneous;
untreated;GSM1220457;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,01736006;cutaneous or subcutaneous;
dabrafenib;GSM1220458;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Neutrophils;0,019486608;Metastasis;
untreated;GSM1220459;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0;cutaneous or subcutaneous;
vemurafenib;GSM1220460;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,016185828;cutaneous or subcutaneous;
untreated;GSM1220461;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,042476305;cutaneous or subcutaneous;
untreated;GSM1220462;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,042051223;cutaneous or subcutaneous;
vemurafenib;GSM1220463;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,006980148;cutaneous or subcutaneous;
untreated;GSM1220464;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Neutrophils;0,033646396;Metastasis;
vemurafenib;GSM1220465;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,009959318;cutaneous or subcutaneous;
untreated;GSM1220466;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,015073196;cutaneous or subcutaneous;
vemurafenib;GSM1220467;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,008127809;cutaneous or subcutaneous;
vemurafenib;GSM1220468;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,001126004;cutaneous or subcutaneous;
vemurafenib;GSM1220469;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,00983477;cutaneous or subcutaneous;
vemurafenib;GSM1220470;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,053592077;cutaneous or subcutaneous;
untreated;GSM1220471;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Neutrophils;0,045440538;cutaneous or subcutaneous;
vemurafenib;GSM1220472;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;Neutrophils;0,050420962;Metastasis;
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;Neutrophils;4,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;Neutrophils;4,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;4,69E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;4,69E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;3,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;3,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;Neutrophils;4,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;Neutrophils;4,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;5,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;5,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;Neutrophils;3,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;Neutrophils;3,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;Neutrophils;2,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;Neutrophils;2,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;Neutrophils;0,001621022;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;Neutrophils;0,001621022;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;2,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;2,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;9,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;9,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;Neutrophils;6,42E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;Neutrophils;6,42E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;Neutrophils;3,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;Neutrophils;3,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;Neutrophils;5,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;Neutrophils;5,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;6,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;6,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;Neutrophils;7,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;Neutrophils;7,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,51E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,51E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;Neutrophils;3,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;Neutrophils;3,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;5,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;5,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;Neutrophils;3,77E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;Neutrophils;3,77E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;Neutrophils;4,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;Neutrophils;4,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Neutrophils;5,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Neutrophils;5,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;Neutrophils;0,00159969;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;Neutrophils;0,00159969;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;4,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;4,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;Neutrophils;8,26E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;Neutrophils;8,26E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;7,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;7,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;4,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;4,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Neutrophils;4,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Neutrophils;4,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;Neutrophils;2,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;Neutrophils;2,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;4,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;4,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;3,26E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;3,26E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;Neutrophils;2,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;Neutrophils;2,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;1,20E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;1,20E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;Neutrophils;3,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;Neutrophils;3,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;4,72E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;4,72E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;8,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;8,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;Neutrophils;2,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;Neutrophils;2,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;Neutrophils;4,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;Neutrophils;4,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;5,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;5,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;Neutrophils;9,51E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;Neutrophils;9,51E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;Neutrophils;9,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;Neutrophils;9,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;Neutrophils;0,001348462;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;Neutrophils;0,001348462;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;2,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;2,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;Neutrophils;2,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;Neutrophils;2,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;3,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;3,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;Neutrophils;5,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;Neutrophils;5,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;6,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;6,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;Neutrophils;3,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;Neutrophils;3,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;Neutrophils;4,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;Neutrophils;4,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;Neutrophils;3,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;Neutrophils;3,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;Neutrophils;3,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;Neutrophils;3,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;2,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;2,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,49E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,49E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;7,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;7,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Neutrophils;0,001958591;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Neutrophils;0,001958591;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;2,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;2,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;2,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;2,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;Neutrophils;3,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;Neutrophils;3,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Neutrophils;3,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Neutrophils;3,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;2,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;2,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;Neutrophils;7,33E-04;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;Neutrophils;7,33E-04;NA
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;Neutrophils;3,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;Neutrophils;3,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;4,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;4,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;Neutrophils;6,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;Neutrophils;6,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;Neutrophils;3,24E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;Neutrophils;3,24E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;Neutrophils;3,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;Neutrophils;3,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;Neutrophils;0,001071186;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;Neutrophils;0,001071186;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;2,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;2,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Neutrophils;5,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Neutrophils;5,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;7,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;7,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;7,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;7,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;7,57E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;7,57E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;2,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;2,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;6,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;6,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;Neutrophils;0,004112969;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;Neutrophils;0,004112969;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;Neutrophils;4,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;Neutrophils;4,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Neutrophils;8,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Neutrophils;8,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;7,24E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;7,24E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;Neutrophils;4,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;Neutrophils;4,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;Neutrophils;0,001284507;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;Neutrophils;0,001284507;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;Neutrophils;5,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;Neutrophils;5,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;Neutrophils;3,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;Neutrophils;3,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;3,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;3,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;5,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;5,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;Neutrophils;4,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;Neutrophils;4,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;2,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;2,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;Neutrophils;1,00E-03;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;Neutrophils;1,00E-03;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;4,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;4,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Neutrophils;6,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Neutrophils;6,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;Neutrophils;6,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;Neutrophils;6,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;Neutrophils;4,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;Neutrophils;4,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;Neutrophils;4,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;Neutrophils;4,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;Neutrophils;3,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;Neutrophils;3,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Neutrophils;8,72E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Neutrophils;8,72E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;Neutrophils;5,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;Neutrophils;5,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;Neutrophils;3,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;Neutrophils;3,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;Neutrophils;5,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;Neutrophils;5,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;7,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;7,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;Neutrophils;3,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;Neutrophils;3,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;Neutrophils;3,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;Neutrophils;3,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;Neutrophils;4,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;Neutrophils;4,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;Neutrophils;0,001449526;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;Neutrophils;0,001449526;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;Neutrophils;7,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;Neutrophils;7,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;Neutrophils;2,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;Neutrophils;2,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;Neutrophils;3,49E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;Neutrophils;3,49E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;4,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;4,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;Neutrophils;5,23E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;Neutrophils;5,23E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;Neutrophils;5,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;Neutrophils;5,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;1,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;1,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;Neutrophils;6,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;Neutrophils;6,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;Neutrophils;4,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;Neutrophils;4,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Neutrophils;2,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Neutrophils;2,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;Neutrophils;7,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;Neutrophils;7,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Neutrophils;2,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Neutrophils;2,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;9,96E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;9,96E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;Neutrophils;1,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;Neutrophils;1,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;0,001116337;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;0,001116337;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;Neutrophils;5,41E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;Neutrophils;5,41E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;5,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;5,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;Neutrophils;3,97E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;Neutrophils;3,97E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;Neutrophils;5,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;Neutrophils;5,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;1,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;1,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;Neutrophils;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;Neutrophils;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;Neutrophils;5,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;Neutrophils;5,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Neutrophils;2,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Neutrophils;2,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;3,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;3,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;Neutrophils;0,002649638;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;Neutrophils;0,002649638;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;3,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;3,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;Neutrophils;3,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;Neutrophils;3,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;7,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;7,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;Neutrophils;4,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;Neutrophils;4,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Neutrophils;7,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Neutrophils;7,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;7,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;7,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;0,000428016;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;0,000428016;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;4,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;4,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;Neutrophils;4,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;Neutrophils;4,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;Neutrophils;6,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;Neutrophils;6,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;4,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;4,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;3,57E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;3,57E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;Neutrophils;3,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;Neutrophils;3,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;3,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;3,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;Neutrophils;0,00367586;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;Neutrophils;0,00367586;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;0,001030489;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;0,001030489;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;Neutrophils;4,41E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;Neutrophils;4,41E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;5,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;5,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;3,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;3,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;6,01E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;6,01E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;Neutrophils;1,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;Neutrophils;1,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;Neutrophils;3,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;Neutrophils;3,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;Neutrophils;3,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;Neutrophils;3,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;Neutrophils;2,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;Neutrophils;2,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Neutrophils;2,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Neutrophils;2,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;8,77E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;8,77E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;7,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;7,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;Neutrophils;5,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;Neutrophils;5,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;Neutrophils;3,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;Neutrophils;3,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Neutrophils;3,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Neutrophils;3,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;2,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;2,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;Neutrophils;0,001692628;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;Neutrophils;0,001692628;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;8,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;8,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;3,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;3,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;Neutrophils;4,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;Neutrophils;4,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,77E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,77E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;Neutrophils;5,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;Neutrophils;5,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Neutrophils;1,92E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Neutrophils;1,92E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;Neutrophils;6,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;Neutrophils;6,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;8,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;8,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;Neutrophils;0,001764708;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;Neutrophils;0,001764708;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;Neutrophils;4,68E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;Neutrophils;4,68E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;Neutrophils;0,001033205;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;Neutrophils;0,001033205;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Neutrophils;4,72E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Neutrophils;4,72E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;Neutrophils;0,001238719;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;Neutrophils;0,001238719;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;Neutrophils;5,76E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;Neutrophils;5,76E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;Neutrophils;2,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;Neutrophils;2,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;3,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;3,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Neutrophils;2,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Neutrophils;2,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;Neutrophils;3,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;Neutrophils;3,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;Neutrophils;6,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;Neutrophils;6,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;Neutrophils;3,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;Neutrophils;3,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;Neutrophils;5,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;Neutrophils;5,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Neutrophils;2,92E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Neutrophils;2,92E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;Neutrophils;3,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;Neutrophils;3,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Neutrophils;2,72E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Neutrophils;2,72E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;Neutrophils;0,001371849;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;Neutrophils;0,001371849;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;Neutrophils;3,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;Neutrophils;3,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;Neutrophils;6,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;Neutrophils;6,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;Neutrophils;3,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;Neutrophils;3,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;Neutrophils;2,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;Neutrophils;2,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;2,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;2,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;Neutrophils;5,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;Neutrophils;5,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;Neutrophils;3,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;Neutrophils;3,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;5,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;5,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;Neutrophils;9,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;Neutrophils;9,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;Neutrophils;7,42E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;Neutrophils;7,42E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;9,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;9,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;8,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;8,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;5,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;5,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;Neutrophils;5,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;Neutrophils;5,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;Neutrophils;6,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;Neutrophils;6,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;1,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;1,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;Neutrophils;4,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;Neutrophils;4,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Neutrophils;3,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Neutrophils;3,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;4,49E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;4,49E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;2,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;2,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;4,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;4,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;Neutrophils;7,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;Neutrophils;7,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;6,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;6,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,53E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,53E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;5,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;5,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;Neutrophils;3,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;Neutrophils;3,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;Neutrophils;3,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;Neutrophils;3,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;Neutrophils;4,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;Neutrophils;4,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;1,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;1,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;2,20E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;2,20E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;4,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;4,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;Neutrophils;5,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;Neutrophils;5,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;3,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;3,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;3,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;3,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;Neutrophils;4,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;Neutrophils;4,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;Neutrophils;7,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;Neutrophils;7,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;Neutrophils;3,24E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;Neutrophils;3,24E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;8,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;8,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;Neutrophils;3,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;Neutrophils;3,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Neutrophils;3,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Neutrophils;3,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;Neutrophils;7,01E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;Neutrophils;7,01E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Neutrophils;2,88E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Neutrophils;2,88E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;Neutrophils;4,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;Neutrophils;4,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;0,000509537;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;0,000509537;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;Neutrophils;6,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;Neutrophils;6,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;Neutrophils;0,001054122;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;Neutrophils;0,001054122;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;Neutrophils;7,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;Neutrophils;7,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;2,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;2,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Neutrophils;6,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Neutrophils;6,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;7,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;7,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;Neutrophils;3,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;Neutrophils;3,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;Neutrophils;4,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;Neutrophils;4,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;Neutrophils;2,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;Neutrophils;2,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,69E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,69E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;Neutrophils;6,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;Neutrophils;6,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;Neutrophils;7,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;Neutrophils;7,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;Neutrophils;6,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;Neutrophils;6,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;3,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;3,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;Neutrophils;2,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;Neutrophils;2,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;Neutrophils;6,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;Neutrophils;6,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;0,001646202;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;0,001646202;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;Neutrophils;0,001829235;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;Neutrophils;0,001829235;NA
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;Neutrophils;3,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;Neutrophils;3,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;Neutrophils;5,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;Neutrophils;5,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;Neutrophils;8,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;Neutrophils;8,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;Neutrophils;5,69E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;Neutrophils;5,69E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;Neutrophils;2,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;Neutrophils;2,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;Neutrophils;5,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;Neutrophils;5,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;5,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;5,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;Neutrophils;2,23E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;Neutrophils;2,23E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;3,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;3,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;3,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;3,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;Neutrophils;6,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;Neutrophils;6,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;Neutrophils;6,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;Neutrophils;6,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;Neutrophils;7,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;Neutrophils;7,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;2,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;2,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;Neutrophils;4,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;Neutrophils;4,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;3,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;3,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;Neutrophils;4,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;Neutrophils;4,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;Neutrophils;4,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;Neutrophils;4,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;Neutrophils;8,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;Neutrophils;8,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;2,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Neutrophils;8,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Neutrophils;8,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;Neutrophils;4,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;Neutrophils;4,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Neutrophils;2,15E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Neutrophils;2,15E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;Neutrophils;3,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;Neutrophils;3,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;Neutrophils;4,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;Neutrophils;4,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;Neutrophils;2,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;Neutrophils;2,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;Neutrophils;2,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;Neutrophils;2,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;Neutrophils;3,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;Neutrophils;3,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;Neutrophils;8,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;Neutrophils;8,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;Neutrophils;7,97E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;Neutrophils;7,97E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;Neutrophils;0,001076555;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;Neutrophils;0,001076555;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;6,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;6,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;Neutrophils;4,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;Neutrophils;4,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Neutrophils;2,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Neutrophils;2,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;Neutrophils;1,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;Neutrophils;1,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;Neutrophils;3,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;Neutrophils;3,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Neutrophils;3,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Neutrophils;3,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Neutrophils;0,00155871;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Neutrophils;0,00155871;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;3,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;3,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;Neutrophils;3,77E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;Neutrophils;3,77E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;1,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;1,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;1,97E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;1,97E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;0,001139378;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;0,001139378;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;6,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;6,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;Neutrophils;3,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;Neutrophils;3,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;3,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;3,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Neutrophils;1,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Neutrophils;1,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;Neutrophils;4,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;Neutrophils;4,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Neutrophils;3,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Neutrophils;3,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;Neutrophils;2,97E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;Neutrophils;2,97E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;Neutrophils;1,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;Neutrophils;1,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;Neutrophils;4,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;Neutrophils;4,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;1,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;1,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;Neutrophils;0,0015901;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;Neutrophils;0,0015901;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;4,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;4,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;Neutrophils;2,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;Neutrophils;2,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;1,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;1,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;Neutrophils;2,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;Neutrophils;2,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,24E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,24E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;6,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;6,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;5,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;5,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;Neutrophils;3,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;Neutrophils;3,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;5,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;5,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;Neutrophils;3,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;Neutrophils;3,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;5,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;5,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;Neutrophils;2,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;Neutrophils;2,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;1,68E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;1,68E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;4,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;4,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;Neutrophils;6,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;Neutrophils;6,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;Neutrophils;4,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;Neutrophils;4,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;7,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;7,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;Neutrophils;3,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;Neutrophils;3,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Neutrophils;6,41E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Neutrophils;6,41E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;2,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;2,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;5,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;5,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;5,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;5,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;Neutrophils;4,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;Neutrophils;4,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;5,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;5,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;7,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;7,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;0,001610909;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;0,001610909;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Neutrophils;7,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Neutrophils;7,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;Neutrophils;4,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;Neutrophils;4,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;5,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;5,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Neutrophils;4,41E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Neutrophils;4,41E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;Neutrophils;2,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;Neutrophils;2,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;7,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Neutrophils;7,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;Neutrophils;7,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;Neutrophils;7,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;7,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;7,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;1,92E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;1,92E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;3,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;3,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;4,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;4,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;Neutrophils;3,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;Neutrophils;3,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;7,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;7,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;3,05E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;3,05E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;Neutrophils;7,15E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;Neutrophils;7,15E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;7,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;7,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;Neutrophils;3,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;Neutrophils;3,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;Neutrophils;2,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;Neutrophils;2,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;Neutrophils;5,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;Neutrophils;5,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;0,001209163;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;0,001209163;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;1,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;1,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;Neutrophils;6,72E-04;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;Neutrophils;6,72E-04;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;Neutrophils;3,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;Neutrophils;3,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;Neutrophils;1,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;Neutrophils;1,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;6,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;6,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;Neutrophils;3,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;Neutrophils;3,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;Neutrophils;3,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;Neutrophils;3,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Neutrophils;2,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Neutrophils;2,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;Neutrophils;1,76E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;Neutrophils;1,76E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;0,002220443;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;0,002220443;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;5,04E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;5,04E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;Neutrophils;5,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;Neutrophils;5,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;2,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;2,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;Neutrophils;3,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;Neutrophils;3,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;Neutrophils;7,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;Neutrophils;7,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Neutrophils;0,001106904;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Neutrophils;0,001106904;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;Neutrophils;2,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;Neutrophils;2,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;Neutrophils;4,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;Neutrophils;4,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;1,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;1,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;Neutrophils;7,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;Neutrophils;7,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;2,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;2,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;9,05E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;9,05E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;Neutrophils;4,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;Neutrophils;4,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;Neutrophils;0,004826658;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;Neutrophils;0,004826658;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;Neutrophils;0,001162341;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;Neutrophils;0,001162341;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;2,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;2,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;Neutrophils;4,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;Neutrophils;4,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;8,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;8,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;Neutrophils;2,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;Neutrophils;2,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;3,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;3,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;Neutrophils;2,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;Neutrophils;2,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;8,72E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;8,72E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;Neutrophils;3,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;Neutrophils;3,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;5,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;5,73E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;Neutrophils;3,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;Neutrophils;3,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;Neutrophils;4,49E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;Neutrophils;4,49E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;4,03E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Neutrophils;4,03E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;0,001684891;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;0,001684891;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;Neutrophils;7,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;Neutrophils;7,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;Neutrophils;7,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;Neutrophils;7,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;1,51E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;1,51E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;Neutrophils;5,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;Neutrophils;5,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;Neutrophils;1,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;Neutrophils;1,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;5,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;5,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;Neutrophils;1,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;Neutrophils;1,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;Neutrophils;0,001098302;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;Neutrophils;0,001098302;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;Neutrophils;4,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;Neutrophils;4,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;5,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;5,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;Neutrophils;4,26E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;Neutrophils;4,26E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;Neutrophils;3,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;Neutrophils;3,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;3,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;3,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;9,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;9,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Neutrophils;7,68E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Neutrophils;7,68E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;Neutrophils;4,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;Neutrophils;4,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;Neutrophils;4,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;Neutrophils;4,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;5,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Neutrophils;5,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;2,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;2,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Neutrophils;6,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Neutrophils;6,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;0,00100403;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;0,00100403;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;5,68E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;5,68E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Neutrophils;4,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Neutrophils;4,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;3,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;3,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;Neutrophils;8,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;Neutrophils;8,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;Neutrophils;4,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;Neutrophils;4,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;Neutrophils;5,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;Neutrophils;5,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;4,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;Neutrophils;5,04E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;Neutrophils;5,04E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;Neutrophils;1,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;Neutrophils;1,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;2,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;2,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;3,53E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Neutrophils;3,53E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;Neutrophils;7,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;Neutrophils;7,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;2,51E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;2,51E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;Neutrophils;1,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;Neutrophils;1,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;Neutrophils;3,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;Neutrophils;3,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;Neutrophils;3,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;Neutrophils;3,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Neutrophils;3,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Neutrophils;3,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;Neutrophils;3,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;Neutrophils;3,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;Neutrophils;8,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;Neutrophils;8,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;8,35E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;8,35E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;2,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Neutrophils;2,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;0,00186065;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Neutrophils;0,00186065;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;Neutrophils;6,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;Neutrophils;6,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;3,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;Neutrophils;0,001543563;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;Neutrophils;0,001543563;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;Neutrophils;8,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;Neutrophils;8,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;8,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Neutrophils;8,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;Neutrophils;4,00E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;Neutrophils;4,00E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;Neutrophils;2,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;Neutrophils;2,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;9,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;9,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;Neutrophils;3,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;Neutrophils;3,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;4,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;6,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Neutrophils;6,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;Neutrophils;2,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;Neutrophils;2,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;8,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Neutrophils;8,40E-04;Metastasis
untreated;GSM1315904;Primary Tumor;Australia;19;22;Female;NA;0;4342,8;Stage II;not sustained response;GSE54467;Neutrophils;0,066954395;NA;
untreated;GSM1315905;Primary Tumor;Australia;53;56;Male;NA;1;1418,4;Stage II;NA;GSE54467;Neutrophils;0,142908519;NA;
untreated;GSM1315906;Primary Tumor;Australia;52;53;Female;NA;1;698,4;Stage II;NA;GSE54467;Neutrophils;0,090855579;NA;
untreated;GSM1315907;Primary Tumor;Australia;51;52;Male;NA;0;3330,6;Stage I;not sustained response;GSE54467;Neutrophils;0,08061604;NA;
untreated;GSM1315908;Primary Tumor;Australia;47;51;Male;NA;1;4283,4;Stage II;NA;GSE54467;Neutrophils;0,079612637;NA;
untreated;GSM1315909;Primary Tumor;Australia;61;64;Male;NA;1;1540,5;Stage I;NA;GSE54467;Neutrophils;0,062083223;NA;
untreated;GSM1315910;Primary Tumor;Australia;46;52;Female;NA;0;6957,3;Stage I;not sustained response;GSE54467;Neutrophils;0,077605927;NA;
untreated;GSM1315911;Primary Tumor;Australia;61;75;Male;NA;1;5484,9;Stage I;NA;GSE54467;Neutrophils;0,069792754;NA;
untreated;GSM1315912;Primary Tumor;Australia;84;87;Female;NA;1;1491,3;Stage I;NA;GSE54467;Neutrophils;0,080952267;NA;
untreated;GSM1315913;Primary Tumor;Australia;44;44;Female;NA;0;3899,7;Stage III;not sustained response;GSE54467;Neutrophils;0,081579254;NA;
untreated;GSM1315914;Primary Tumor;Australia;64;72;Male;NA;1;3322,8;Stage I;NA;GSE54467;Neutrophils;0,077240731;NA;
untreated;GSM1315915;Primary Tumor;Australia;31;31;Male;NA;0;3034,8;Stage III;not sustained response;GSE54467;Neutrophils;0,115422335;NA;
untreated;GSM1315916;Primary Tumor;Australia;63;65;Male;NA;1;654,9;Stage II;NA;GSE54467;Neutrophils;0,068170447;NA;
untreated;GSM1315917;Primary Tumor;Australia;58;59;Male;NA;1;1098,6;Stage III;NA;GSE54467;Neutrophils;0,107401038;NA;
untreated;GSM1315918;Primary Tumor;Australia;56;67;Male;NA;0;6538,2;Stage Unknown;not sustained response;GSE54467;Neutrophils;0,094744308;NA;
untreated;GSM1315919;Primary Tumor;Australia;48;57;Female;NA;1;3603,9;Stage II;NA;GSE54467;Neutrophils;0,071714417;NA;
untreated;GSM1315920;Primary Tumor;Australia;69;70;Male;NA;1;261,3;Stage III;NA;GSE54467;Neutrophils;0,05836445;NA;
untreated;GSM1315921;Primary Tumor;Australia;76;77;Male;NA;1;593,7;Stage II;NA;GSE54467;Neutrophils;0,056730403;NA;
untreated;GSM1315922;Primary Tumor;Australia;54;55;Female;NA;1;592,8;Stage III;NA;GSE54467;Neutrophils;0,073016385;NA;
untreated;GSM1315923;Primary Tumor;Australia;82;85;Male;NA;1;2242,8;Stage II;responder;GSE54467;Neutrophils;0,103636568;NA;
untreated;GSM1315924;Primary Tumor;Australia;79;80;Male;NA;0;2393,7;Stage I;not sustained response;GSE54467;Neutrophils;0,111486515;NA;
untreated;GSM1315925;Primary Tumor;Australia;50;54;Male;NA;0;2986,5;Stage II;not sustained response;GSE54467;Neutrophils;0,061460502;NA;
untreated;GSM1315926;Primary Tumor;Australia;57;57;Female;NA;0;305,7;Stage III;non-responder;GSE54467;Neutrophils;0,065568942;NA;
untreated;GSM1315927;Primary Tumor;Australia;32;45;Male;NA;0;7826,4;Stage I;not sustained response;GSE54467;Neutrophils;0,10423311;NA;
untreated;GSM1315928;Primary Tumor;Australia;77;78;Female;NA;1;589,8;Stage III;NA;GSE54467;Neutrophils;0,072888004;NA;
untreated;GSM1315929;Primary Tumor;Australia;56;56;Male;NA;1;588,9;Stage III;NA;GSE54467;Neutrophils;0,105631706;NA;
untreated;GSM1315930;Primary Tumor;Australia;39;40;Female;NA;1;644,1;Stage II;NA;GSE54467;Neutrophils;0,049490003;NA;
untreated;GSM1315931;Primary Tumor;Australia;84;87;Female;NA;1;3090;Stage II;NA;GSE54467;Neutrophils;0,089018336;NA;
untreated;GSM1315932;Primary Tumor;Australia;57;60;Female;NA;1;1734,9;Stage II;NA;GSE54467;Neutrophils;0,064142442;NA;
untreated;GSM1315933;Primary Tumor;Australia;23;28;Male;NA;1;3096;Stage I;NA;GSE54467;Neutrophils;0,099477483;NA;
untreated;GSM1315934;Primary Tumor;Australia;63;66;Male;NA;1;3007,2;Stage I;NA;GSE54467;Neutrophils;0,183663209;NA;
untreated;GSM1315935;Primary Tumor;Australia;53;54;Male;NA;1;723,9;Stage II;NA;GSE54467;Neutrophils;0,067337813;NA;
untreated;GSM1315936;Primary Tumor;Australia;72;72;Male;NA;0;3205,5;Stage II;not sustained response;GSE54467;Neutrophils;0,071174795;NA;
untreated;GSM1315937;Primary Tumor;Australia;60;67;Male;NA;1;3228,3;Stage I;NA;GSE54467;Neutrophils;0,073316533;NA;
untreated;GSM1315938;Primary Tumor;Australia;67;69;Male;NA;1;864,9;Stage II;NA;GSE54467;Neutrophils;0,06988997;NA;
untreated;GSM1315939;Primary Tumor;Australia;61;61;Male;NA;1;325,5;Stage III;NA;GSE54467;Neutrophils;0,084330524;NA;
untreated;GSM1315940;Primary Tumor;Australia;35;54;Male;NA;0;8526,6;Stage II;not sustained response;GSE54467;Neutrophils;0,069365169;NA;
untreated;GSM1315941;Primary Tumor;Australia;60;63;Male;NA;1;2886,9;Stage II;responder;GSE54467;Neutrophils;0,08637355;NA;
untreated;GSM1315942;Primary Tumor;Australia;30;30;Male;NA;0;2114,7;Stage III;not sustained response;GSE54467;Neutrophils;0,072610506;NA;
untreated;GSM1315943;Primary Tumor;Australia;66;67;Male;NA;1;508,8;Stage II;NA;GSE54467;Neutrophils;0,067630664;NA;
untreated;GSM1315944;Primary Tumor;Australia;50;54;Female;NA;1;2062,5;Stage II;NA;GSE54467;Neutrophils;0,058687462;NA;
untreated;GSM1315945;Primary Tumor;Australia;28;30;Male;NA;1;3093,9;Stage II;NA;GSE54467;Neutrophils;0,101644897;NA;
untreated;GSM1315946;Primary Tumor;Australia;58;60;Male;NA;1;1426,2;Stage I;NA;GSE54467;Neutrophils;0,072332766;NA;
untreated;GSM1315947;Primary Tumor;Australia;66;69;Female;NA;1;1518,9;Stage III;NA;GSE54467;Neutrophils;0,076885895;NA;
untreated;GSM1315948;Primary Tumor;Australia;49;57;Female;NA;0;6582,6;Stage I;not sustained response;GSE54467;Neutrophils;0,095092974;NA;
untreated;GSM1315949;Primary Tumor;Australia;69;69;Male;NA;1;446,7;Stage III;NA;GSE54467;Neutrophils;0,072487914;NA;
untreated;GSM1315950;Primary Tumor;Australia;55;56;Male;NA;0;3286,5;Stage III;not sustained response;GSE54467;Neutrophils;0,088122398;NA;
untreated;GSM1315951;Primary Tumor;Australia;52;58;Male;NA;1;3098,1;Stage I;NA;GSE54467;Neutrophils;0,081991217;NA;
untreated;GSM1315952;Primary Tumor;Australia;61;74;Female;NA;1;4687,8;Stage I;NA;GSE54467;Neutrophils;0,089798007;NA;
untreated;GSM1315953;Primary Tumor;Australia;74;75;Male;NA;1;1845,3;Stage I;responder;GSE54467;Neutrophils;0,064436311;NA;
untreated;GSM1315954;Primary Tumor;Australia;40;40;Male;NA;0;2916,6;Stage III;not sustained response;GSE54467;Neutrophils;0,055807163;NA;
untreated;GSM1315955;Primary Tumor;Australia;36;44;Male;NA;0;6242,4;Stage II;non-responder;GSE54467;Neutrophils;0,061009566;NA;
untreated;GSM1315956;Primary Tumor;Australia;70;73;Female;NA;0;3861,3;Stage II;not sustained response;GSE54467;Neutrophils;0,049385448;NA;
untreated;GSM1315957;Primary Tumor;Australia;67;67;Male;NA;0;1219,2;Stage III;not sustained response;GSE54467;Neutrophils;0,093106464;NA;
untreated;GSM1315958;Primary Tumor;Australia;53;66;Male;NA;1;5252,1;Stage I;NA;GSE54467;Neutrophils;0,069282615;NA;
untreated;GSM1315959;Primary Tumor;Australia;64;64;Female;NA;0;3633,6;Stage III;not sustained response;GSE54467;Neutrophils;0,062190239;NA;
untreated;GSM1315960;Primary Tumor;Australia;59;61;Male;NA;0;5126,7;Stage I;not sustained response;GSE54467;Neutrophils;0,076236752;NA;
untreated;GSM1315961;Primary Tumor;Australia;78;88;Male;NA;1;6904,2;Stage I;NA;GSE54467;Neutrophils;0,075026082;NA;
untreated;GSM1315962;Primary Tumor;Australia;62;64;Male;NA;0;3878,1;Stage I;not sustained response;GSE54467;Neutrophils;0,040786541;NA;
untreated;GSM1315963;Primary Tumor;Australia;30;63;Male;NA;1;12093,9;Stage I;NA;GSE54467;Neutrophils;0,159937361;NA;
untreated;GSM1315964;Primary Tumor;Australia;40;46;Female;NA;1;2208,3;Stage III;NA;GSE54467;Neutrophils;0,110017553;NA;
untreated;GSM1315965;Primary Tumor;Australia;58;63;Female;NA;1;3665,1;Stage II;NA;GSE54467;Neutrophils;0,066458521;NA;
untreated;GSM1315966;Primary Tumor;Australia;39;40;Female;NA;0;3431,4;Stage I;not sustained response;GSE54467;Neutrophils;0,075071799;NA;
untreated;GSM1315967;Primary Tumor;Australia;49;50;Male;NA;1;650,1;Stage I;NA;GSE54467;Neutrophils;0,110638867;NA;
untreated;GSM1315968;Primary Tumor;Australia;50;51;Male;NA;0;4334,7;Stage II;not sustained response;GSE54467;Neutrophils;0,08226137;NA;
untreated;GSM1315969;Primary Tumor;Australia;24;24;Male;NA;0;1256,4;Stage III;not sustained response;GSE54467;Neutrophils;0,087658765;NA;
untreated;GSM1315970;Primary Tumor;Australia;70;73;Female;NA;0;2782,5;Stage II;not sustained response;GSE54467;Neutrophils;0,155184051;NA;
untreated;GSM1315971;Primary Tumor;Australia;83;86;Male;NA;1;1875;Stage II;responder;GSE54467;Neutrophils;0,013741665;NA;
untreated;GSM1315972;Primary Tumor;Australia;68;75;Female;NA;0;6019,5;Stage I;not sustained response;GSE54467;Neutrophils;0,068094255;NA;
untreated;GSM1315973;Primary Tumor;Australia;47;47;Male;NA;0;1506;Stage III;not sustained response;GSE54467;Neutrophils;0,065656608;NA;
untreated;GSM1315974;Primary Tumor;Australia;48;48;Female;NA;0;2405,7;Stage I;not sustained response;GSE54467;Neutrophils;0,065724682;NA;
untreated;GSM1315975;Primary Tumor;Australia;52;53;Male;NA;1;582;Stage III;NA;GSE54467;Neutrophils;0,085032079;NA;
untreated;GSM1315976;Primary Tumor;Australia;60;67;Female;NA;0;5314,2;Stage I;non-responder;GSE54467;Neutrophils;0,148169143;NA;
untreated;GSM1315977;Primary Tumor;Australia;45;50;Female;NA;1;3722,4;Stage II;NA;GSE54467;Neutrophils;0,066027333;NA;
untreated;GSM1315978;Primary Tumor;Australia;68;73;Female;NA;1;3316,8;Stage I;NA;GSE54467;Neutrophils;0,077986145;NA;
untreated;GSM1315979;Primary Tumor;Australia;78;80;Male;NA;0;1305,9;Stage I;NA;GSE54467;Neutrophils;0,105831972;NA;
untreated;GSM1315980;Primary Tumor;Australia;56;56;Female;NA;1;708,3;Stage II;NA;GSE54467;Neutrophils;0,079068893;NA;
untreated;GSM1315981;Primary Tumor;Australia;74;74;Female;NA;1;121,2;Stage II;NA;GSE54467;Neutrophils;0,09040017;NA;
untreated;GSM1315982;Primary Tumor;Australia;66;75;Male;NA;1;3691,8;Stage I;NA;GSE54467;Neutrophils;0,064598638;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872328;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,021620588;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872329;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,026861486;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872330;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,009793946;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872331;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,023759699;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872332;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0,024375783;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872333;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872334;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872335;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,004620446;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872336;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0,010606679;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872337;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,002988112;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872338;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872339;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872340;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872341;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;9,07E-06;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872342;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,014462364;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872343;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872344;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872345;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,014971635;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872346;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,036946508;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872347;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872348;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0,003205071;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872349;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0,016193331;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872350;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,007180977;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872351;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,014760124;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872352;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,003874448;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872353;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872354;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0,008101655;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872355;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,01744652;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872356;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0,016384864;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872357;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872358;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0,003287318;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872359;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0,028182489;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872360;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,027095619;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872361;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,023692195;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872362;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,019140414;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872363;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0,002785246;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872364;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,005675476;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872365;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,011309398;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872366;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872367;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,011329419;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872368;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,016465307;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872369;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,030216867;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872370;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872371;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,025589853;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872372;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0,016293785;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872373;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,009267411;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872374;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872375;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0,010188317;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872376;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872377;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,013744872;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872378;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,014129756;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872379;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,01479746;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872380;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,030914004;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872381;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0,004097983;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872382;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;NK.cells;0,016483502;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872383;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;NK.cells;0,012450843;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872384;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;NK.cells;0,018305517;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872385;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;NK.cells;0,020527407;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872386;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;NK.cells;0,012786569;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872387;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;NK.cells;6,69E-04;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872388;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;NK.cells;0,01894548;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872389;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;NK.cells;0,017585945;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872390;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;NK.cells;0,016311596;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872391;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;NK.cells;0,006239634;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872392;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;NK.cells;0,00776973;NA;
Standard (dacarbazine monotherapy; DTIC);GSM550966;Metastatic;Sweden;60;62;Male;Trunk;1;373;IV;NA;GSE22155_GPL6102;NK.cells;0,018885657;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550967;Metastatic;Sweden;54;59;Female;Lower extremity;1;181;IV;NA;GSE22155_GPL6102;NK.cells;0,035623555;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550968;Metastatic;Sweden;40;53;Male;Head;1;436;IV;NA;GSE22155_GPL6102;NK.cells;0,046980918;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550969;Metastatic;Sweden;54;61;Female;Lower extremity;1;82;IV;NA;GSE22155_GPL6102;NK.cells;0,058949876;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550970;Metastatic;Sweden;45;47;Male;Lower extremity;1;646;IV;NA;GSE22155_GPL6102;NK.cells;0,03324899;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550971;Metastatic;Sweden;68;68;Male;No primary detected;1;114;IV;NA;GSE22155_GPL6102;NK.cells;0,030120611;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550972;Metastatic;Sweden;36;38;Male;Upper extremity, acral;1;322;IV;NA;GSE22155_GPL6102;NK.cells;0,037828462;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550973;Metastatic;Sweden;63;65;Female;Trunk;1;46;IV;NA;GSE22155_GPL6102;NK.cells;0,025492381;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550974;Metastatic;Sweden;51;51;Male;No primary detected;0;3509;IV;NA;GSE22155_GPL6102;NK.cells;0,030050812;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550975;Metastatic;Sweden;79;86;Male;Head;1;65;IV;NA;GSE22155_GPL6102;NK.cells;0,026879367;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550976;Metastatic;Sweden;50;51;Male;Trunk;1;14;IV;NA;GSE22155_GPL6102;NK.cells;0,050719573;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550977;Metastatic;Sweden;58;59;Female;Upper extremity;1;27;IV;NA;GSE22155_GPL6102;NK.cells;0,038380475;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550978;Metastatic;Sweden;36;36;Male;No primary detected;-;-;III;NA;GSE22155_GPL6102;NK.cells;0,054161071;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550979;Metastatic;Sweden;60;66;Female;Upper extremity;1;45;IV;NA;GSE22155_GPL6102;NK.cells;0,066149004;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550980;Metastatic;Sweden;53;53;Female;No primary detected;1;10;IV;NA;GSE22155_GPL6102;NK.cells;0,005204848;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550981;Metastatic;Sweden;27;32;Female;Trunk;0;2711;IV;NA;GSE22155_GPL6102;NK.cells;0,040726869;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550982;Metastatic;Sweden;49;51;Male;Lower extremity;1;32;IV;NA;GSE22155_GPL6102;NK.cells;0,055863942;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550983;Metastatic;Sweden;62;63;Male;No primary detected;1;55;IV;NA;GSE22155_GPL6102;NK.cells;0,035448859;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550984;Metastatic;Sweden;50;71;Male;Upper extremity;1;91;IV;NA;GSE22155_GPL6102;NK.cells;0,011868021;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550985;Metastatic;Sweden;49;63;Female;Trunk;1;804;IV;NA;GSE22155_GPL6102;NK.cells;0,009493219;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550986;Metastatic;Sweden;55;61;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;NK.cells;0,04588979;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550987;Metastatic;Sweden;55;80;Male;Trunk;1;25;IV;NA;GSE22155_GPL6102;NK.cells;0,023754;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550988;Metastatic;Sweden;78;78;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;NK.cells;0,016805587;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550989;Metastatic;Sweden;56;57;Male;No primary detected;1;50;IV;NA;GSE22155_GPL6102;NK.cells;0,049602059;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550990;Metastatic;Sweden;74;76;Female;Head;1;156;IV;NA;GSE22155_GPL6102;NK.cells;0,050687396;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550991;Metastatic;Sweden;53;70;Male;Trunk;1;219;IV;NA;GSE22155_GPL6102;NK.cells;0,028950847;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550992;Metastatic;Sweden;36;49;Male;Trunk;1;266;IV;NA;GSE22155_GPL6102;NK.cells;0,052393382;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550993;Metastatic;Sweden;33;33;Male;No primary detected;1;1075;IV;NA;GSE22155_GPL6102;NK.cells;0,035261744;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550994;Metastatic;Sweden;67;67;Female;No primary detected;1;201;IV;NA;GSE22155_GPL6102;NK.cells;0,050562635;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550995;Metastatic;Sweden;72;74;Male;Trunk;1;247;IV;NA;GSE22155_GPL6102;NK.cells;0,030235791;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550996;Metastatic;Sweden;27;31;Female;Trunk;1;414;IV;NA;GSE22155_GPL6102;NK.cells;0,043559557;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550997;Metastatic;Sweden;32;43;Female;No primary detected;1;108;IV;NA;GSE22155_GPL6102;NK.cells;0,035882283;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550998;Metastatic;Sweden;59;61;Female;Trunk;-;-;III;NA;GSE22155_GPL6102;NK.cells;0,035675941;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550999;Metastatic;Sweden;61;61;Male;No primary detected;1;281;IV;NA;GSE22155_GPL6102;NK.cells;0,014091411;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551000;Metastatic;Sweden;73;73;Male;Head and eye;1;221;IV;NA;GSE22155_GPL6102;NK.cells;0,017330441;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551001;Metastatic;Sweden;54;55;Male;Trunk;1;102;IV;NA;GSE22155_GPL6102;NK.cells;0,019101922;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551002;Metastatic;Sweden;68;68;Female;No primary detected;1;301;IV;NA;GSE22155_GPL6102;NK.cells;0,061107474;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551003;Metastatic;Sweden;62;68;Female;Trunk;1;64;IV;NA;GSE22155_GPL6102;NK.cells;0,022099368;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551004;Metastatic;Sweden;35;36;Female;No primary detected;1;375;IV;NA;GSE22155_GPL6102;NK.cells;0,041593319;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551005;Metastatic;Sweden;76;79;Female;Trunk;1;218;IV;NA;GSE22155_GPL6102;NK.cells;0,050308001;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551006;Metastatic;Sweden;66;68;Male;Head;1;1478;IV;NA;GSE22155_GPL6102;NK.cells;0,021709025;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551007;Metastatic;Sweden;46;52;Female;Trunk;1;13;IV;NA;GSE22155_GPL6102;NK.cells;0,016890822;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551008;Metastatic;Sweden;65;67;Male;Trunk;1;254;IV;NA;GSE22155_GPL6102;NK.cells;0,022664399;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551009;Metastatic;Sweden;70;70;Female;Upper extremity;1;16;IV;NA;GSE22155_GPL6102;NK.cells;0,017570322;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551010;Metastatic;Sweden;68;72;Male;Trunk;1;430;IV;NA;GSE22155_GPL6102;NK.cells;0,045032335;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551011;Metastatic;Sweden;82;84;Male;Trunk;1;63;IV;NA;GSE22155_GPL6102;NK.cells;0,028635701;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551012;Metastatic;Sweden;35;68;Male;Upper extremity;0;1198;IV;NA;GSE22155_GPL6102;NK.cells;0,012807915;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551013;Metastatic;Sweden;31;38;Male;Trunk;-;-;III;NA;GSE22155_GPL6102;NK.cells;0,019452534;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551014;Metastatic;Sweden;79;79;Female;Trunk;0;927;IV;NA;GSE22155_GPL6102;NK.cells;0,007032386;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551015;Metastatic;Sweden;77;82;Female;Upper extremity;1;325;IV;NA;GSE22155_GPL6102;NK.cells;0,016974377;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551016;Metastatic;Sweden;72;76;Male;Lower extremity;1;44;IV;NA;GSE22155_GPL6102;NK.cells;0,07350947;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551017;Metastatic;Sweden;75;75;Female;Lower extremity;0;895;IV;NA;GSE22155_GPL6102;NK.cells;0,031463498;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551018;Metastatic;Sweden;58;61;Male;Trunk;0;836;IV;NA;GSE22155_GPL6102;NK.cells;0,032247237;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551019;Metastatic;Sweden;71;74;Female;Lower extremity, acral;0;786;IV;NA;GSE22155_GPL6102;NK.cells;0,028928671;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551020;Metastatic;Sweden;65;76;Male;Trunk;1;244;IV;NA;GSE22155_GPL6102;NK.cells;0,044276399;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551021;Metastatic;Sweden;25;25;Female;Lower extremity;1;78;IV;NA;GSE22155_GPL6102;NK.cells;0,033204866;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551022;Metastatic;Sweden;50;75;Male;Trunk;1;29;IV;NA;GSE22155_GPL6102;NK.cells;0,061181941;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551023;Metastatic;Sweden;75;76;Male;Acral;1;44;IV;NA;GSE22155_GPL6947;NK.cells;0,093575345;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551024;Metastatic;Sweden;63;64;Female;Genital;1;747;IV;NA;GSE22155_GPL6947;NK.cells;0,04240941;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551025;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;NK.cells;0,054668881;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551026;Metastatic;Sweden;68;68;Female;GI tractus;1;367;IV;NA;GSE22155_GPL6947;NK.cells;0,031638869;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551027;Metastatic;Sweden;58;60;Male;Eye;1;7;IV;NA;GSE22155_GPL6947;NK.cells;0,046700677;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551028;Metastatic;Sweden;49;63;Male;Trunk;1;309;IV;NA;GSE22155_GPL6947;NK.cells;0,02040084;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551029;Metastatic;Sweden;56;55;Female;Trunk;1;32;IV;NA;GSE22155_GPL6947;NK.cells;0,019124293;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551030;Metastatic;Sweden;74;74;Male;Trunk;1;79;IV;NA;GSE22155_GPL6947;NK.cells;0,062221333;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551031;Metastatic;Sweden;41;42;Female;Eye;1;349;IV;NA;GSE22155_GPL6947;NK.cells;0,058827738;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551032;Metastatic;Sweden;49;51;Female;Mucosa, head;1;13;IV;NA;GSE22155_GPL6947;NK.cells;0,052571392;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551033;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;NK.cells;0,045752264;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551034;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;NK.cells;0,043533066;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551035;Metastatic;Sweden;56;56;Male;GI tractus;1;37;IV;NA;GSE22155_GPL6947;NK.cells;0,042938114;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551036;Metastatic;Sweden;45;74;Male;No primary;1;183;IV;NA;GSE22155_GPL6947;NK.cells;0,032525547;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551037;Metastatic;Sweden;72;75;Female;Head;1;39;IV;NA;GSE22155_GPL6947;NK.cells;0,012525911;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551038;Metastatic;Sweden;61;68;Female;Eye;1;513;IV;NA;GSE22155_GPL6947;NK.cells;0,041511362;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551039;Metastatic;Sweden;66;68;Male;Trunk;1;584;IV;NA;GSE22155_GPL6947;NK.cells;0,045303808;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551040;Metastatic;Sweden;42;44;Male;Head;1;1148;IV;NA;GSE22155_GPL6947;NK.cells;0,044871257;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551041;Metastatic;Sweden;54;56;Female;Trunk;1;153;IV;NA;GSE22155_GPL6947;NK.cells;0,051046599;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551042;Metastatic;Sweden;48;50;Male;Trunk;1;141;IV;NA;GSE22155_GPL6947;NK.cells;0,075046683;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551043;Metastatic;Sweden;58;67;Female;Acral;1;334;IV;NA;GSE22155_GPL6947;NK.cells;0,056219799;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551044;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;NK.cells;0,056475665;Metastasis
untreated;GSM1220412;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;NK.cells;0,026658037;Metastasis;
dabrafenib;GSM1220413;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,065437505;cutaneous or subcutaneous;
untreated;GSM1220414;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,01544712;cutaneous or subcutaneous;
dabrafenib;GSM1220415;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,018697666;cutaneous or subcutaneous;
untreated;GSM1220416;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,01912142;cutaneous or subcutaneous;
dabrafenib;GSM1220417;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,036812101;cutaneous or subcutaneous;
dabrafenib;GSM1220418;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,018172735;cutaneous or subcutaneous;
untreated;GSM1220419;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;NK.cells;0,045239851;Metastasis;
dabrafenib;GSM1220420;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;NK.cells;0,047995015;Metastasis;
untreated;GSM1220421;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,004504411;cutaneous or subcutaneous;
dabrafenib;GSM1220422;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,003364937;cutaneous or subcutaneous;
dabrafenib;GSM1220423;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,006172004;cutaneous or subcutaneous;
untreated;GSM1220424;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,019399496;cutaneous or subcutaneous;
untreated;GSM1220425;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,020562292;cutaneous or subcutaneous;
dabrafenib;GSM1220426;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;NK.cells;0,010663926;Metastasis;
untreated;GSM1220427;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,022260667;cutaneous or subcutaneous;
untreated;GSM1220428;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,031925201;cutaneous or subcutaneous;
dabrafenib;GSM1220429;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,03605112;cutaneous or subcutaneous;
dabrafenib;GSM1220430;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,047721603;cutaneous or subcutaneous;
untreated;GSM1220431;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,01833221;cutaneous or subcutaneous;
dabrafenib;GSM1220432;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,019926156;cutaneous or subcutaneous;
untreated;GSM1220433;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,020241307;cutaneous or subcutaneous;
untreated;GSM1220434;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,021525934;cutaneous or subcutaneous;
dabrafenib;GSM1220435;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,031530702;cutaneous or subcutaneous;
dabrafenib;GSM1220436;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,046929474;cutaneous or subcutaneous;
dabrafenib;GSM1220437;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,016518102;cutaneous or subcutaneous;
untreated;GSM1220438;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;NK.cells;0,035792691;Metastasis;
untreated;GSM1220439;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;NK.cells;0,03391074;Metastasis;
dabrafenib;GSM1220440;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,029760276;cutaneous or subcutaneous;
dabrafenib;GSM1220441;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;NK.cells;0,035204839;Metastasis;
dabrafenib;GSM1220442;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,029874638;cutaneous or subcutaneous;
dabrafenib;GSM1220443;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;NK.cells;0,034229558;Metastasis;
untreated;GSM1220444;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;NK.cells;0,005176877;Metastasis;
dabrafenib;GSM1220445;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0;cutaneous or subcutaneous;
untreated;GSM1220446;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,029783488;cutaneous or subcutaneous;
untreated;GSM1220447;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,026993056;cutaneous or subcutaneous;
dabrafenib;GSM1220448;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,032186456;cutaneous or subcutaneous;
untreated;GSM1220449;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;NK.cells;0,017978352;Metastasis;
dabrafenib;GSM1220450;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,017282327;cutaneous or subcutaneous;
untreated;GSM1220451;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;NK.cells;0,033711089;Metastasis;
dabrafenib;GSM1220452;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;NK.cells;0,019446784;Metastasis;
untreated;GSM1220453;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0;cutaneous or subcutaneous;
untreated;GSM1220454;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0;cutaneous or subcutaneous;
dabrafenib;GSM1220455;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;NK.cells;0,030504705;Metastasis;
dabrafenib;GSM1220456;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,020846236;cutaneous or subcutaneous;
untreated;GSM1220457;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,02546642;cutaneous or subcutaneous;
dabrafenib;GSM1220458;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;NK.cells;0,022307743;Metastasis;
untreated;GSM1220459;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,0196284;cutaneous or subcutaneous;
vemurafenib;GSM1220460;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,017025801;cutaneous or subcutaneous;
untreated;GSM1220461;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,012560345;cutaneous or subcutaneous;
untreated;GSM1220462;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,012648975;cutaneous or subcutaneous;
vemurafenib;GSM1220463;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,015162815;cutaneous or subcutaneous;
untreated;GSM1220464;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;NK.cells;0,014101357;Metastasis;
vemurafenib;GSM1220465;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,014675451;cutaneous or subcutaneous;
untreated;GSM1220466;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,006346633;cutaneous or subcutaneous;
vemurafenib;GSM1220467;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,011953847;cutaneous or subcutaneous;
vemurafenib;GSM1220468;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,012300202;cutaneous or subcutaneous;
vemurafenib;GSM1220469;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,011191803;cutaneous or subcutaneous;
vemurafenib;GSM1220470;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,011415946;cutaneous or subcutaneous;
untreated;GSM1220471;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;NK.cells;0,020811625;cutaneous or subcutaneous;
vemurafenib;GSM1220472;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;NK.cells;0,00800879;Metastasis;
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;NK.cells;1,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;NK.cells;1,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,00E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,00E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;1,40E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;1,40E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;NK.cells;1,76E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;NK.cells;1,76E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,19E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,19E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;NK.cells;1,33E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;NK.cells;1,33E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;NK.cells;8,92E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;NK.cells;8,92E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;NK.cells;6,90E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;NK.cells;6,90E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;1,23E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;1,23E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;4,11E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;4,11E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;NK.cells;2,73E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;NK.cells;2,73E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;NK.cells;1,64E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;NK.cells;1,64E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;NK.cells;2,20E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;NK.cells;2,20E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;2,73E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;2,73E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;NK.cells;3,22E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;NK.cells;3,22E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,07E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,07E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;NK.cells;1,44E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;NK.cells;1,44E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;2,14E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;2,14E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;NK.cells;1,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;NK.cells;1,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;NK.cells;1,85E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;NK.cells;1,85E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;NK.cells;2,21E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;NK.cells;2,21E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;NK.cells;6,81E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;NK.cells;6,81E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;1,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;1,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;NK.cells;3,52E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;NK.cells;3,52E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,37E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,37E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;1,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;1,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;NK.cells;1,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;NK.cells;1,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;NK.cells;1,00E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;NK.cells;1,00E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,02E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,02E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;1,39E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;1,39E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;NK.cells;1,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;NK.cells;1,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;5,13E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;5,13E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;NK.cells;1,63E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;NK.cells;1,63E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;2,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;2,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;3,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;3,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;NK.cells;9,59E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;NK.cells;9,59E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;NK.cells;1,83E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;NK.cells;1,83E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;NK.cells;4,05E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;NK.cells;4,05E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;NK.cells;3,88E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;NK.cells;3,88E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;NK.cells;5,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;NK.cells;5,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;NK.cells;1,09E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;NK.cells;1,09E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;1,35E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;1,35E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;NK.cells;2,43E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;NK.cells;2,43E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;NK.cells;1,59E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;NK.cells;1,59E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;NK.cells;1,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;NK.cells;1,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;NK.cells;1,68E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;NK.cells;1,68E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;NK.cells;1,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;NK.cells;1,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,06E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,06E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,73E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,73E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,15E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,15E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,82E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,82E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;NK.cells;8,34E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;NK.cells;8,34E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;8,82E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;8,82E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;8,97E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;8,97E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;NK.cells;1,50E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;NK.cells;1,50E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;NK.cells;1,51E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;NK.cells;1,51E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,16E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,16E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;NK.cells;3,12E-05;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;NK.cells;3,12E-05;NA
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;NK.cells;1,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;NK.cells;1,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;2,09E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;2,09E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,35E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,35E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;NK.cells;2,93E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;NK.cells;2,93E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,65E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,65E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,59E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,59E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;NK.cells;1,38E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;NK.cells;1,38E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;NK.cells;1,31E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;NK.cells;1,31E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;NK.cells;4,56E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;NK.cells;4,56E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;NK.cells;2,46E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;NK.cells;2,46E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;3,18E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;3,18E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;3,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;3,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;3,22E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;3,22E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,83E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,83E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,19E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,19E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,79E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,79E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,87E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,87E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;NK.cells;1,75E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;NK.cells;1,75E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;NK.cells;1,91E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;NK.cells;1,91E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;NK.cells;3,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;NK.cells;3,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,08E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,08E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;NK.cells;1,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;NK.cells;1,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;NK.cells;5,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;NK.cells;5,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;NK.cells;2,41E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;NK.cells;2,41E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;NK.cells;1,54E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;NK.cells;1,54E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;1,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;1,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,46E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,46E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;NK.cells;2,11E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;NK.cells;2,11E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;9,44E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;9,44E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;NK.cells;4,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;NK.cells;4,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;2,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;2,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;NK.cells;2,86E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;NK.cells;2,86E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;NK.cells;2,56E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;NK.cells;2,56E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;NK.cells;2,02E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;NK.cells;2,02E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;NK.cells;1,94E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;NK.cells;1,94E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;NK.cells;1,31E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;NK.cells;1,31E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;NK.cells;3,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;NK.cells;3,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;NK.cells;2,29E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;NK.cells;2,29E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;NK.cells;1,41E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;NK.cells;1,41E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;NK.cells;2,22E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;NK.cells;2,22E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;3,30E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;3,30E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;NK.cells;1,68E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;NK.cells;1,68E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;NK.cells;1,52E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;NK.cells;1,52E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;NK.cells;1,94E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;NK.cells;1,94E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;NK.cells;6,17E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;NK.cells;6,17E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;NK.cells;3,39E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;NK.cells;3,39E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;NK.cells;1,02E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;NK.cells;1,02E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;NK.cells;1,49E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;NK.cells;1,49E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,98E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,98E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;NK.cells;2,23E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;NK.cells;2,23E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;NK.cells;2,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;NK.cells;2,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;7,85E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;7,85E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;NK.cells;2,83E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;NK.cells;2,83E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;NK.cells;1,98E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;NK.cells;1,98E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;NK.cells;1,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;NK.cells;1,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;NK.cells;3,34E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;NK.cells;3,34E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;NK.cells;1,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;NK.cells;1,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;4,24E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;4,24E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;NK.cells;7,71E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;NK.cells;7,71E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;4,75E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;4,75E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;NK.cells;2,31E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;NK.cells;2,31E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;2,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;2,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;NK.cells;1,69E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;NK.cells;1,69E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;NK.cells;2,46E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;NK.cells;2,46E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;6,71E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;6,71E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;NK.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;NK.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;NK.cells;2,16E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;NK.cells;2,16E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;NK.cells;1,28E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;NK.cells;1,28E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;1,70E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;1,70E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;NK.cells;1,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;NK.cells;1,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;1,68E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;1,68E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;NK.cells;1,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;NK.cells;1,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;3,33E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;3,33E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;NK.cells;1,98E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;NK.cells;1,98E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;NK.cells;3,03E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;NK.cells;3,03E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,87E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,87E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;3,33E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;3,33E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,82E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,82E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;1,79E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;1,79E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,13E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,13E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;NK.cells;1,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;NK.cells;1,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;NK.cells;2,76E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;NK.cells;2,76E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;2,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;2,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;1,52E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;1,52E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;NK.cells;1,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;NK.cells;1,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,31E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,31E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;NK.cells;1,57E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;NK.cells;1,57E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;4,39E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;4,39E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,76E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,76E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,00E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,00E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;NK.cells;1,88E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;NK.cells;1,88E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,21E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,21E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,40E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,40E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,56E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,56E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;NK.cells;6,23E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;NK.cells;6,23E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;NK.cells;1,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;NK.cells;1,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;NK.cells;1,39E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;NK.cells;1,39E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;NK.cells;1,19E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;NK.cells;1,19E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;NK.cells;1,13E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;NK.cells;1,13E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,73E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,73E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;3,21E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;3,21E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;NK.cells;2,35E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;NK.cells;2,35E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;NK.cells;1,64E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;NK.cells;1,64E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;NK.cells;1,70E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;NK.cells;1,70E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;1,05E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;1,05E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;NK.cells;7,21E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;NK.cells;7,21E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;NK.cells;1,94E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;NK.cells;1,94E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,03E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,03E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;NK.cells;2,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;NK.cells;2,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;NK.cells;8,18E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;NK.cells;8,18E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;NK.cells;2,65E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;NK.cells;2,65E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;3,46E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;3,46E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;NK.cells;7,51E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;NK.cells;7,51E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;NK.cells;1,99E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;NK.cells;1,99E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;9,87E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;9,87E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,73E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,73E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;NK.cells;4,40E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;NK.cells;4,40E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;NK.cells;2,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;NK.cells;2,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;NK.cells;5,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;NK.cells;5,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;NK.cells;2,45E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;NK.cells;2,45E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;NK.cells;1,20E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;NK.cells;1,20E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;NK.cells;1,14E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;NK.cells;1,14E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;NK.cells;1,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;NK.cells;1,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;NK.cells;2,95E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;NK.cells;2,95E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;NK.cells;1,52E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;NK.cells;1,52E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;NK.cells;2,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;NK.cells;2,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;NK.cells;1,24E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;NK.cells;1,24E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;9,57E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;9,57E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;NK.cells;1,65E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;NK.cells;1,65E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;NK.cells;1,16E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;NK.cells;1,16E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;NK.cells;5,84E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;NK.cells;5,84E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;NK.cells;1,51E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;NK.cells;1,51E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;NK.cells;2,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;NK.cells;2,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;NK.cells;1,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;NK.cells;1,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;NK.cells;1,20E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;NK.cells;1,20E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,00E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,00E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;NK.cells;2,22E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;NK.cells;2,22E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;NK.cells;1,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;NK.cells;1,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,20E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,20E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;NK.cells;4,24E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;NK.cells;4,24E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;NK.cells;3,16E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;NK.cells;3,16E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;3,90E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;3,90E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;NK.cells;2,49E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;NK.cells;2,49E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;NK.cells;2,96E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;NK.cells;2,96E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;7,57E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;7,57E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;NK.cells;1,92E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;NK.cells;1,92E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;NK.cells;1,46E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;NK.cells;1,46E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;1,91E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;1,91E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,04E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,04E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;1,93E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;1,93E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;NK.cells;3,24E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;NK.cells;3,24E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,82E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,82E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,58E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,58E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,93E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,93E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;2,38E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;2,38E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;NK.cells;1,55E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;NK.cells;1,55E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;NK.cells;1,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;NK.cells;1,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;NK.cells;1,90E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;NK.cells;1,90E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;7,78E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;7,78E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;9,39E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;9,39E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;2,00E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;2,00E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;NK.cells;2,16E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;NK.cells;2,16E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,50E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,50E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;1,59E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;1,59E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;NK.cells;1,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;NK.cells;1,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;NK.cells;3,06E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;NK.cells;3,06E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;NK.cells;1,38E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;NK.cells;1,38E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;3,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;3,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;9,30E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;9,30E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;NK.cells;1,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;NK.cells;1,47E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;NK.cells;1,56E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;NK.cells;1,56E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;NK.cells;2,98E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;NK.cells;2,98E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;NK.cells;1,23E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;NK.cells;1,23E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;NK.cells;1,95E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;NK.cells;1,95E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,17E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,17E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;NK.cells;2,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;NK.cells;2,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;NK.cells;4,49E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;NK.cells;4,49E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;NK.cells;3,33E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;NK.cells;3,33E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;1,00E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;1,00E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,04E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,04E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;NK.cells;2,59E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;NK.cells;2,59E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;3,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;3,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;NK.cells;1,43E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;NK.cells;1,43E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;NK.cells;1,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;NK.cells;1,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;NK.cells;1,20E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;NK.cells;1,20E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,57E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,57E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;NK.cells;2,64E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;NK.cells;2,64E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;NK.cells;3,13E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;NK.cells;3,13E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;NK.cells;2,69E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;NK.cells;2,69E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;1,33E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;1,33E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;NK.cells;9,80E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;NK.cells;9,80E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;NK.cells;2,58E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;NK.cells;2,58E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;7,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;7,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;NK.cells;7,79E-05;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;NK.cells;7,79E-05;NA
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;NK.cells;1,35E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;NK.cells;1,35E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;NK.cells;2,45E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;NK.cells;2,45E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;NK.cells;3,77E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;NK.cells;3,77E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;NK.cells;2,42E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;NK.cells;2,42E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;NK.cells;9,45E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;NK.cells;9,45E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;NK.cells;2,32E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;NK.cells;2,32E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;2,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;2,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;NK.cells;9,51E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;NK.cells;9,51E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,63E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,63E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;1,54E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;1,54E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;NK.cells;2,86E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;NK.cells;2,86E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;NK.cells;2,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;NK.cells;2,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;NK.cells;3,34E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;NK.cells;3,34E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;1,15E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;1,15E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;NK.cells;2,05E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;NK.cells;2,05E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;1,67E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;1,67E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;NK.cells;1,98E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;NK.cells;1,98E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;NK.cells;1,92E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;NK.cells;1,92E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;NK.cells;3,68E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;NK.cells;3,68E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,05E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,05E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;NK.cells;3,60E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;NK.cells;3,60E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;NK.cells;1,89E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;NK.cells;1,89E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;NK.cells;9,16E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;NK.cells;9,16E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;NK.cells;1,35E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;NK.cells;1,35E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;NK.cells;1,81E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;NK.cells;1,81E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;NK.cells;1,13E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;NK.cells;1,13E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;NK.cells;8,88E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;NK.cells;8,88E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;NK.cells;1,38E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;NK.cells;1,38E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;NK.cells;3,44E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;NK.cells;3,44E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;NK.cells;3,39E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;NK.cells;3,39E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;NK.cells;4,58E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;NK.cells;4,58E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;2,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;2,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;NK.cells;2,06E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;NK.cells;2,06E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;NK.cells;9,80E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;NK.cells;9,80E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;NK.cells;7,77E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;NK.cells;7,77E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;NK.cells;1,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;NK.cells;1,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;NK.cells;1,55E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;NK.cells;1,55E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;NK.cells;6,64E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;NK.cells;6,64E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,62E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,62E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;NK.cells;1,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;NK.cells;1,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;6,20E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;6,20E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;8,38E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;8,38E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;4,85E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;4,85E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;NK.cells;1,56E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;NK.cells;1,56E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,66E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,66E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;NK.cells;6,63E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;NK.cells;6,63E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;NK.cells;2,08E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;NK.cells;2,08E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;NK.cells;1,32E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;NK.cells;1,32E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;NK.cells;1,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;NK.cells;1,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;NK.cells;8,30E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;NK.cells;8,30E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;NK.cells;1,97E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;NK.cells;1,97E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;8,03E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;8,03E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;NK.cells;6,77E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;NK.cells;6,77E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,83E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,83E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;1,89E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;1,89E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;NK.cells;1,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;NK.cells;1,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;7,75E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;7,75E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;NK.cells;1,12E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;NK.cells;1,12E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,92E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,92E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,80E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,80E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,87E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,87E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,17E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,17E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;NK.cells;1,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;NK.cells;1,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,44E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,44E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;NK.cells;1,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;NK.cells;1,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,16E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,16E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;NK.cells;1,09E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;NK.cells;1,09E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,44E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,44E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;7,16E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;7,16E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;1,79E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;1,79E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,04E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,04E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;NK.cells;2,81E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;NK.cells;2,81E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;NK.cells;1,97E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;NK.cells;1,97E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;3,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;3,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;NK.cells;1,63E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;NK.cells;1,63E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,54E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,54E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,86E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,86E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,34E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,34E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;NK.cells;2,73E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;NK.cells;2,73E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;1,23E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;1,23E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,17E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,17E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,19E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,19E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;NK.cells;1,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;NK.cells;1,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;2,31E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;2,31E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,32E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,32E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;6,86E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;6,86E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;NK.cells;3,32E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;NK.cells;3,32E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;NK.cells;1,87E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;NK.cells;1,87E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;2,19E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;2,19E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;NK.cells;1,88E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;NK.cells;1,88E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;NK.cells;1,02E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;NK.cells;1,02E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;3,33E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;NK.cells;3,33E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;NK.cells;3,34E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;NK.cells;3,34E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;3,32E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;3,32E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;8,18E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;8,18E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,69E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,69E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,08E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;2,08E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;NK.cells;1,38E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;NK.cells;1,38E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;3,07E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;3,07E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,30E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,30E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;NK.cells;3,04E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;NK.cells;3,04E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,29E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,29E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;NK.cells;1,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;NK.cells;1,61E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;NK.cells;1,10E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;NK.cells;1,10E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;NK.cells;2,33E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;NK.cells;2,33E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;5,15E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;5,15E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;7,85E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;7,85E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;NK.cells;2,86E-05;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;NK.cells;2,86E-05;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;NK.cells;1,68E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;NK.cells;1,68E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;NK.cells;5,55E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;NK.cells;5,55E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,79E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,79E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;NK.cells;1,37E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;NK.cells;1,37E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;NK.cells;1,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;NK.cells;1,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;NK.cells;1,23E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;NK.cells;1,23E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;NK.cells;7,49E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;NK.cells;7,49E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;9,45E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;9,45E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;2,15E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;2,15E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;NK.cells;2,32E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;NK.cells;2,32E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,12E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,12E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;NK.cells;1,58E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;NK.cells;1,58E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,89E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,89E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;NK.cells;3,23E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;NK.cells;3,23E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;NK.cells;4,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;NK.cells;4,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;NK.cells;1,05E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;NK.cells;1,05E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;NK.cells;1,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;NK.cells;1,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;8,11E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;8,11E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;NK.cells;3,10E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;NK.cells;3,10E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;1,15E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;1,15E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,85E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,85E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;NK.cells;1,89E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;NK.cells;1,89E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;NK.cells;2,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;NK.cells;2,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;NK.cells;4,95E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;NK.cells;4,95E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,26E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;NK.cells;1,85E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;NK.cells;1,85E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,65E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,65E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;NK.cells;1,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;NK.cells;1,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,36E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;NK.cells;1,02E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;NK.cells;1,02E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;3,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;3,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;NK.cells;1,59E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;NK.cells;1,59E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,44E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,44E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;NK.cells;1,30E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;NK.cells;1,30E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;NK.cells;1,91E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;NK.cells;1,91E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;1,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;NK.cells;1,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;7,17E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;7,17E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;NK.cells;3,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;NK.cells;3,01E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;NK.cells;3,10E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;NK.cells;3,10E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;6,42E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;6,42E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;NK.cells;2,24E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;NK.cells;2,24E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;NK.cells;6,24E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;NK.cells;6,24E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;2,36E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;2,36E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;NK.cells;4,70E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;NK.cells;4,70E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;NK.cells;4,68E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;NK.cells;4,68E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;NK.cells;1,91E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;NK.cells;1,91E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,10E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;2,10E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,55E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,55E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;NK.cells;1,81E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;NK.cells;1,81E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;NK.cells;1,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;NK.cells;1,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,63E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,63E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;4,06E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;4,06E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;NK.cells;3,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;NK.cells;3,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;NK.cells;1,98E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;NK.cells;1,98E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;NK.cells;1,86E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;NK.cells;1,86E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;2,22E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;NK.cells;2,22E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;9,84E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;9,84E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;NK.cells;2,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;NK.cells;2,74E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;4,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;4,27E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,42E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,42E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;NK.cells;2,07E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;NK.cells;2,07E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;1,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;NK.cells;3,66E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;NK.cells;3,66E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;NK.cells;1,75E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;NK.cells;1,75E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;NK.cells;2,18E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;NK.cells;2,18E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,97E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;1,97E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;NK.cells;2,15E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;NK.cells;2,15E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;NK.cells;6,28E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;NK.cells;6,28E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;1,05E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;1,05E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;1,50E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;NK.cells;1,50E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;NK.cells;3,02E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;NK.cells;3,02E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,07E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,07E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;NK.cells;5,90E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;NK.cells;5,90E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;NK.cells;1,31E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;NK.cells;1,31E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;NK.cells;1,39E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;NK.cells;1,39E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;NK.cells;1,41E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;NK.cells;1,41E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;NK.cells;1,44E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;NK.cells;1,44E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;NK.cells;3,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;NK.cells;3,53E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,55E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,55E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;1,02E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;NK.cells;1,02E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;7,92E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;NK.cells;7,92E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;NK.cells;2,82E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;NK.cells;2,82E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,29E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,29E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;NK.cells;6,57E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;NK.cells;6,57E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;NK.cells;3,54E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;NK.cells;3,54E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;3,76E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;NK.cells;3,76E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;NK.cells;1,70E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;NK.cells;1,70E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;NK.cells;9,87E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;NK.cells;9,87E-06;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;4,10E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;4,10E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;NK.cells;1,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;NK.cells;1,48E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;1,71E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;NK.cells;2,78E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;NK.cells;1,21E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;NK.cells;1,21E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,58E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;NK.cells;3,58E-05;Metastasis
untreated;GSM1315904;Primary Tumor;Australia;19;22;Female;NA;0;4342,8;Stage II;not sustained response;GSE54467;NK.cells;0,03984747;NA;
untreated;GSM1315905;Primary Tumor;Australia;53;56;Male;NA;1;1418,4;Stage II;NA;GSE54467;NK.cells;0,020664885;NA;
untreated;GSM1315906;Primary Tumor;Australia;52;53;Female;NA;1;698,4;Stage II;NA;GSE54467;NK.cells;0,028264622;NA;
untreated;GSM1315907;Primary Tumor;Australia;51;52;Male;NA;0;3330,6;Stage I;not sustained response;GSE54467;NK.cells;0,037222965;NA;
untreated;GSM1315908;Primary Tumor;Australia;47;51;Male;NA;1;4283,4;Stage II;NA;GSE54467;NK.cells;0,045629325;NA;
untreated;GSM1315909;Primary Tumor;Australia;61;64;Male;NA;1;1540,5;Stage I;NA;GSE54467;NK.cells;0,035191676;NA;
untreated;GSM1315910;Primary Tumor;Australia;46;52;Female;NA;0;6957,3;Stage I;not sustained response;GSE54467;NK.cells;0,046998559;NA;
untreated;GSM1315911;Primary Tumor;Australia;61;75;Male;NA;1;5484,9;Stage I;NA;GSE54467;NK.cells;0,043808363;NA;
untreated;GSM1315912;Primary Tumor;Australia;84;87;Female;NA;1;1491,3;Stage I;NA;GSE54467;NK.cells;0,046672261;NA;
untreated;GSM1315913;Primary Tumor;Australia;44;44;Female;NA;0;3899,7;Stage III;not sustained response;GSE54467;NK.cells;0,02328776;NA;
untreated;GSM1315914;Primary Tumor;Australia;64;72;Male;NA;1;3322,8;Stage I;NA;GSE54467;NK.cells;0,027086197;NA;
untreated;GSM1315915;Primary Tumor;Australia;31;31;Male;NA;0;3034,8;Stage III;not sustained response;GSE54467;NK.cells;0,037225182;NA;
untreated;GSM1315916;Primary Tumor;Australia;63;65;Male;NA;1;654,9;Stage II;NA;GSE54467;NK.cells;0,019839562;NA;
untreated;GSM1315917;Primary Tumor;Australia;58;59;Male;NA;1;1098,6;Stage III;NA;GSE54467;NK.cells;0,035957814;NA;
untreated;GSM1315918;Primary Tumor;Australia;56;67;Male;NA;0;6538,2;Stage Unknown;not sustained response;GSE54467;NK.cells;0,021051244;NA;
untreated;GSM1315919;Primary Tumor;Australia;48;57;Female;NA;1;3603,9;Stage II;NA;GSE54467;NK.cells;0,048681637;NA;
untreated;GSM1315920;Primary Tumor;Australia;69;70;Male;NA;1;261,3;Stage III;NA;GSE54467;NK.cells;0,053604019;NA;
untreated;GSM1315921;Primary Tumor;Australia;76;77;Male;NA;1;593,7;Stage II;NA;GSE54467;NK.cells;0,039379467;NA;
untreated;GSM1315922;Primary Tumor;Australia;54;55;Female;NA;1;592,8;Stage III;NA;GSE54467;NK.cells;0,043622985;NA;
untreated;GSM1315923;Primary Tumor;Australia;82;85;Male;NA;1;2242,8;Stage II;responder;GSE54467;NK.cells;0,029771169;NA;
untreated;GSM1315924;Primary Tumor;Australia;79;80;Male;NA;0;2393,7;Stage I;not sustained response;GSE54467;NK.cells;0,035476022;NA;
untreated;GSM1315925;Primary Tumor;Australia;50;54;Male;NA;0;2986,5;Stage II;not sustained response;GSE54467;NK.cells;0,040783284;NA;
untreated;GSM1315926;Primary Tumor;Australia;57;57;Female;NA;0;305,7;Stage III;non-responder;GSE54467;NK.cells;0,028138503;NA;
untreated;GSM1315927;Primary Tumor;Australia;32;45;Male;NA;0;7826,4;Stage I;not sustained response;GSE54467;NK.cells;0,025937382;NA;
untreated;GSM1315928;Primary Tumor;Australia;77;78;Female;NA;1;589,8;Stage III;NA;GSE54467;NK.cells;0,073699884;NA;
untreated;GSM1315929;Primary Tumor;Australia;56;56;Male;NA;1;588,9;Stage III;NA;GSE54467;NK.cells;0,022283911;NA;
untreated;GSM1315930;Primary Tumor;Australia;39;40;Female;NA;1;644,1;Stage II;NA;GSE54467;NK.cells;0,042122401;NA;
untreated;GSM1315931;Primary Tumor;Australia;84;87;Female;NA;1;3090;Stage II;NA;GSE54467;NK.cells;0,028826249;NA;
untreated;GSM1315932;Primary Tumor;Australia;57;60;Female;NA;1;1734,9;Stage II;NA;GSE54467;NK.cells;0,058767996;NA;
untreated;GSM1315933;Primary Tumor;Australia;23;28;Male;NA;1;3096;Stage I;NA;GSE54467;NK.cells;0,022569306;NA;
untreated;GSM1315934;Primary Tumor;Australia;63;66;Male;NA;1;3007,2;Stage I;NA;GSE54467;NK.cells;0,026816748;NA;
untreated;GSM1315935;Primary Tumor;Australia;53;54;Male;NA;1;723,9;Stage II;NA;GSE54467;NK.cells;0,038038928;NA;
untreated;GSM1315936;Primary Tumor;Australia;72;72;Male;NA;0;3205,5;Stage II;not sustained response;GSE54467;NK.cells;0,034518786;NA;
untreated;GSM1315937;Primary Tumor;Australia;60;67;Male;NA;1;3228,3;Stage I;NA;GSE54467;NK.cells;0,038912842;NA;
untreated;GSM1315938;Primary Tumor;Australia;67;69;Male;NA;1;864,9;Stage II;NA;GSE54467;NK.cells;0,048071395;NA;
untreated;GSM1315939;Primary Tumor;Australia;61;61;Male;NA;1;325,5;Stage III;NA;GSE54467;NK.cells;0,040554815;NA;
untreated;GSM1315940;Primary Tumor;Australia;35;54;Male;NA;0;8526,6;Stage II;not sustained response;GSE54467;NK.cells;0,027876754;NA;
untreated;GSM1315941;Primary Tumor;Australia;60;63;Male;NA;1;2886,9;Stage II;responder;GSE54467;NK.cells;0,022677877;NA;
untreated;GSM1315942;Primary Tumor;Australia;30;30;Male;NA;0;2114,7;Stage III;not sustained response;GSE54467;NK.cells;0,038337078;NA;
untreated;GSM1315943;Primary Tumor;Australia;66;67;Male;NA;1;508,8;Stage II;NA;GSE54467;NK.cells;0,025496646;NA;
untreated;GSM1315944;Primary Tumor;Australia;50;54;Female;NA;1;2062,5;Stage II;NA;GSE54467;NK.cells;0,032327712;NA;
untreated;GSM1315945;Primary Tumor;Australia;28;30;Male;NA;1;3093,9;Stage II;NA;GSE54467;NK.cells;0,0269854;NA;
untreated;GSM1315946;Primary Tumor;Australia;58;60;Male;NA;1;1426,2;Stage I;NA;GSE54467;NK.cells;0,032797537;NA;
untreated;GSM1315947;Primary Tumor;Australia;66;69;Female;NA;1;1518,9;Stage III;NA;GSE54467;NK.cells;0,016992441;NA;
untreated;GSM1315948;Primary Tumor;Australia;49;57;Female;NA;0;6582,6;Stage I;not sustained response;GSE54467;NK.cells;0,016077735;NA;
untreated;GSM1315949;Primary Tumor;Australia;69;69;Male;NA;1;446,7;Stage III;NA;GSE54467;NK.cells;0,02083357;NA;
untreated;GSM1315950;Primary Tumor;Australia;55;56;Male;NA;0;3286,5;Stage III;not sustained response;GSE54467;NK.cells;0,035196553;NA;
untreated;GSM1315951;Primary Tumor;Australia;52;58;Male;NA;1;3098,1;Stage I;NA;GSE54467;NK.cells;0,049499747;NA;
untreated;GSM1315952;Primary Tumor;Australia;61;74;Female;NA;1;4687,8;Stage I;NA;GSE54467;NK.cells;0,033507475;NA;
untreated;GSM1315953;Primary Tumor;Australia;74;75;Male;NA;1;1845,3;Stage I;responder;GSE54467;NK.cells;0,018392555;NA;
untreated;GSM1315954;Primary Tumor;Australia;40;40;Male;NA;0;2916,6;Stage III;not sustained response;GSE54467;NK.cells;0,042892666;NA;
untreated;GSM1315955;Primary Tumor;Australia;36;44;Male;NA;0;6242,4;Stage II;non-responder;GSE54467;NK.cells;0,028997428;NA;
untreated;GSM1315956;Primary Tumor;Australia;70;73;Female;NA;0;3861,3;Stage II;not sustained response;GSE54467;NK.cells;0,034530056;NA;
untreated;GSM1315957;Primary Tumor;Australia;67;67;Male;NA;0;1219,2;Stage III;not sustained response;GSE54467;NK.cells;0,023901181;NA;
untreated;GSM1315958;Primary Tumor;Australia;53;66;Male;NA;1;5252,1;Stage I;NA;GSE54467;NK.cells;0,038894008;NA;
untreated;GSM1315959;Primary Tumor;Australia;64;64;Female;NA;0;3633,6;Stage III;not sustained response;GSE54467;NK.cells;0,033027522;NA;
untreated;GSM1315960;Primary Tumor;Australia;59;61;Male;NA;0;5126,7;Stage I;not sustained response;GSE54467;NK.cells;0,029719061;NA;
untreated;GSM1315961;Primary Tumor;Australia;78;88;Male;NA;1;6904,2;Stage I;NA;GSE54467;NK.cells;0,032085433;NA;
untreated;GSM1315962;Primary Tumor;Australia;62;64;Male;NA;0;3878,1;Stage I;not sustained response;GSE54467;NK.cells;0,041267875;NA;
untreated;GSM1315963;Primary Tumor;Australia;30;63;Male;NA;1;12093,9;Stage I;NA;GSE54467;NK.cells;0,028240142;NA;
untreated;GSM1315964;Primary Tumor;Australia;40;46;Female;NA;1;2208,3;Stage III;NA;GSE54467;NK.cells;0,033874207;NA;
untreated;GSM1315965;Primary Tumor;Australia;58;63;Female;NA;1;3665,1;Stage II;NA;GSE54467;NK.cells;0,025713602;NA;
untreated;GSM1315966;Primary Tumor;Australia;39;40;Female;NA;0;3431,4;Stage I;not sustained response;GSE54467;NK.cells;0,031517862;NA;
untreated;GSM1315967;Primary Tumor;Australia;49;50;Male;NA;1;650,1;Stage I;NA;GSE54467;NK.cells;0,023466243;NA;
untreated;GSM1315968;Primary Tumor;Australia;50;51;Male;NA;0;4334,7;Stage II;not sustained response;GSE54467;NK.cells;0,025271106;NA;
untreated;GSM1315969;Primary Tumor;Australia;24;24;Male;NA;0;1256,4;Stage III;not sustained response;GSE54467;NK.cells;0,026702652;NA;
untreated;GSM1315970;Primary Tumor;Australia;70;73;Female;NA;0;2782,5;Stage II;not sustained response;GSE54467;NK.cells;0,030713337;NA;
untreated;GSM1315971;Primary Tumor;Australia;83;86;Male;NA;1;1875;Stage II;responder;GSE54467;NK.cells;0,009515262;NA;
untreated;GSM1315972;Primary Tumor;Australia;68;75;Female;NA;0;6019,5;Stage I;not sustained response;GSE54467;NK.cells;0,04564317;NA;
untreated;GSM1315973;Primary Tumor;Australia;47;47;Male;NA;0;1506;Stage III;not sustained response;GSE54467;NK.cells;0,034873173;NA;
untreated;GSM1315974;Primary Tumor;Australia;48;48;Female;NA;0;2405,7;Stage I;not sustained response;GSE54467;NK.cells;0,042067927;NA;
untreated;GSM1315975;Primary Tumor;Australia;52;53;Male;NA;1;582;Stage III;NA;GSE54467;NK.cells;0,051078804;NA;
untreated;GSM1315976;Primary Tumor;Australia;60;67;Female;NA;0;5314,2;Stage I;non-responder;GSE54467;NK.cells;0,026808232;NA;
untreated;GSM1315977;Primary Tumor;Australia;45;50;Female;NA;1;3722,4;Stage II;NA;GSE54467;NK.cells;0,027490353;NA;
untreated;GSM1315978;Primary Tumor;Australia;68;73;Female;NA;1;3316,8;Stage I;NA;GSE54467;NK.cells;0,030955454;NA;
untreated;GSM1315979;Primary Tumor;Australia;78;80;Male;NA;0;1305,9;Stage I;NA;GSE54467;NK.cells;0,052452613;NA;
untreated;GSM1315980;Primary Tumor;Australia;56;56;Female;NA;1;708,3;Stage II;NA;GSE54467;NK.cells;0,037506653;NA;
untreated;GSM1315981;Primary Tumor;Australia;74;74;Female;NA;1;121,2;Stage II;NA;GSE54467;NK.cells;0,028491129;NA;
untreated;GSM1315982;Primary Tumor;Australia;66;75;Male;NA;1;3691,8;Stage I;NA;GSE54467;NK.cells;0,041641999;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872328;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872329;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872330;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872331;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872332;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872333;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0,017350572;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872334;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872335;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872336;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0,037922694;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872337;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0,038263254;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872338;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0,053965584;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872339;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0,00539939;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872340;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872341;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872342;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0,003772537;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872343;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872344;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872345;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872346;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872347;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872348;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872349;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0,009429548;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872350;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872351;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872352;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0,007971594;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872353;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0,067320762;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872354;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0,037090466;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872355;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872356;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872357;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872358;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872359;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872360;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;1,32E-04;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872361;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872362;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0,023442929;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872363;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0,016698582;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872364;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0,013326643;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872365;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872366;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0,010153044;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872367;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872368;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872369;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872370;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872371;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872372;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872373;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0,006441273;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872374;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872375;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872376;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872377;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872378;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0,004176937;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872379;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872380;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872381;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0,010618184;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872382;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872383;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872384;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD4;0,029192813;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872385;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872386;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872387;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872388;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872389;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872390;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD4;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872391;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD4;0,028717101;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872392;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD4;0;NA;
Standard (dacarbazine monotherapy; DTIC);GSM550966;Metastatic;Sweden;60;62;Male;Trunk;1;373;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550967;Metastatic;Sweden;54;59;Female;Lower extremity;1;181;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,141594552;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550968;Metastatic;Sweden;40;53;Male;Head;1;436;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,120696614;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550969;Metastatic;Sweden;54;61;Female;Lower extremity;1;82;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550970;Metastatic;Sweden;45;47;Male;Lower extremity;1;646;IV;NA;GSE22155_GPL6102;T.cells.CD4;1,85E-04;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550971;Metastatic;Sweden;68;68;Male;No primary detected;1;114;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,126123427;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550972;Metastatic;Sweden;36;38;Male;Upper extremity, acral;1;322;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550973;Metastatic;Sweden;63;65;Female;Trunk;1;46;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,121159683;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550974;Metastatic;Sweden;51;51;Male;No primary detected;0;3509;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550975;Metastatic;Sweden;79;86;Male;Head;1;65;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,144513768;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550976;Metastatic;Sweden;50;51;Male;Trunk;1;14;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,006310806;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550977;Metastatic;Sweden;58;59;Female;Upper extremity;1;27;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550978;Metastatic;Sweden;36;36;Male;No primary detected;-;-;III;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550979;Metastatic;Sweden;60;66;Female;Upper extremity;1;45;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550980;Metastatic;Sweden;53;53;Female;No primary detected;1;10;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550981;Metastatic;Sweden;27;32;Female;Trunk;0;2711;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,020447229;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550982;Metastatic;Sweden;49;51;Male;Lower extremity;1;32;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550983;Metastatic;Sweden;62;63;Male;No primary detected;1;55;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550984;Metastatic;Sweden;50;71;Male;Upper extremity;1;91;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550985;Metastatic;Sweden;49;63;Female;Trunk;1;804;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550986;Metastatic;Sweden;55;61;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,023860093;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550987;Metastatic;Sweden;55;80;Male;Trunk;1;25;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,028340797;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550988;Metastatic;Sweden;78;78;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,312704175;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550989;Metastatic;Sweden;56;57;Male;No primary detected;1;50;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550990;Metastatic;Sweden;74;76;Female;Head;1;156;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,031065334;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550991;Metastatic;Sweden;53;70;Male;Trunk;1;219;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,004247775;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550992;Metastatic;Sweden;36;49;Male;Trunk;1;266;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,093216435;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550993;Metastatic;Sweden;33;33;Male;No primary detected;1;1075;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550994;Metastatic;Sweden;67;67;Female;No primary detected;1;201;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550995;Metastatic;Sweden;72;74;Male;Trunk;1;247;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,111802026;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550996;Metastatic;Sweden;27;31;Female;Trunk;1;414;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550997;Metastatic;Sweden;32;43;Female;No primary detected;1;108;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,019262539;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550998;Metastatic;Sweden;59;61;Female;Trunk;-;-;III;NA;GSE22155_GPL6102;T.cells.CD4;0,041459819;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550999;Metastatic;Sweden;61;61;Male;No primary detected;1;281;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,31956766;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551000;Metastatic;Sweden;73;73;Male;Head and eye;1;221;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,327037386;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551001;Metastatic;Sweden;54;55;Male;Trunk;1;102;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,017086182;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551002;Metastatic;Sweden;68;68;Female;No primary detected;1;301;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,055046845;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551003;Metastatic;Sweden;62;68;Female;Trunk;1;64;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,144596902;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551004;Metastatic;Sweden;35;36;Female;No primary detected;1;375;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551005;Metastatic;Sweden;76;79;Female;Trunk;1;218;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551006;Metastatic;Sweden;66;68;Male;Head;1;1478;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551007;Metastatic;Sweden;46;52;Female;Trunk;1;13;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551008;Metastatic;Sweden;65;67;Male;Trunk;1;254;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,048055789;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551009;Metastatic;Sweden;70;70;Female;Upper extremity;1;16;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,108666346;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551010;Metastatic;Sweden;68;72;Male;Trunk;1;430;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551011;Metastatic;Sweden;82;84;Male;Trunk;1;63;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,047601903;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551012;Metastatic;Sweden;35;68;Male;Upper extremity;0;1198;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551013;Metastatic;Sweden;31;38;Male;Trunk;-;-;III;NA;GSE22155_GPL6102;T.cells.CD4;0,087957809;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551014;Metastatic;Sweden;79;79;Female;Trunk;0;927;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551015;Metastatic;Sweden;77;82;Female;Upper extremity;1;325;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,179810617;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551016;Metastatic;Sweden;72;76;Male;Lower extremity;1;44;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,016612105;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551017;Metastatic;Sweden;75;75;Female;Lower extremity;0;895;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551018;Metastatic;Sweden;58;61;Male;Trunk;0;836;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,135715449;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551019;Metastatic;Sweden;71;74;Female;Lower extremity, acral;0;786;IV;NA;GSE22155_GPL6102;T.cells.CD4;0,008024533;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551020;Metastatic;Sweden;65;76;Male;Trunk;1;244;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551021;Metastatic;Sweden;25;25;Female;Lower extremity;1;78;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551022;Metastatic;Sweden;50;75;Male;Trunk;1;29;IV;NA;GSE22155_GPL6102;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551023;Metastatic;Sweden;75;76;Male;Acral;1;44;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551024;Metastatic;Sweden;63;64;Female;Genital;1;747;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551025;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551026;Metastatic;Sweden;68;68;Female;GI tractus;1;367;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551027;Metastatic;Sweden;58;60;Male;Eye;1;7;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551028;Metastatic;Sweden;49;63;Male;Trunk;1;309;IV;NA;GSE22155_GPL6947;T.cells.CD4;0,097205069;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551029;Metastatic;Sweden;56;55;Female;Trunk;1;32;IV;NA;GSE22155_GPL6947;T.cells.CD4;0,223183259;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551030;Metastatic;Sweden;74;74;Male;Trunk;1;79;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551031;Metastatic;Sweden;41;42;Female;Eye;1;349;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551032;Metastatic;Sweden;49;51;Female;Mucosa, head;1;13;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551033;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551034;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551035;Metastatic;Sweden;56;56;Male;GI tractus;1;37;IV;NA;GSE22155_GPL6947;T.cells.CD4;0,043846668;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551036;Metastatic;Sweden;45;74;Male;No primary;1;183;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551037;Metastatic;Sweden;72;75;Female;Head;1;39;IV;NA;GSE22155_GPL6947;T.cells.CD4;0,316683714;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551038;Metastatic;Sweden;61;68;Female;Eye;1;513;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551039;Metastatic;Sweden;66;68;Male;Trunk;1;584;IV;NA;GSE22155_GPL6947;T.cells.CD4;0,004656551;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551040;Metastatic;Sweden;42;44;Male;Head;1;1148;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551041;Metastatic;Sweden;54;56;Female;Trunk;1;153;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551042;Metastatic;Sweden;48;50;Male;Trunk;1;141;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551043;Metastatic;Sweden;58;67;Female;Acral;1;334;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551044;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;T.cells.CD4;0;Metastasis
untreated;GSM1220412;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,022859188;Metastasis;
dabrafenib;GSM1220413;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,039387999;cutaneous or subcutaneous;
untreated;GSM1220414;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,059329691;cutaneous or subcutaneous;
dabrafenib;GSM1220415;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,033784303;cutaneous or subcutaneous;
untreated;GSM1220416;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,383057996;cutaneous or subcutaneous;
dabrafenib;GSM1220417;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,109779062;cutaneous or subcutaneous;
dabrafenib;GSM1220418;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,182611838;cutaneous or subcutaneous;
untreated;GSM1220419;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,022293632;Metastasis;
dabrafenib;GSM1220420;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;Metastasis;
untreated;GSM1220421;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,167719019;cutaneous or subcutaneous;
dabrafenib;GSM1220422;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,160536835;cutaneous or subcutaneous;
dabrafenib;GSM1220423;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,111789149;cutaneous or subcutaneous;
untreated;GSM1220424;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,004648415;cutaneous or subcutaneous;
untreated;GSM1220425;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;cutaneous or subcutaneous;
dabrafenib;GSM1220426;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,267179777;Metastasis;
untreated;GSM1220427;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;cutaneous or subcutaneous;
untreated;GSM1220428;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;cutaneous or subcutaneous;
dabrafenib;GSM1220429;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;cutaneous or subcutaneous;
dabrafenib;GSM1220430;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;cutaneous or subcutaneous;
untreated;GSM1220431;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,001841522;cutaneous or subcutaneous;
dabrafenib;GSM1220432;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;cutaneous or subcutaneous;
untreated;GSM1220433;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,010897912;cutaneous or subcutaneous;
untreated;GSM1220434;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,002127942;cutaneous or subcutaneous;
dabrafenib;GSM1220435;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;cutaneous or subcutaneous;
dabrafenib;GSM1220436;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;cutaneous or subcutaneous;
dabrafenib;GSM1220437;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,074354011;cutaneous or subcutaneous;
untreated;GSM1220438;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,042240006;Metastasis;
untreated;GSM1220439;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,046344406;Metastasis;
dabrafenib;GSM1220440;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;cutaneous or subcutaneous;
dabrafenib;GSM1220441;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,06050476;Metastasis;
dabrafenib;GSM1220442;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;cutaneous or subcutaneous;
dabrafenib;GSM1220443;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,064008811;Metastasis;
untreated;GSM1220444;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,161653812;Metastasis;
dabrafenib;GSM1220445;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,295478536;cutaneous or subcutaneous;
untreated;GSM1220446;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,010220425;cutaneous or subcutaneous;
untreated;GSM1220447;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,019673703;cutaneous or subcutaneous;
dabrafenib;GSM1220448;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,067182819;cutaneous or subcutaneous;
untreated;GSM1220449;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;Metastasis;
dabrafenib;GSM1220450;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,030747719;cutaneous or subcutaneous;
untreated;GSM1220451;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;Metastasis;
dabrafenib;GSM1220452;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;Metastasis;
untreated;GSM1220453;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,21670062;cutaneous or subcutaneous;
untreated;GSM1220454;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,240865155;cutaneous or subcutaneous;
dabrafenib;GSM1220455;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,122098812;Metastasis;
dabrafenib;GSM1220456;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;cutaneous or subcutaneous;
untreated;GSM1220457;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0;cutaneous or subcutaneous;
dabrafenib;GSM1220458;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,026796655;Metastasis;
untreated;GSM1220459;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,137394925;cutaneous or subcutaneous;
vemurafenib;GSM1220460;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,06257145;cutaneous or subcutaneous;
untreated;GSM1220461;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,08011906;cutaneous or subcutaneous;
untreated;GSM1220462;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,072852986;cutaneous or subcutaneous;
vemurafenib;GSM1220463;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,063374515;cutaneous or subcutaneous;
untreated;GSM1220464;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,08470836;Metastasis;
vemurafenib;GSM1220465;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,015511315;cutaneous or subcutaneous;
untreated;GSM1220466;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,220809996;cutaneous or subcutaneous;
vemurafenib;GSM1220467;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,219693583;cutaneous or subcutaneous;
vemurafenib;GSM1220468;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,303225193;cutaneous or subcutaneous;
vemurafenib;GSM1220469;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,104523471;cutaneous or subcutaneous;
vemurafenib;GSM1220470;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,111317213;cutaneous or subcutaneous;
untreated;GSM1220471;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,030884242;cutaneous or subcutaneous;
vemurafenib;GSM1220472;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;T.cells.CD4;0,245477949;Metastasis;
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;T.cells.CD4;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;T.cells.CD4;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD4;0;Metastasis
untreated;GSM1315904;Primary Tumor;Australia;19;22;Female;NA;0;4342,8;Stage II;not sustained response;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315905;Primary Tumor;Australia;53;56;Male;NA;1;1418,4;Stage II;NA;GSE54467;T.cells.CD4;0,159580432;NA;
untreated;GSM1315906;Primary Tumor;Australia;52;53;Female;NA;1;698,4;Stage II;NA;GSE54467;T.cells.CD4;0,038372435;NA;
untreated;GSM1315907;Primary Tumor;Australia;51;52;Male;NA;0;3330,6;Stage I;not sustained response;GSE54467;T.cells.CD4;0,084942675;NA;
untreated;GSM1315908;Primary Tumor;Australia;47;51;Male;NA;1;4283,4;Stage II;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315909;Primary Tumor;Australia;61;64;Male;NA;1;1540,5;Stage I;NA;GSE54467;T.cells.CD4;0,057261194;NA;
untreated;GSM1315910;Primary Tumor;Australia;46;52;Female;NA;0;6957,3;Stage I;not sustained response;GSE54467;T.cells.CD4;0,007826592;NA;
untreated;GSM1315911;Primary Tumor;Australia;61;75;Male;NA;1;5484,9;Stage I;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315912;Primary Tumor;Australia;84;87;Female;NA;1;1491,3;Stage I;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315913;Primary Tumor;Australia;44;44;Female;NA;0;3899,7;Stage III;not sustained response;GSE54467;T.cells.CD4;0,565614167;NA;
untreated;GSM1315914;Primary Tumor;Australia;64;72;Male;NA;1;3322,8;Stage I;NA;GSE54467;T.cells.CD4;0,127153165;NA;
untreated;GSM1315915;Primary Tumor;Australia;31;31;Male;NA;0;3034,8;Stage III;not sustained response;GSE54467;T.cells.CD4;0,07674288;NA;
untreated;GSM1315916;Primary Tumor;Australia;63;65;Male;NA;1;654,9;Stage II;NA;GSE54467;T.cells.CD4;0,226124126;NA;
untreated;GSM1315917;Primary Tumor;Australia;58;59;Male;NA;1;1098,6;Stage III;NA;GSE54467;T.cells.CD4;0,009864163;NA;
untreated;GSM1315918;Primary Tumor;Australia;56;67;Male;NA;0;6538,2;Stage Unknown;not sustained response;GSE54467;T.cells.CD4;0,366305788;NA;
untreated;GSM1315919;Primary Tumor;Australia;48;57;Female;NA;1;3603,9;Stage II;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315920;Primary Tumor;Australia;69;70;Male;NA;1;261,3;Stage III;NA;GSE54467;T.cells.CD4;0,021825129;NA;
untreated;GSM1315921;Primary Tumor;Australia;76;77;Male;NA;1;593,7;Stage II;NA;GSE54467;T.cells.CD4;0,021179538;NA;
untreated;GSM1315922;Primary Tumor;Australia;54;55;Female;NA;1;592,8;Stage III;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315923;Primary Tumor;Australia;82;85;Male;NA;1;2242,8;Stage II;responder;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315924;Primary Tumor;Australia;79;80;Male;NA;0;2393,7;Stage I;not sustained response;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315925;Primary Tumor;Australia;50;54;Male;NA;0;2986,5;Stage II;not sustained response;GSE54467;T.cells.CD4;0,016117685;NA;
untreated;GSM1315926;Primary Tumor;Australia;57;57;Female;NA;0;305,7;Stage III;non-responder;GSE54467;T.cells.CD4;0,138461205;NA;
untreated;GSM1315927;Primary Tumor;Australia;32;45;Male;NA;0;7826,4;Stage I;not sustained response;GSE54467;T.cells.CD4;0,116259842;NA;
untreated;GSM1315928;Primary Tumor;Australia;77;78;Female;NA;1;589,8;Stage III;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315929;Primary Tumor;Australia;56;56;Male;NA;1;588,9;Stage III;NA;GSE54467;T.cells.CD4;0,19946823;NA;
untreated;GSM1315930;Primary Tumor;Australia;39;40;Female;NA;1;644,1;Stage II;NA;GSE54467;T.cells.CD4;0,133656104;NA;
untreated;GSM1315931;Primary Tumor;Australia;84;87;Female;NA;1;3090;Stage II;NA;GSE54467;T.cells.CD4;0,416768438;NA;
untreated;GSM1315932;Primary Tumor;Australia;57;60;Female;NA;1;1734,9;Stage II;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315933;Primary Tumor;Australia;23;28;Male;NA;1;3096;Stage I;NA;GSE54467;T.cells.CD4;0,046538101;NA;
untreated;GSM1315934;Primary Tumor;Australia;63;66;Male;NA;1;3007,2;Stage I;NA;GSE54467;T.cells.CD4;0,174103626;NA;
untreated;GSM1315935;Primary Tumor;Australia;53;54;Male;NA;1;723,9;Stage II;NA;GSE54467;T.cells.CD4;0,01057537;NA;
untreated;GSM1315936;Primary Tumor;Australia;72;72;Male;NA;0;3205,5;Stage II;not sustained response;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315937;Primary Tumor;Australia;60;67;Male;NA;1;3228,3;Stage I;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315938;Primary Tumor;Australia;67;69;Male;NA;1;864,9;Stage II;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315939;Primary Tumor;Australia;61;61;Male;NA;1;325,5;Stage III;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315940;Primary Tumor;Australia;35;54;Male;NA;0;8526,6;Stage II;not sustained response;GSE54467;T.cells.CD4;0,199601607;NA;
untreated;GSM1315941;Primary Tumor;Australia;60;63;Male;NA;1;2886,9;Stage II;responder;GSE54467;T.cells.CD4;0,186873597;NA;
untreated;GSM1315942;Primary Tumor;Australia;30;30;Male;NA;0;2114,7;Stage III;not sustained response;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315943;Primary Tumor;Australia;66;67;Male;NA;1;508,8;Stage II;NA;GSE54467;T.cells.CD4;0,305715178;NA;
untreated;GSM1315944;Primary Tumor;Australia;50;54;Female;NA;1;2062,5;Stage II;NA;GSE54467;T.cells.CD4;0,214380346;NA;
untreated;GSM1315945;Primary Tumor;Australia;28;30;Male;NA;1;3093,9;Stage II;NA;GSE54467;T.cells.CD4;0,096199502;NA;
untreated;GSM1315946;Primary Tumor;Australia;58;60;Male;NA;1;1426,2;Stage I;NA;GSE54467;T.cells.CD4;0,02231798;NA;
untreated;GSM1315947;Primary Tumor;Australia;66;69;Female;NA;1;1518,9;Stage III;NA;GSE54467;T.cells.CD4;0,341457709;NA;
untreated;GSM1315948;Primary Tumor;Australia;49;57;Female;NA;0;6582,6;Stage I;not sustained response;GSE54467;T.cells.CD4;0,349872063;NA;
untreated;GSM1315949;Primary Tumor;Australia;69;69;Male;NA;1;446,7;Stage III;NA;GSE54467;T.cells.CD4;0,190474462;NA;
untreated;GSM1315950;Primary Tumor;Australia;55;56;Male;NA;0;3286,5;Stage III;not sustained response;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315951;Primary Tumor;Australia;52;58;Male;NA;1;3098,1;Stage I;NA;GSE54467;T.cells.CD4;0,010238035;NA;
untreated;GSM1315952;Primary Tumor;Australia;61;74;Female;NA;1;4687,8;Stage I;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315953;Primary Tumor;Australia;74;75;Male;NA;1;1845,3;Stage I;responder;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315954;Primary Tumor;Australia;40;40;Male;NA;0;2916,6;Stage III;not sustained response;GSE54467;T.cells.CD4;0,002462368;NA;
untreated;GSM1315955;Primary Tumor;Australia;36;44;Male;NA;0;6242,4;Stage II;non-responder;GSE54467;T.cells.CD4;0,174855878;NA;
untreated;GSM1315956;Primary Tumor;Australia;70;73;Female;NA;0;3861,3;Stage II;not sustained response;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315957;Primary Tumor;Australia;67;67;Male;NA;0;1219,2;Stage III;not sustained response;GSE54467;T.cells.CD4;0,220072126;NA;
untreated;GSM1315958;Primary Tumor;Australia;53;66;Male;NA;1;5252,1;Stage I;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315959;Primary Tumor;Australia;64;64;Female;NA;0;3633,6;Stage III;not sustained response;GSE54467;T.cells.CD4;0,076827991;NA;
untreated;GSM1315960;Primary Tumor;Australia;59;61;Male;NA;0;5126,7;Stage I;not sustained response;GSE54467;T.cells.CD4;0,17391852;NA;
untreated;GSM1315961;Primary Tumor;Australia;78;88;Male;NA;1;6904,2;Stage I;NA;GSE54467;T.cells.CD4;0,015588518;NA;
untreated;GSM1315962;Primary Tumor;Australia;62;64;Male;NA;0;3878,1;Stage I;not sustained response;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315963;Primary Tumor;Australia;30;63;Male;NA;1;12093,9;Stage I;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315964;Primary Tumor;Australia;40;46;Female;NA;1;2208,3;Stage III;NA;GSE54467;T.cells.CD4;0,010123207;NA;
untreated;GSM1315965;Primary Tumor;Australia;58;63;Female;NA;1;3665,1;Stage II;NA;GSE54467;T.cells.CD4;0,172994871;NA;
untreated;GSM1315966;Primary Tumor;Australia;39;40;Female;NA;0;3431,4;Stage I;not sustained response;GSE54467;T.cells.CD4;0,051512271;NA;
untreated;GSM1315967;Primary Tumor;Australia;49;50;Male;NA;1;650,1;Stage I;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315968;Primary Tumor;Australia;50;51;Male;NA;0;4334,7;Stage II;not sustained response;GSE54467;T.cells.CD4;0,214172821;NA;
untreated;GSM1315969;Primary Tumor;Australia;24;24;Male;NA;0;1256,4;Stage III;not sustained response;GSE54467;T.cells.CD4;0,144098065;NA;
untreated;GSM1315970;Primary Tumor;Australia;70;73;Female;NA;0;2782,5;Stage II;not sustained response;GSE54467;T.cells.CD4;0,130979321;NA;
untreated;GSM1315971;Primary Tumor;Australia;83;86;Male;NA;1;1875;Stage II;responder;GSE54467;T.cells.CD4;0,190037504;NA;
untreated;GSM1315972;Primary Tumor;Australia;68;75;Female;NA;0;6019,5;Stage I;not sustained response;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315973;Primary Tumor;Australia;47;47;Male;NA;0;1506;Stage III;not sustained response;GSE54467;T.cells.CD4;0,041922434;NA;
untreated;GSM1315974;Primary Tumor;Australia;48;48;Female;NA;0;2405,7;Stage I;not sustained response;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315975;Primary Tumor;Australia;52;53;Male;NA;1;582;Stage III;NA;GSE54467;T.cells.CD4;0,025514083;NA;
untreated;GSM1315976;Primary Tumor;Australia;60;67;Female;NA;0;5314,2;Stage I;non-responder;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315977;Primary Tumor;Australia;45;50;Female;NA;1;3722,4;Stage II;NA;GSE54467;T.cells.CD4;0,054281479;NA;
untreated;GSM1315978;Primary Tumor;Australia;68;73;Female;NA;1;3316,8;Stage I;NA;GSE54467;T.cells.CD4;0,208667395;NA;
untreated;GSM1315979;Primary Tumor;Australia;78;80;Male;NA;0;1305,9;Stage I;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315980;Primary Tumor;Australia;56;56;Female;NA;1;708,3;Stage II;NA;GSE54467;T.cells.CD4;0;NA;
untreated;GSM1315981;Primary Tumor;Australia;74;74;Female;NA;1;121,2;Stage II;NA;GSE54467;T.cells.CD4;0,059722475;NA;
untreated;GSM1315982;Primary Tumor;Australia;66;75;Male;NA;1;3691,8;Stage I;NA;GSE54467;T.cells.CD4;0,113061962;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872328;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,003036241;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872329;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872330;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872331;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872332;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,046073182;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872333;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,132503552;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872334;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,344928794;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872335;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,085530834;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872336;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,030475746;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872337;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,060626699;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872338;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,277745197;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872339;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,136520934;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872340;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,135136701;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872341;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,067920118;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872342;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,010394878;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872343;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,044585061;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872344;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,072447513;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872345;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,007274545;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872346;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872347;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,289209872;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872348;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,051365553;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872349;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872350;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,169424383;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872351;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872352;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,009793403;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872353;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,132590837;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872354;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;9,44E-04;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872355;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872356;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,040253972;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872357;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,320884745;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872358;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,138555185;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872359;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,050556134;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872360;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872361;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872362;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872363;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,00855686;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872364;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,071184145;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872365;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,075242739;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872366;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,246926205;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872367;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872368;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872369;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872370;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,287804372;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872371;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,012263616;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872372;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;4,13E-05;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872373;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;7,48E-04;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872374;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,417206362;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872375;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,063615976;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872376;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,207052847;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872377;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,010143056;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872378;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0,045836976;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872379;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872380;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872381;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872382;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;T.cells.CD8;0,018401273;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872383;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;T.cells.CD8;1,53E-04;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872384;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD8;0,008048345;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872385;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872386;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872387;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD8;0,106029885;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872388;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD8;0,014873672;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872389;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872390;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD8;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872391;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD8;0,014669461;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872392;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;T.cells.CD8;0,004177216;NA;
Standard (dacarbazine monotherapy; DTIC);GSM550966;Metastatic;Sweden;60;62;Male;Trunk;1;373;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550967;Metastatic;Sweden;54;59;Female;Lower extremity;1;181;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,005357777;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550968;Metastatic;Sweden;40;53;Male;Head;1;436;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,119604358;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550969;Metastatic;Sweden;54;61;Female;Lower extremity;1;82;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,007654027;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550970;Metastatic;Sweden;45;47;Male;Lower extremity;1;646;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550971;Metastatic;Sweden;68;68;Male;No primary detected;1;114;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,028671611;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550972;Metastatic;Sweden;36;38;Male;Upper extremity, acral;1;322;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550973;Metastatic;Sweden;63;65;Female;Trunk;1;46;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,002731291;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550974;Metastatic;Sweden;51;51;Male;No primary detected;0;3509;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,004602642;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550975;Metastatic;Sweden;79;86;Male;Head;1;65;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,00145153;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550976;Metastatic;Sweden;50;51;Male;Trunk;1;14;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550977;Metastatic;Sweden;58;59;Female;Upper extremity;1;27;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550978;Metastatic;Sweden;36;36;Male;No primary detected;-;-;III;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550979;Metastatic;Sweden;60;66;Female;Upper extremity;1;45;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550980;Metastatic;Sweden;53;53;Female;No primary detected;1;10;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550981;Metastatic;Sweden;27;32;Female;Trunk;0;2711;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,012451491;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550982;Metastatic;Sweden;49;51;Male;Lower extremity;1;32;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,001329164;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550983;Metastatic;Sweden;62;63;Male;No primary detected;1;55;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,004701365;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550984;Metastatic;Sweden;50;71;Male;Upper extremity;1;91;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550985;Metastatic;Sweden;49;63;Female;Trunk;1;804;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550986;Metastatic;Sweden;55;61;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,015427949;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550987;Metastatic;Sweden;55;80;Male;Trunk;1;25;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550988;Metastatic;Sweden;78;78;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,035599156;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550989;Metastatic;Sweden;56;57;Male;No primary detected;1;50;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550990;Metastatic;Sweden;74;76;Female;Head;1;156;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,080845931;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550991;Metastatic;Sweden;53;70;Male;Trunk;1;219;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,080769904;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550992;Metastatic;Sweden;36;49;Male;Trunk;1;266;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,01948052;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550993;Metastatic;Sweden;33;33;Male;No primary detected;1;1075;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,150663008;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550994;Metastatic;Sweden;67;67;Female;No primary detected;1;201;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,012865908;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550995;Metastatic;Sweden;72;74;Male;Trunk;1;247;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,047141451;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550996;Metastatic;Sweden;27;31;Female;Trunk;1;414;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,038662249;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550997;Metastatic;Sweden;32;43;Female;No primary detected;1;108;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,044090205;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550998;Metastatic;Sweden;59;61;Female;Trunk;-;-;III;NA;GSE22155_GPL6102;T.cells.CD8;0,042285463;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550999;Metastatic;Sweden;61;61;Male;No primary detected;1;281;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,006825333;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551000;Metastatic;Sweden;73;73;Male;Head and eye;1;221;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,030221513;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551001;Metastatic;Sweden;54;55;Male;Trunk;1;102;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,003009176;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551002;Metastatic;Sweden;68;68;Female;No primary detected;1;301;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,026583158;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551003;Metastatic;Sweden;62;68;Female;Trunk;1;64;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551004;Metastatic;Sweden;35;36;Female;No primary detected;1;375;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551005;Metastatic;Sweden;76;79;Female;Trunk;1;218;IV;NA;GSE22155_GPL6102;T.cells.CD8;4,93E-04;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551006;Metastatic;Sweden;66;68;Male;Head;1;1478;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,068424454;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551007;Metastatic;Sweden;46;52;Female;Trunk;1;13;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,008381049;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551008;Metastatic;Sweden;65;67;Male;Trunk;1;254;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,002450982;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551009;Metastatic;Sweden;70;70;Female;Upper extremity;1;16;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551010;Metastatic;Sweden;68;72;Male;Trunk;1;430;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,016437518;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551011;Metastatic;Sweden;82;84;Male;Trunk;1;63;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,032323185;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551012;Metastatic;Sweden;35;68;Male;Upper extremity;0;1198;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,002320508;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551013;Metastatic;Sweden;31;38;Male;Trunk;-;-;III;NA;GSE22155_GPL6102;T.cells.CD8;0,036091202;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551014;Metastatic;Sweden;79;79;Female;Trunk;0;927;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,00169547;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551015;Metastatic;Sweden;77;82;Female;Upper extremity;1;325;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,005203936;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551016;Metastatic;Sweden;72;76;Male;Lower extremity;1;44;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551017;Metastatic;Sweden;75;75;Female;Lower extremity;0;895;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,133900489;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551018;Metastatic;Sweden;58;61;Male;Trunk;0;836;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,018830229;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551019;Metastatic;Sweden;71;74;Female;Lower extremity, acral;0;786;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,018954063;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551020;Metastatic;Sweden;65;76;Male;Trunk;1;244;IV;NA;GSE22155_GPL6102;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551021;Metastatic;Sweden;25;25;Female;Lower extremity;1;78;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,004218867;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551022;Metastatic;Sweden;50;75;Male;Trunk;1;29;IV;NA;GSE22155_GPL6102;T.cells.CD8;0,009733513;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551023;Metastatic;Sweden;75;76;Male;Acral;1;44;IV;NA;GSE22155_GPL6947;T.cells.CD8;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551024;Metastatic;Sweden;63;64;Female;Genital;1;747;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,025099153;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551025;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,014949846;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551026;Metastatic;Sweden;68;68;Female;GI tractus;1;367;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,018819173;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551027;Metastatic;Sweden;58;60;Male;Eye;1;7;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,019095802;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551028;Metastatic;Sweden;49;63;Male;Trunk;1;309;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,047285746;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551029;Metastatic;Sweden;56;55;Female;Trunk;1;32;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,029337287;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551030;Metastatic;Sweden;74;74;Male;Trunk;1;79;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,018975159;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551031;Metastatic;Sweden;41;42;Female;Eye;1;349;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,0108393;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551032;Metastatic;Sweden;49;51;Female;Mucosa, head;1;13;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,011166994;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551033;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,009895645;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551034;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,011504338;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551035;Metastatic;Sweden;56;56;Male;GI tractus;1;37;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,018506633;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551036;Metastatic;Sweden;45;74;Male;No primary;1;183;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,016403121;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551037;Metastatic;Sweden;72;75;Female;Head;1;39;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,016858109;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551038;Metastatic;Sweden;61;68;Female;Eye;1;513;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,024160746;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551039;Metastatic;Sweden;66;68;Male;Trunk;1;584;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,013785544;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551040;Metastatic;Sweden;42;44;Male;Head;1;1148;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,086027621;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551041;Metastatic;Sweden;54;56;Female;Trunk;1;153;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,050903576;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551042;Metastatic;Sweden;48;50;Male;Trunk;1;141;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,007071061;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551043;Metastatic;Sweden;58;67;Female;Acral;1;334;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,00951103;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551044;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;T.cells.CD8;0,014182456;Metastasis
untreated;GSM1220412;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,089450797;Metastasis;
dabrafenib;GSM1220413;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,004565263;cutaneous or subcutaneous;
untreated;GSM1220414;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,041551811;cutaneous or subcutaneous;
dabrafenib;GSM1220415;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,055538151;cutaneous or subcutaneous;
untreated;GSM1220416;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0;cutaneous or subcutaneous;
dabrafenib;GSM1220417;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0;cutaneous or subcutaneous;
dabrafenib;GSM1220418;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,003953709;cutaneous or subcutaneous;
untreated;GSM1220419;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,00422257;Metastasis;
dabrafenib;GSM1220420;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;T.cells.CD8;0;Metastasis;
untreated;GSM1220421;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,019348956;cutaneous or subcutaneous;
dabrafenib;GSM1220422;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,153990918;cutaneous or subcutaneous;
dabrafenib;GSM1220423;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;7,09E-04;cutaneous or subcutaneous;
untreated;GSM1220424;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,187638222;cutaneous or subcutaneous;
untreated;GSM1220425;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,180067375;cutaneous or subcutaneous;
dabrafenib;GSM1220426;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,01693951;Metastasis;
untreated;GSM1220427;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,00377863;cutaneous or subcutaneous;
untreated;GSM1220428;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,005636616;cutaneous or subcutaneous;
dabrafenib;GSM1220429;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,052461091;cutaneous or subcutaneous;
dabrafenib;GSM1220430;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;5,08E-04;cutaneous or subcutaneous;
untreated;GSM1220431;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,139899028;cutaneous or subcutaneous;
dabrafenib;GSM1220432;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,091304955;cutaneous or subcutaneous;
untreated;GSM1220433;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,080691307;cutaneous or subcutaneous;
untreated;GSM1220434;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,08160937;cutaneous or subcutaneous;
dabrafenib;GSM1220435;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,054755597;cutaneous or subcutaneous;
dabrafenib;GSM1220436;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0;cutaneous or subcutaneous;
dabrafenib;GSM1220437;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,005240795;cutaneous or subcutaneous;
untreated;GSM1220438;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;T.cells.CD8;0;Metastasis;
untreated;GSM1220439;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;T.cells.CD8;0;Metastasis;
dabrafenib;GSM1220440;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,063613105;cutaneous or subcutaneous;
dabrafenib;GSM1220441;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;T.cells.CD8;0;Metastasis;
dabrafenib;GSM1220442;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,067218681;cutaneous or subcutaneous;
dabrafenib;GSM1220443;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;T.cells.CD8;8,20E-04;Metastasis;
untreated;GSM1220444;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,033376825;Metastasis;
dabrafenib;GSM1220445;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,028267035;cutaneous or subcutaneous;
untreated;GSM1220446;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0;cutaneous or subcutaneous;
untreated;GSM1220447;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0;cutaneous or subcutaneous;
dabrafenib;GSM1220448;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,084025783;cutaneous or subcutaneous;
untreated;GSM1220449;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,029007702;Metastasis;
dabrafenib;GSM1220450;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,039737503;cutaneous or subcutaneous;
untreated;GSM1220451;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,013923409;Metastasis;
dabrafenib;GSM1220452;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,158885402;Metastasis;
untreated;GSM1220453;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,133444784;cutaneous or subcutaneous;
untreated;GSM1220454;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,134408638;cutaneous or subcutaneous;
dabrafenib;GSM1220455;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,016463799;Metastasis;
dabrafenib;GSM1220456;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,006319802;cutaneous or subcutaneous;
untreated;GSM1220457;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,004424086;cutaneous or subcutaneous;
dabrafenib;GSM1220458;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,006185311;Metastasis;
untreated;GSM1220459;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,006453851;cutaneous or subcutaneous;
vemurafenib;GSM1220460;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0;cutaneous or subcutaneous;
untreated;GSM1220461;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,010230923;cutaneous or subcutaneous;
untreated;GSM1220462;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,01121472;cutaneous or subcutaneous;
vemurafenib;GSM1220463;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0;cutaneous or subcutaneous;
untreated;GSM1220464;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,005451343;Metastasis;
vemurafenib;GSM1220465;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,06686082;cutaneous or subcutaneous;
untreated;GSM1220466;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0;cutaneous or subcutaneous;
vemurafenib;GSM1220467;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;3,70E-04;cutaneous or subcutaneous;
vemurafenib;GSM1220468;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,001634752;cutaneous or subcutaneous;
vemurafenib;GSM1220469;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,024218418;cutaneous or subcutaneous;
vemurafenib;GSM1220470;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;5,20E-04;cutaneous or subcutaneous;
untreated;GSM1220471;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,00703681;cutaneous or subcutaneous;
vemurafenib;GSM1220472;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;T.cells.CD8;0,09396579;Metastasis;
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;T.cells.CD8;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;T.cells.CD8;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;T.cells.CD8;0;Metastasis
untreated;GSM1315904;Primary Tumor;Australia;19;22;Female;NA;0;4342,8;Stage II;not sustained response;GSE54467;T.cells.CD8;0,062531412;NA;
untreated;GSM1315905;Primary Tumor;Australia;53;56;Male;NA;1;1418,4;Stage II;NA;GSE54467;T.cells.CD8;0,018260153;NA;
untreated;GSM1315906;Primary Tumor;Australia;52;53;Female;NA;1;698,4;Stage II;NA;GSE54467;T.cells.CD8;0,020557031;NA;
untreated;GSM1315907;Primary Tumor;Australia;51;52;Male;NA;0;3330,6;Stage I;not sustained response;GSE54467;T.cells.CD8;0,066935175;NA;
untreated;GSM1315908;Primary Tumor;Australia;47;51;Male;NA;1;4283,4;Stage II;NA;GSE54467;T.cells.CD8;0,031053531;NA;
untreated;GSM1315909;Primary Tumor;Australia;61;64;Male;NA;1;1540,5;Stage I;NA;GSE54467;T.cells.CD8;0,020641532;NA;
untreated;GSM1315910;Primary Tumor;Australia;46;52;Female;NA;0;6957,3;Stage I;not sustained response;GSE54467;T.cells.CD8;0,118907528;NA;
untreated;GSM1315911;Primary Tumor;Australia;61;75;Male;NA;1;5484,9;Stage I;NA;GSE54467;T.cells.CD8;0,021171779;NA;
untreated;GSM1315912;Primary Tumor;Australia;84;87;Female;NA;1;1491,3;Stage I;NA;GSE54467;T.cells.CD8;0,017122689;NA;
untreated;GSM1315913;Primary Tumor;Australia;44;44;Female;NA;0;3899,7;Stage III;not sustained response;GSE54467;T.cells.CD8;0,02813922;NA;
untreated;GSM1315914;Primary Tumor;Australia;64;72;Male;NA;1;3322,8;Stage I;NA;GSE54467;T.cells.CD8;0,018313462;NA;
untreated;GSM1315915;Primary Tumor;Australia;31;31;Male;NA;0;3034,8;Stage III;not sustained response;GSE54467;T.cells.CD8;0,030585313;NA;
untreated;GSM1315916;Primary Tumor;Australia;63;65;Male;NA;1;654,9;Stage II;NA;GSE54467;T.cells.CD8;0,025931117;NA;
untreated;GSM1315917;Primary Tumor;Australia;58;59;Male;NA;1;1098,6;Stage III;NA;GSE54467;T.cells.CD8;0,060682601;NA;
untreated;GSM1315918;Primary Tumor;Australia;56;67;Male;NA;0;6538,2;Stage Unknown;not sustained response;GSE54467;T.cells.CD8;0,069873114;NA;
untreated;GSM1315919;Primary Tumor;Australia;48;57;Female;NA;1;3603,9;Stage II;NA;GSE54467;T.cells.CD8;0,032442708;NA;
untreated;GSM1315920;Primary Tumor;Australia;69;70;Male;NA;1;261,3;Stage III;NA;GSE54467;T.cells.CD8;0,021011076;NA;
untreated;GSM1315921;Primary Tumor;Australia;76;77;Male;NA;1;593,7;Stage II;NA;GSE54467;T.cells.CD8;0,227948071;NA;
untreated;GSM1315922;Primary Tumor;Australia;54;55;Female;NA;1;592,8;Stage III;NA;GSE54467;T.cells.CD8;0,296816998;NA;
untreated;GSM1315923;Primary Tumor;Australia;82;85;Male;NA;1;2242,8;Stage II;responder;GSE54467;T.cells.CD8;0,070461877;NA;
untreated;GSM1315924;Primary Tumor;Australia;79;80;Male;NA;0;2393,7;Stage I;not sustained response;GSE54467;T.cells.CD8;0,103512363;NA;
untreated;GSM1315925;Primary Tumor;Australia;50;54;Male;NA;0;2986,5;Stage II;not sustained response;GSE54467;T.cells.CD8;0,030249427;NA;
untreated;GSM1315926;Primary Tumor;Australia;57;57;Female;NA;0;305,7;Stage III;non-responder;GSE54467;T.cells.CD8;0,020706412;NA;
untreated;GSM1315927;Primary Tumor;Australia;32;45;Male;NA;0;7826,4;Stage I;not sustained response;GSE54467;T.cells.CD8;0,087551444;NA;
untreated;GSM1315928;Primary Tumor;Australia;77;78;Female;NA;1;589,8;Stage III;NA;GSE54467;T.cells.CD8;0,016498319;NA;
untreated;GSM1315929;Primary Tumor;Australia;56;56;Male;NA;1;588,9;Stage III;NA;GSE54467;T.cells.CD8;0,021396468;NA;
untreated;GSM1315930;Primary Tumor;Australia;39;40;Female;NA;1;644,1;Stage II;NA;GSE54467;T.cells.CD8;0,066466639;NA;
untreated;GSM1315931;Primary Tumor;Australia;84;87;Female;NA;1;3090;Stage II;NA;GSE54467;T.cells.CD8;0,04266142;NA;
untreated;GSM1315932;Primary Tumor;Australia;57;60;Female;NA;1;1734,9;Stage II;NA;GSE54467;T.cells.CD8;0,018735925;NA;
untreated;GSM1315933;Primary Tumor;Australia;23;28;Male;NA;1;3096;Stage I;NA;GSE54467;T.cells.CD8;0,066529623;NA;
untreated;GSM1315934;Primary Tumor;Australia;63;66;Male;NA;1;3007,2;Stage I;NA;GSE54467;T.cells.CD8;0,025575103;NA;
untreated;GSM1315935;Primary Tumor;Australia;53;54;Male;NA;1;723,9;Stage II;NA;GSE54467;T.cells.CD8;0,022222952;NA;
untreated;GSM1315936;Primary Tumor;Australia;72;72;Male;NA;0;3205,5;Stage II;not sustained response;GSE54467;T.cells.CD8;0,035503952;NA;
untreated;GSM1315937;Primary Tumor;Australia;60;67;Male;NA;1;3228,3;Stage I;NA;GSE54467;T.cells.CD8;0,018109282;NA;
untreated;GSM1315938;Primary Tumor;Australia;67;69;Male;NA;1;864,9;Stage II;NA;GSE54467;T.cells.CD8;0,013612361;NA;
untreated;GSM1315939;Primary Tumor;Australia;61;61;Male;NA;1;325,5;Stage III;NA;GSE54467;T.cells.CD8;0,030088391;NA;
untreated;GSM1315940;Primary Tumor;Australia;35;54;Male;NA;0;8526,6;Stage II;not sustained response;GSE54467;T.cells.CD8;0,088627153;NA;
untreated;GSM1315941;Primary Tumor;Australia;60;63;Male;NA;1;2886,9;Stage II;responder;GSE54467;T.cells.CD8;0,094871227;NA;
untreated;GSM1315942;Primary Tumor;Australia;30;30;Male;NA;0;2114,7;Stage III;not sustained response;GSE54467;T.cells.CD8;0,024890586;NA;
untreated;GSM1315943;Primary Tumor;Australia;66;67;Male;NA;1;508,8;Stage II;NA;GSE54467;T.cells.CD8;0,04128338;NA;
untreated;GSM1315944;Primary Tumor;Australia;50;54;Female;NA;1;2062,5;Stage II;NA;GSE54467;T.cells.CD8;0,074207467;NA;
untreated;GSM1315945;Primary Tumor;Australia;28;30;Male;NA;1;3093,9;Stage II;NA;GSE54467;T.cells.CD8;0,038829521;NA;
untreated;GSM1315946;Primary Tumor;Australia;58;60;Male;NA;1;1426,2;Stage I;NA;GSE54467;T.cells.CD8;0,092272098;NA;
untreated;GSM1315947;Primary Tumor;Australia;66;69;Female;NA;1;1518,9;Stage III;NA;GSE54467;T.cells.CD8;0,036411153;NA;
untreated;GSM1315948;Primary Tumor;Australia;49;57;Female;NA;0;6582,6;Stage I;not sustained response;GSE54467;T.cells.CD8;0,020905037;NA;
untreated;GSM1315949;Primary Tumor;Australia;69;69;Male;NA;1;446,7;Stage III;NA;GSE54467;T.cells.CD8;0,069405868;NA;
untreated;GSM1315950;Primary Tumor;Australia;55;56;Male;NA;0;3286,5;Stage III;not sustained response;GSE54467;T.cells.CD8;0,017839347;NA;
untreated;GSM1315951;Primary Tumor;Australia;52;58;Male;NA;1;3098,1;Stage I;NA;GSE54467;T.cells.CD8;0,049812257;NA;
untreated;GSM1315952;Primary Tumor;Australia;61;74;Female;NA;1;4687,8;Stage I;NA;GSE54467;T.cells.CD8;0,01729685;NA;
untreated;GSM1315953;Primary Tumor;Australia;74;75;Male;NA;1;1845,3;Stage I;responder;GSE54467;T.cells.CD8;0,228402219;NA;
untreated;GSM1315954;Primary Tumor;Australia;40;40;Male;NA;0;2916,6;Stage III;not sustained response;GSE54467;T.cells.CD8;0,02679004;NA;
untreated;GSM1315955;Primary Tumor;Australia;36;44;Male;NA;0;6242,4;Stage II;non-responder;GSE54467;T.cells.CD8;0,071672122;NA;
untreated;GSM1315956;Primary Tumor;Australia;70;73;Female;NA;0;3861,3;Stage II;not sustained response;GSE54467;T.cells.CD8;0,209644926;NA;
untreated;GSM1315957;Primary Tumor;Australia;67;67;Male;NA;0;1219,2;Stage III;not sustained response;GSE54467;T.cells.CD8;0,085806763;NA;
untreated;GSM1315958;Primary Tumor;Australia;53;66;Male;NA;1;5252,1;Stage I;NA;GSE54467;T.cells.CD8;0,032070864;NA;
untreated;GSM1315959;Primary Tumor;Australia;64;64;Female;NA;0;3633,6;Stage III;not sustained response;GSE54467;T.cells.CD8;0,029798338;NA;
untreated;GSM1315960;Primary Tumor;Australia;59;61;Male;NA;0;5126,7;Stage I;not sustained response;GSE54467;T.cells.CD8;0,057703872;NA;
untreated;GSM1315961;Primary Tumor;Australia;78;88;Male;NA;1;6904,2;Stage I;NA;GSE54467;T.cells.CD8;0,107784525;NA;
untreated;GSM1315962;Primary Tumor;Australia;62;64;Male;NA;0;3878,1;Stage I;not sustained response;GSE54467;T.cells.CD8;0,078948088;NA;
untreated;GSM1315963;Primary Tumor;Australia;30;63;Male;NA;1;12093,9;Stage I;NA;GSE54467;T.cells.CD8;0,024304861;NA;
untreated;GSM1315964;Primary Tumor;Australia;40;46;Female;NA;1;2208,3;Stage III;NA;GSE54467;T.cells.CD8;0,022717583;NA;
untreated;GSM1315965;Primary Tumor;Australia;58;63;Female;NA;1;3665,1;Stage II;NA;GSE54467;T.cells.CD8;0,041908015;NA;
untreated;GSM1315966;Primary Tumor;Australia;39;40;Female;NA;0;3431,4;Stage I;not sustained response;GSE54467;T.cells.CD8;0,055098033;NA;
untreated;GSM1315967;Primary Tumor;Australia;49;50;Male;NA;1;650,1;Stage I;NA;GSE54467;T.cells.CD8;0,079432848;NA;
untreated;GSM1315968;Primary Tumor;Australia;50;51;Male;NA;0;4334,7;Stage II;not sustained response;GSE54467;T.cells.CD8;0,093978218;NA;
untreated;GSM1315969;Primary Tumor;Australia;24;24;Male;NA;0;1256,4;Stage III;not sustained response;GSE54467;T.cells.CD8;0,072452957;NA;
untreated;GSM1315970;Primary Tumor;Australia;70;73;Female;NA;0;2782,5;Stage II;not sustained response;GSE54467;T.cells.CD8;0,032560211;NA;
untreated;GSM1315971;Primary Tumor;Australia;83;86;Male;NA;1;1875;Stage II;responder;GSE54467;T.cells.CD8;0,10900056;NA;
untreated;GSM1315972;Primary Tumor;Australia;68;75;Female;NA;0;6019,5;Stage I;not sustained response;GSE54467;T.cells.CD8;0,047061931;NA;
untreated;GSM1315973;Primary Tumor;Australia;47;47;Male;NA;0;1506;Stage III;not sustained response;GSE54467;T.cells.CD8;0,029772823;NA;
untreated;GSM1315974;Primary Tumor;Australia;48;48;Female;NA;0;2405,7;Stage I;not sustained response;GSE54467;T.cells.CD8;0,056044323;NA;
untreated;GSM1315975;Primary Tumor;Australia;52;53;Male;NA;1;582;Stage III;NA;GSE54467;T.cells.CD8;0,015942772;NA;
untreated;GSM1315976;Primary Tumor;Australia;60;67;Female;NA;0;5314,2;Stage I;non-responder;GSE54467;T.cells.CD8;0,10172729;NA;
untreated;GSM1315977;Primary Tumor;Australia;45;50;Female;NA;1;3722,4;Stage II;NA;GSE54467;T.cells.CD8;0,035416194;NA;
untreated;GSM1315978;Primary Tumor;Australia;68;73;Female;NA;1;3316,8;Stage I;NA;GSE54467;T.cells.CD8;0,021276812;NA;
untreated;GSM1315979;Primary Tumor;Australia;78;80;Male;NA;0;1305,9;Stage I;NA;GSE54467;T.cells.CD8;0,022504509;NA;
untreated;GSM1315980;Primary Tumor;Australia;56;56;Female;NA;1;708,3;Stage II;NA;GSE54467;T.cells.CD8;0,010764912;NA;
untreated;GSM1315981;Primary Tumor;Australia;74;74;Female;NA;1;121,2;Stage II;NA;GSE54467;T.cells.CD8;0,03327165;NA;
untreated;GSM1315982;Primary Tumor;Australia;66;75;Male;NA;1;3691,8;Stage I;NA;GSE54467;T.cells.CD8;0,09361703;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872328;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,006315791;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872329;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,007984927;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872330;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,003477447;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872331;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,001796744;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872332;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0,001851392;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872333;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,002654673;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872334;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872335;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872336;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0,011297574;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872337;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,004126326;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872338;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872339;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872340;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872341;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872342;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,019731601;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872343;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872344;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0,001541641;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872345;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,002480613;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872346;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,013012123;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872347;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872348;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;2,62E-04;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872349;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0,010170818;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872350;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872351;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,004015672;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872352;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,006030699;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872353;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0,010100757;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872354;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0,007321411;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872355;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,001398459;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872356;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0,008228246;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872357;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872358;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872359;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872360;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,014316731;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872361;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,002344288;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872362;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,002506136;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872363;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0,007090275;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872364;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,009805881;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872365;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872366;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872367;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,002824772;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872368;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,003333438;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872369;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,006035101;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872370;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872371;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,004835428;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872372;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0,002724312;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872373;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,008327117;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872374;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872375;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0,002897179;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872376;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872377;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,006859803;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872378;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872379;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,005299992;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872380;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,008802978;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872381;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0,002922378;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872382;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Tregs;0,005400745;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872383;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Tregs;0,006344959;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872384;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Tregs;0,00813491;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872385;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872386;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Tregs;0,007105802;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872387;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Tregs;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872388;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Tregs;0,006316971;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872389;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Tregs;0,004618667;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872390;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Tregs;0,004315608;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872391;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Tregs;0,004826444;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872392;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Tregs;0,006842277;NA;
Standard (dacarbazine monotherapy; DTIC);GSM550966;Metastatic;Sweden;60;62;Male;Trunk;1;373;IV;NA;GSE22155_GPL6102;Tregs;0,11211466;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550967;Metastatic;Sweden;54;59;Female;Lower extremity;1;181;IV;NA;GSE22155_GPL6102;Tregs;0,027005865;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550968;Metastatic;Sweden;40;53;Male;Head;1;436;IV;NA;GSE22155_GPL6102;Tregs;0,095967363;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550969;Metastatic;Sweden;54;61;Female;Lower extremity;1;82;IV;NA;GSE22155_GPL6102;Tregs;0,034985349;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550970;Metastatic;Sweden;45;47;Male;Lower extremity;1;646;IV;NA;GSE22155_GPL6102;Tregs;0,012844172;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550971;Metastatic;Sweden;68;68;Male;No primary detected;1;114;IV;NA;GSE22155_GPL6102;Tregs;0,022831942;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550972;Metastatic;Sweden;36;38;Male;Upper extremity, acral;1;322;IV;NA;GSE22155_GPL6102;Tregs;0,010618209;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550973;Metastatic;Sweden;63;65;Female;Trunk;1;46;IV;NA;GSE22155_GPL6102;Tregs;0,019660348;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550974;Metastatic;Sweden;51;51;Male;No primary detected;0;3509;IV;NA;GSE22155_GPL6102;Tregs;0,041029578;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550975;Metastatic;Sweden;79;86;Male;Head;1;65;IV;NA;GSE22155_GPL6102;Tregs;0,1298468;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550976;Metastatic;Sweden;50;51;Male;Trunk;1;14;IV;NA;GSE22155_GPL6102;Tregs;0,011542127;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550977;Metastatic;Sweden;58;59;Female;Upper extremity;1;27;IV;NA;GSE22155_GPL6102;Tregs;0,020654288;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550978;Metastatic;Sweden;36;36;Male;No primary detected;-;-;III;NA;GSE22155_GPL6102;Tregs;0,031211843;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550979;Metastatic;Sweden;60;66;Female;Upper extremity;1;45;IV;NA;GSE22155_GPL6102;Tregs;0,017299737;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550980;Metastatic;Sweden;53;53;Female;No primary detected;1;10;IV;NA;GSE22155_GPL6102;Tregs;0;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550981;Metastatic;Sweden;27;32;Female;Trunk;0;2711;IV;NA;GSE22155_GPL6102;Tregs;0,077791753;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550982;Metastatic;Sweden;49;51;Male;Lower extremity;1;32;IV;NA;GSE22155_GPL6102;Tregs;0,02019521;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550983;Metastatic;Sweden;62;63;Male;No primary detected;1;55;IV;NA;GSE22155_GPL6102;Tregs;0,032224032;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550984;Metastatic;Sweden;50;71;Male;Upper extremity;1;91;IV;NA;GSE22155_GPL6102;Tregs;0,371821608;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550985;Metastatic;Sweden;49;63;Female;Trunk;1;804;IV;NA;GSE22155_GPL6102;Tregs;0,564651962;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550986;Metastatic;Sweden;55;61;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;Tregs;0,042830094;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550987;Metastatic;Sweden;55;80;Male;Trunk;1;25;IV;NA;GSE22155_GPL6102;Tregs;0,011152661;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550988;Metastatic;Sweden;78;78;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;Tregs;0,050210723;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550989;Metastatic;Sweden;56;57;Male;No primary detected;1;50;IV;NA;GSE22155_GPL6102;Tregs;0,018794656;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550990;Metastatic;Sweden;74;76;Female;Head;1;156;IV;NA;GSE22155_GPL6102;Tregs;0,162807363;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550991;Metastatic;Sweden;53;70;Male;Trunk;1;219;IV;NA;GSE22155_GPL6102;Tregs;0,054413154;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550992;Metastatic;Sweden;36;49;Male;Trunk;1;266;IV;NA;GSE22155_GPL6102;Tregs;0,074892705;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550993;Metastatic;Sweden;33;33;Male;No primary detected;1;1075;IV;NA;GSE22155_GPL6102;Tregs;0,154076616;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550994;Metastatic;Sweden;67;67;Female;No primary detected;1;201;IV;NA;GSE22155_GPL6102;Tregs;0,044611732;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550995;Metastatic;Sweden;72;74;Male;Trunk;1;247;IV;NA;GSE22155_GPL6102;Tregs;0,046783046;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550996;Metastatic;Sweden;27;31;Female;Trunk;1;414;IV;NA;GSE22155_GPL6102;Tregs;0,078170334;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550997;Metastatic;Sweden;32;43;Female;No primary detected;1;108;IV;NA;GSE22155_GPL6102;Tregs;0,061379562;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550998;Metastatic;Sweden;59;61;Female;Trunk;-;-;III;NA;GSE22155_GPL6102;Tregs;0,165646854;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550999;Metastatic;Sweden;61;61;Male;No primary detected;1;281;IV;NA;GSE22155_GPL6102;Tregs;0,0351497;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551000;Metastatic;Sweden;73;73;Male;Head and eye;1;221;IV;NA;GSE22155_GPL6102;Tregs;0,057988324;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551001;Metastatic;Sweden;54;55;Male;Trunk;1;102;IV;NA;GSE22155_GPL6102;Tregs;0,022584201;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551002;Metastatic;Sweden;68;68;Female;No primary detected;1;301;IV;NA;GSE22155_GPL6102;Tregs;0,05074647;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551003;Metastatic;Sweden;62;68;Female;Trunk;1;64;IV;NA;GSE22155_GPL6102;Tregs;0,022416214;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551004;Metastatic;Sweden;35;36;Female;No primary detected;1;375;IV;NA;GSE22155_GPL6102;Tregs;0,017733426;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551005;Metastatic;Sweden;76;79;Female;Trunk;1;218;IV;NA;GSE22155_GPL6102;Tregs;0,009723258;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551006;Metastatic;Sweden;66;68;Male;Head;1;1478;IV;NA;GSE22155_GPL6102;Tregs;0,090897293;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551007;Metastatic;Sweden;46;52;Female;Trunk;1;13;IV;NA;GSE22155_GPL6102;Tregs;0,036252332;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551008;Metastatic;Sweden;65;67;Male;Trunk;1;254;IV;NA;GSE22155_GPL6102;Tregs;0,224629721;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551009;Metastatic;Sweden;70;70;Female;Upper extremity;1;16;IV;NA;GSE22155_GPL6102;Tregs;0,129733823;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551010;Metastatic;Sweden;68;72;Male;Trunk;1;430;IV;NA;GSE22155_GPL6102;Tregs;0,041446383;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551011;Metastatic;Sweden;82;84;Male;Trunk;1;63;IV;NA;GSE22155_GPL6102;Tregs;0,047930462;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551012;Metastatic;Sweden;35;68;Male;Upper extremity;0;1198;IV;NA;GSE22155_GPL6102;Tregs;0,253897892;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551013;Metastatic;Sweden;31;38;Male;Trunk;-;-;III;NA;GSE22155_GPL6102;Tregs;0,111034318;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551014;Metastatic;Sweden;79;79;Female;Trunk;0;927;IV;NA;GSE22155_GPL6102;Tregs;0,51751994;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551015;Metastatic;Sweden;77;82;Female;Upper extremity;1;325;IV;NA;GSE22155_GPL6102;Tregs;0,031693399;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551016;Metastatic;Sweden;72;76;Male;Lower extremity;1;44;IV;NA;GSE22155_GPL6102;Tregs;0,007995117;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551017;Metastatic;Sweden;75;75;Female;Lower extremity;0;895;IV;NA;GSE22155_GPL6102;Tregs;0,121357022;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551018;Metastatic;Sweden;58;61;Male;Trunk;0;836;IV;NA;GSE22155_GPL6102;Tregs;0,035852543;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551019;Metastatic;Sweden;71;74;Female;Lower extremity, acral;0;786;IV;NA;GSE22155_GPL6102;Tregs;0,085709983;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551020;Metastatic;Sweden;65;76;Male;Trunk;1;244;IV;NA;GSE22155_GPL6102;Tregs;0,021142478;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551021;Metastatic;Sweden;25;25;Female;Lower extremity;1;78;IV;NA;GSE22155_GPL6102;Tregs;0,023664165;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551022;Metastatic;Sweden;50;75;Male;Trunk;1;29;IV;NA;GSE22155_GPL6102;Tregs;0,014832988;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551023;Metastatic;Sweden;75;76;Male;Acral;1;44;IV;NA;GSE22155_GPL6947;Tregs;0,021862226;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551024;Metastatic;Sweden;63;64;Female;Genital;1;747;IV;NA;GSE22155_GPL6947;Tregs;0,051953738;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551025;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;Tregs;0,038361013;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551026;Metastatic;Sweden;68;68;Female;GI tractus;1;367;IV;NA;GSE22155_GPL6947;Tregs;0,046468269;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551027;Metastatic;Sweden;58;60;Male;Eye;1;7;IV;NA;GSE22155_GPL6947;Tregs;0,04460987;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551028;Metastatic;Sweden;49;63;Male;Trunk;1;309;IV;NA;GSE22155_GPL6947;Tregs;0,065577212;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551029;Metastatic;Sweden;56;55;Female;Trunk;1;32;IV;NA;GSE22155_GPL6947;Tregs;0,040095481;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551030;Metastatic;Sweden;74;74;Male;Trunk;1;79;IV;NA;GSE22155_GPL6947;Tregs;0,038492211;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551031;Metastatic;Sweden;41;42;Female;Eye;1;349;IV;NA;GSE22155_GPL6947;Tregs;0,031110396;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551032;Metastatic;Sweden;49;51;Female;Mucosa, head;1;13;IV;NA;GSE22155_GPL6947;Tregs;0,037142889;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551033;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;Tregs;0,043466085;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551034;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;Tregs;0,044271098;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551035;Metastatic;Sweden;56;56;Male;GI tractus;1;37;IV;NA;GSE22155_GPL6947;Tregs;0,035441028;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551036;Metastatic;Sweden;45;74;Male;No primary;1;183;IV;NA;GSE22155_GPL6947;Tregs;0,046122392;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551037;Metastatic;Sweden;72;75;Female;Head;1;39;IV;NA;GSE22155_GPL6947;Tregs;0,044417835;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551038;Metastatic;Sweden;61;68;Female;Eye;1;513;IV;NA;GSE22155_GPL6947;Tregs;0,055563629;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551039;Metastatic;Sweden;66;68;Male;Trunk;1;584;IV;NA;GSE22155_GPL6947;Tregs;0,056388013;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551040;Metastatic;Sweden;42;44;Male;Head;1;1148;IV;NA;GSE22155_GPL6947;Tregs;0,060402547;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551041;Metastatic;Sweden;54;56;Female;Trunk;1;153;IV;NA;GSE22155_GPL6947;Tregs;0,047764616;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551042;Metastatic;Sweden;48;50;Male;Trunk;1;141;IV;NA;GSE22155_GPL6947;Tregs;0,02531643;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551043;Metastatic;Sweden;58;67;Female;Acral;1;334;IV;NA;GSE22155_GPL6947;Tregs;0,036809279;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551044;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;Tregs;0,043166251;Metastasis
untreated;GSM1220412;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Tregs;0,002900463;Metastasis;
dabrafenib;GSM1220413;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0;cutaneous or subcutaneous;
untreated;GSM1220414;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,02890212;cutaneous or subcutaneous;
dabrafenib;GSM1220415;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,025768449;cutaneous or subcutaneous;
untreated;GSM1220416;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,035458307;cutaneous or subcutaneous;
dabrafenib;GSM1220417;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,018461968;cutaneous or subcutaneous;
dabrafenib;GSM1220418;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,01483034;cutaneous or subcutaneous;
untreated;GSM1220419;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Tregs;0,005972885;Metastasis;
dabrafenib;GSM1220420;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;Tregs;0,003244977;Metastasis;
untreated;GSM1220421;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,016953758;cutaneous or subcutaneous;
dabrafenib;GSM1220422;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,018114108;cutaneous or subcutaneous;
dabrafenib;GSM1220423;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,081708446;cutaneous or subcutaneous;
untreated;GSM1220424;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,022700282;cutaneous or subcutaneous;
untreated;GSM1220425;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,027057068;cutaneous or subcutaneous;
dabrafenib;GSM1220426;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Tregs;0,030405018;Metastasis;
untreated;GSM1220427;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,023344292;cutaneous or subcutaneous;
untreated;GSM1220428;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,015376024;cutaneous or subcutaneous;
dabrafenib;GSM1220429;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,040005127;cutaneous or subcutaneous;
dabrafenib;GSM1220430;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,01606473;cutaneous or subcutaneous;
untreated;GSM1220431;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,07237559;cutaneous or subcutaneous;
dabrafenib;GSM1220432;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,025252162;cutaneous or subcutaneous;
untreated;GSM1220433;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,02235954;cutaneous or subcutaneous;
untreated;GSM1220434;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,022473212;cutaneous or subcutaneous;
dabrafenib;GSM1220435;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,031962834;cutaneous or subcutaneous;
dabrafenib;GSM1220436;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0;cutaneous or subcutaneous;
dabrafenib;GSM1220437;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,013090324;cutaneous or subcutaneous;
untreated;GSM1220438;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Tregs;0,01398558;Metastasis;
untreated;GSM1220439;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Tregs;0,011974509;Metastasis;
dabrafenib;GSM1220440;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,046215223;cutaneous or subcutaneous;
dabrafenib;GSM1220441;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Tregs;0,004501849;Metastasis;
dabrafenib;GSM1220442;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,050004454;cutaneous or subcutaneous;
dabrafenib;GSM1220443;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Tregs;0,005541471;Metastasis;
untreated;GSM1220444;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Tregs;0,025180188;Metastasis;
dabrafenib;GSM1220445;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,029313178;cutaneous or subcutaneous;
untreated;GSM1220446;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,006148607;cutaneous or subcutaneous;
untreated;GSM1220447;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,006873957;cutaneous or subcutaneous;
dabrafenib;GSM1220448;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,038028359;cutaneous or subcutaneous;
untreated;GSM1220449;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Tregs;0,03504394;Metastasis;
dabrafenib;GSM1220450;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,009872193;cutaneous or subcutaneous;
untreated;GSM1220451;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Tregs;0,013187125;Metastasis;
dabrafenib;GSM1220452;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;Tregs;0,052157034;Metastasis;
untreated;GSM1220453;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,025868083;cutaneous or subcutaneous;
untreated;GSM1220454;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,031875457;cutaneous or subcutaneous;
dabrafenib;GSM1220455;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;Tregs;0,004674428;Metastasis;
dabrafenib;GSM1220456;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,006501677;cutaneous or subcutaneous;
untreated;GSM1220457;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,032466846;cutaneous or subcutaneous;
dabrafenib;GSM1220458;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Tregs;0,013236691;Metastasis;
untreated;GSM1220459;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,03026081;cutaneous or subcutaneous;
vemurafenib;GSM1220460;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,013798339;cutaneous or subcutaneous;
untreated;GSM1220461;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,01229171;cutaneous or subcutaneous;
untreated;GSM1220462;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,010559553;cutaneous or subcutaneous;
vemurafenib;GSM1220463;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,013480595;cutaneous or subcutaneous;
untreated;GSM1220464;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Tregs;0,015931261;Metastasis;
vemurafenib;GSM1220465;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,020586165;cutaneous or subcutaneous;
untreated;GSM1220466;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,022516555;cutaneous or subcutaneous;
vemurafenib;GSM1220467;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,01599359;cutaneous or subcutaneous;
vemurafenib;GSM1220468;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,024659259;cutaneous or subcutaneous;
vemurafenib;GSM1220469;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,01684096;cutaneous or subcutaneous;
vemurafenib;GSM1220470;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,018274885;cutaneous or subcutaneous;
untreated;GSM1220471;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Tregs;0,005878691;cutaneous or subcutaneous;
vemurafenib;GSM1220472;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;Tregs;0,021916714;Metastasis;
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;Tregs;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;Tregs;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;Tregs;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;Tregs;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;Tregs;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;Tregs;0;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Tregs;0;Metastasis
untreated;GSM1315904;Primary Tumor;Australia;19;22;Female;NA;0;4342,8;Stage II;not sustained response;GSE54467;Tregs;0,061835986;NA;
untreated;GSM1315905;Primary Tumor;Australia;53;56;Male;NA;1;1418,4;Stage II;NA;GSE54467;Tregs;0,041459444;NA;
untreated;GSM1315906;Primary Tumor;Australia;52;53;Female;NA;1;698,4;Stage II;NA;GSE54467;Tregs;0,036415222;NA;
untreated;GSM1315907;Primary Tumor;Australia;51;52;Male;NA;0;3330,6;Stage I;not sustained response;GSE54467;Tregs;0,061573957;NA;
untreated;GSM1315908;Primary Tumor;Australia;47;51;Male;NA;1;4283,4;Stage II;NA;GSE54467;Tregs;0,062522189;NA;
untreated;GSM1315909;Primary Tumor;Australia;61;64;Male;NA;1;1540,5;Stage I;NA;GSE54467;Tregs;0,041984152;NA;
untreated;GSM1315910;Primary Tumor;Australia;46;52;Female;NA;0;6957,3;Stage I;not sustained response;GSE54467;Tregs;0,079615394;NA;
untreated;GSM1315911;Primary Tumor;Australia;61;75;Male;NA;1;5484,9;Stage I;NA;GSE54467;Tregs;0,05167959;NA;
untreated;GSM1315912;Primary Tumor;Australia;84;87;Female;NA;1;1491,3;Stage I;NA;GSE54467;Tregs;0,055097202;NA;
untreated;GSM1315913;Primary Tumor;Australia;44;44;Female;NA;0;3899,7;Stage III;not sustained response;GSE54467;Tregs;0,084100561;NA;
untreated;GSM1315914;Primary Tumor;Australia;64;72;Male;NA;1;3322,8;Stage I;NA;GSE54467;Tregs;0,055659013;NA;
untreated;GSM1315915;Primary Tumor;Australia;31;31;Male;NA;0;3034,8;Stage III;not sustained response;GSE54467;Tregs;0,061147427;NA;
untreated;GSM1315916;Primary Tumor;Australia;63;65;Male;NA;1;654,9;Stage II;NA;GSE54467;Tregs;0,047960327;NA;
untreated;GSM1315917;Primary Tumor;Australia;58;59;Male;NA;1;1098,6;Stage III;NA;GSE54467;Tregs;0,044693371;NA;
untreated;GSM1315918;Primary Tumor;Australia;56;67;Male;NA;0;6538,2;Stage Unknown;not sustained response;GSE54467;Tregs;0,094252113;NA;
untreated;GSM1315919;Primary Tumor;Australia;48;57;Female;NA;1;3603,9;Stage II;NA;GSE54467;Tregs;0,060832928;NA;
untreated;GSM1315920;Primary Tumor;Australia;69;70;Male;NA;1;261,3;Stage III;NA;GSE54467;Tregs;0,037576629;NA;
untreated;GSM1315921;Primary Tumor;Australia;76;77;Male;NA;1;593,7;Stage II;NA;GSE54467;Tregs;0,061772344;NA;
untreated;GSM1315922;Primary Tumor;Australia;54;55;Female;NA;1;592,8;Stage III;NA;GSE54467;Tregs;0,121918905;NA;
untreated;GSM1315923;Primary Tumor;Australia;82;85;Male;NA;1;2242,8;Stage II;responder;GSE54467;Tregs;0,078271512;NA;
untreated;GSM1315924;Primary Tumor;Australia;79;80;Male;NA;0;2393,7;Stage I;not sustained response;GSE54467;Tregs;0,071653768;NA;
untreated;GSM1315925;Primary Tumor;Australia;50;54;Male;NA;0;2986,5;Stage II;not sustained response;GSE54467;Tregs;0,053572261;NA;
untreated;GSM1315926;Primary Tumor;Australia;57;57;Female;NA;0;305,7;Stage III;non-responder;GSE54467;Tregs;0,038994937;NA;
untreated;GSM1315927;Primary Tumor;Australia;32;45;Male;NA;0;7826,4;Stage I;not sustained response;GSE54467;Tregs;0,045749363;NA;
untreated;GSM1315928;Primary Tumor;Australia;77;78;Female;NA;1;589,8;Stage III;NA;GSE54467;Tregs;0,039593835;NA;
untreated;GSM1315929;Primary Tumor;Australia;56;56;Male;NA;1;588,9;Stage III;NA;GSE54467;Tregs;0,046642624;NA;
untreated;GSM1315930;Primary Tumor;Australia;39;40;Female;NA;1;644,1;Stage II;NA;GSE54467;Tregs;0,057318846;NA;
untreated;GSM1315931;Primary Tumor;Australia;84;87;Female;NA;1;3090;Stage II;NA;GSE54467;Tregs;0,075344163;NA;
untreated;GSM1315932;Primary Tumor;Australia;57;60;Female;NA;1;1734,9;Stage II;NA;GSE54467;Tregs;0,067609852;NA;
untreated;GSM1315933;Primary Tumor;Australia;23;28;Male;NA;1;3096;Stage I;NA;GSE54467;Tregs;0,064854394;NA;
untreated;GSM1315934;Primary Tumor;Australia;63;66;Male;NA;1;3007,2;Stage I;NA;GSE54467;Tregs;0,042954423;NA;
untreated;GSM1315935;Primary Tumor;Australia;53;54;Male;NA;1;723,9;Stage II;NA;GSE54467;Tregs;0,058632922;NA;
untreated;GSM1315936;Primary Tumor;Australia;72;72;Male;NA;0;3205,5;Stage II;not sustained response;GSE54467;Tregs;0,050174195;NA;
untreated;GSM1315937;Primary Tumor;Australia;60;67;Male;NA;1;3228,3;Stage I;NA;GSE54467;Tregs;0,060973066;NA;
untreated;GSM1315938;Primary Tumor;Australia;67;69;Male;NA;1;864,9;Stage II;NA;GSE54467;Tregs;0,1121457;NA;
untreated;GSM1315939;Primary Tumor;Australia;61;61;Male;NA;1;325,5;Stage III;NA;GSE54467;Tregs;0,053517619;NA;
untreated;GSM1315940;Primary Tumor;Australia;35;54;Male;NA;0;8526,6;Stage II;not sustained response;GSE54467;Tregs;0,065620478;NA;
untreated;GSM1315941;Primary Tumor;Australia;60;63;Male;NA;1;2886,9;Stage II;responder;GSE54467;Tregs;0,063009407;NA;
untreated;GSM1315942;Primary Tumor;Australia;30;30;Male;NA;0;2114,7;Stage III;not sustained response;GSE54467;Tregs;0,102780724;NA;
untreated;GSM1315943;Primary Tumor;Australia;66;67;Male;NA;1;508,8;Stage II;NA;GSE54467;Tregs;0,080342382;NA;
untreated;GSM1315944;Primary Tumor;Australia;50;54;Female;NA;1;2062,5;Stage II;NA;GSE54467;Tregs;0,032280306;NA;
untreated;GSM1315945;Primary Tumor;Australia;28;30;Male;NA;1;3093,9;Stage II;NA;GSE54467;Tregs;0,041542134;NA;
untreated;GSM1315946;Primary Tumor;Australia;58;60;Male;NA;1;1426,2;Stage I;NA;GSE54467;Tregs;0,076815977;NA;
untreated;GSM1315947;Primary Tumor;Australia;66;69;Female;NA;1;1518,9;Stage III;NA;GSE54467;Tregs;0,06618793;NA;
untreated;GSM1315948;Primary Tumor;Australia;49;57;Female;NA;0;6582,6;Stage I;not sustained response;GSE54467;Tregs;0,0653303;NA;
untreated;GSM1315949;Primary Tumor;Australia;69;69;Male;NA;1;446,7;Stage III;NA;GSE54467;Tregs;0,058635864;NA;
untreated;GSM1315950;Primary Tumor;Australia;55;56;Male;NA;0;3286,5;Stage III;not sustained response;GSE54467;Tregs;0,095962795;NA;
untreated;GSM1315951;Primary Tumor;Australia;52;58;Male;NA;1;3098,1;Stage I;NA;GSE54467;Tregs;0,083443986;NA;
untreated;GSM1315952;Primary Tumor;Australia;61;74;Female;NA;1;4687,8;Stage I;NA;GSE54467;Tregs;0,067838783;NA;
untreated;GSM1315953;Primary Tumor;Australia;74;75;Male;NA;1;1845,3;Stage I;responder;GSE54467;Tregs;0,125560621;NA;
untreated;GSM1315954;Primary Tumor;Australia;40;40;Male;NA;0;2916,6;Stage III;not sustained response;GSE54467;Tregs;0,061926595;NA;
untreated;GSM1315955;Primary Tumor;Australia;36;44;Male;NA;0;6242,4;Stage II;non-responder;GSE54467;Tregs;0,040967518;NA;
untreated;GSM1315956;Primary Tumor;Australia;70;73;Female;NA;0;3861,3;Stage II;not sustained response;GSE54467;Tregs;0,127880703;NA;
untreated;GSM1315957;Primary Tumor;Australia;67;67;Male;NA;0;1219,2;Stage III;not sustained response;GSE54467;Tregs;0,021047588;NA;
untreated;GSM1315958;Primary Tumor;Australia;53;66;Male;NA;1;5252,1;Stage I;NA;GSE54467;Tregs;0,072595763;NA;
untreated;GSM1315959;Primary Tumor;Australia;64;64;Female;NA;0;3633,6;Stage III;not sustained response;GSE54467;Tregs;0,051207414;NA;
untreated;GSM1315960;Primary Tumor;Australia;59;61;Male;NA;0;5126,7;Stage I;not sustained response;GSE54467;Tregs;0,057906036;NA;
untreated;GSM1315961;Primary Tumor;Australia;78;88;Male;NA;1;6904,2;Stage I;NA;GSE54467;Tregs;0,046699693;NA;
untreated;GSM1315962;Primary Tumor;Australia;62;64;Male;NA;0;3878,1;Stage I;not sustained response;GSE54467;Tregs;0,078093817;NA;
untreated;GSM1315963;Primary Tumor;Australia;30;63;Male;NA;1;12093,9;Stage I;NA;GSE54467;Tregs;0,067180761;NA;
untreated;GSM1315964;Primary Tumor;Australia;40;46;Female;NA;1;2208,3;Stage III;NA;GSE54467;Tregs;0,077624582;NA;
untreated;GSM1315965;Primary Tumor;Australia;58;63;Female;NA;1;3665,1;Stage II;NA;GSE54467;Tregs;0,049615662;NA;
untreated;GSM1315966;Primary Tumor;Australia;39;40;Female;NA;0;3431,4;Stage I;not sustained response;GSE54467;Tregs;0,062996309;NA;
untreated;GSM1315967;Primary Tumor;Australia;49;50;Male;NA;1;650,1;Stage I;NA;GSE54467;Tregs;0,056616871;NA;
untreated;GSM1315968;Primary Tumor;Australia;50;51;Male;NA;0;4334,7;Stage II;not sustained response;GSE54467;Tregs;0,029042042;NA;
untreated;GSM1315969;Primary Tumor;Australia;24;24;Male;NA;0;1256,4;Stage III;not sustained response;GSE54467;Tregs;0,051757949;NA;
untreated;GSM1315970;Primary Tumor;Australia;70;73;Female;NA;0;2782,5;Stage II;not sustained response;GSE54467;Tregs;0,032590269;NA;
untreated;GSM1315971;Primary Tumor;Australia;83;86;Male;NA;1;1875;Stage II;responder;GSE54467;Tregs;0,084469874;NA;
untreated;GSM1315972;Primary Tumor;Australia;68;75;Female;NA;0;6019,5;Stage I;not sustained response;GSE54467;Tregs;0,112643761;NA;
untreated;GSM1315973;Primary Tumor;Australia;47;47;Male;NA;0;1506;Stage III;not sustained response;GSE54467;Tregs;0,053347891;NA;
untreated;GSM1315974;Primary Tumor;Australia;48;48;Female;NA;0;2405,7;Stage I;not sustained response;GSE54467;Tregs;0,087550034;NA;
untreated;GSM1315975;Primary Tumor;Australia;52;53;Male;NA;1;582;Stage III;NA;GSE54467;Tregs;0,029720647;NA;
untreated;GSM1315976;Primary Tumor;Australia;60;67;Female;NA;0;5314,2;Stage I;non-responder;GSE54467;Tregs;0,062008427;NA;
untreated;GSM1315977;Primary Tumor;Australia;45;50;Female;NA;1;3722,4;Stage II;NA;GSE54467;Tregs;0,06502478;NA;
untreated;GSM1315978;Primary Tumor;Australia;68;73;Female;NA;1;3316,8;Stage I;NA;GSE54467;Tregs;0,057433294;NA;
untreated;GSM1315979;Primary Tumor;Australia;78;80;Male;NA;0;1305,9;Stage I;NA;GSE54467;Tregs;0,068037352;NA;
untreated;GSM1315980;Primary Tumor;Australia;56;56;Female;NA;1;708,3;Stage II;NA;GSE54467;Tregs;0,159595042;NA;
untreated;GSM1315981;Primary Tumor;Australia;74;74;Female;NA;1;121,2;Stage II;NA;GSE54467;Tregs;0,058476546;NA;
untreated;GSM1315982;Primary Tumor;Australia;66;75;Male;NA;1;3691,8;Stage I;NA;GSE54467;Tregs;0,025087759;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872328;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872329;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872330;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872331;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872332;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872333;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872334;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872335;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872336;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872337;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872338;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872339;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872340;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0,006156253;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872341;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872342;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872343;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872344;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872345;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872346;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872347;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872348;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872349;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872350;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872351;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872352;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872353;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872354;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872355;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872356;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872357;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872358;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872359;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872360;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0,003829961;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872361;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0,01717541;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872362;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872363;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872364;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872365;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872366;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872367;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872368;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872369;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872370;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872371;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872372;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872373;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0,002171545;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872374;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872375;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872376;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872377;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872378;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872379;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872380;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872381;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872382;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872383;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;non-responder;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872384;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Dendritic.cells;0,005910342;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872385;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872386;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Dendritic.cells;0,003420243;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872387;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872388;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Dendritic.cells;0,002327068;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872389;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872390;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872391;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Dendritic.cells;0;NA;
Recombinant_MAGE_A3_antigen_with_immunological_adj;GSM872392;Primary Tumor;Belgium;NA;NA;NA;NA;NA;NA;NA;not evaluable;GSE35640;Dendritic.cells;0;NA;
Standard (dacarbazine monotherapy; DTIC);GSM550966;Metastatic;Sweden;60;62;Male;Trunk;1;373;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,058199431;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550967;Metastatic;Sweden;54;59;Female;Lower extremity;1;181;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,022846396;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550968;Metastatic;Sweden;40;53;Male;Head;1;436;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,109783694;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550969;Metastatic;Sweden;54;61;Female;Lower extremity;1;82;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,242158545;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550970;Metastatic;Sweden;45;47;Male;Lower extremity;1;646;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,059817747;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550971;Metastatic;Sweden;68;68;Male;No primary detected;1;114;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,060217583;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550972;Metastatic;Sweden;36;38;Male;Upper extremity, acral;1;322;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,031165225;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550973;Metastatic;Sweden;63;65;Female;Trunk;1;46;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,064051351;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550974;Metastatic;Sweden;51;51;Male;No primary detected;0;3509;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,172292188;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550975;Metastatic;Sweden;79;86;Male;Head;1;65;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,078727957;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550976;Metastatic;Sweden;50;51;Male;Trunk;1;14;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,013890198;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550977;Metastatic;Sweden;58;59;Female;Upper extremity;1;27;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,114890386;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550978;Metastatic;Sweden;36;36;Male;No primary detected;-;-;III;NA;GSE22155_GPL6102;Dendritic.cells;0,019964349;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550979;Metastatic;Sweden;60;66;Female;Upper extremity;1;45;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,022762465;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550980;Metastatic;Sweden;53;53;Female;No primary detected;1;10;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,123321757;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550981;Metastatic;Sweden;27;32;Female;Trunk;0;2711;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,024005069;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550982;Metastatic;Sweden;49;51;Male;Lower extremity;1;32;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,055075325;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550983;Metastatic;Sweden;62;63;Male;No primary detected;1;55;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,046386259;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550984;Metastatic;Sweden;50;71;Male;Upper extremity;1;91;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,065681149;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550985;Metastatic;Sweden;49;63;Female;Trunk;1;804;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,021929847;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550986;Metastatic;Sweden;55;61;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,068199941;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550987;Metastatic;Sweden;55;80;Male;Trunk;1;25;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,077840498;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550988;Metastatic;Sweden;78;78;Female;Lower extremity;1;316;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,042501518;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550989;Metastatic;Sweden;56;57;Male;No primary detected;1;50;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,006003378;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550990;Metastatic;Sweden;74;76;Female;Head;1;156;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,148437126;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550991;Metastatic;Sweden;53;70;Male;Trunk;1;219;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,084769733;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550992;Metastatic;Sweden;36;49;Male;Trunk;1;266;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,041728642;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550993;Metastatic;Sweden;33;33;Male;No primary detected;1;1075;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,150161662;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550994;Metastatic;Sweden;67;67;Female;No primary detected;1;201;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,047462146;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550995;Metastatic;Sweden;72;74;Male;Trunk;1;247;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,087534993;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550996;Metastatic;Sweden;27;31;Female;Trunk;1;414;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,058272782;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550997;Metastatic;Sweden;32;43;Female;No primary detected;1;108;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,164193055;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550998;Metastatic;Sweden;59;61;Female;Trunk;-;-;III;NA;GSE22155_GPL6102;Dendritic.cells;0,085173836;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM550999;Metastatic;Sweden;61;61;Male;No primary detected;1;281;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,028305783;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551000;Metastatic;Sweden;73;73;Male;Head and eye;1;221;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,058794629;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551001;Metastatic;Sweden;54;55;Male;Trunk;1;102;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,041234694;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551002;Metastatic;Sweden;68;68;Female;No primary detected;1;301;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,089601359;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551003;Metastatic;Sweden;62;68;Female;Trunk;1;64;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,029935448;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551004;Metastatic;Sweden;35;36;Female;No primary detected;1;375;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,050728951;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551005;Metastatic;Sweden;76;79;Female;Trunk;1;218;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,082249916;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551006;Metastatic;Sweden;66;68;Male;Head;1;1478;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,08894097;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551007;Metastatic;Sweden;46;52;Female;Trunk;1;13;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,07562465;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551008;Metastatic;Sweden;65;67;Male;Trunk;1;254;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,016336572;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551009;Metastatic;Sweden;70;70;Female;Upper extremity;1;16;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,042960065;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551010;Metastatic;Sweden;68;72;Male;Trunk;1;430;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,110783342;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551011;Metastatic;Sweden;82;84;Male;Trunk;1;63;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,141904664;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551012;Metastatic;Sweden;35;68;Male;Upper extremity;0;1198;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,044769075;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551013;Metastatic;Sweden;31;38;Male;Trunk;-;-;III;NA;GSE22155_GPL6102;Dendritic.cells;0,02296642;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551014;Metastatic;Sweden;79;79;Female;Trunk;0;927;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,031321329;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551015;Metastatic;Sweden;77;82;Female;Upper extremity;1;325;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,02163449;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551016;Metastatic;Sweden;72;76;Male;Lower extremity;1;44;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,007855914;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551017;Metastatic;Sweden;75;75;Female;Lower extremity;0;895;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,078173348;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551018;Metastatic;Sweden;58;61;Male;Trunk;0;836;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,029041655;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551019;Metastatic;Sweden;71;74;Female;Lower extremity, acral;0;786;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,054177583;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551020;Metastatic;Sweden;65;76;Male;Trunk;1;244;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,075639573;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551021;Metastatic;Sweden;25;25;Female;Lower extremity;1;78;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,059228524;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551022;Metastatic;Sweden;50;75;Male;Trunk;1;29;IV;NA;GSE22155_GPL6102;Dendritic.cells;0,01079985;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551023;Metastatic;Sweden;75;76;Male;Acral;1;44;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,014758167;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551024;Metastatic;Sweden;63;64;Female;Genital;1;747;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,052032796;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551025;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,023086136;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551026;Metastatic;Sweden;68;68;Female;GI tractus;1;367;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,032714131;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551027;Metastatic;Sweden;58;60;Male;Eye;1;7;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,024809319;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551028;Metastatic;Sweden;49;63;Male;Trunk;1;309;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,016418301;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551029;Metastatic;Sweden;56;55;Female;Trunk;1;32;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,025377708;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551030;Metastatic;Sweden;74;74;Male;Trunk;1;79;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,032434771;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551031;Metastatic;Sweden;41;42;Female;Eye;1;349;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,00878348;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551032;Metastatic;Sweden;49;51;Female;Mucosa, head;1;13;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,022851501;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551033;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,018279752;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551034;Metastatic;Sweden;59;59;Female;GI tractus;1;25;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,009624028;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551035;Metastatic;Sweden;56;56;Male;GI tractus;1;37;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,021966188;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551036;Metastatic;Sweden;45;74;Male;No primary;1;183;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,031434567;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551037;Metastatic;Sweden;72;75;Female;Head;1;39;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,014767324;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551038;Metastatic;Sweden;61;68;Female;Eye;1;513;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,044980335;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551039;Metastatic;Sweden;66;68;Male;Trunk;1;584;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,024635222;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551040;Metastatic;Sweden;42;44;Male;Head;1;1148;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,047920475;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551041;Metastatic;Sweden;54;56;Female;Trunk;1;153;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,025024109;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551042;Metastatic;Sweden;48;50;Male;Trunk;1;141;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,001339919;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551043;Metastatic;Sweden;58;67;Female;Acral;1;334;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,016247099;Metastasis
Standard (dacarbazine monotherapy; DTIC);GSM551044;Metastatic;Sweden;57;58;Male;Trunk;1;97;IV;NA;GSE22155_GPL6947;Dendritic.cells;0,034123293;Metastasis
untreated;GSM1220412;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,061014162;Metastasis;
dabrafenib;GSM1220413;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,083853918;cutaneous or subcutaneous;
untreated;GSM1220414;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,036064214;cutaneous or subcutaneous;
dabrafenib;GSM1220415;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,051733296;cutaneous or subcutaneous;
untreated;GSM1220416;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,028690995;cutaneous or subcutaneous;
dabrafenib;GSM1220417;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,053859883;cutaneous or subcutaneous;
dabrafenib;GSM1220418;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,010989326;cutaneous or subcutaneous;
untreated;GSM1220419;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,044309553;Metastasis;
dabrafenib;GSM1220420;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,004971606;Metastasis;
untreated;GSM1220421;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,028655512;cutaneous or subcutaneous;
dabrafenib;GSM1220422;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,055480359;cutaneous or subcutaneous;
dabrafenib;GSM1220423;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,018963248;cutaneous or subcutaneous;
untreated;GSM1220424;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,028200049;cutaneous or subcutaneous;
untreated;GSM1220425;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,023092217;cutaneous or subcutaneous;
dabrafenib;GSM1220426;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,009738757;Metastasis;
untreated;GSM1220427;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,032071129;cutaneous or subcutaneous;
untreated;GSM1220428;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,03847802;cutaneous or subcutaneous;
dabrafenib;GSM1220429;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,035380088;cutaneous or subcutaneous;
dabrafenib;GSM1220430;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,059897197;cutaneous or subcutaneous;
untreated;GSM1220431;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,033403116;cutaneous or subcutaneous;
dabrafenib;GSM1220432;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,079260761;cutaneous or subcutaneous;
untreated;GSM1220433;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,013735389;cutaneous or subcutaneous;
untreated;GSM1220434;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,024196841;cutaneous or subcutaneous;
dabrafenib;GSM1220435;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,028264267;cutaneous or subcutaneous;
dabrafenib;GSM1220436;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,038452024;cutaneous or subcutaneous;
dabrafenib;GSM1220437;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,034241483;cutaneous or subcutaneous;
untreated;GSM1220438;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,082129741;Metastasis;
untreated;GSM1220439;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,082750352;Metastasis;
dabrafenib;GSM1220440;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,111513742;cutaneous or subcutaneous;
dabrafenib;GSM1220441;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,050219365;Metastasis;
dabrafenib;GSM1220442;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,11193544;cutaneous or subcutaneous;
dabrafenib;GSM1220443;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,073082391;Metastasis;
untreated;GSM1220444;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,015128117;Metastasis;
dabrafenib;GSM1220445;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,029069938;cutaneous or subcutaneous;
untreated;GSM1220446;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0;cutaneous or subcutaneous;
untreated;GSM1220447;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0;cutaneous or subcutaneous;
dabrafenib;GSM1220448;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,044935381;cutaneous or subcutaneous;
untreated;GSM1220449;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,037977032;Metastasis;
dabrafenib;GSM1220450;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,020805097;cutaneous or subcutaneous;
untreated;GSM1220451;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Dendritic.cells;0;Metastasis;
dabrafenib;GSM1220452;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,04793113;Metastasis;
untreated;GSM1220453;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,016224161;cutaneous or subcutaneous;
untreated;GSM1220454;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,013943656;cutaneous or subcutaneous;
dabrafenib;GSM1220455;Primary Tumor;Australia;NA;NA;NA;bowel;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,055413918;Metastasis;
dabrafenib;GSM1220456;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,027897531;cutaneous or subcutaneous;
untreated;GSM1220457;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,012571984;cutaneous or subcutaneous;
dabrafenib;GSM1220458;Primary Tumor;Australia;NA;NA;NA;brain;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,035436148;Metastasis;
untreated;GSM1220459;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,03685462;cutaneous or subcutaneous;
vemurafenib;GSM1220460;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,033471282;cutaneous or subcutaneous;
untreated;GSM1220461;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,015860719;cutaneous or subcutaneous;
untreated;GSM1220462;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,018935822;cutaneous or subcutaneous;
vemurafenib;GSM1220463;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,003941321;cutaneous or subcutaneous;
untreated;GSM1220464;Primary Tumor;Australia;NA;NA;NA;lymph node;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,031772976;Metastasis;
vemurafenib;GSM1220465;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,086603354;cutaneous or subcutaneous;
untreated;GSM1220466;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,019150131;cutaneous or subcutaneous;
vemurafenib;GSM1220467;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,018300991;cutaneous or subcutaneous;
vemurafenib;GSM1220468;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,024140391;cutaneous or subcutaneous;
vemurafenib;GSM1220469;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,018867899;cutaneous or subcutaneous;
vemurafenib;GSM1220470;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0;cutaneous or subcutaneous;
untreated;GSM1220471;Primary Tumor;Australia;NA;NA;NA;subcutaneous;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,009203844;cutaneous or subcutaneous;
vemurafenib;GSM1220472;Primary Tumor;Australia;NA;NA;NA;lung;NA;NA;NA;NA;GSE50509;Dendritic.cells;0,034871284;Metastasis;
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;Dendritic.cells;4,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GJ-06A;Metastatic;University of Sydney;83;NA;Male;lymph node;1;2270;I;NA;tcga_skcm;Dendritic.cells;4,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;4,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GI-06A;Metastatic;University of Sydney;39;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;4,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZM-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;Dendritic.cells;4,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IA-06A;Metastatic;Yale;32;NA;Female;Distant Metastasis;1;2005;III;NA;tcga_skcm;Dendritic.cells;4,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51H-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;6,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9VZ-01A;Primary Tumor;Capital Biosciences;90;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;6,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;Dendritic.cells;3,24E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZE-06A;Metastatic;Essen;40;NA;Male;Distant Metastasis;1;1413;II;NA;tcga_skcm;Dendritic.cells;3,24E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;Dendritic.cells;2,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GB-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;938;III;NA;tcga_skcm;Dendritic.cells;2,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;Dendritic.cells;0,001676459;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GL-06A;Metastatic;MD Anderson;43;NA;Male;Cutaneous or Subcutaneous;1;2711;III;NA;tcga_skcm;Dendritic.cells;0,001676459;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EP-01A;Primary Tumor;Cureline;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;9,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZS-06A;Metastatic;Essen;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;9,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;Dendritic.cells;6,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19D-06A;Metastatic;University of Pittsburgh;46;NA;Female;Cutaneous or Subcutaneous;1;383;I;NA;tcga_skcm;Dendritic.cells;6,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;Dendritic.cells;3,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J6-06A;Metastatic;MD Anderson;65;NA;Male;lymph node;1;1321;II;NA;tcga_skcm;Dendritic.cells;3,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;Dendritic.cells;5,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AF-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;1;420;III;NA;tcga_skcm;Dendritic.cells;5,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;6,62E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP6-01A;Primary Tumor;Cureline;55;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;6,62E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;Dendritic.cells;7,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GM-06A;Metastatic;MD Anderson;73;NA;Male;lymph node;1;3259;II;NA;tcga_skcm;Dendritic.cells;7,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z3-06A;Metastatic;Greater Poland Cancer Center;39;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;Dendritic.cells;3,50E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MH-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;516;III;NA;tcga_skcm;Dendritic.cells;3,50E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GC-06A;Metastatic;University of Sydney;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;Dendritic.cells;3,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K5-06A;Metastatic;Norfolk and Norwich Hospital;65;NA;Male;Cutaneous or Subcutaneous;1;1860;IV;NA;tcga_skcm;Dendritic.cells;3,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;Dendritic.cells;4,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Z-06A;Metastatic;University of Sydney;57;NA;Male;lymph node;1;263;II;NA;tcga_skcm;Dendritic.cells;4,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Dendritic.cells;5,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-01A;Primary Tumor;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Dendritic.cells;5,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;Dendritic.cells;0,001654397;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FC-06A;Metastatic;Essen;75;NA;Female;Cutaneous or Subcutaneous;1;1655;II;NA;tcga_skcm;Dendritic.cells;0,001654397;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;4,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W5-01A;Primary Tumor;Capital Biosciences;51;NA;Male;primary detected;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;4,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;Dendritic.cells;8,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42H-01A;Primary Tumor;University of Pittsburgh;76;NA;Male;primary detected;1;426;not reported;NA;tcga_skcm;Dendritic.cells;8,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44P-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;4,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C1-06A;Metastatic;MD Anderson;NA;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;4,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZT-06A;Metastatic;Essen;55;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;Dendritic.cells;2,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LK-06A;Metastatic;Roswell;70;NA;Male;Distant Metastasis;1;1524;I;NA;tcga_skcm;Dendritic.cells;2,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;4,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A729-06A;Metastatic;University of North Carolina;38;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;4,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51J-06A;Metastatic;MD Anderson;19;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;Dendritic.cells;3,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A57M-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;472;III;NA;tcga_skcm;Dendritic.cells;3,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;1,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZN-06A;Metastatic;Norfolk and Norwich Hospital;57;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;1,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;Dendritic.cells;3,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MD-06A;Metastatic;University of Sydney;52;NA;Male;lymph node;1;1438;II;NA;tcga_skcm;Dendritic.cells;3,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,88E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I1-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,88E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;9,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82B-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;9,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;Dendritic.cells;2,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FB-06A;Metastatic;Essen;46;NA;Female;lymph node;1;813;III;NA;tcga_skcm;Dendritic.cells;2,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;Dendritic.cells;4,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J8-06A;Metastatic;University of Sydney;59;NA;Male;Cutaneous or Subcutaneous;1;1044;III;NA;tcga_skcm;Dendritic.cells;4,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q7-06A;Metastatic;MD Anderson;42;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;Dendritic.cells;9,84E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A267-06A;Metastatic;Roswell;38;NA;Male;lymph node;1;1960;III;NA;tcga_skcm;Dendritic.cells;9,84E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;Dendritic.cells;9,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A266-06A;Metastatic;Roswell;45;NA;Male;Cutaneous or Subcutaneous;1;308;not reported;NA;tcga_skcm;Dendritic.cells;9,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;Dendritic.cells;0,001394577;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GC-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;2421;III;NA;tcga_skcm;Dendritic.cells;0,001394577;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,05E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOX-01A;Primary Tumor;Cureline;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,05E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;Dendritic.cells;2,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GS-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;0;NA;IV;NA;tcga_skcm;Dendritic.cells;2,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Z-01A;Primary Tumor;Asterand;49;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;Dendritic.cells;5,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A42Y-01A;Primary Tumor;Asterand;73;NA;Female;primary detected;1;721;II;NA;tcga_skcm;Dendritic.cells;5,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;6,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3S-06A;Metastatic;IDI-IRCCS;58;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;6,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;Dendritic.cells;3,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3EV-06A;Metastatic;University of Pittsburgh;55;NA;Male;Distant Metastasis;1;1429;III;NA;tcga_skcm;Dendritic.cells;3,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;Dendritic.cells;4,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5FP-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;1;454;IV;NA;tcga_skcm;Dendritic.cells;4,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;Dendritic.cells;4,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TU-06A;Metastatic;International Genomics Consortium;72;NA;Female;Distant Metastasis;1;1691;not reported;NA;tcga_skcm;Dendritic.cells;4,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;Dendritic.cells;3,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4FD-06A;Metastatic;Essen;39;NA;Male;lymph node;1;2454;III;NA;tcga_skcm;Dendritic.cells;3,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GE-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F9-06A;Metastatic;Essen;80;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,20E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3R1-01A;Primary Tumor;University of North Carolina;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,20E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;7,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XF-01A;Primary Tumor;Asterand;57;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;7,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K4-01A;Primary Tumor;Norfolk and Norwich Hospital;85;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;0,002025572;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TA-06A;Metastatic;Spectrum Health;75;NA;Male;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;0,002025572;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;2,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SG-06A;Metastatic;Asterand;57;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;2,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95V-06A;Metastatic;Yale;83;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;Dendritic.cells;3,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YX-06A;Metastatic;Essen;39;NA;Female;Cutaneous or Subcutaneous;1;1478;I;NA;tcga_skcm;Dendritic.cells;3,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;3,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A9TB-06A;Metastatic;Spectrum Health;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;3,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XE-01A;Primary Tumor;Asterand;77;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;Dendritic.cells;7,58E-04;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z5-01A;Primary Tumor;Greater Poland Cancer Center;68;NA;Male;NA;0;NA;II;NA;tcga_skcm;Dendritic.cells;7,58E-04;NA
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;Dendritic.cells;3,92E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JN-06A;Metastatic;MD Anderson;46;NA;Female;lymph node;1;2022;III;NA;tcga_skcm;Dendritic.cells;3,92E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZQ-06A;Metastatic;Norfolk and Norwich Hospital;48;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A1NK-01A;Primary Tumor;Asterand;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;Dendritic.cells;7,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19F-06A;Metastatic;University of Pittsburgh;82;NA;Male;lymph node;1;802;not reported;NA;tcga_skcm;Dendritic.cells;7,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,01E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3HV-01A;Primary Tumor;Asterand;37;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,01E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP2-01A;Primary Tumor;Cureline;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;Dendritic.cells;3,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QZ-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;1;352;II;NA;tcga_skcm;Dendritic.cells;3,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;Dendritic.cells;3,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z1-06A;Metastatic;Greater Poland Cancer Center;66;NA;Male;lymph node;1;468;III;NA;tcga_skcm;Dendritic.cells;3,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;Dendritic.cells;0,001107819;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZC-06A;Metastatic;Essen;51;NA;Male;Distant Metastasis;1;10870;i/ii nos;NA;tcga_skcm;Dendritic.cells;0,001107819;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-AA3V-06A;Metastatic;IDI-IRCCS;57;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JH-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;7,72E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GT-01A;Primary Tumor;MD Anderson;43;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;7,72E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;8,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GD-06A;Metastatic;MD Anderson;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;8,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;7,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29M-06A;Metastatic;University of Sydney;33;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;7,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IS-01A;Primary Tumor;Asterand;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;2,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YN-06A;Metastatic;University of North Carolina;44;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;2,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ES-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;6,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41B-01A;Primary Tumor;Asterand;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;6,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;Dendritic.cells;0,004253626;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GD-06A;Metastatic;University of Sydney;58;NA;Female;Cutaneous or Subcutaneous;1;10346;II;NA;tcga_skcm;Dendritic.cells;0,004253626;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;Dendritic.cells;4,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A195-06A;Metastatic;University of Pittsburgh;46;NA;Male;lymph node;1;1078;not reported;NA;tcga_skcm;Dendritic.cells;4,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Dendritic.cells;8,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I5-06A;Metastatic;Yale;27;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Dendritic.cells;8,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;7,49E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PV-01A;Primary Tumor;Cureline;74;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;7,49E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;Dendritic.cells;4,24E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29Q-06A;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;1;2030;II;NA;tcga_skcm;Dendritic.cells;4,24E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;Dendritic.cells;0,001328435;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A2OS-01A;Primary Tumor;University of North Carolina;49;NA;Female;primary detected;1;368;II;NA;tcga_skcm;Dendritic.cells;0,001328435;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;Dendritic.cells;5,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NG-06A;Metastatic;University of Pittsburgh;43;NA;Female;lymph node;1;1490;III;NA;tcga_skcm;Dendritic.cells;5,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;Dendritic.cells;3,75E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1O-06A;Metastatic;John Wayne Cancer Center;85;NA;Male;lymph node;1;122;III;NA;tcga_skcm;Dendritic.cells;3,75E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K1-06A;Metastatic;Norfolk and Norwich Hospital;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GU-06A;Metastatic;University of Sydney;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;Dendritic.cells;5,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29L-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;79;III;NA;tcga_skcm;Dendritic.cells;5,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;2,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JL-06A;Metastatic;MD Anderson;43;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;2,29E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;Dendritic.cells;0,001034193;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MM-06A;Metastatic;University of Sydney;63;NA;Female;lymph node;1;5107;I;NA;tcga_skcm;Dendritic.cells;0,001034193;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;4,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A148-06A;Metastatic;Greater Poland Cancer Center;40;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;4,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;6,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-LH-A9QB-06A;Metastatic;Hartford Hospital;24;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;6,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;Dendritic.cells;6,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SE-01A;Primary Tumor;Asterand;73;NA;Male;primary detected;1;401;II;NA;tcga_skcm;Dendritic.cells;6,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;Dendritic.cells;4,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZR-06A;Metastatic;Norfolk and Norwich Hospital;49;NA;Male;lymph node;1;274;III;NA;tcga_skcm;Dendritic.cells;4,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;Dendritic.cells;4,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZJ-06A;Metastatic;Essen;75;NA;Female;lymph node;1;1441;I;NA;tcga_skcm;Dendritic.cells;4,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;Dendritic.cells;3,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZW-01A;Primary Tumor;Capital Biosciences;62;NA;Female;primary detected;1;393;II;NA;tcga_skcm;Dendritic.cells;3,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Dendritic.cells;9,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GE-06A;Metastatic;MD Anderson;26;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Dendritic.cells;9,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JF-06A;Metastatic;MD Anderson;74;NA;Male;Distant Metastasis;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;Dendritic.cells;3,42E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZR-06A;Metastatic;Essen;36;NA;Male;Cutaneous or Subcutaneous;1;347;II;NA;tcga_skcm;Dendritic.cells;3,42E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;Dendritic.cells;5,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29B-06A;Metastatic;University of Sydney;67;NA;Male;Distant Metastasis;1;2588;II;NA;tcga_skcm;Dendritic.cells;5,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;8,01E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U9-06A;Metastatic;University of North Carolina;63;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;8,01E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;Dendritic.cells;4,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y7-01A;Primary Tumor;Asterand;86;NA;Female;primary detected;1;326;III;NA;tcga_skcm;Dendritic.cells;4,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;Dendritic.cells;3,69E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M8-06A;Metastatic;University of Sydney;54;NA;Female;lymph node;1;601;III;NA;tcga_skcm;Dendritic.cells;3,69E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;Dendritic.cells;4,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29N-06A;Metastatic;University of Sydney;78;NA;Male;lymph node;1;566;i/ii nos;NA;tcga_skcm;Dendritic.cells;4,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;Dendritic.cells;0,001499098;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MQ-06A;Metastatic;University of Sydney;70;NA;Female;lymph node;1;1315;III;NA;tcga_skcm;Dendritic.cells;0,001499098;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;Dendritic.cells;8,23E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZZ-06A;Metastatic;Essen;54;NA;Female;Distant Metastasis;1;822;II;NA;tcga_skcm;Dendritic.cells;8,23E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;Dendritic.cells;2,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JD-06A;Metastatic;MD Anderson;58;NA;Male;lymph node;1;361;III;NA;tcga_skcm;Dendritic.cells;2,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;Dendritic.cells;3,61E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A182-06A;Metastatic;University of Sydney;84;NA;Female;Distant Metastasis;1;447;III;NA;tcga_skcm;Dendritic.cells;3,61E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;4,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A6-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;4,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;Dendritic.cells;5,41E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NE-06A;Metastatic;University of Pittsburgh;39;NA;Male;Distant Metastasis;1;613;stage 0;NA;tcga_skcm;Dendritic.cells;5,41E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;Dendritic.cells;5,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A9SD-06A;Metastatic;Roswell;59;NA;Female;lymph node;1;1807;I;NA;tcga_skcm;Dendritic.cells;5,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;1,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZY-01A;Primary Tumor;Capital Biosciences;76;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;1,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;Dendritic.cells;6,88E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A198-06A;Metastatic;University of Pittsburgh;45;NA;Male;Cutaneous or Subcutaneous;1;1544;not reported;NA;tcga_skcm;Dendritic.cells;6,88E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;Dendritic.cells;4,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z6-06A;Metastatic;Greater Poland Cancer Center;54;NA;Male;lymph node;1;561;III;NA;tcga_skcm;Dendritic.cells;4,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Dendritic.cells;2,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-06A;Metastatic;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Dendritic.cells;2,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;Dendritic.cells;8,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZG-06A;Metastatic;Essen;60;NA;Female;lymph node;1;295;III;NA;tcga_skcm;Dendritic.cells;8,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Dendritic.cells;3,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3I3-06A;Metastatic;International Genomics Consortium;59;NA;Female;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Dendritic.cells;3,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;1,03E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OY-01A;Primary Tumor;Asterand;65;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;1,03E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;Dendritic.cells;1,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5KH-06A;Metastatic;Asterand;55;NA;Male;lymph node;1;619;III;NA;tcga_skcm;Dendritic.cells;1,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;0,001154514;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85J-01A;Primary Tumor;Asterand;66;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;0,001154514;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;Dendritic.cells;5,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29V-06A;Metastatic;University of Sydney;85;NA;Male;Distant Metastasis;1;787;III;NA;tcga_skcm;Dendritic.cells;5,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;6,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GT-06A;Metastatic;University of Sydney;77;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;6,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;Dendritic.cells;4,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A268-06A;Metastatic;Roswell;83;NA;Female;lymph node;1;1910;II;NA;tcga_skcm;Dendritic.cells;4,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;Dendritic.cells;5,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AH-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;1;4222;II;NA;tcga_skcm;Dendritic.cells;5,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;1,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6L9-06A;Metastatic;Asterand;55;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;1,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;Dendritic.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M5-06A;Metastatic;University of Sydney;49;NA;Male;lymph node;1;659;I;NA;tcga_skcm;Dendritic.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;Dendritic.cells;5,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q3-06A;Metastatic;MD Anderson;64;NA;Male;lymph node;1;507;II;NA;tcga_skcm;Dendritic.cells;5,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Dendritic.cells;3,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZT-06A;Metastatic;Norfolk and Norwich Hospital;25;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Dendritic.cells;3,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;4,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JW-06A;Metastatic;Greater Poland Cancer Center;82;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;4,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;Dendritic.cells;0,002740252;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MC-06A;Metastatic;University of Sydney;73;NA;Male;lymph node;1;1871;I;NA;tcga_skcm;Dendritic.cells;0,002740252;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DL-01A;Primary Tumor;Cureline;84;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;Dendritic.cells;3,57E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29A-06A;Metastatic;University of Sydney;68;NA;Male;Distant Metastasis;1;1927;III;NA;tcga_skcm;Dendritic.cells;3,57E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;8,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A728-01A;Primary Tumor;University of North Carolina;54;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;8,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;Dendritic.cells;4,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JG-06A;Metastatic;MD Anderson;30;NA;Female;lymph node;1;3453;III;NA;tcga_skcm;Dendritic.cells;4,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Dendritic.cells;7,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1W-06A;Metastatic;John Wayne Cancer Center;64;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Dendritic.cells;7,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6QY-01A;Primary Tumor;Asterand;71;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;8,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DN-01A;Primary Tumor;Cureline;81;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;8,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JC-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZM-06A;Metastatic;Essen;74;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-A6FS-06A;Metastatic;Emory University;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;Dendritic.cells;4,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A5-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;1;1195;I;NA;tcga_skcm;Dendritic.cells;4,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;Dendritic.cells;6,69E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I8-06A;Metastatic;Yale;63;NA;Female;Cutaneous or Subcutaneous;1;1640;II;NA;tcga_skcm;Dendritic.cells;6,69E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I7-06A;Metastatic;Yale;62;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;3,69E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CB-06A;Metastatic;MD Anderson;39;NA;Male;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;3,69E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;Dendritic.cells;3,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z2-01A;Primary Tumor;Greater Poland Cancer Center;50;NA;Male;primary detected;1;190;III;NA;tcga_skcm;Dendritic.cells;3,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AA9Y-06A;Metastatic;Norfolk and Norwich Hospital;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;Dendritic.cells;0,003801569;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F5-06A;Metastatic;Yale;45;NA;Male;lymph node;1;6873;I;NA;tcga_skcm;Dendritic.cells;0,003801569;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;0,00106573;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GL-06A;Metastatic;University of Sydney;40;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;0,00106573;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,26E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HV-06A;Metastatic;Yale;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,26E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51F-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;Dendritic.cells;4,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19Q-06A;Metastatic;University of Pittsburgh;37;NA;Female;lymph node;1;1548;not reported;NA;tcga_skcm;Dendritic.cells;4,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YE-06A;Metastatic;University of North Carolina;41;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GR-06A;Metastatic;MD Anderson;23;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;6,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP4-01A;Primary Tumor;Cureline;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;6,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;Dendritic.cells;1,51E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1Q-06A;Metastatic;John Wayne Cancer Center;57;NA;Male;Distant Metastasis;1;2101;III;NA;tcga_skcm;Dendritic.cells;1,51E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;Dendritic.cells;3,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WB-06A;Metastatic;Greenville Health System;71;NA;Male;Distant Metastasis;1;518;I;NA;tcga_skcm;Dendritic.cells;3,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;Dendritic.cells;3,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EG-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;Cutaneous or Subcutaneous;1;698;III;NA;tcga_skcm;Dendritic.cells;3,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;Dendritic.cells;2,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MJ-06A;Metastatic;University of Sydney;60;NA;Male;lymph node;1;2927;III;NA;tcga_skcm;Dendritic.cells;2,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,75E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GK-06A;Metastatic;MD Anderson;45;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,75E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;9,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DM-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;9,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;7,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MR-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;7,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;Dendritic.cells;5,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZQ-06A;Metastatic;Essen;31;NA;Male;Distant Metastasis;1;4062;i/ii nos;NA;tcga_skcm;Dendritic.cells;5,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;3,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24C-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;3,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Dendritic.cells;4,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A693-06A;Metastatic;St. Joseph's Hospital AZ;77;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Dendritic.cells;4,12E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JE-06A;Metastatic;University of Sydney;75;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;Dendritic.cells;0,001750513;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1V-06B;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;1;1280;II;NA;tcga_skcm;Dendritic.cells;0,001750513;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XC-01A;Primary Tumor;Asterand;74;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7UA-06A;Metastatic;University of North Carolina;65;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;Dendritic.cells;4,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZK-06A;Metastatic;Essen;68;NA;Male;Distant Metastasis;1;728;II;NA;tcga_skcm;Dendritic.cells;4,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51T-06A;Metastatic;MD Anderson;59;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;Dendritic.cells;5,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z0-06A;Metastatic;Essen;32;NA;Female;Distant Metastasis;1;6164;I;NA;tcga_skcm;Dendritic.cells;5,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;1,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A6K9-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;1,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;Dendritic.cells;6,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20H-06A;Metastatic;University of Sydney;56;NA;Male;Distant Metastasis;1;5118;I;NA;tcga_skcm;Dendritic.cells;6,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;0,000840989;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA4-06A;Metastatic;Norfolk and Norwich Hospital;56;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;0,000840989;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;Dendritic.cells;0,001825058;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A828-06A;Metastatic;John Wayne Cancer Center;66;NA;Male;Distant Metastasis;1;3683;II;NA;tcga_skcm;Dendritic.cells;0,001825058;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;Dendritic.cells;4,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C6-06A;Metastatic;MD Anderson;54;NA;Female;lymph node;1;1766;I;NA;tcga_skcm;Dendritic.cells;4,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JP-06A;Metastatic;MD Anderson;37;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,20E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q4-06A;Metastatic;MD Anderson;53;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,20E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;Dendritic.cells;0,001068539;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZN-01A;Primary Tumor;Essen;43;NA;Male;primary detected;1;730;III;NA;tcga_skcm;Dendritic.cells;0,001068539;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Dendritic.cells;4,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A694-06A;Metastatic;St. Joseph's Hospital AZ;71;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Dendritic.cells;4,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;Dendritic.cells;0,001281082;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A825-06A;Metastatic;John Wayne Cancer Center;60;NA;Female;Distant Metastasis;1;1917;II;NA;tcga_skcm;Dendritic.cells;0,001281082;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;Dendritic.cells;5,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F2-06A;Metastatic;Essen;46;NA;Female;Cutaneous or Subcutaneous;1;1525;II;NA;tcga_skcm;Dendritic.cells;5,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;Dendritic.cells;2,92E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YW-06A;Metastatic;Essen;52;NA;Male;lymph node;1;6598;I;NA;tcga_skcm;Dendritic.cells;2,92E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F8-06A;Metastatic;Yale;39;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Dendritic.cells;2,76E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Z-06A;Metastatic;Yale;87;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Dendritic.cells;2,76E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;Dendritic.cells;3,57E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z3-06A;Metastatic;Essen;72;NA;Female;Distant Metastasis;1;636;IV;NA;tcga_skcm;Dendritic.cells;3,57E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;Dendritic.cells;7,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19E-06A;Metastatic;University of Pittsburgh;36;NA;Female;lymph node;1;396;I;NA;tcga_skcm;Dendritic.cells;7,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;Dendritic.cells;3,68E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J9-06A;Metastatic;MD Anderson;75;NA;Male;lymph node;1;723;III;NA;tcga_skcm;Dendritic.cells;3,68E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;Dendritic.cells;6,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A6R0-01A;Primary Tumor;Asterand;58;NA;Female;primary detected;1;608;II;NA;tcga_skcm;Dendritic.cells;6,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J7-06A;Metastatic;University of Sydney;43;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZW-06A;Metastatic;Essen;65;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;Dendritic.cells;4,00E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4P0-01A;Primary Tumor;Asterand;82;NA;Male;primary detected;1;326;II;NA;tcga_skcm;Dendritic.cells;4,00E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;2,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A690-06A;Metastatic;St. Joseph's Hospital AZ;66;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;2,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;Dendritic.cells;0,001418764;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29W-06A;Metastatic;University of Sydney;42;NA;Male;lymph node;0;NA;stage 0;NA;tcga_skcm;Dendritic.cells;0,001418764;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;Dendritic.cells;3,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1YY-06A;Metastatic;Essen;55;NA;Female;Distant Metastasis;1;6953;II;NA;tcga_skcm;Dendritic.cells;3,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;Dendritic.cells;6,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F3-06A;Metastatic;Yale;52;NA;Male;lymph node;1;319;III;NA;tcga_skcm;Dendritic.cells;6,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;Dendritic.cells;3,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19P-06A;Metastatic;University of Pittsburgh;47;NA;Female;lymph node;1;4930;not reported;NA;tcga_skcm;Dendritic.cells;3,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;Dendritic.cells;2,92E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IB-06A;Metastatic;Yale;69;NA;Female;lymph node;1;1235;III;NA;tcga_skcm;Dendritic.cells;2,92E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;2,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GH-06A;Metastatic;University of Sydney;34;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;2,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;Dendritic.cells;5,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20C-06A;Metastatic;University of Sydney;59;NA;Male;Distant Metastasis;1;4601;stage 0;NA;tcga_skcm;Dendritic.cells;5,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;Dendritic.cells;3,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19B-06A;Metastatic;University of Pittsburgh;42;NA;Male;Cutaneous or Subcutaneous;1;2993;not reported;NA;tcga_skcm;Dendritic.cells;3,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA0-06A;Metastatic;Norfolk and Norwich Hospital;47;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;Dendritic.cells;0,001030121;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YD-A89C-06A;Metastatic;Spectrum Health;43;NA;Female;Distant Metastasis;0;NA;I;NA;tcga_skcm;Dendritic.cells;0,001030121;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;Dendritic.cells;7,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I2-06A;Metastatic;Yale;45;NA;Male;lymph node;1;5370;III;NA;tcga_skcm;Dendritic.cells;7,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;9,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29E-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;9,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EO-01A;Primary Tumor;Cureline;65;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,50E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GK-06A;Metastatic;University of Sydney;46;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,50E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;Dendritic.cells;6,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZA-06A;Metastatic;Essen;45;NA;Female;Distant Metastasis;1;843;III;NA;tcga_skcm;Dendritic.cells;6,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;Dendritic.cells;7,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19M-06A;Metastatic;University of Pittsburgh;36;NA;Male;lymph node;1;1857;I;NA;tcga_skcm;Dendritic.cells;7,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;1,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UM-01A;Primary Tumor;Asterand;48;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;1,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;Dendritic.cells;4,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A180-06A;Metastatic;University of Sydney;69;NA;Male;Distant Metastasis;1;2889;III;NA;tcga_skcm;Dendritic.cells;4,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A7U8-06A;Metastatic;University of North Carolina;50;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-Z2-A8RT-06A;Metastatic;IDI-IRCCS;42;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;2,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JH-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;2,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;4,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19G-06A;Metastatic;University of Pittsburgh;48;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;4,70E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;Dendritic.cells;7,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JI-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;4648;I;NA;tcga_skcm;Dendritic.cells;7,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,42E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PU-01A;Primary Tumor;Cureline;46;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,42E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;6,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A1-06A;Metastatic;University of Sydney;46;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;6,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,68E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP1-01A;Primary Tumor;Cureline;86;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,68E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,77E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3BZ-06A;Metastatic;MD Anderson;63;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,77E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;Dendritic.cells;3,76E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-QB-AA9O-06A;Metastatic;Emory University;73;NA;Male;lymph node;1;549;III;NA;tcga_skcm;Dendritic.cells;3,76E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;Dendritic.cells;3,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19L-06A;Metastatic;University of Pittsburgh;35;NA;Male;lymph node;1;4000;not reported;NA;tcga_skcm;Dendritic.cells;3,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QB-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;Dendritic.cells;4,62E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29C-06A;Metastatic;University of Sydney;20;NA;Male;lymph node;1;2402;I;NA;tcga_skcm;Dendritic.cells;4,62E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;1,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP8-01A;Primary Tumor;Cureline;58;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;1,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MR-06A;Metastatic;MD Anderson;42;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JO-06A;Metastatic;MD Anderson;50;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;Dendritic.cells;5,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CF-06A;Metastatic;MD Anderson;61;NA;Female;lymph node;1;746;III;NA;tcga_skcm;Dendritic.cells;5,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A4EO-06A;Metastatic;ABS - IUPUI;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MV-06A;Metastatic;MD Anderson;38;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3P-06A;Metastatic;University of Puerto Rico;63;NA;Female;Distant Metastasis;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;Dendritic.cells;7,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26C-01A;Primary Tumor;Roswell;77;NA;Male;primary detected;1;821;III;NA;tcga_skcm;Dendritic.cells;7,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;Dendritic.cells;3,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GS-06A;Metastatic;MD Anderson;52;NA;Male;Distant Metastasis;1;3564;I;NA;tcga_skcm;Dendritic.cells;3,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;9,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3R5-06A;Metastatic;International Genomics Consortium;68;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;9,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,26E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SH-06A;Metastatic;Asterand;60;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,26E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;Dendritic.cells;3,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F5-06A;Metastatic;Essen;77;NA;Female;Cutaneous or Subcutaneous;1;874;I;NA;tcga_skcm;Dendritic.cells;3,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Dendritic.cells;3,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19T-06A;Metastatic;University of Pittsburgh;51;NA;Male;primary detected;1;270;IV;NA;tcga_skcm;Dendritic.cells;3,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;Dendritic.cells;7,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AD-06A;Metastatic;University of Sydney;50;NA;Male;lymph node;1;875;III;NA;tcga_skcm;Dendritic.cells;7,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U3-06A;Metastatic;Roswell;30;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;Dendritic.cells;4,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I0-06A;Metastatic;Yale;63;NA;Male;Cutaneous or Subcutaneous;1;620;IV;NA;tcga_skcm;Dendritic.cells;4,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;5,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GB-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;5,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;Dendritic.cells;6,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JE-06A;Metastatic;MD Anderson;75;NA;Female;lymph node;1;841;III;NA;tcga_skcm;Dendritic.cells;6,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;Dendritic.cells;0,001090171;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZD-06A;Metastatic;Essen;63;NA;Male;lymph node;1;1628;II;NA;tcga_skcm;Dendritic.cells;0,001090171;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;Dendritic.cells;8,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AG-06A;Metastatic;University of Sydney;25;NA;Male;Cutaneous or Subcutaneous;1;1265;III;NA;tcga_skcm;Dendritic.cells;8,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A24D-01A;Primary Tumor;Asterand;72;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,53E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95W-06A;Metastatic;Yale;52;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,53E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Dendritic.cells;6,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GJ-06A;Metastatic;MD Anderson;18;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Dendritic.cells;6,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;8,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JA-06A;Metastatic;MD Anderson;68;NA;Male;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;8,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;Dendritic.cells;3,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MN-06A;Metastatic;University of Sydney;58;NA;Male;lymph node;1;1446;I;NA;tcga_skcm;Dendritic.cells;3,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;Dendritic.cells;4,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WD-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;1;395;III;NA;tcga_skcm;Dendritic.cells;4,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;Dendritic.cells;2,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ME-06A;Metastatic;University of Sydney;51;NA;Male;lymph node;1;3141;I;NA;tcga_skcm;Dendritic.cells;2,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A9VF-01A;Primary Tumor;Cureline;77;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XB-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;Dendritic.cells;6,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GR-06A;Metastatic;University of Sydney;78;NA;Male;Cutaneous or Subcutaneous;1;1301;II;NA;tcga_skcm;Dendritic.cells;6,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;Dendritic.cells;7,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A550-01A;Primary Tumor;Asterand;75;NA;Female;primary detected;1;264;II;NA;tcga_skcm;Dendritic.cells;7,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;Dendritic.cells;6,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19W-06A;Metastatic;University of Pittsburgh;48;NA;Female;Cutaneous or Subcutaneous;1;4507;not reported;NA;tcga_skcm;Dendritic.cells;6,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;3,23E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U8-06A;Metastatic;Roswell;51;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;3,23E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;Dendritic.cells;2,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F8-06A;Metastatic;Essen;52;NA;Male;lymph node;1;5318;I;NA;tcga_skcm;Dendritic.cells;2,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;Dendritic.cells;6,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19H-06A;Metastatic;University of Pittsburgh;40;NA;Male;Cutaneous or Subcutaneous;1;4634;not reported;NA;tcga_skcm;Dendritic.cells;6,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;0,001702499;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1QA-06A;Metastatic;MD Anderson;55;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;0,001702499;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;Dendritic.cells;0,001891792;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A197-06A;Metastatic;University of Pittsburgh;83;NA;Female;NA;1;424;III;NA;tcga_skcm;Dendritic.cells;0,001891792;NA
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;Dendritic.cells;3,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1IC-06A;Metastatic;Yale;81;NA;Male;Cutaneous or Subcutaneous;1;2071;III;NA;tcga_skcm;Dendritic.cells;3,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;Dendritic.cells;5,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20I-06A;Metastatic;University of Sydney;79;NA;Male;Cutaneous or Subcutaneous;1;412;IV;NA;tcga_skcm;Dendritic.cells;5,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;Dendritic.cells;9,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GQ-06A;Metastatic;MD Anderson;66;NA;Male;Distant Metastasis;1;884;II;NA;tcga_skcm;Dendritic.cells;9,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;Dendritic.cells;5,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A181-06A;Metastatic;University of Sydney;82;NA;Female;lymph node;1;1026;II;NA;tcga_skcm;Dendritic.cells;5,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;Dendritic.cells;2,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YD-06A;Metastatic;University of North Carolina;56;NA;Female;Distant Metastasis;1;1103;II;NA;tcga_skcm;Dendritic.cells;2,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;Dendritic.cells;5,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29D-06A;Metastatic;University of Sydney;87;NA;Male;lymph node;1;425;III;NA;tcga_skcm;Dendritic.cells;5,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C8-06A;Metastatic;ABS - IUPUI;62;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;Dendritic.cells;2,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZY-06A;Metastatic;Essen;71;NA;Male;Distant Metastasis;1;824;II;NA;tcga_skcm;Dendritic.cells;2,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,97E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-A824-06A;Metastatic;John Wayne Cancer Center;63;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,97E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,75E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-3N-A9WC-06A;Metastatic;Greenville Health System;82;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,75E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;Dendritic.cells;6,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA1R-06A;Metastatic;John Wayne Cancer Center;71;NA;Male;lymph node;1;3379;II;NA;tcga_skcm;Dendritic.cells;6,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;Dendritic.cells;6,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ET-06A;Metastatic;University of Pittsburgh;64;NA;Female;Cutaneous or Subcutaneous;1;2829;III;NA;tcga_skcm;Dendritic.cells;6,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;Dendritic.cells;8,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MO-06A;Metastatic;MD Anderson;47;NA;Male;Cutaneous or Subcutaneous;1;284;III;NA;tcga_skcm;Dendritic.cells;8,10E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DX-01A;Primary Tumor;International Genomics Consortium;71;NA;Male;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;Dendritic.cells;4,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19J-06A;Metastatic;University of Pittsburgh;54;NA;Male;lymph node;1;196;IV;NA;tcga_skcm;Dendritic.cells;4,98E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,05E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A44A-06A;Metastatic;University of North Carolina;29;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,05E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;Dendritic.cells;4,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J7-06A;Metastatic;MD Anderson;67;NA;Male;lymph node;1;3136;III;NA;tcga_skcm;Dendritic.cells;4,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;Dendritic.cells;4,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VU-01A;Primary Tumor;Asterand;56;NA;Male;primary detected;1;321;III;NA;tcga_skcm;Dendritic.cells;4,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;Dendritic.cells;8,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q5-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;1;3424;i/ii nos;NA;tcga_skcm;Dendritic.cells;8,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-AAA3-06A;Metastatic;Norfolk and Norwich Hospital;84;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,75E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GO-06A;Metastatic;MD Anderson;61;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,75E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;Dendritic.cells;4,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z7-06A;Metastatic;Essen;19;NA;Male;lymph node;1;237;III;NA;tcga_skcm;Dendritic.cells;4,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Dendritic.cells;2,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-RP-A695-06A;Metastatic;St. Joseph's Hospital AZ;NA;NA;Male;Distant Metastasis;0;NA;IV;NA;tcga_skcm;Dendritic.cells;2,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;Dendritic.cells;3,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZB-06A;Metastatic;Essen;57;NA;Male;Distant Metastasis;1;1486;II;NA;tcga_skcm;Dendritic.cells;3,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;Dendritic.cells;4,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GI-06A;Metastatic;MD Anderson;68;NA;Male;lymph node;1;1780;I;NA;tcga_skcm;Dendritic.cells;4,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;Dendritic.cells;2,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A0-06A;Metastatic;University of Sydney;77;NA;Female;lymph node;1;1424;II;NA;tcga_skcm;Dendritic.cells;2,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;Dendritic.cells;2,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5SF-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;1;369;II;NA;tcga_skcm;Dendritic.cells;2,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;Dendritic.cells;3,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A184-06A;Metastatic;University of Sydney;72;NA;Male;Distant Metastasis;1;2073;I;NA;tcga_skcm;Dendritic.cells;3,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;Dendritic.cells;8,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17Y-06A;Metastatic;University of Sydney;69;NA;Male;Cutaneous or Subcutaneous;1;828;III;NA;tcga_skcm;Dendritic.cells;8,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;Dendritic.cells;8,24E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42K-06A;Metastatic;University of Pittsburgh;40;NA;Female;lymph node;1;394;III;NA;tcga_skcm;Dendritic.cells;8,24E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;Dendritic.cells;0,001113372;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q6-06A;Metastatic;MD Anderson;55;NA;Male;Cutaneous or Subcutaneous;1;2184;III;NA;tcga_skcm;Dendritic.cells;0,001113372;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;6,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A265-06A;Metastatic;Roswell;53;NA;Male;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;6,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;Dendritic.cells;5,01E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26D-06A;Metastatic;Roswell;72;NA;Female;lymph node;1;1460;II;NA;tcga_skcm;Dendritic.cells;5,01E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Dendritic.cells;2,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NF-01A;Primary Tumor;University of Pittsburgh;53;NA;Male;primary detected;1;877;III;NA;tcga_skcm;Dendritic.cells;2,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;Dendritic.cells;1,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2ND-06A;Metastatic;University of Pittsburgh;57;NA;Female;Distant Metastasis;1;710;III;NA;tcga_skcm;Dendritic.cells;1,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;Dendritic.cells;3,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A185-06A;Metastatic;University of Sydney;55;NA;Female;lymph node;1;151;III;NA;tcga_skcm;Dendritic.cells;3,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Dendritic.cells;3,75E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP0-06A;Metastatic;Cureline;40;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Dendritic.cells;3,75E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Dendritic.cells;0,001612015;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UN-06A;Metastatic;Asterand;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Dendritic.cells;0,001612015;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GN-06A;Metastatic;MD Anderson;15;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;Dendritic.cells;3,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GV-06A;Metastatic;MD Anderson;25;NA;Male;Distant Metastasis;1;5101;i/ii nos;NA;tcga_skcm;Dendritic.cells;3,90E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;1,50E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5ER-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;1,50E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A3OT-06A;Metastatic;ABS - IUPUI;58;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;0;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,04E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A551-01A;Primary Tumor;Asterand;78;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,04E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;0,001178343;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29R-06A;Metastatic;University of Sydney;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;0,001178343;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;6,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MK-06A;Metastatic;University of Sydney;18;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;6,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;Dendritic.cells;3,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29G-06A;Metastatic;University of Sydney;53;NA;Male;Cutaneous or Subcutaneous;1;2192;III;NA;tcga_skcm;Dendritic.cells;3,78E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;4,03E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20F-06A;Metastatic;University of Sydney;53;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;4,03E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;1,61E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A262-06A;Metastatic;Roswell;47;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;1,61E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A85I-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;Dendritic.cells;5,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HW-06A;Metastatic;Yale;37;NA;Female;lymph node;1;1096;III;NA;tcga_skcm;Dendritic.cells;5,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A42L-06A;Metastatic;University of Pittsburgh;49;NA;Male;Distant Metastasis;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;Dendritic.cells;3,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3ML-06A;Metastatic;MD Anderson;70;NA;Male;lymph node;1;422;III;NA;tcga_skcm;Dendritic.cells;3,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;Dendritic.cells;2,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A3F2-06A;Metastatic;Yale;55;NA;Male;Cutaneous or Subcutaneous;1;1032;III;NA;tcga_skcm;Dendritic.cells;2,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;Dendritic.cells;4,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1I4-06A;Metastatic;Yale;51;NA;Male;Cutaneous or Subcutaneous;1;1093;III;NA;tcga_skcm;Dendritic.cells;4,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;1,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U4-06A;Metastatic;Roswell;73;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;1,95E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;Dendritic.cells;0,001644479;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29S-06A;Metastatic;University of Sydney;79;NA;Male;lymph node;1;1864;II;NA;tcga_skcm;Dendritic.cells;0,001644479;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZX-06A;Metastatic;Norfolk and Norwich Hospital;45;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C8-06A;Metastatic;MD Anderson;58;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;3,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A5NC-01A;Primary Tumor;Ontario Institute for Cancer Research (OICR);90;NA;Female;primary detected;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;3,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;1,88E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3N-01A;Primary Tumor;University of Puerto Rico;67;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;1,88E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;Dendritic.cells;2,72E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q9-06A;Metastatic;MD Anderson;72;NA;Male;lymph node;1;961;III;NA;tcga_skcm;Dendritic.cells;2,72E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZO-06A;Metastatic;Norfolk and Norwich Hospital;73;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,67E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44Q-06A;Metastatic;Asterand;51;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,38E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;6,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LN-01A;Primary Tumor;Roswell;68;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;6,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A430-01A;Primary Tumor;Asterand;83;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;Dendritic.cells;3,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A3Z4-01A;Primary Tumor;Greater Poland Cancer Center;54;NA;Male;primary detected;1;519;III;NA;tcga_skcm;Dendritic.cells;3,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;5,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A1HY-06A;Metastatic;Yale;42;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;5,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U5-01A;Primary Tumor;Roswell;61;NA;Female;primary detected;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,71E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;5,26E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8K6-06A;Metastatic;Norfolk and Norwich Hospital;79;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;5,26E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;Dendritic.cells;2,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95Y-06A;Metastatic;Yale;68;NA;Male;lymph node;1;430;II;NA;tcga_skcm;Dendritic.cells;2,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,50E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A2C7-01A;Primary Tumor;ABS - IUPUI;48;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,50E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;1,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4OZ-01A;Primary Tumor;Asterand;41;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;1,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MS-06A;Metastatic;University of Sydney;72;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PZ-01A;Primary Tumor;Cureline;71;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;Dendritic.cells;6,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GS-06A;Metastatic;University of Sydney;28;NA;Female;Cutaneous or Subcutaneous;1;2470;I;NA;tcga_skcm;Dendritic.cells;6,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;Dendritic.cells;4,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q8-06A;Metastatic;MD Anderson;33;NA;Male;lymph node;1;854;IV;NA;tcga_skcm;Dendritic.cells;4,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;7,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A3DJ-01A;Primary Tumor;Cureline;36;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;7,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;Dendritic.cells;3,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19N-06A;Metastatic;University of Pittsburgh;47;NA;Male;lymph node;1;1341;not reported;NA;tcga_skcm;Dendritic.cells;3,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,75E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3XD-01A;Primary Tumor;Asterand;53;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,75E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,51E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C7-06A;Metastatic;MD Anderson;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,51E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAP7-01A;Primary Tumor;Cureline;76;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Dendritic.cells;6,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MU-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;0;NA;I;NA;tcga_skcm;Dendritic.cells;6,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CC-06A;Metastatic;MD Anderson;69;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;5,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A1A1-06A;Metastatic;University of Pittsburgh;58;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;5,27E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;5,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NH-06A;Metastatic;University of Pittsburgh;49;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;5,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;Dendritic.cells;4,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19O-06A;Metastatic;University of Pittsburgh;56;NA;Male;lymph node;1;NA;III;NA;tcga_skcm;Dendritic.cells;4,22E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;5,61E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51E-06A;Metastatic;MD Anderson;39;NA;Female;Cutaneous or Subcutaneous;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;5,61E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-IH-A3EA-01A;Primary Tumor;University of Miami;61;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;0,001665999;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F0-06A;Metastatic;Essen;67;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;0,001665999;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;8,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OG-06A;Metastatic;Ontario Institute for Cancer Research (OICR);50;NA;Female;Distant Metastasis;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;8,07E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;Dendritic.cells;4,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MG-06A;Metastatic;University of Sydney;23;NA;Male;lymph node;1;3139;I;NA;tcga_skcm;Dendritic.cells;4,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;5,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19S-06A;Metastatic;University of Pittsburgh;81;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;5,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Dendritic.cells;4,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3PL-06A;Metastatic;University of Pittsburgh;30;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Dendritic.cells;4,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;Dendritic.cells;2,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19C-06A;Metastatic;University of Pittsburgh;77;NA;Male;lymph node;1;1487;I;NA;tcga_skcm;Dendritic.cells;2,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;8,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JB-06A;Metastatic;University of Sydney;60;NA;Female;Cutaneous or Subcutaneous;0;NA;III;NA;tcga_skcm;Dendritic.cells;8,09E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;Dendritic.cells;8,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M7-06A;Metastatic;University of Sydney;66;NA;Male;lymph node;1;877;II;NA;tcga_skcm;Dendritic.cells;8,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;8,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A69P-06A;Metastatic;University of North Carolina;34;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;8,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;1,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51K-06A;Metastatic;MD Anderson;51;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;1,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A3TV-06A;Metastatic;International Genomics Consortium;57;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MT-06A;Metastatic;University of Sydney;45;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;5,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;Dendritic.cells;3,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JB-06A;Metastatic;MD Anderson;70;NA;Female;lymph node;1;5110;stage 0;NA;tcga_skcm;Dendritic.cells;3,36E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;7,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A20B-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;7,46E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,15E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3MU-06A;Metastatic;MD Anderson;53;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,15E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;Dendritic.cells;7,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZH-06A;Metastatic;Essen;71;NA;Female;lymph node;1;996;IV;NA;tcga_skcm;Dendritic.cells;7,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,00E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A82C-01A;Primary Tumor;Asterand;70;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,00E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;Dendritic.cells;3,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1JX-06A;Metastatic;Greater Poland Cancer Center;80;NA;Female;lymph node;1;216;not reported;NA;tcga_skcm;Dendritic.cells;3,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;Dendritic.cells;2,68E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A263-01A;Primary Tumor;Roswell;24;NA;Male;primary detected;1;467;IV;NA;tcga_skcm;Dendritic.cells;2,68E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;Dendritic.cells;5,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3CE-06A;Metastatic;MD Anderson;74;NA;Female;lymph node;1;1832;III;NA;tcga_skcm;Dendritic.cells;5,66E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;0,001250514;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GO-06A;Metastatic;University of Sydney;66;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;0,001250514;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;1,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AB01-06A;Metastatic;Capital Biosciences;54;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;1,91E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;Dendritic.cells;6,94E-04;NA
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EA-06A;Metastatic;Greater Poland Cancer Center;70;NA;Male;NA;0;NA;III;NA;tcga_skcm;Dendritic.cells;6,94E-04;NA
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;Dendritic.cells;4,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19K-01A;Primary Tumor;University of Pittsburgh;79;NA;Female;primary detected;1;469;II;NA;tcga_skcm;Dendritic.cells;4,08E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;Dendritic.cells;1,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GR-06A;Metastatic;MD Anderson;54;NA;Female;Distant Metastasis;1;3943;stage 0;NA;tcga_skcm;Dendritic.cells;1,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;6,77E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AB-06A;Metastatic;University of Sydney;30;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;6,77E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;Dendritic.cells;3,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A199-06A;Metastatic;University of Pittsburgh;86;NA;Female;lymph node;1;279;III;NA;tcga_skcm;Dendritic.cells;3,32E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;Dendritic.cells;3,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4IQ-01A;Primary Tumor;Asterand;42;NA;Female;primary detected;1;636;III;NA;tcga_skcm;Dendritic.cells;3,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Dendritic.cells;2,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51N-06A;Metastatic;MD Anderson;56;NA;Female;lymph node;0;NA;IV;NA;tcga_skcm;Dendritic.cells;2,99E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;1,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GO-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;1;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;1,82E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;0,002296379;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A95X-06A;Metastatic;Yale;62;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;0,002296379;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;5,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A3C3-06A;Metastatic;MD Anderson;NA;NA;Female;lymph node;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;5,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;Dendritic.cells;5,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-HR-A2OH-06A;Metastatic;Ontario Institute for Cancer Research (OICR);46;NA;Female;Distant Metastasis;1;2004;III;NA;tcga_skcm;Dendritic.cells;5,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,72E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A3Y6-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,72E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;Dendritic.cells;3,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NB-01A;Primary Tumor;University of Pittsburgh;57;NA;Male;primary detected;1;857;III;NA;tcga_skcm;Dendritic.cells;3,83E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A299-01A;Primary Tumor;Asterand;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;Dendritic.cells;7,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JD-06A;Metastatic;University of Sydney;70;NA;Male;lymph node;1;832;III;NA;tcga_skcm;Dendritic.cells;7,84E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Dendritic.cells;0,001144758;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A19A-06A;Metastatic;University of Pittsburgh;79;NA;Male;Cutaneous or Subcutaneous;0;NA;IV;NA;tcga_skcm;Dendritic.cells;0,001144758;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;Dendritic.cells;2,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-W3-AA21-06A;Metastatic;John Wayne Cancer Center;26;NA;Male;lymph node;1;3195;I;NA;tcga_skcm;Dendritic.cells;2,55E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;Dendritic.cells;4,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3JA-06A;Metastatic;University of Sydney;44;NA;Male;lymph node;1;1618;I;NA;tcga_skcm;Dendritic.cells;4,33E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;1,97E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GU-06A;Metastatic;MD Anderson;36;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;1,97E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;Dendritic.cells;7,53E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZU-06A;Metastatic;Essen;70;NA;Female;Distant Metastasis;1;808;II;NA;tcga_skcm;Dendritic.cells;7,53E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29P-06A;Metastatic;University of Sydney;73;NA;Female;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,80E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;9,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A196-01A;Primary Tumor;University of Pittsburgh;64;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;9,35E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;Dendritic.cells;4,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-YG-AA3O-06A;Metastatic;University of Puerto Rico;62;NA;Male;lymph node;1;1154;not reported;NA;tcga_skcm;Dendritic.cells;4,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;Dendritic.cells;0,004991722;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2J8-06A;Metastatic;MD Anderson;48;NA;Male;lymph node;1;1992;I;NA;tcga_skcm;Dendritic.cells;0,004991722;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;Dendritic.cells;0,001202092;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A726-01A;Primary Tumor;University of North Carolina;90;NA;Male;primary detected;1;0;II;NA;tcga_skcm;Dendritic.cells;0,001202092;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MP-06A;Metastatic;University of Sydney;34;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,06E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;Dendritic.cells;4,49E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A8LL-06A;Metastatic;Roswell;68;NA;Female;lymph node;1;650;II;NA;tcga_skcm;Dendritic.cells;4,49E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-AAOU-01A;Primary Tumor;Cureline;73;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,86E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;Dendritic.cells;2,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1PX-01A;Primary Tumor;Cureline;56;NA;Male;primary detected;1;282;III;NA;tcga_skcm;Dendritic.cells;2,44E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5UL-06A;Metastatic;Asterand;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,30E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;Dendritic.cells;2,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A2JK-06A;Metastatic;MD Anderson;24;NA;Male;lymph node;1;368;III;NA;tcga_skcm;Dendritic.cells;2,47E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;9,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AA-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;9,02E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;Dendritic.cells;3,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A17X-06A;Metastatic;University of Sydney;54;NA;Male;lymph node;1;907;I;NA;tcga_skcm;Dendritic.cells;3,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A431-01A;Primary Tumor;Asterand;34;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;Dendritic.cells;3,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A193-06A;Metastatic;University of Pittsburgh;62;NA;Male;lymph node;1;955;II;NA;tcga_skcm;Dendritic.cells;3,17E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;Dendritic.cells;4,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MF-06A;Metastatic;University of Sydney;39;NA;Female;lymph node;1;8174;I;NA;tcga_skcm;Dendritic.cells;4,64E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;4,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29T-06A;Metastatic;University of Sydney;51;NA;Female;lymph node;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;4,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;0,001742511;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A3YO-06A;Metastatic;University of North Carolina;NA;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;0,001742511;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;Dendritic.cells;7,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A264-06A;Metastatic;Roswell;60;NA;Male;lymph node;1;3587;not reported;NA;tcga_skcm;Dendritic.cells;7,31E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;Dendritic.cells;7,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44N-01A;Primary Tumor;Asterand;59;NA;Male;primary detected;1;205;II;NA;tcga_skcm;Dendritic.cells;7,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;1,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FW-A5DY-06A;Metastatic;International Genomics Consortium;48;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;1,56E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;Dendritic.cells;5,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GN-06A;Metastatic;University of Sydney;67;NA;Male;Cutaneous or Subcutaneous;1;3106;II;NA;tcga_skcm;Dendritic.cells;5,45E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;Dendritic.cells;1,51E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A3ES-06A;Metastatic;University of Pittsburgh;25;NA;Male;Distant Metastasis;1;7514;not reported;NA;tcga_skcm;Dendritic.cells;1,51E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,72E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-DA-A960-01A;Primary Tumor;Yale;73;NA;Male;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,72E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;Dendritic.cells;1,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A194-01A;Primary Tumor;University of Pittsburgh;77;NA;Male;primary detected;1;1354;not reported;NA;tcga_skcm;Dendritic.cells;1,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;Dendritic.cells;0,001135862;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A26A-06A;Metastatic;Roswell;63;NA;Female;Cutaneous or Subcutaneous;1;988;III;NA;tcga_skcm;Dendritic.cells;0,001135862;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;Dendritic.cells;4,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44R-06A;Metastatic;Asterand;52;NA;Male;lymph node;1;315;III;NA;tcga_skcm;Dendritic.cells;4,63E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-AAZV-01A;Primary Tumor;Capital Biosciences;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,11E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;6,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A5VV-06A;Metastatic;Asterand;74;NA;Female;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;6,19E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;Dendritic.cells;4,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-OD-A75X-06A;Metastatic;Saint Mary's Health Care;49;NA;Male;Distant Metastasis;1;9061;not reported;NA;tcga_skcm;Dendritic.cells;4,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;Dendritic.cells;3,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A769-01A;Primary Tumor;ABS - IUPUI;39;NA;Male;primary detected;1;1070;II;NA;tcga_skcm;Dendritic.cells;3,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29H-06A;Metastatic;University of Sydney;59;NA;Female;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;9,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A51B-01A;Primary Tumor;Asterand;53;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;9,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;7,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A1X3-06A;Metastatic;Greater Poland Cancer Center;63;NA;Male;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;7,94E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;Dendritic.cells;4,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A183-06A;Metastatic;University of Sydney;48;NA;Male;lymph node;1;818;stage 0;NA;tcga_skcm;Dendritic.cells;4,81E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;Dendritic.cells;4,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1Z4-06A;Metastatic;Essen;62;NA;Male;lymph node;1;854;I;NA;tcga_skcm;Dendritic.cells;4,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51R-06A;Metastatic;MD Anderson;60;NA;Male;lymph node;0;NA;II;NA;tcga_skcm;Dendritic.cells;5,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A41A-01A;Primary Tumor;Asterand;90;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,39E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;6,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A149-06A;Metastatic;Greater Poland Cancer Center;65;NA;Female;Cutaneous or Subcutaneous;0;NA;not reported;NA;tcga_skcm;Dendritic.cells;6,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;0,001038367;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A44O-01A;Primary Tumor;Asterand;69;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;0,001038367;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;5,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2A2-06A;Metastatic;University of Sydney;71;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;5,87E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Dendritic.cells;5,03E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GF-A6C9-06A;Metastatic;ABS - IUPUI;78;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Dendritic.cells;5,03E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A5GL-06A;Metastatic;MD Anderson;74;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,59E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;Dendritic.cells;8,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2MI-06A;Metastatic;University of Sydney;43;NA;Male;lymph node;1;6225;II;NA;tcga_skcm;Dendritic.cells;8,89E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;Dendritic.cells;4,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8ZY-06A;Metastatic;Norfolk and Norwich Hospital;62;NA;Male;Cutaneous or Subcutaneous;1;1506;II;NA;tcga_skcm;Dendritic.cells;4,25E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;Dendritic.cells;5,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A29X-06A;Metastatic;University of Sydney;58;NA;Female;lymph node;1;545;I;NA;tcga_skcm;Dendritic.cells;5,28E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-WE-A8JZ-06A;Metastatic;Norfolk and Norwich Hospital;70;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;4,79E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;Dendritic.cells;5,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U9-06A;Metastatic;Roswell;71;NA;Male;lymph node;1;673;III;NA;tcga_skcm;Dendritic.cells;5,21E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;Dendritic.cells;1,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A4F4-06A;Metastatic;Essen;64;NA;Male;Cutaneous or Subcutaneous;1;2028;II;NA;tcga_skcm;Dendritic.cells;1,52E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A4Z3-01A;Primary Tumor;Greater Poland Cancer Center;73;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;2,54E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6E9-06A;Metastatic;Greater Poland Cancer Center;75;NA;Female;primary detected;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,65E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;Dendritic.cells;7,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-ER-A2NC-06A;Metastatic;University of Pittsburgh;50;NA;Male;Distant Metastasis;1;1333;I;NA;tcga_skcm;Dendritic.cells;7,34E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A97M-01A;Primary Tumor;Asterand;66;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;Dendritic.cells;1,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-GN-A4U7-06A;Metastatic;Roswell;56;NA;Female;lymph node;1;317;III;NA;tcga_skcm;Dendritic.cells;1,43E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;Dendritic.cells;3,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZP-06A;Metastatic;Essen;52;NA;Male;lymph node;1;2273;II;NA;tcga_skcm;Dendritic.cells;3,18E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;Dendritic.cells;3,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J5-06A;Metastatic;University of Sydney;71;NA;Male;Cutaneous or Subcutaneous;1;1124;III;NA;tcga_skcm;Dendritic.cells;3,37E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,42E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GP-06A;Metastatic;MD Anderson;77;NA;Male;Distant Metastasis;0;NA;III;NA;tcga_skcm;Dendritic.cells;3,42E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,49E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-XV-A9W2-01A;Primary Tumor;Capital Biosciences;81;NA;Male;primary detected;0;NA;I;NA;tcga_skcm;Dendritic.cells;3,49E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;Dendritic.cells;8,57E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A51G-06A;Metastatic;MD Anderson;NA;NA;Male;Cutaneous or Subcutaneous;0;NA;stage 0;NA;tcga_skcm;Dendritic.cells;8,57E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,63E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A553-01A;Primary Tumor;Asterand;62;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,63E-05;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GM-06B;Metastatic;University of Sydney;70;NA;Female;Cutaneous or Subcutaneous;0;NA;II;NA;tcga_skcm;Dendritic.cells;2,48E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;0,001924281;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A8GN-06A;Metastatic;MD Anderson;27;NA;Female;Distant Metastasis;0;NA;i/ii nos;NA;tcga_skcm;Dendritic.cells;0,001924281;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;Dendritic.cells;6,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D3-A1Q1-06A;Metastatic;MD Anderson;79;NA;Female;lymph node;1;504;III;NA;tcga_skcm;Dendritic.cells;6,85E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A5EQ-01A;Primary Tumor;Cureline;63;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;3,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;Dendritic.cells;0,001596351;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2ML-06A;Metastatic;University of Sydney;35;NA;Male;lymph node;1;6590;II;NA;tcga_skcm;Dendritic.cells;0,001596351;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;Dendritic.cells;8,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2GP-06A;Metastatic;University of Sydney;80;NA;Male;Cutaneous or Subcutaneous;1;423;III;NA;tcga_skcm;Dendritic.cells;8,60E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;9,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A2M6-06A;Metastatic;University of Sydney;61;NA;Male;lymph node;0;NA;I;NA;tcga_skcm;Dendritic.cells;9,13E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;Dendritic.cells;4,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J3-06A;Metastatic;University of Sydney;42;NA;Male;Cutaneous or Subcutaneous;1;5237;I;NA;tcga_skcm;Dendritic.cells;4,14E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;Dendritic.cells;2,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FS-A1ZF-06A;Metastatic;Essen;78;NA;Female;Distant Metastasis;1;470;II;NA;tcga_skcm;Dendritic.cells;2,40E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;9,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-D9-A6EC-06A;Metastatic;Greater Poland Cancer Center;56;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;9,96E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;Dendritic.cells;3,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-FR-A8YC-06A;Metastatic;University of North Carolina;78;NA;Male;Distant Metastasis;1;1059;II;NA;tcga_skcm;Dendritic.cells;3,58E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EB-A4XL-01A;Primary Tumor;Asterand;56;NA;Female;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;4,16E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;6,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3AC-06A;Metastatic;University of Sydney;47;NA;Male;lymph node;0;NA;III;NA;tcga_skcm;Dendritic.cells;6,74E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;Dendritic.cells;2,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-EE-A3J4-06A;Metastatic;University of Sydney;72;NA;Male;Cutaneous or Subcutaneous;1;3869;II;NA;tcga_skcm;Dendritic.cells;2,93E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,69E-04;Metastasis
NOS; pharmaceutical and radiation therapies;TCGA-BF-A1Q0-01A;Primary Tumor;Cureline;80;NA;Male;primary detected;0;NA;II;NA;tcga_skcm;Dendritic.cells;8,69E-04;Metastasis
untreated;GSM1315904;Primary Tumor;Australia;19;22;Female;NA;0;4342,8;Stage II;not sustained response;GSE54467;Dendritic.cells;0,034671407;NA;
untreated;GSM1315905;Primary Tumor;Australia;53;56;Male;NA;1;1418,4;Stage II;NA;GSE54467;Dendritic.cells;0,026806607;NA;
untreated;GSM1315906;Primary Tumor;Australia;52;53;Female;NA;1;698,4;Stage II;NA;GSE54467;Dendritic.cells;0,035982486;NA;
untreated;GSM1315907;Primary Tumor;Australia;51;52;Male;NA;0;3330,6;Stage I;not sustained response;GSE54467;Dendritic.cells;0,041242204;NA;
untreated;GSM1315908;Primary Tumor;Australia;47;51;Male;NA;1;4283,4;Stage II;NA;GSE54467;Dendritic.cells;0,04131809;NA;
untreated;GSM1315909;Primary Tumor;Australia;61;64;Male;NA;1;1540,5;Stage I;NA;GSE54467;Dendritic.cells;0,023092719;NA;
untreated;GSM1315910;Primary Tumor;Australia;46;52;Female;NA;0;6957,3;Stage I;not sustained response;GSE54467;Dendritic.cells;0,053688969;NA;
untreated;GSM1315911;Primary Tumor;Australia;61;75;Male;NA;1;5484,9;Stage I;NA;GSE54467;Dendritic.cells;0,059557896;NA;
untreated;GSM1315912;Primary Tumor;Australia;84;87;Female;NA;1;1491,3;Stage I;NA;GSE54467;Dendritic.cells;0,040557362;NA;
untreated;GSM1315913;Primary Tumor;Australia;44;44;Female;NA;0;3899,7;Stage III;not sustained response;GSE54467;Dendritic.cells;0,02160566;NA;
untreated;GSM1315914;Primary Tumor;Australia;64;72;Male;NA;1;3322,8;Stage I;NA;GSE54467;Dendritic.cells;0,036157746;NA;
untreated;GSM1315915;Primary Tumor;Australia;31;31;Male;NA;0;3034,8;Stage III;not sustained response;GSE54467;Dendritic.cells;0,063848903;NA;
untreated;GSM1315916;Primary Tumor;Australia;63;65;Male;NA;1;654,9;Stage II;NA;GSE54467;Dendritic.cells;0,034866515;NA;
untreated;GSM1315917;Primary Tumor;Australia;58;59;Male;NA;1;1098,6;Stage III;NA;GSE54467;Dendritic.cells;0,064035727;NA;
untreated;GSM1315918;Primary Tumor;Australia;56;67;Male;NA;0;6538,2;Stage Unknown;not sustained response;GSE54467;Dendritic.cells;0,064333915;NA;
untreated;GSM1315919;Primary Tumor;Australia;48;57;Female;NA;1;3603,9;Stage II;NA;GSE54467;Dendritic.cells;0,042815659;NA;
untreated;GSM1315920;Primary Tumor;Australia;69;70;Male;NA;1;261,3;Stage III;NA;GSE54467;Dendritic.cells;0,024729858;NA;
untreated;GSM1315921;Primary Tumor;Australia;76;77;Male;NA;1;593,7;Stage II;NA;GSE54467;Dendritic.cells;0,048623093;NA;
untreated;GSM1315922;Primary Tumor;Australia;54;55;Female;NA;1;592,8;Stage III;NA;GSE54467;Dendritic.cells;0,091304211;NA;
untreated;GSM1315923;Primary Tumor;Australia;82;85;Male;NA;1;2242,8;Stage II;responder;GSE54467;Dendritic.cells;0,029496905;NA;
untreated;GSM1315924;Primary Tumor;Australia;79;80;Male;NA;0;2393,7;Stage I;not sustained response;GSE54467;Dendritic.cells;0,041331292;NA;
untreated;GSM1315925;Primary Tumor;Australia;50;54;Male;NA;0;2986,5;Stage II;not sustained response;GSE54467;Dendritic.cells;0,029029417;NA;
untreated;GSM1315926;Primary Tumor;Australia;57;57;Female;NA;0;305,7;Stage III;non-responder;GSE54467;Dendritic.cells;0,04651681;NA;
untreated;GSM1315927;Primary Tumor;Australia;32;45;Male;NA;0;7826,4;Stage I;not sustained response;GSE54467;Dendritic.cells;0,039072978;NA;
untreated;GSM1315928;Primary Tumor;Australia;77;78;Female;NA;1;589,8;Stage III;NA;GSE54467;Dendritic.cells;0,041952584;NA;
untreated;GSM1315929;Primary Tumor;Australia;56;56;Male;NA;1;588,9;Stage III;NA;GSE54467;Dendritic.cells;0,061211466;NA;
untreated;GSM1315930;Primary Tumor;Australia;39;40;Female;NA;1;644,1;Stage II;NA;GSE54467;Dendritic.cells;0,143175577;NA;
untreated;GSM1315931;Primary Tumor;Australia;84;87;Female;NA;1;3090;Stage II;NA;GSE54467;Dendritic.cells;0,085330102;NA;
untreated;GSM1315932;Primary Tumor;Australia;57;60;Female;NA;1;1734,9;Stage II;NA;GSE54467;Dendritic.cells;0,035134086;NA;
untreated;GSM1315933;Primary Tumor;Australia;23;28;Male;NA;1;3096;Stage I;NA;GSE54467;Dendritic.cells;0,06616329;NA;
untreated;GSM1315934;Primary Tumor;Australia;63;66;Male;NA;1;3007,2;Stage I;NA;GSE54467;Dendritic.cells;0,019012572;NA;
untreated;GSM1315935;Primary Tumor;Australia;53;54;Male;NA;1;723,9;Stage II;NA;GSE54467;Dendritic.cells;0,021030851;NA;
untreated;GSM1315936;Primary Tumor;Australia;72;72;Male;NA;0;3205,5;Stage II;not sustained response;GSE54467;Dendritic.cells;0,031142349;NA;
untreated;GSM1315937;Primary Tumor;Australia;60;67;Male;NA;1;3228,3;Stage I;NA;GSE54467;Dendritic.cells;0,024896122;NA;
untreated;GSM1315938;Primary Tumor;Australia;67;69;Male;NA;1;864,9;Stage II;NA;GSE54467;Dendritic.cells;0,023809768;NA;
untreated;GSM1315939;Primary Tumor;Australia;61;61;Male;NA;1;325,5;Stage III;NA;GSE54467;Dendritic.cells;0,036377955;NA;
untreated;GSM1315940;Primary Tumor;Australia;35;54;Male;NA;0;8526,6;Stage II;not sustained response;GSE54467;Dendritic.cells;0,064687784;NA;
untreated;GSM1315941;Primary Tumor;Australia;60;63;Male;NA;1;2886,9;Stage II;responder;GSE54467;Dendritic.cells;0,036243879;NA;
untreated;GSM1315942;Primary Tumor;Australia;30;30;Male;NA;0;2114,7;Stage III;not sustained response;GSE54467;Dendritic.cells;0,040050836;NA;
untreated;GSM1315943;Primary Tumor;Australia;66;67;Male;NA;1;508,8;Stage II;NA;GSE54467;Dendritic.cells;0,026781914;NA;
untreated;GSM1315944;Primary Tumor;Australia;50;54;Female;NA;1;2062,5;Stage II;NA;GSE54467;Dendritic.cells;0,049128579;NA;
untreated;GSM1315945;Primary Tumor;Australia;28;30;Male;NA;1;3093,9;Stage II;NA;GSE54467;Dendritic.cells;0,023886466;NA;
untreated;GSM1315946;Primary Tumor;Australia;58;60;Male;NA;1;1426,2;Stage I;NA;GSE54467;Dendritic.cells;0,064590744;NA;
untreated;GSM1315947;Primary Tumor;Australia;66;69;Female;NA;1;1518,9;Stage III;NA;GSE54467;Dendritic.cells;0,031370133;NA;
untreated;GSM1315948;Primary Tumor;Australia;49;57;Female;NA;0;6582,6;Stage I;not sustained response;GSE54467;Dendritic.cells;0,031494114;NA;
untreated;GSM1315949;Primary Tumor;Australia;69;69;Male;NA;1;446,7;Stage III;NA;GSE54467;Dendritic.cells;0,068692595;NA;
untreated;GSM1315950;Primary Tumor;Australia;55;56;Male;NA;0;3286,5;Stage III;not sustained response;GSE54467;Dendritic.cells;0,046527032;NA;
untreated;GSM1315951;Primary Tumor;Australia;52;58;Male;NA;1;3098,1;Stage I;NA;GSE54467;Dendritic.cells;0,052800888;NA;
untreated;GSM1315952;Primary Tumor;Australia;61;74;Female;NA;1;4687,8;Stage I;NA;GSE54467;Dendritic.cells;0,024843031;NA;
untreated;GSM1315953;Primary Tumor;Australia;74;75;Male;NA;1;1845,3;Stage I;responder;GSE54467;Dendritic.cells;0,099649536;NA;
untreated;GSM1315954;Primary Tumor;Australia;40;40;Male;NA;0;2916,6;Stage III;not sustained response;GSE54467;Dendritic.cells;0,056069918;NA;
untreated;GSM1315955;Primary Tumor;Australia;36;44;Male;NA;0;6242,4;Stage II;non-responder;GSE54467;Dendritic.cells;0,034313837;NA;
untreated;GSM1315956;Primary Tumor;Australia;70;73;Female;NA;0;3861,3;Stage II;not sustained response;GSE54467;Dendritic.cells;0,066969949;NA;
untreated;GSM1315957;Primary Tumor;Australia;67;67;Male;NA;0;1219,2;Stage III;not sustained response;GSE54467;Dendritic.cells;0,056404687;NA;
untreated;GSM1315958;Primary Tumor;Australia;53;66;Male;NA;1;5252,1;Stage I;NA;GSE54467;Dendritic.cells;0,023569977;NA;
untreated;GSM1315959;Primary Tumor;Australia;64;64;Female;NA;0;3633,6;Stage III;not sustained response;GSE54467;Dendritic.cells;0,027304561;NA;
untreated;GSM1315960;Primary Tumor;Australia;59;61;Male;NA;0;5126,7;Stage I;not sustained response;GSE54467;Dendritic.cells;0,061917163;NA;
untreated;GSM1315961;Primary Tumor;Australia;78;88;Male;NA;1;6904,2;Stage I;NA;GSE54467;Dendritic.cells;0,053206665;NA;
untreated;GSM1315962;Primary Tumor;Australia;62;64;Male;NA;0;3878,1;Stage I;not sustained response;GSE54467;Dendritic.cells;0,066009063;NA;
untreated;GSM1315963;Primary Tumor;Australia;30;63;Male;NA;1;12093,9;Stage I;NA;GSE54467;Dendritic.cells;0,049670257;NA;
untreated;GSM1315964;Primary Tumor;Australia;40;46;Female;NA;1;2208,3;Stage III;NA;GSE54467;Dendritic.cells;0,062937172;NA;
untreated;GSM1315965;Primary Tumor;Australia;58;63;Female;NA;1;3665,1;Stage II;NA;GSE54467;Dendritic.cells;0,039717828;NA;
untreated;GSM1315966;Primary Tumor;Australia;39;40;Female;NA;0;3431,4;Stage I;not sustained response;GSE54467;Dendritic.cells;0,032201684;NA;
untreated;GSM1315967;Primary Tumor;Australia;49;50;Male;NA;1;650,1;Stage I;NA;GSE54467;Dendritic.cells;0,052946009;NA;
untreated;GSM1315968;Primary Tumor;Australia;50;51;Male;NA;0;4334,7;Stage II;not sustained response;GSE54467;Dendritic.cells;0,049583245;NA;
untreated;GSM1315969;Primary Tumor;Australia;24;24;Male;NA;0;1256,4;Stage III;not sustained response;GSE54467;Dendritic.cells;0,06208087;NA;
untreated;GSM1315970;Primary Tumor;Australia;70;73;Female;NA;0;2782,5;Stage II;not sustained response;GSE54467;Dendritic.cells;0,025146607;NA;
untreated;GSM1315971;Primary Tumor;Australia;83;86;Male;NA;1;1875;Stage II;responder;GSE54467;Dendritic.cells;0,036970206;NA;
untreated;GSM1315972;Primary Tumor;Australia;68;75;Female;NA;0;6019,5;Stage I;not sustained response;GSE54467;Dendritic.cells;0,055816529;NA;
untreated;GSM1315973;Primary Tumor;Australia;47;47;Male;NA;0;1506;Stage III;not sustained response;GSE54467;Dendritic.cells;0,03133494;NA;
untreated;GSM1315974;Primary Tumor;Australia;48;48;Female;NA;0;2405,7;Stage I;not sustained response;GSE54467;Dendritic.cells;0,050467288;NA;
untreated;GSM1315975;Primary Tumor;Australia;52;53;Male;NA;1;582;Stage III;NA;GSE54467;Dendritic.cells;0,028079561;NA;
untreated;GSM1315976;Primary Tumor;Australia;60;67;Female;NA;0;5314,2;Stage I;non-responder;GSE54467;Dendritic.cells;0,077883329;NA;
untreated;GSM1315977;Primary Tumor;Australia;45;50;Female;NA;1;3722,4;Stage II;NA;GSE54467;Dendritic.cells;0,038135306;NA;
untreated;GSM1315978;Primary Tumor;Australia;68;73;Female;NA;1;3316,8;Stage I;NA;GSE54467;Dendritic.cells;0,023569325;NA;
untreated;GSM1315979;Primary Tumor;Australia;78;80;Male;NA;0;1305,9;Stage I;NA;GSE54467;Dendritic.cells;0,06032379;NA;
untreated;GSM1315980;Primary Tumor;Australia;56;56;Female;NA;1;708,3;Stage II;NA;GSE54467;Dendritic.cells;0,031679769;NA;
untreated;GSM1315981;Primary Tumor;Australia;74;74;Female;NA;1;121,2;Stage II;NA;GSE54467;Dendritic.cells;0,036475689;NA;
untreated;GSM1315982;Primary Tumor;Australia;66;75;Male;NA;1;3691,8;Stage I;NA;GSE54467;Dendritic.cells;0,087279399;NA;